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Global, regional, and national disability-adjusted life-years 
(DALYs) for 359 diseases and injuries and healthy life 
expectancy (HALE) for 195 countries and territories, 
1990–2017: a systematic analysis for the Global Burden of 
Disease Study 2017
GBD 2017 DALYs and HALE Collaborators*
Summary
Background How long one lives, how many years of life are spent in good and poor health, and how the population’s 
state of health and leading causes of disability change over time all have implications for policy, planning, and provision 
of services. We comparatively assessed the patterns and trends of healthy life expectancy (HALE), which quantifies the 
number of years of life expected to be lived in good health, and the complementary measure of disability-adjusted life-
years (DALYs), a composite measure of disease burden capturing both premature mortality and prevalence and severity 
of ill health, for 359 diseases and injuries for 195 countries and territories over the past 28 years.
Methods We used data for age-specific mortality rates, years of life lost (YLLs) due to premature mortality, and years 
lived with disability (YLDs) from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to 
calculate HALE and DALYs from 1990 to 2017. We calculated HALE using age-specific mortality rates and YLDs per 
capita for each location, age, sex, and year. We calculated DALYs for 359 causes as the sum of YLLs and YLDs. We 
assessed how observed HALE and DALYs differed by country and sex from expected trends based on Socio-
demographic Index (SDI). We also analysed HALE by decomposing years of life gained into years spent in good 
health and in poor health, between 1990 and 2017, and extra years lived by females compared with males.
Findings Globally, from 1990 to 2017, life expectancy at birth increased by 7·4 years (95% uncertainty interval 7·1–7·8), 
from 65·6 years (65·3–65·8) in 1990 to 73·0 years (72·7–73·3) in 2017. The increase in years of life varied from 5·1 years 
(5·0–5·3) in high SDI countries to 12·0 years (11·3–12·8) in low SDI countries. Of the additional years of life expected 
at birth, 26·3% (20·1–33·1) were expected to be spent in poor health in high SDI countries compared with 11·7% 
(8·8–15·1) in low-middle SDI countries. HALE at birth increased by 6·3 years (5·9–6·7), from 57·0 years (54·6–59·1) 
in 1990 to 63·3 years (60·5–65·7) in 2017. The increase varied from 3·8 years (3·4–4·1) in high SDI countries to 
10·5 years (9·8–11·2) in low SDI countries. Even larger variations in HALE than these were observed between countries, 
ranging from 1·0 year (0·4–1·7) in Saint Vincent and the Grenadines (62·4 years [59·9–64·7] in 1990 to 63·5 years 
[60·9–65·8] in 2017) to 23·7 years (21·9–25·6) in Eritrea (30·7 years [28·9–32·2] in 1990 to 54·4 years [51·5–57·1] 
in 2017). In most countries, the increase in HALE was smaller than the increase in overall life expectancy, indicating 
more years lived in poor health. In 180 of 195 countries and territories, females were expected to live longer than males 
in 2017, with extra years lived varying from 1·4 years (0·6–2·3) in Algeria to 11·9 years (10·9–12·9) in Ukraine. Of the 
extra years gained, the proportion spent in poor health varied largely across countries, with less than 20% of additional 
years spent in poor health in Bosnia and Herzegovina, Burundi, and Slovakia, whereas in Bahrain all the extra years were 
spent in poor health. In 2017, the highest estimate of HALE at birth was in Singapore for both females (75·8 years 
[72·4–78·7]) and males (72·6 years [69·8–75·0]) and the lowest estimates were in Central African Republic (47·0 years 
[43·7–50·2] for females and 42·8 years [40·1–45·6] for males). Globally, in 2017, the five leading causes of DALYs were 
neonatal disorders, ischaemic heart disease, stroke, lower respiratory infections, and chronic obstructive pulmonary 
disease. Between 1990 and 2017, age-standardised DALY rates decreased by 41·3% (38·8–43·5) for communicable 
diseases and by 49·8% (47·9–51·6) for neonatal disorders. For non-communicable diseases, global DALYs increased by 
40·1% (36·8–43·0), although age-standardised DALY rates decreased by 18·1% (16·0–20·2).
Interpretation With increasing life expectancy in most countries, the question of whether the additional years of life 
gained are spent in good health or poor health has been increasingly relevant because of the potential policy 
implications, such as health-care provisions and extending retirement ages. In some locations, a large proportion of 
those additional years are spent in poor health. Large inequalities in HALE and disease burden exist across countries 
in different SDI quintiles and between sexes. The burden of disabling conditions has serious implications for health 
system planning and health-related expenditures. Despite the progress made in reducing the burden of communicable 
diseases and neonatal disorders in low SDI countries, the speed of this progress could be increased by scaling up 
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Introduction
Understanding global trends in the health status of 
populations and changes in the leading causes of 
disease burden over time is crucial to tracking progress 
towards the Sustainable Development Goal to ensure 
healthy lives and promote wellbeing for all at all ages. 1 
Robust assessment of these trends requires objective 
and comparable measures of population health that can 
help countries identify priorities and address challenges 
to achieving this goal. The Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD) 2017, the third 
annual update in the series, uses all available up-to-date 
epidemiological data and improved standardised 
methods to provide a com parative assessment of health 
loss across 359 diseases and injuries and 73 age and sex 
groups for 195 countries and territories. The availability 
of GBD 2017 data for years of life lost (YLLs) because of 
premature mortality and years lived with disability 
(YLDs) provides an opportunity to assess trends in 
population health over the past 28 years by analysing 
two complementary summary measures: healthy life 
expectancy (HALE), which quantifies the number of 
proven interventions. The global trends among non-communicable diseases indicate that more effort is needed to 
maximise HALE, such as risk prevention and attention to upstream determinants of health.
Funding Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Research in context
Evidence before this study
The Global Burden of Diseases, Injuries, and Risk Factors Study 
2016 (GBD 2016) estimated 333 causes of disability-adjusted 
life-years (DALYs) for 195 countries and territories from 
1990 to 2016. GBD 2016 also provided estimates for life 
expectancy and healthy life expectancy (HALE) at birth and at 
age 65 years, by sex, for each location over time. GBD 2016 
included analysis of the epidemiological transition as a function 
of the Socio-demographic Index. The WHO Global Health 
Estimates has also published estimates of HALE and DALYs, 
although these estimates largely relied on GBD 2016 results.
Added value of this study
In GBD 2017, we expanded the scope of the study compared 
with previous iterations to include subnational estimates for 
five more countries (Ethiopia, Iran, New Zealand, Norway, 
and Russia) and 19 additional causes. The new causes estimated 
are invasive non-typhoidal salmonella disease; liver cancer due 
to non-alcoholic steatohepatitis; cirrhosis due to non-alcoholic 
steatohepatitis; myelodysplastic, myeloproliferative, and other 
haemopoietic neoplasms; benign and in-situ intestinal 
neoplasms; benign and in-situ cervical and uterine neoplasms; 
other benign and in-situ neoplasms; subarachnoid 
haemorrhage; non-rheumatic valvular heart disease; 
non-rheumatic calcific aortic valve disease; non-rheumatic 
degenerative mitral valve disease; other non-rheumatic valve 
diseases; gastro-oesophageal reflux disease; type 1 diabetes; 
type 2 diabetes; chronic kidney disease due to type 1 diabetes; 
chronic kidney disease due to type 2 diabetes; poisoning by 
carbon monoxide; and poisoning by other means. In addition to 
broadening our estimation by cause, location, and time, 
a substantial amount of new data were added for GBD 2017. 
For cause-specific non-fatal estimations, we added new data 
from epidemiological surveillance, disease registries, scientific 
literature sources, and survey sources. Similarly, for 
cause-specific fatal estimation, we added new data from verbal 
autopsy studies, vital registration, and cancer registries. For 
age-specific all-cause mortality estimations, we added vital 
registration data, complete birth history sources, summary birth 
history sources, and sibling history surveys. These improvements 
are reflected in the summary measures of population health, 
DALYs and HALE, reported in this paper. We also provided a 
more detailed assessment for HALE than in previous GBD papers 
by examining the following: distinguishing the years of life 
gained over the past 28 years into years spent in good health 
and in poor health, by sex, for each location; determining which 
extra years lived were spent in good health and in poor health 
for females compared with males for each location; and 
assessing the male–female difference in HALE and years lived in 
poor health for the period 1990–2017 across 
Socio-demographic Index (SDI) quintiles. With increasing 
longevity, such information has relevance for policy 
development, health systems planning, and resource allocation.
Implications of all the available evidence
Over the past 28 years, the world has had tremendous gains in 
life expectancy; however, in many locations simply gaining 
years of life has not meant living those years in good health. 
In some locations, a large proportion of those years are spent in 
poor health. By distinguishing where, among whom, and how 
many of these additional years of life gained are spent in good 
health versus poor health, we have more insight to inform 
policy, planning, and resource prioritisation for improving 
health and reducing disparities. Our results showed large 
disparities in health and disease burden by SDI and sex, 
suggesting that much could be done to narrow these gaps, such 
as targeted approaches to reduce risk factors and scale up 
proven cost-effective interventions to decrease the burden of 
disease and make additional improvements to HALE more 
equitable. Our results not only provide the most up-to-date 
evidence, but also serve as a baseline for evaluating the 
effectiveness of interventions and programmes over time.
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years expected to be lived in good health, and disability-
adjusted life-years (DALYs), which quantifies the health 
loss due to specific diseases and injuries. HALE provides 
a snapshot of overall population health and DALYs are 
useful for quantifying and ranking disease burden due 
to specific causes. DALYs can be utilised to help decision 
makers and the public understand the leading causes of 
health burden and whether improvement occurs over 
time.
The continuing trend of increasing life expectancy 
and decreasing mortality because of improvements in 
living conditions, income per capita, education, and 
medical practices is well known and understood.2–5 
Previous GBD papers have reported that increases in 
HALE have been slower than increases in life 
expectancy, resulting in more years of poor health, and 
suggesting an absolute expansion of morbidity.6–9 
However, details of how many of the additional years of 
life gained are spent in good health versus poor health 
across countries and socio demographic groups have not 
been well characterised. As people live longer, such 
information becomes increasingly relevant for policy 
development, health systems planning, and resource 
allocation, the effects of which cannot be understated 
for population health. The estimates herein provide 
insight into the importance of access to services and 
appropriate health care, and the potential societal 
burden of caregiving and excess health-care expenditure 
for years lived in poor health.10
In this study, we present GBD 2017 results for HALE 
and DALYs by age and sex from 1990 to 2017 for 
195 countries and territories. GBD 2017 includes new 
morbidity and mortality data (epidemiological sur-
veillance data, disease registry data, scientific literature 
sources, survey sources, verbal autopsy studies, vital 
registration systems, cancer registries, complete birth 
history sources, summary birth history sources, and 
sibling history surveys); refined methods; and new 
estimations at the subnational level for Ethiopia, Iran, 
Norway, and Russia, and stratified by ethnicity for 
New Zealand. Also, the disaggregation of larger cause 
categories (eg, diabetes) has allowed separate estimation 
for several additional diseases (eg, type 1 and type 2 
diabetes). GBD 2017 provides a complete reanalysis of all 
available data by country from 1990 to 2017, and thus 
supersedes all previously published GBD estimations of 
HALE and DALYs.
Methods
Overview
The GBD study comprehensively and systematically 
quantifies the comparative magnitude of health loss due 
to diseases and injuries by age, sex, and location over 
time. We estimated all-cause and cause-specific mortality 
using the following key principles: identification of all 
data sources that are available, assessment of the quality 
of the data and correction for known bias, application of 
highly standardised analytical procedures, and assess-
ment of model performance using cross-validation 
analysis. We used similar principles to identify, enhance 
comparability, and analyse data to estimate the incidence, 
prevalence, and YLDs of diseases and injuries.7 Using the 
GBD 2017 results for YLLs and YLDs, we calculated 
DALYs for 359 diseases and injuries.11,12 We used age-
specific mortality and YLDs per person to calculate 
HALE, defined as the average number of years that a 
person at a given age can expect to live in good health, 
taking into account mortality and loss of functional 
health.13 Additional details for computing HALE can be 
found in appendix 1. We calculated years lived in poor 
health (ie, years lived with functional health loss) as life 
expectancy minus HALE. Estimations for GBD 2017 
cover the period 1990 to 2017 for 195 countries and 
territories. We did analyses using Python versions 2.7.12 
and 2.7.3, Stata version 13.1, and R version 3.2.2.
For this study, we followed the Guidelines for Accurate 
and Transparent Health Estimates Reporting 
(GATHER),14 which include recommendations on docu-
mentation of data sources, estimation methods, and 
statistical analysis (appendix 1). Interactive online tools 
are available to explore GBD 2017 data sources in detail 
using our online sourcing tool, the Global Health Data 
Exchange. Data before and after adjustments and the fit 
of the model to the data for causes of death and non-
fatal outcomes can be explored with the available data 
visualisation tool.
Cause and location hierarchies
In GBD 2017, as in previous GBDs, causes of mortality 
and morbidity are structured using a four-level 
classification hierarchy to produce results that are 
mutually exclusive and collectively exhaustive. GBD 2017 
estimates 359 causes of DALYs, 77 of which are a source 
of disability but not a cause of death (eg, attention-deficit 
hyperactivity disorder, headache disorders, low back 
pain, and neck pain), and five of which are causes 
of death but not sources of morbidity (sudden infant 
death syndrome, aortic aneurysm, late maternal deaths, 
indirect maternal deaths, and maternal deaths aggravated 
by HIV/AIDS). In the GBD hierarchy, the number of 
mutually exclusive and collectively exhaustive fatal and 
non-fatal causes in each level for which GBD estimates is 
three at Level 1, 22 at Level 2, 169 at Level 3, and 293 at 
Level 4. The full GBD cause hierarchy, including 
corresponding International Classification of Diseases 
(ICD)-9 and ICD-10 codes and detailed cause-specific 
methods, is in GBD 2017 publications on cause-specific 
mortality11 and non-fatal health outcomes12 in the 
corresponding appendices.
GBD 2017 includes 195 countries and territories that 
are grouped into 21 regions on the basis of epidemiological 
similarities and geographical proximity.15 For the 
purposes of statistical analyses, we further grouped 
regions into seven super-regions (central Europe, eastern 
See Online for appendix 1
For the online data 
visualisation tool see 
https://vizhub.healthdata.org
For the Global Health Data 
Exchange see http://ghdx.
healthdata.org
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Europe, and central Asia; high income; Latin America 
and Caribbean; north Africa and Middle East; south Asia; 
southeast Asia, east Asia and Oceania; and sub-Saharan 
Africa). Each year, GBD includes subnational analyses 
for a few new countries and continues to provide 
subnational estimates for countries that were added in 
previous cycles. Subnational estimation in GBD 2017 
includes five new countries (Ethiopia, Iran, New Zealand, 
Norway, and Russia) and countries previously estimated 
at subnational levels (GBD 2013: China, Mexico, and the 
UK [regional level]; GBD 2015: Brazil, India, Japan, 
Kenya, South Africa, Sweden, and the USA; and GBD 
2016: Indonesia and the UK [local government authority 
level]). All analyses are at the first level of administrative 
organisation within each country except for New Zealand 
(by Māori ethnicity),  Sweden (by Stockholm and non-
Stockholm), and the UK (by local government authorites). 
All subnational estimates for these countries were 
incorporated into model development and evaluation as 
part of GBD 2017. To meet data use requirements, we 
present all subnational estimates excluding those 
pending publication (Brazil, India, Japan, Kenya, Mexico, 
Sweden, the UK, and the USA); these results are 
presented in appendix tables and figures (appendix 2). 
Subnational estimates for countries with populations 
larger than 200 million people (as measured according to 
our most recent year of published estimates) that have 
not yet been published elsewhere are presented wherever 
estimates are illustrated with maps but are not included 
in data tables.
Estimation of mortality and non-fatal health loss
We estimated age-specific mortality using data from 
vital registration systems, sample registration systems, 
household surveys, censuses, and demographic sur-
veillance sites.13 We estimated cause-specific mortality 
and YLLs using the GBD cause of death database, 
composed of vital registration and verbal autopsy data, 
survey and census data for injuries and maternal 
mortality, surveillance data for maternal and child 
mortality, cancer registries, and police records for 
interpersonal violence and road injuries.11 The quality 
and comparability of the cause of death data were 
evaluated and improved through several steps, including 
adjustment of data from vital registration systems 
for incompleteness, conversion of causes found in 
the original data to the GBD 2017 cause list, and 
redistribution of deaths assigned to ICD codes that 
cannot be underlying causes of death. Detailed methods 
for each step are available in the appendix of the GBD 
2017 causes of death paper.11 We estimated cause-specific 
mortality using standardised modelling processes, most 
commonly the Cause of Death Ensemble model 
(CODEm), which uses a covariate selection algorithm to 
generate several plausible combinations of covariates 
that are then run through four model classes—namely, 
mixed effects linear models and spatiotemporal 
Gaussian process regression models for cause fractions 
and death rates. For a given cause, we categorised 
covariates into three groups on the basis of the following 
criteria: evidence of proximal or causal association 
(Level 1), strong evidence for an association but without 
adequate evidence of a causal link (Level 2), and 
covariates that are distal in the causal pathway and 
therefore might be mediated by other factors in Levels 1 
or 2 (Level 3).16 The programme then selects an 
ensemble of models that performs best on out-of-
sample predictive validity tests for each cause of death. 
Ensemble models have been shown to produce smaller 
errors in estimated cause-specific mortality and more 
accurate trends than single-component models.16 
Additional detail, including model specifications and 
data availability for each cause-specific model, can be 
found in the appendices of the GBD 2017 causes of 
death11 and mortality13 publications. We calculated YLLs 
from the sum of each death multiplied by the standard 
life expectancy at each age. The standard life expectancy 
was taken from the lowest observed risk of death for 
each 5-year age group in all populations greater than 
5 million people. For consistency across all fatal and 
non-fatal estimates in GBD 2017, we calculated our own 
population and fertility estimates.17 We then used the 
GBD world population age standard to calculate age-
standardised rates for cause-specific deaths and YLLs. 
The GBD world population age standard and the 
standard life expectancies are available in the appendix 
of the GBD 2017 mortality publication.13
Changes we have implemented since GBD 2016 for 
cause-specific mortality include the addition of important 
sources of new mortality data (detailed at the beginning 
of this section) and the expansion of the GBD location 
hierarchy, refinements in the calculation of Socio-
demographic Index (SDI), and disaggregation of specific 
causes into sub groupings to provide additional detail. We 
estimated the following specific causes separately for the 
first time: invasive non-typhoidal salmonella disease; 
liver cancer due to non-alcoholic steatohepatitis (NASH); 
cirrhosis due to non-alcoholic steatohepatitis; myelo-
dysplastic, myelo proliferative, and other haemopoietic 
neoplasms; benign and in-situ intestinal neoplasms; 
benign and in-situ cervical and uterine neoplasms; 
other benign and in-situ neoplasms; subarachnoid 
haemorrhage; non-rheumatic valvular heart disease; 
non-rheumatic calcific aortic valve disease; non-
rheumatic degenerative mitral valve disease; other non-
rheumatic valve diseases; gastro-oesophageal reflux 
disease; type 1 diabetes; type 2 diabetes; chronic kidney 
disease due to type 1 diabetes; chronic kidney disease due 
to type 2 diabetes; poisoning by carbon monoxide; and 
poisoning by other means. Specific data sources are 
available in the appendices of the GBD 2017 non-fatal 
diseases and injuries12 and causes of death11 publications. 
Additional information on data sources used can be 
found in our online source tool.
See Online for appendix 2
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For estimation of non-fatal health loss, we most 
commonly used the Bayesian meta-regression tool 
DisMod-MR 2.1, which synthesises variable data sources 
to produce internally consistent estimates of incidence, 
prevalence, remission, and excess mortality.18 If DisMod-
MR 2.1 did not capture the complexity of the disease, or if 
incidence and prevalence needed to be calculated from 
other data, we used custom models; detailed methods for 
each cause are in the appendices of the GBD 2017 non-
fatal diseases and injuries publication.12
We estimated each non-fatal sequela separately and 
assessed the occurrence of comorbidity for each age 
group, sex, location, and year separately using a micro-
simulation framework.12 Disability estimated for co-
morbid conditions was distributed to each contributing 
cause during the comorbidity estimation process. 
Although the distribution of sequelae and the severity 
and cumulative disability per case of a condition might 
be different by age, sex, location, and year, previous 
studies have found that disability weights do not 
substantially vary between locations, income per capita, 
or levels of educational attainment.19,20 Additional details, 
including model specifications, data availability, data 
adjustments to enhance comparability for each cause-
specific model, and the development of disability weights 
by cause and their use in the estimation of non-fatal 
health loss, are available in the appendices of the GBD 
2017 non-fatal diseases and injuries publication.12
Estimation of DALYs, HALE, and corresponding 
uncertainty
To calculate HALE, we used the following inputs from 
GBD 2017: age-specific mortality rates; estimates of the 
prevalence of sequelae by age, sex, location, and year; and 
disability weights for all unique health states. We used 
the method originally developed by Sullivan21 to estimate 
HALE (appendix 1). We calculated DALYs as the sum of 
YLLs11 and YLDs12 for each location, year, age group, and 
cause, by sex.
We calculated 95% uncertainty intervals (UIs) on the 
basis of 1000 draws from the posterior distribution of 
each step in the estimation process using the 2·5th and 
97·5th percentiles of the ordered 1000 values. We 
attributed the uncertainty associated with estimation of 
mortality and YLLs to multiple sources, including sample 
size variability in data sources, adjustment and standard-
isation methods applied to data, and model specifications. 
We attributed the uncertainty associated with estimation 
of YLDs to sampling error of data inputs, adjustment and 
standardisation methods applied to data, the uncertainty 
in coefficients from model fit, and the uncertainty of 
severity distributions and disability weights.
Estimation of SDI and expected DALYs and HALE on the 
basis of SDI
The SDI is the geometric mean of three rescaled 
components: total fertility rate under age 25 years (ie, the 
number of births expected per woman aged 10–24 years), 
lag-distributed income per capita, and average edu-
cational attainment in populations aged 15 years or 
older. The methods we used to calculate the SDI are in 
appendix 1. SDI scores were scaled from 0 (lowest 
income, fewest years of schooling, and highest fertility) 
to 1 (highest income, most years of schooling, and lowest 
fertility). We estimated the association between SDI and 
cause-specific mortality using a generalised additive 
model with a Loess smoother on SDI; we then used this 
association to calculate expected YLLs. Expected YLDs 
were calculated on the basis of the relationship between 
SDI and YLD rates. We then calculated expected DALYs 
as the sum of expected YLLs and YLDs, and expected 
HALE using expected YLDs and expected life tables. All 
results are available both in appendix 2 and through our 
online visualisation tool.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Levels and trends in life expectancy and HALE at birth
Globally, life expectancy at birth for both sexes combined 
increased by 7·4 years (95% UI 7·1–7·8), rising from 
65·6 years (65·3–65·8) in 1990 to 73·0 years (72·7–73·3) 
in 2017 (appendix 2). The increase in life expectancy at 
Life expectancy at birth HALE at birth
Females Males Females Males
1990 2017 1990 2017 1990 2017 1990 2017
Global 68·0 (67·8–68·3) 75·6 (75·3–75·9) 63·2 (62·9–63·4) 70·5 (70·1–70·8) 58·4 (55·7–60·8) 64·8 (61·7–67·4) 55·6 (53·5–57·5) 61·8 (59·4–64·0)
Low SDI 54·8 (54·3–55·4) 67·3 (66·7–67·9) 53·0 (52·4–53·6) 64·5 (63·8–65·1) 46·4 (44·0–48·5) 57·3 (54·5–59·8) 46·1 (44·1–47·9) 56·2 (53·9–58·4)
Low-middle SDI 61·9 (61·5–62·3) 70·1 (69·5–70·7) 59·0 (58·5–59·4) 66·3 (65·7–66·9) 52·6 (50·0–55·0) 59·8 (56·9–62·4) 51·5 (49·3–53·5) 58·0 (55·6–60·1)
Middle SDI 70·0 (69·7–70·3) 77·4 (77·1–77·7) 65·7 (65·3–66·1) 71·7 (71·4–72·1) 60·8 (58·2–63·1) 67·0 (64·1–69·5) 58·4 (56·3–60·2) 63·6 (61·2–65·6)
High-middle SDI 73·1 (72·9–73·4) 79·4 (79·1–79·7) 66·8 (66·5–67·0) 73·3 (73·0–73·7) 63·1 (60·4–65·5) 68·5 (65·4–71·1) 59·0 (56·9–61·0) 64·7 (62·2–66·8)
High SDI 79·3 (79·3–79·3) 83·7 (83·5–83·9) 72·6 (72·5–72·6) 78·5 (78·3–78·6) 67·9 (64·6–70·7) 71·1 (67·6–74·2) 63·8 (61·3–66·0) 68·2 (65·4–70·8)
(Table 1 continues on next page)
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Life expectancy at birth HALE at birth
Females Males Females Males
1990 2017 1990 2017 1990 2017 1990 2017
(Continued from previous page)
Central Europe, eastern 
Europe, and central Asia
73·9 (73·8–74·0) 77·6 (77·4–77·7) 64·8 (64·7–64·9) 68·5 (68·3–68·7) 63·3 (60·3–65·9) 66·3 (63·2–69·1) 56·5 (54·2–58·6) 59·7 (57·2–62·0)
Central Asia 71·8 (71·5–72·0) 74·8 (74·3–75·4) 64·1 (63·7–64·4) 67·4 (66·8–67·9) 61·9 (59·0–64·5) 64·8 (61·9–67·4) 56·3 (54·0–58·3) 59·4 (57·0–61·5)
Armenia 73·3 (72·8–73·8) 78·7 (78·2–79·1) 66·7 (66·2–67·2) 72·4 (72·0–72·8) 63·5 (60·7–66·0) 68·1 (65·0–70·7) 58·3 (55·9–60·5) 63·4 (60·7–65·7)
Azerbaijan 71·2 (70·4–71·9) 74·7 (73·7–75·7) 63·4 (62·6–64·3) 67·2 (66·2–68·2) 61·7 (59·0–64·1) 64·9 (61·9–67·6) 56·0 (53·7–58·1) 59·5 (57·2–61·6)
Georgia 73·9 (73·4–74·4) 77·3 (76·9–77·7) 65·9 (65·2–66·6) 68·4 (68·0–68·8) 64·6 (61·8–67·0) 67·2 (64·3–69·7) 58·4 (56·2–60·4) 60·4 (58·1–62·4)
Kazakhstan 73·3 (73·0–73·5) 76·4 (75·8–77·1) 63·4 (63·1–63·7) 67·5 (66·8–68·2) 62·9 (60·0–65·5) 66·1 (63·2–68·6) 55·5 (53·2–57·5) 59·3 (56·9–61·4)
Kyrgyzstan 70·5 (69·7–71·1) 76·3 (75·9–76·6) 62·0 (61·2–62·8) 69·1 (68·7–69·4) 60·8 (57·8–63·3) 66·0 (63·0–68·5) 54·3 (51·9–56·3) 60·9 (58·5–63·0)
Mongolia 64·0 (63·3–64·7) 73·7 (72·5–74·8) 58·6 (57·9–59·4) 64·5 (63·2–65·9) 55·8 (53·4–58·0) 64·0 (61·0–66·7) 51·7 (49·7–53·7) 56·7 (54·3–59·0)
Tajikistan 69·5 (68·9–70·1) 73·3 (72·1–74·5) 64·5 (63·8–65·1) 67·7 (66·3–68·9) 59·9 (57·2–62·4) 63·5 (60·6–66·1) 56·4 (54·0–58·5) 59·4 (56·8–61·8)
Turkmenistan 69·3 (68·8–69·9) 73·9 (72·7–74·9) 62·6 (62·0–63·1) 66·5 (65·4–67·7) 60·4 (57·8–62·7) 64·5 (61·7–67·1) 55·3 (53·2–57·3) 59·0 (56·6–61·2)
Uzbekistan 72·6 (72·2–72·9) 73·7 (72·2–75·3) 66·0 (65·6–66·4) 67·1 (65·5–68·6) 62·3 (59·3–64·9) 63·9 (60·9–66·8) 57·9 (55·4–60·0) 59·4 (56·8–61·8)
Central Europe 74·9 (74·9–75·0) 80·4 (80·2–80·7) 67·2 (67·1–67·2) 73·6 (73·3–73·9) 64·2 (61·1–66·9) 68·8 (65·5–71·7) 58·3 (55·8–60·5) 63·5 (60·6–66·0)
Albania 77·4 (77·0–77·7) 82·1 (79·9–84·3) 69·8 (69·5–70·2) 74·9 (72·8–77·1) 66·3 (63·0–69·1) 70·5 (67·0–73·9) 60·7 (58·0–63·1) 65·0 (61·8–68·2)
Bosnia and 
Herzegovina
76·6 (76·4–76·8) 79·1 (78·4–79·7) 70·5 (70·4–70·7) 74·3 (73·6–75·0) 65·6 (62·5–68·3) 67·7 (64·5–70·5) 61·1 (58·5–63·4) 63·7 (60·7–66·4)
Bulgaria 75·5 (75·4–75·7) 78·6 (77·9–79·2) 68·2 (68·1–68·3) 71·3 (70·6–72·1) 65·2 (62·2–67·8) 67·7 (64·7–70·5) 59·4 (56·9–61·6) 62·2 (59·5–64·5)
Croatia 76·3 (76·1–76·4) 81·6 (80·9–82·3) 68·7 (68·6–68·9) 75·4 (74·7–76·1) 65·7 (62·8–68·4) 69·9 (66·6–72·8) 59·9 (57·3–62·1) 64·9 (62·0–67·4)
Czech Republic 75·5 (75·4–75·6) 82·0 (81·3–82·6) 67·6 (67·5–67·6) 76·3 (75·6–77·0) 64·7 (61·6–67·4) 69·6 (66·0–72·7) 58·9 (56·3–61·1) 65·1 (61·9–68·0)
Hungary 73·9 (73·8–74·0) 80·2 (79·5–80·9) 65·3 (65·2–65·4) 73·2 (72·4–73·9) 62·9 (59·8–65·7) 68·3 (65·1–71·3) 56·6 (54·2–58·7) 63·1 (60·3–65·6)
Macedonia 74·5 (74·2–74·7) 79·7 (79·2–80·3) 69·6 (69·4–69·8) 73·9 (73·2–74·6) 64·1 (61·2–66·7) 68·4 (65·2–71·3) 60·5 (57·9–62·7) 63·9 (61·1–66·3)
Montenegro 77·5 (77·2–77·8) 78·9 (78·1–79·7) 71·1 (70·8–71·5) 74·1 (72·9–75·2) 66·7 (63·6–69·5) 67·9 (64·7–70·7) 61·8 (59·1–64·2) 64·1 (61·1–66·6)
Poland 75·8 (75·7–75·8) 81·8 (81·2–82·4) 66·8 (66·8–66·9) 74·1 (73·3–74·8) 65·0 (61·9–67·7) 69·9 (66·6–72·9) 58·1 (55·6–60·2) 63·7 (60·7–66·4)
Romania 73·2 (73·1–73·3) 79·0 (78·3–79·6) 66·7 (66·6–66·8) 71·5 (70·8–72·3) 62·6 (59·5–65·2) 67·6 (64·3–70·4) 57·4 (54·8–59·7) 61·9 (59·2–64·4)
Serbia 74·5 (74·3–74·6) 77·9 (77·2–78·5) 67·6 (67·4–67·7) 73·6 (72·9–74·2) 64·0 (60·9–66·5) 66·9 (63·8–69·6) 58·8 (56·4–61·0) 63·7 (60·8–66·2)
Slovakia 75·5 (75·3–75·6) 80·6 (79·9–81·3) 66·7 (66·6–66·8) 74·1 (73·4–74·8) 64·9 (61·8–67·5) 68·9 (65·7–71·8) 57·9 (55·4–60·1) 63·7 (60·7–66·3)
Slovenia 77·8 (77·6–78·0) 84·2 (83·5–85·0) 69·7 (69·6–69·9) 77·9 (77·2–78·7) 66·4 (63·3–69·3) 71·2 (67·5–74·4) 60·1 (57·4–62·5) 66·3 (63·0–69·2)
Eastern Europe 74·6 (74·6–74·7) 77·2 (77·1–77·4) 64·5 (64·5–64·6) 66·5 (66·3–66·7) 63·7 (60·7–66·4) 65·9 (62·7–68·6) 56·3 (54·0–58·4) 58·2 (55·8–60·3)
Belarus 75·7 (75·5–75·9) 78·8 (78·1–79·4) 66·1 (65·8–66·3) 69·0 (68·2–69·7) 64·7 (61·7–67·4) 67·3 (64·1–70·2) 57·7 (55·3–59·9) 60·3 (57·7–62·6)
Estonia 75·0 (74·7–75·2) 82·1 (80·7–83·5) 64·7 (64·5–64·9) 73·6 (72·0–75·3) 64·3 (61·2–66·9) 70·0 (66·5–73·4) 56·5 (54·1–58·7) 63·8 (60·8–66·6)
Latvia 74·7 (74·5–74·9) 79·8 (78·4–81·3) 64·6 (64·4–64·8) 70·1 (68·6–71·7) 63·9 (60·9–66·6) 68·0 (64·6–71·0) 56·3 (53·9–58·5) 60·9 (58·2–63·6)
Lithuania 76·2 (76·0–76·3) 80·2 (79·4–81·0) 66·4 (66·2–66·5) 69·6 (68·7–70·5) 65·2 (62·1–67·8) 68·1 (64·8–71·2) 57·8 (55·4–60·0) 60·4 (57·7–62·8)
Moldova 71·4 (71·2–71·7) 77·4 (77·0–77·9) 64·5 (64·2–64·7) 68·2 (67·8–68·7) 61·1 (58·1–63·6) 66·2 (63·1–69·0) 56·1 (53·6–58·2) 59·6 (57·2–61·8)
Russia 74·6 (74·6–74·6) 77·2 (77·1–77·4) 64·0 (64·0–64·0) 66·8 (66·6–66·9) 63·7 (60·6–66·4) 65·8 (62·6–68·6) 55·9 (53·6–58·0) 58·4 (56·0–60·5)
Ukraine 74·7 (74·5–74·9) 76·5 (75·8–77·2) 65·5 (65·3–65·7) 64·7 (63·9–65·4) 63·7 (60·6–66·4) 65·4 (62·1–68·1) 57·2 (54·8–59·3) 56·7 (54·4–58·8)
High income 79·4 (79·4–79·4) 83·6 (83·4–83·7) 72·8 (72·7–72·8) 78·4 (78·2–78·6) 68·0 (64·7–70·8) 71·0 (67·5–74·0) 64·0 (61·4–66·1) 68·2 (65·3–70·7)
Australasia 79·7 (79·6–79·8) 84·4 (83·4–85·4) 73·6 (73·5–73·6) 80·1 (79·1–81·2) 68·0 (64·7–70·9) 71·4 (67·7–74·6) 64·1 (61·4–66·4) 68·9 (65·7–71·8)
Australia 80·0 (79·9–80·1) 84·6 (83·4–85·7) 73·8 (73·7–73·9) 80·2 (78·9–81·5) 68·4 (65·1–71·3) 71·7 (68·0–74·9) 64·3 (61·6–66·7) 69·1 (65·8–72·0)
New Zealand 78·1 (77·9–78·3) 83·6 (83·0–84·2) 72·6 (72·4–72·8) 79·7 (79·0–80·3) 66·3 (62·9–69·3) 70·1 (66·1–73·3) 63·1 (60·2–65·4) 68·0 (64·6–71·0)
High-income Asia Pacific 81·0 (81·0–81·1) 86·9 (86·7–87·2) 74·4 (74·4–74·5) 80·8 (80·5–81·0) 70·1 (67·0–72·8) 74·5 (71·0–77·6) 66·3 (63·9–68·3) 71·1 (68·2–73·4)
Brunei 72·1 (71·5–72·8) 77·5 (76·6–78·4) 69·1 (68·5–69·8) 73·3 (72·3–74·4) 62·9 (60·2–65·3) 67·5 (64·5–70·0) 61·4 (59·2–63·4) 65·0 (62·4–67·3)
Japan 82·2 (82·2–82·2) 87·2 (87·0–87·4) 76·2 (76·2–76·2) 81·1 (80·8–81·3) 71·2 (68·0–73·9) 74·6 (71·1–77·8) 68·0 (65·6–70·0) 71·4 (68·6–73·8)
Singapore 78·8 (78·6–79·0) 87·6 (86·9–88·1) 73·5 (73·3–73·7) 81·9 (81·2–82·6) 68·5 (65·5–71·0) 75·8 (72·4–78·7) 65·6 (63·3–67·6) 72·6 (69·8–75·0)
South Korea 76·4 (76·3–76·5) 85·5 (84·9–86·1) 68·0 (67·9–68·1) 79·5 (78·7–80·3) 66·0 (62·9–68·7) 73·5 (70·0–76·5) 60·3 (58·1–62·2) 69·7 (67·0–72·1)
High-income North 
America
79·1 (79·1–79·2) 81·4 (81·1–81·7) 72·3 (72·3–72·3) 76·5 (76·2–76·8) 67·0 (63·6–69·9) 68·2 (64·7–71·3) 62·9 (60·2–65·1) 65·7 (62·7–68·3)
Canada 80·6 (80·5–80·6) 84·0 (83·4–84·6) 74·1 (74·0–74·2) 79·9 (79·2–80·5) 69·0 (65·6–71·8) 71·4 (67·7–74·5) 65·3 (62·7–67·5) 69·6 (66·6–72·3)
Greenland 69·0 (68·4–69·6) 77·2 (76·2–78·0) 62·1 (61·6–62·6) 70·8 (70·3–71·4) 58·5 (55·7–61·1) 65·3 (62·2–68·3) 54·4 (52·2–56·3) 62·2 (59·7–64·3)
USA 79·0 (79·0–79·0) 81·1 (80·8–81·4) 72·1 (72·1–72·1) 76·1 (75·8–76·4) 66·8 (63·4–69·7) 67·9 (64·3–71·0) 62·6 (59·9–64·9) 65·3 (62·3–67·9)
(Table 1 continues on next page)
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Life expectancy at birth HALE at birth
Females Males Females Males
1990 2017 1990 2017 1990 2017 1990 2017
(Continued from previous page)
Southern Latin America 76·2 (76·1–76·2) 80·4 (79·3–81·3) 69·2 (69·1–69·2) 74·5 (73·3–75·5) 65·9 (62·9–68·5) 69·3 (66·2–72·1) 61·1 (58·8–63·2) 65·3 (62·5–67·9)
Argentina 75·9 (75·8–76·0) 79·7 (78·3–81·0) 68·9 (68·9–69·0) 73·6 (72·0–75·0) 65·9 (62·9–68·4) 68·9 (65·7–71·8) 61·0 (58·7–63·0) 64·7 (61·8–67·4)
Chile 76·4 (76·3–76·5) 82·1 (80·8–83·4) 69·9 (69·8–70·0) 77·2 (75·7–78·7) 65·7 (62·6–68·4) 70·2 (66·6–73·3) 61·5 (59·0–63·6) 67·1 (64·1–70·0)
Uruguay 76·8 (76·6–77·0) 80·4 (79·0–81·9) 69·4 (69·2–69·5) 73·5 (72·1–75·0) 66·6 (63·7–69·2) 69·5 (66·4–72·4) 61·5 (59·2–63·5) 64·8 (62·2–67·4)
Western Europe 79·5 (79·5–79·5) 84·2 (83·9–84·5) 73·0 (73·0–73·0) 79·5 (79·2–79·8) 68·2 (65·0–71·0) 71·8 (68·3–74·8) 64·3 (61·8–66·5) 69·4 (66·5–71·9)
Andorra 82·6 (80·8–84·6) 85·1 (83·6–86·7) 76·1 (74·7–77·3) 80·5 (79·4–81·7) 70·6 (67·0–74·1) 72·4 (68·6–75·8) 66·8 (63·9–69·5) 70·1 (67·1–72·8)
Austria 78·9 (78·8–79·0) 84·0 (83·4–84·6) 72·4 (72·3–72·5) 79·4 (78·8–80·1) 67·9 (64·7–70·6) 71·7 (68·2–74·8) 63·9 (61·4–66·0) 69·1 (66·2–71·8)
Belgium 79·3 (79·2–79·4) 83·8 (83·1–84·5) 72·7 (72·6–72·8) 78·9 (78·2–79·5) 67·8 (64·5–70·6) 70·9 (67·3–74·1) 63·9 (61·4–66·1) 68·3 (65·2–71·0)
Cyprus 78·3 (78·1–78·5) 85·2 (84·3–86·0) 73·6 (73·4–73·8) 78·5 (77·4–79·5) 67·2 (64·1–70·0) 72·8 (69·1–76·0) 64·9 (62·5–67·1) 68·8 (65·9–71·4)
Denmark 77·8 (77·6–77·9) 82·7 (81·9–83·4) 72·2 (72·1–72·4) 78·8 (78·1–79·5) 66·9 (63·7–69·5) 70·6 (67·2–73·6) 63·7 (61·2–65·8) 68·6 (65·6–71·3)
Finland 79·1 (78·9–79·3) 84·3 (83·6–84·9) 71·0 (70·9–71·2) 78·5 (77·8–79·2) 67·6 (64·2–70·5) 71·5 (67·9–74·8) 62·2 (59·6–64·4) 68·0 (64·9–70·7)
France 81·1 (81·0–81·1) 85·7 (85·1–86·3) 73·0 (72·9–73·0) 79·8 (79·2–80·4) 69·8 (66·5–72·6) 73·4 (69·9–76·5) 64·7 (62·2–66·8) 70·0 (67·2–72·5)
Germany 78·6 (78·5–78·6) 83·0 (81·8–84·2) 72·1 (72·1–72·2) 78·2 (76·9–79·5) 67·4 (64·2–70·2) 70·8 (67·2–74·1) 63·5 (61·0–65·7) 68·3 (65·2–70·9)
Greece 80·4 (80·3–80·5) 83·6 (83·0–84·2) 74·7 (74·6–74·8) 78·4 (77·8–79·1) 68·9 (65·6–71·8) 71·3 (67·8–74·4) 65·8 (63·3–68·0) 68·6 (65·8–71·1)
Iceland 80·2 (79·8–80·5) 85·9 (85·5–86·4) 75·6 (75·2–75·9) 79·8 (79·4–80·2) 68·5 (65·2–71·4) 73·1 (69·5–76·2) 66·3 (63·7–68·5) 69·6 (66·5–72·2)
Ireland 77·6 (77·4–77·8) 83·7 (82·9–84·4) 72·2 (72·1–72·4) 80·0 (79·3–80·7) 66·7 (63·6–69·5) 71·3 (67·7–74·4) 63·7 (61·2–65·9) 69·4 (66·3–72·0)
Israel 78·9 (78·8–79·1) 84·6 (83·9–85·2) 75·8 (75·6–76·0) 81·3 (80·6–81·9) 67·6 (64·4–70·4) 72·1 (68·6–75·2) 66·4 (63·7–68·7) 70·6 (67·6–73·4)
Italy 80·3 (80·2–80·4) 85·3 (84·7–85·9) 73·7 (73·7–73·8) 80·8 (80·2–81·4) 68·8 (65·6–71·7) 73·0 (69·5–76·1) 65·0 (62·5–67·2) 70·6 (67·7–73·3)
Luxembourg 78·9 (78·6–79·2) 83·3 (82·3–84·2) 71·8 (71·6–72·1) 80·0 (78·9–81·2) 67·0 (63·6–69·9) 70·4 (66·8–73·7) 62·7 (60·1–64·9) 69·0 (65·6–71·9)
Malta 78·8 (78·5–79·0) 83·0 (82·4–83·6) 74·2 (73·9–74·4) 78·9 (78·4–79·5) 67·7 (64·6–70·5) 70·9 (67·4–73·9) 65·3 (62·7–67·5) 68·7 (65·6–71·3)
Netherlands 80·1 (80·0–80·2) 83·1 (82·4–83·7) 73·8 (73·7–73·9) 79·9 (79·2–80·5) 68·4 (65·1–71·3) 70·7 (67·2–73·9) 64·9 (62·4–67·1) 69·6 (66·6–72·2)
Norway 80·0 (79·9–80·1) 84·2 (84·0–84·4) 73·4 (73·3–73·5) 80·5 (80·2–80·7) 68·1 (64·7–71·0) 71·1 (67·4–74·3) 64·0 (61·3–66·4) 69·3 (66·2–72·0)
Portugal 77·6 (77·5–77·7) 84·2 (83·6–84·8) 70·7 (70·5–70·8) 78·5 (77·9–79·2) 66·2 (62·9–69·0) 71·6 (68·0–74·7) 62·1 (59·6–64·2) 68·6 (65·6–71·2)
Spain 80·5 (80·4–80·6) 85·8 (85·3–86·3) 73·5 (73·4–73·5) 80·2 (79·7–80·8) 69·4 (66·3–72·1) 73·6 (70·0–76·7) 65·0 (62·5–67·1) 70·5 (67·7–72·9)
Sweden 80·5 (80·4–80·6) 84·2 (83·7–84·7) 74·9 (74·8–75·1) 80·8 (80·2–81·4) 68·8 (65·4–71·6) 71·4 (67·8–74·6) 66·0 (63·4–68·3) 70·4 (67·4–73·1)
Switzerland 81·1 (81·0–81·3) 85·7 (85·1–86·3) 74·4 (74·3–74·5) 82·1 (81·5–82·8) 69·0 (65·6–72·0) 72·7 (69·0–75·9) 65·1 (62·4–67·4) 71·2 (68·1–74·0)
UK 78·5 (78·4–78·5) 82·7 (82·6–82·8) 72·9 (72·9–73·0) 79·2 (79·0–79·3) 67·3 (64·0–70·0) 70·0 (66·5–73·1) 64·1 (61·6–66·3) 68·5 (65·5–71·1)
England 78·7 (78·7–78·7) 82·9 (82·8–83·0) 73·2 (73·1–73·2) 79·5 (79·4–79·6) 67·4 (64·2–70·2) 70·1 (66·5–73·2) 64·4 (61·8–66·5) 68·7 (65·6–71·3)
Northern Ireland 77·3 (77·0–77·6) 82·5 (81·5–83·4) 71·5 (71·3–71·7) 78·7 (77·7–79·8) 66·4 (63·3–69·0) 70·3 (67·0–73·5) 63·1 (60·6–65·2) 68·5 (65·5–71·3)
Scotland 76·8 (76·7–77·0) 81·2 (80·3–82·1) 71·2 (71·0–71·3) 76·9 (76·0–78·0) 65·8 (62·7–68·5) 69·3 (66·0–72·2) 62·5 (60·0–64·6) 66·8 (64·0–69·5)
Wales 78·6 (78·4–78·7) 82·5 (81·7–83·2) 72·9 (72·8–73·1) 78·3 (77·5–79·1) 67·3 (64·1–70·1) 70·4 (66·9–73·6) 64·1 (61·5–66·3) 68·1 (65·1–70·7)
Latin America and 
Caribbean
72·5 (72·3–72·6) 78·9 (78·6–79·2) 66·2 (66·0–66·4) 72·8 (72·4–73·2) 62·6 (59·8–65·0) 68·3 (65·2–70·8) 58·6 (56·3–60·5) 64·2 (61·7–66·3)
Andean Latin America 70·6 (70·0–71·2) 79·5 (78·4–80·6) 66·7 (66·1–67·3) 76·2 (74·9–77·4) 61·4 (58·8–63·8) 69·2 (66·1–72·0) 58·9 (56·5–60·9) 67·0 (64·3–69·6)
Bolivia 62·1 (60·8–63·3) 74·2 (72·1–76·6) 59·7 (58·5–61·0) 71·3 (68·8–73·9) 54·0 (51·5–56·3) 64·4 (61·2–67·7) 52·6 (50·2–54·6) 62·8 (59·8–65·8)
Ecuador 74·4 (74·1–74·6) 78·7 (77·5–79·9) 69·7 (69·5–70·0) 74·8 (73·3–76·1) 64·8 (62·0–67·3) 68·7 (65·6–71·4) 61·5 (59·0–63·5) 65·8 (63·0–68·2)
Peru 72·2 (71·3–73·2) 81·9 (80·1–83·7) 67·9 (66·9–68·9) 78·7 (76·8–80·8) 62·7 (59·8–65·3) 71·3 (68·1–74·5) 60·0 (57·6–62·2) 69·3 (66·2–72·4)
Caribbean 70·4 (69·9–70·8) 75·4 (74·4–76·4) 66·4 (65·9–66·8) 70·3 (69·3–71·4) 61·2 (58·5–63·6) 65·3 (62·5–67·9) 58·9 (56·7–60·9) 62·2 (59·7–64·5)
Antigua and Barbuda 77·9 (77·2–78·7) 78·7 (78·1–79·4) 70·8 (70·1–71·4) 75·3 (74·4–76·2) 67·3 (64·1–70·2) 68·1 (65·0–70·8) 62·6 (60·1–64·8) 66·4 (63·7–68·7)
The Bahamas 74·7 (74·3–75·1) 76·6 (75·4–77·9) 67·6 (67·2–68·0) 70·8 (69·6–72·1) 65·4 (62·7–67·7) 66·9 (63·9–69·5) 60·5 (58·5–62·3) 63·2 (60·7–65·5)
Barbados 76·1 (75·7–76·5) 78·6 (77·7–79·6) 71·2 (70·8–71·5) 75·5 (74·4–76·6) 66·7 (63·9–69·0) 68·6 (65·5–71·2) 63·8 (61·6–65·7) 67·2 (64·5–69·5)
Belize 73·8 (73·1–74·4) 77·4 (76·9–77·9) 70·3 (69·5–71·0) 71·2 (70·7–71·8) 64·0 (61·0–66·5) 67·0 (64·0–69·5) 62·4 (60·0–64·6) 63·1 (60·6–65·3)
Bermuda 78·3 (77·9–78·6) 85·7 (84·8–86·5) 69·7 (69·3–70·2) 77·1 (76·4–77·6) 68·5 (65·7–70·9) 74·3 (71·0–77·3) 62·5 (60·5–64·4) 68·5 (66·0–70·7)
Cuba 76·8 (76·6–76·9) 80·7 (79·3–82·1) 73·0 (72·9–73·1) 76·2 (74·6–77·7) 66·8 (63·9–69·4) 70·4 (67·4–73·2) 65·3 (63·0–67·2) 67·9 (65·4–70·5)
Dominica 75·3 (74·7–75·7) 75·4 (74·3–76·4) 70·4 (70·0–70·8) 70·4 (69·4–71·4) 65·6 (62·7–68·0) 65·8 (62·9–68·3) 62·7 (60·5–64·8) 62·6 (60·2–64·7)
Dominican Republic 74·4 (73·4–75·4) 76·8 (75·2–78·5) 69·6 (68·4–70·7) 69·8 (67·8–71·9) 64·6 (61·6–67·2) 66·8 (63·6–69·5) 61·5 (59·0–63·8) 62·0 (59·3–64·7)
Grenada 71·6 (71·0–72·1) 75·4 (74·7–76·2) 67·1 (66·6–67·6) 73·0 (72·3–73·6) 62·5 (59·8–64·9) 65·8 (62·9–68·3) 60·0 (57·9–61·9) 64·8 (62·2–66·9)
Guyana 69·0 (68·7–69·4) 72·2 (70·5–73·9) 62·4 (62·0–62·8) 66·4 (64·6–68·2) 59·6 (56·9–62·0) 62·4 (59·3–65·3) 54·9 (52·7–56·9) 58·6 (56·0–60·9)
(Table 1 continues on next page)
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Haiti 55·0 (53·6–56·5) 66·0 (63·3–68·8) 53·9 (52·3–55·5) 63·8 (61·4–66·4) 47·4 (44·9–49·8) 56·8 (53·6–59·9) 47·3 (44·9–49·5) 55·8 (52·7–58·6)
Jamaica 76·4 (75·7–77·1) 77·5 (75·4–79·4) 73·6 (73·0–74·3) 72·0 (69·8–74·1) 66·6 (63·5–69·0) 67·4 (64·2–70·3) 65·4 (62·9–67·5) 63·9 (61·0–66·6)
Puerto Rico 78·4 (78·2–78·6) 81·6 (80·9–82·3) 70·0 (69·8–70·1) 74·5 (73·7–75·4) 68·6 (65·8–71·1) 70·8 (67·7–73·6) 62·3 (60·0–64·1) 65·8 (63·1–68·1)
Saint Lucia 73·2 (72·8–73·6) 78·1 (77·2–78·9) 67·8 (67·4–68·2) 73·1 (72·2–74·0) 63·7 (61·1–66·2) 67·9 (64·9–70·6) 60·4 (58·3–62·3) 64·9 (62·5–67·0)
Saint Vincent and the 
Grenadines
72·9 (72·4–73·5) 75·4 (74·6–76·3) 69·1 (68·5–69·6) 69·6 (68·9–70·4) 63·5 (60·5–65·9) 65·5 (62·6–68·1) 61·4 (59·2–63·4) 61·7 (59·5–63·9)
Suriname 71·3 (70·5–72·2) 75·3 (74·0–76·6) 66·4 (65·4–67·4) 68·9 (67·2–70·7) 62·1 (59·4–64·5) 65·2 (62·2–68·0) 59·2 (56·9–61·3) 61·2 (58·7–63·7)
Trinidad and Tobago 72·5 (72·1–72·8) 77·6 (74·8–80·3) 67·5 (67·2–67·8) 71·1 (68·4–74·0) 63·0 (60·3–65·4) 67·2 (63·6–70·6) 60·1 (57·9–62·0) 63·0 (59·9–66·0)
Virgin Islands 76·2 (75·1–77·0) 78·8 (77·2–80·1) 69·0 (68·2–69·7) 69·5 (67·9–71·8) 66·9 (64·1–69·4) 69·0 (65·9–71·7) 61·9 (59·7–63·7) 62·2 (59·7–64·9)
Central Latin America 74·0 (73·9–74·2) 79·4 (79·0–79·8) 68·1 (67·9–68·3) 73·3 (72·8–73·8) 64·4 (61·8–66·8) 69·1 (66·1–71·6) 60·6 (58·4–62·4) 65·0 (62·5–67·1)
Colombia 74·8 (74·6–75·0) 82·7 (81·4–83·9) 68·1 (67·9–68·4) 77·4 (75·9–79·0) 65·1 (62·4–67·6) 72·1 (68·9–75·0) 60·7 (58·6–62·5) 68·7 (66·1–71·4)
Costa Rica 78·7 (78·5–79·0) 82·7 (81·9–83·4) 74·4 (74·2–74·6) 76·3 (75·5–77·1) 68·4 (65·4–71·0) 71·9 (68·8–74·4) 66·4 (64·1–68·3) 67·9 (65·2–70·0)
El Salvador 73·6 (73·2–73·9) 78·3 (76·0–80·4) 64·9 (64·5–65·2) 69·3 (66·7–72·0) 64·0 (61·4–66·5) 68·3 (65·0–71·3) 57·2 (55·0–59·2) 61·5 (58·4–64·3)
Guatemala 65·7 (65·3–66·2) 76·0 (74·5–77·4) 60·4 (59·9–60·9) 69·1 (67·4–70·8) 57·1 (54·5–59·3) 66·1 (63·1–69·0) 53·5 (51·4–55·3) 61·2 (58·7–63·7)
Honduras 71·2 (69·6–72·8) 75·0 (72·4–78·2) 66·6 (64·8–68·6) 72·9 (70·2–75·6) 61·7 (58·7–64·3) 65·3 (61·8–68·7) 59·0 (56·4–61·7) 64·6 (61·4–67·7)
Mexico 74·3 (74–74·6·0) 78·5 (78·2–78·8) 68·6 (68·2–68·9) 72·6 (72·3–72·9) 64·7 (62·1–67·0) 68·2 (65·3–70·7) 61·0 (58·9–62·9) 64·2 (61·8–66·3)
Nicaragua 74·1 (73·2–74·9) 80·6 (79·4–82·0) 69·7 (68·6–70·7) 76·9 (75·3–78·4) 63·5 (60·5–66·2) 69·8 (66·6–72·7) 61·2 (58·6–63·4) 67·8 (65·1–70·5)
Panama 78·1 (77·7–78·4) 81·7 (80·9–82·5) 73·8 (73·4–74·1) 77·0 (76·2–77·9) 67·8 (64·8–70·4) 70·9 (67·8–73·6) 65·7 (63·2–67·7) 68·1 (65·4–70·5)
Venezuela 75·1 (75·0–75·2) 79·6 (77·7–81·5) 69·2 (69·1–69·3) 71·2 (68·9–73·7) 65·5 (62·9–67·9) 69·3 (66·0–72·3) 61·8 (59·6–63·6) 63·4 (60·5–66·1)
Tropical Latin America 71·7 (71·4–72·0) 79·1 (78·8–79·3) 64·0 (63·7–64·4) 72·0 (71·8–72·3) 61·2 (58·2–63·8) 67·8 (64·6–70·5) 56·3 (54·0–58·3) 63·1 (60·5–65·3)
Brazil 71·6 (71·2–71·9) 79·1 (78·8–79·3) 63·8 (63·4–64·2) 72·0 (71·7–72·2) 61·1 (58·1–63·7) 67·7 (64·6–70·5) 56·1 (53·9–58·1) 63·1 (60·5–65·3)
Paraguay 76·4 (75·6–77·2) 78·9 (76·8–81·2) 72·3 (71·4–73·0) 73·4 (71·0–76·0) 65·5 (62·3–68·4) 67·9 (64·4–71·0) 63·3 (60·7–65·7) 64·4 (61·1–67·4)
North Africa and Middle 
East
68·2 (67·9–68·6) 76·8 (76·4–77·3) 64·5 (64·1–64·9) 72·0 (71·5–72·5) 57·5 (54·5–60·2) 64·8 (61·4–67·7) 55·9 (53·5–58·1) 62·1 (59·4–64·5)
Afghanistan 52·0 (49·9–54·3) 63·2 (60·6–65·8) 53·1 (51·0–55·2) 63·6 (61·3–65·9) 42·9 (40·0–45·9) 52·5 (49·2–56·2) 44·1 (41·1–46·8) 53·6 (50·4–56·5)
Algeria 73·2 (72·3–74·1) 78·5 (77·9–79·1) 70·3 (69·4–71·2) 77·0 (76·4–77·6) 61·9 (58·6–64·9) 66·6 (63·1–69·6) 60·9 (58·2–63·4) 66·4 (63·4–69·0)
Bahrain 71·9 (71·4–72·4) 80·4 (79·5–81·4) 69·4 (69·0–70·0) 78·8 (77·8–79·8) 60·9 (57·8–63·6) 67·6 (64·0–70·9) 60·5 (58·0–62·7) 67·8 (64·7–70·8)
Egypt 66·6 (66·1–67·1) 74·3 (72·9–75·8) 62·6 (62·1–63·0) 68·0 (66·6–69·3) 56·3 (53·3–58·9) 63·0 (59·8–66·0) 54·5 (52·1–56·6) 59·3 (56·7–61·7)
Iran 70·8 (70·1–71·4) 79·4 (79·3–79·5) 65·7 (65·0–66·3) 75·5 (75·4–75·6) 59·6 (56·4–62·4) 66·5 (63·0–69·7) 56·9 (54·5–59·3) 65·0 (62·1–67·5)
Iraq 67·6 (65·8–69·3) 78·8 (78·1–79·6) 64·4 (62·5–66·4) 74·8 (73·9–75·6) 56·6 (53·4–59·7) 65·7 (61·9–69·0) 54·8 (51·9–57·7) 63·3 (60·1–66·2)
Jordan 71·7 (70·3–73·0) 81·1 (79·8–82·3) 70·5 (69·0–71·9) 77·8 (76·3–79·2) 60·9 (57·8–63·7) 68·5 (65·0–71·7) 61·1 (58·3–63·8) 67·1 (63·8–70·0)
Kuwait 77·1 (76·9–77·4) 87·2 (86·7–87·7) 73·3 (73·1–73·6) 80·7 (80·0–81·3) 65·3 (62·0–68·2) 73·1 (69·1–76·6) 63·7 (61·0–66·1) 69·4 (66·1–72·2)
Lebanon 73·4 (72·2–75·0) 80·0 (79·4–80·7) 67·3 (66·1–68·8) 75·8 (75·1–76·4) 62·1 (58·9–65·2) 67·4 (63·9–70·5) 58·3 (55·8–60·7) 65·0 (62·0–67·7)
Libya 73·5 (71·7–75·2) 75·0 (73·3–76·9) 70·8 (69·0–72·6) 71·1 (69·4–73·2) 62·3 (59·0–65·4) 63·5 (60·0–66·7) 61·2 (58·1–63·9) 60·9 (58·1–64·1)
Morocco 66·2 (65·3–67·2) 74·7 (72·7–76·8) 67·1 (66·1–68·1) 73·2 (71·0–75·5) 56·0 (53·1–58·6) 63·3 (59·9–66·7) 57·8 (55·0–60·1) 63·0 (59·7–66·2)
Oman 71·4 (69·2–73·7) 79·4 (78·2–81·2) 66·9 (64·4–69·4) 75·5 (73·3–77·9) 59·6 (55·8–63·1) 66·9 (63·1–70·3) 57·8 (54·7–61·0) 65·0 (61·7–68·5)
Palestine 72·6 (70·7–74·5) 78·0 (77·3–78·9) 68·5 (66·7–70·7) 75·6 (74·7–76·4) 61·1 (57·6–64·3) 65·6 (62·1–68·7) 59·1 (56·0–62·1) 64·6 (61·6–67·4)
Qatar 72·8 (71·2–74·3) 81·7 (79·8–83·5) 70·7 (69·1–72·4) 79·6 (77·7–81·6) 61·7 (58·7–64·6) 68·7 (65·0–72·1) 61·0 (58·0–63·8) 68·1 (64·7–71·5)
Saudi Arabia 73·6 (71·6–75·8) 79·4 (78·0–80·2) 70·3 (68·0–72·5) 75·3 (73·9–76·6) 62·2 (58·8–65·5) 67·8 (64·4–70·7) 61·1 (57·9–64·2) 65·4 (62·7–68·2)
Sudan 59·9 (58·0–61·7) 72·0 (69·5–74·7) 57·4 (55·6–59·1) 68·8 (66·4–71·5) 50·5 (47·3–53·4) 60·9 (57·4–64·3) 49·6 (47·0–52·1) 59·4 (56·2–62·6)
Syria 72·3 (71·2–73·4) 75·0 (74·0–76·3) 67·7 (66·3–69·0) 65·5 (63·8–67·2) 61·2 (58·1–64·0) 63·5 (60·2–66·5) 59·1 (56·4–61·5) 56·7 (54·0–59·3)
Tunisia 74·5 (73·9–75·0) 80·7 (78·5–83·0) 70·8 (70·3–71·5) 76·1 (73·7–78·6) 63·5 (60·4–66·2) 69·0 (65·3–72·2) 61·4 (58·8–63·7) 65·8 (62·5–69·1)
Turkey 72·1 (71·3–72·8) 83·0 (82·0–84·0) 65·6 (64·8–66·3) 75·2 (74·1–76·3) 60·8 (57·5–63·6) 70·3 (66·8–73·6) 57·3 (55·0–59·4) 65·7 (62·9–68·2)
United Arab Emirates 73·0 (71·2–75·0) 76·9 (74·7–79·2) 70·2 (68·2–72·4) 71·7 (69·3–74·0) 62·1 (58·7–65·3) 65·6 (62·2–69·0) 60·8 (57·9–63·7) 62·0 (58·8–65·0)
Yemen 59·8 (57·3–62·6) 70·3 (67·6–72·7) 57·5 (55·0–60·1) 66·0 (63·6–68·3) 48·6 (45·0–52·3) 57·8 (54·1–61·7) 48·5 (45·3–51·7) 55·8 (52·6–59·1)
South Asia 60·3 (59·7–61·0) 70·2 (69·7–70·7) 59·0 (58·4–59·5) 67·9 (67·4–68·4) 50·9 (48·2–53·3) 59·6 (56·7–62·1) 51·5 (49·3–53·4) 59·4 (57·1–61·5)
Bangladesh 59·5 (58·5–60·6) 74·6 (73·1–76·0) 57·3 (56·4–58·3) 71·8 (70·3–73·3) 50·5 (47·9–52·9) 63·3 (60·1–66·3) 50·4 (48·3–52·3) 62·9 (60·2–65·2)
Bhutan 59·9 (57·8–62·1) 76·0 (73·9–78·1) 60·0 (57·9–62·3) 72·3 (69·8–74·8) 50·6 (47·6–53·7) 64·9 (61·6–68·2) 52·4 (49·6–55·0) 63·5 (60·4–66·4)
India 60·4 (59·6–61·1) 70·2 (69·5–70·8) 58·9 (58·3–59·6) 67·8 (67·2–68·3) 50·8 (48·1–53·2) 59·5 (56·5–62·1) 51·4 (49·2–53·4) 59·3 (56·9–61·4)
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Nepal 59·0 (57·3–60·9) 73·3 (71·5–75·1) 57·7 (56·0–59·5) 68·7 (67·2–70·6) 49·7 (47·0–52·4) 62·3 (59·3–65·2) 50·0 (47·3–52·4) 60·1 (57·4–62·6)
Pakistan 61·6 (60·8–62·4) 67·4 (65·1–70·1) 61·7 (60·9–62·6) 66·3 (63·8–69·1) 52·5 (50·0–55·0) 57·8 (54·6–60·9) 54·1 (51·8–56·2) 58·2 (55·3–61·1)
Southeast Asia, 
east Asia, and Oceania
69·9 (69·5–70·3) 78·6 (78·2–78·9) 65·8 (65·3–66·2) 72·9 (72·5–73·3) 61·1 (58·7–63·2) 68·4 (65·6–70·9) 58·8 (56·9–60·5) 65·0 (62·7–66·9)
East Asia 70·8 (70·3–71·3) 79·9 (79·4–80·3) 67·0 (66·4–67·6) 74·5 (74·0–74·9) 62·0 (59·6–64·1) 69·7 (66·9–72·1) 60·1 (58·2–61·9) 66·6 (64·4–68·5)
China 70·7 (70·1–71·2) 79·9 (79·4–80·4) 66·9 (66·3–67·5) 74·5 (74·1–75·0) 61·9 (59·5–63·9) 69·7 (66·9–72·1) 60·0 (58·1–61·8) 66·6 (64·4–68·6)
North Korea 74·3 (72·1–76·5) 75·0 (72·9–77·2) 68·5 (66·7–70·7) 68·6 (67·1–70·2) 64·7 (61·8–67·6) 65·2 (62·3–68·0) 61·8 (59·2–64·3) 61·6 (59·2–64·0)
Taiwan (province of 
China)
77·3 (77·2–77·4) 83·3 (82·6–83·9) 72·1 (72·1–72·2) 76·8 (76·1–77·5) 67·5 (64·9–69·9) 71·8 (68·7–74·5) 64·9 (62·8–66·7) 68·2 (65·8–70·3)
Oceania 60·7 (58·8–62·6) 63·4 (61·1–65·5) 55·3 (53·5–57·3) 58·2 (55·9–60·6) 52·4 (49·7–54·9) 54·4 (51·4–57·0) 48·9 (46·5–51·2) 51·1 (48·3–53·8)
American Samoa 74·9 (74·2–75·8) 73·8 (72·9–74·8) 67·6 (66·9–68·4) 70·0 (68·5–71·7) 64·4 (61·5–67·0) 63·2 (60·1–66) 59·5 (57·0–61·6) 61·2 (58·5–63·8)
Federated States of 
Micronesia
65·5 (63·4–67·7) 69·6 (67·2–71·7) 61·7 (59·2–64·2) 65·0 (62·8–67·2) 56·8 (53·6–59·7) 59·7 (56·2–62·7) 54·4 (51·5–57·3) 56·9 (54·0–59·5)
Fiji 70·1 (68·7–71·7) 70·4 (68·4–72·5) 65·6 (64·0–67·0) 65·9 (64·2–67·7) 60·7 (57·8–63·3) 60·5 (57·3–63·6) 57·5 (54·9–59·9) 57·9 (55·2–60·3)
Guam 77·0 (76·4–77·5) 76·4 (75·3–77·5) 70·8 (70·3–71·3) 70·2 (69·2–71·3) 66·8 (63·9–69·4) 65·8 (62·6–68·6) 63·1 (60·8–65·1) 61·8 (59·2–64·1)
Kiribati 61·4 (60·0–62·6) 66·3 (63·9–68·9) 55·7 (54·5–57·0) 58·6 (56·2–61·0) 53·0 (50·3–55·4) 56·7 (53·6–59·8) 49·3 (47·2–51·3) 51·4 (48·7–54·1)
Marshall Islands 66·4 (65·7–67·0) 66·8 (64·5–69) 59·9 (59·2–60·6) 62·6 (60·6–64·6) 57·6 (55·0–59·9) 57·7 (54·7–60·7) 53·3 (51·4–55·1) 55·3 (52·7–57·9)
Northern Mariana 
Islands
76·0 (74·3–78·0) 79·2 (78·0–80·2) 72·9 (70·7–74·6) 73·6 (72·3–75·0) 66·0 (63·0–68·9) 68·0 (64·7–71·0) 64·6 (61·8–67·1) 64·6 (61·8–66·9)
Papua New Guinea 57·3 (55·0–59·9) 61·2 (58·6–63·9) 52·0 (49·7–54·5) 56·2 (53·6–59·2) 49·5 (46·7–52·2) 52·6 (49·5–55·3) 46·0 (43·3–48·6) 49·4 (46·4–52·4)
Samoa 73·8 (71·8–75·9) 74·5 (72·9–76·7) 68·1 (66·0–70·2) 71·3 (70·0–72·7) 64·0 (60·7–66·8) 64·0 (61·0–67·0) 60·1 (57·4–62·8) 62·5 (59·8–65·0)
Solomon Islands 63·5 (61·0–65·8) 67·5 (65·4–69·4) 59·9 (57·2–62·5) 64·1 (62·0–66·3) 55·1 (52·1–58·0) 58·0 (54·8–60·9) 53·1 (50·2–55·9) 56·5 (53·7–59·1)
Tonga 72·1 (71·2–73·1) 75·1 (73·3–77·2) 68·3 (67·6–69·1) 68·6 (66·7–70·1) 62·1 (59·2–64·7) 64·3 (61·0–67·5) 60·5 (58·0–62·6) 60·5 (57·7–62·8)
Vanuatu 65·8 (63·1–68·3) 67·8 (65·0–70·2) 59·7 (57·0–62·6) 62·1 (59·2–65·0) 56·5 (53·1–59·7) 57·9 (54·6–60·9) 52·9 (49·8–56·0) 54·9 (51·9–57·8)
Southeast Asia 67·8 (67·4–68·3) 75·8 (75·2–76·3) 62·6 (62·0–63·0) 69·4 (68·9–70·0) 58·9 (56·3–61·1) 65·8 (63·0–68·3) 55·2 (53·1–57·2) 61·5 (59·1–63·5)
Cambodia 59·8 (58·6–61·1) 72·7 (70·6–74·2) 55·3 (54·0–56·6) 66·8 (65·3–68·3) 51·4 (48·7–53·8) 62·6 (59·6–65·5) 48·4 (46·2–50·5) 58·7 (56·1–61·1)
Indonesia 65·4 (64·8–66·0) 73·9 (73·0–74·7) 62·4 (61·8–63·0) 69·2 (68·4–70·1) 56·8 (54·3–58·9) 64·0 (61·2–66·4) 55·0 (52·9–57·0) 61·4 (59·0–63·6)
Laos 54·3 (52·4–56·5) 70·3 (68·3–72·3) 49·6 (47·4–51·7) 65·0 (63·0–67·1) 47·4 (44·6–49·9) 61·3 (58·3–64·2) 44·3 (42·0–46·6) 57·8 (55·2–60·4)
Malaysia 73·7 (73·6–73·8) 77·3 (76·4–78·4) 69·2 (69·1–69·2) 72·4 (71·3–73·5) 64·5 (61·9–66·8) 67·7 (65·0–70·2) 61·6 (59·4–63·5) 64·4 (61·9–66·7)
Maldives 64·6 (64·1–65·0) 83·4 (82·6–84·1) 65·5 (64·9–66·1) 79·9 (79·2–80·6) 55·5 (52·9–57·8) 72·0 (68·7–74·9) 57·6 (55·3–59·7) 70·4 (67·7–72·9)
Mauritius 74·2 (73·9–74·5) 78·1 (77·2–79·0) 66·3 (66·1–66·5) 71·5 (70·6–72·5) 64·3 (61·4–66·8) 67·2 (63·9–70·0) 58·5 (56·2–60·5) 62·5 (59·9–64·8)
Myanmar 58·4 (56·1–60·8) 72·2 (70·3–74·2) 52·5 (50·0–54·9) 64·9 (63·2–66·7) 50·4 (47·7–53·4) 62·4 (59·4–65·4) 46·2 (43·5–48·8) 57·4 (55·1–59·8)
Philippines 71·4 (70·7–72·2) 73·1 (71·2–75·0) 64·6 (63·7–65·6) 66·6 (64·7–68·6) 61·7 (58·9–64·1) 63·5 (60·5–66·2) 56·5 (54·1–58·6) 58·7 (56·1–61·4)
Sri Lanka 74·8 (74·5–75·2) 81·1 (79·6–83·3) 65·6 (65·3–65·9) 73·8 (71·7–76·0) 64·8 (61·8–67·3) 70·6 (67·1–73·9) 58·2 (56·0–60·1) 65·2 (62·2–68·0)
Seychelles 75·6 (75·1–76·1) 77·7 (77·0–78·4) 66·1 (65·7–66·5) 70·1 (69·5–70·7) 66·3 (63·5–68·6) 67·9 (65·1–70·4) 59·3 (57·3–61·1) 62·4 (60·1–64·4)
Thailand 74·3 (73·8–74·8) 82·0 (80·9–83·1) 67·4 (66·7–68·1) 74·3 (72·9–75·9) 64·9 (62·1–67·2) 71·3 (68·2–74·1) 59·6 (57·4–61·7) 65·7 (63·0–68·3)
Timor-Leste 60·7 (58·8–62·9) 73·0 (71·3–74·8) 59·7 (58·0–61·4) 68·8 (67·3–70·7) 52·1 (49·2–55·0) 63·0 (59·8–65·9) 51·3 (48·6–54·0) 59·7 (56·8–62·5)
Vietnam 72·7 (71·4–74·3) 79·2 (77·8–80·9) 64·9 (63·5–66·5) 70·0 (68·3–71·2) 63·1 (60·2–66·0) 69·2 (66·2–72·3) 57·8 (55·2–60·2) 62·4 (60·0–64·6)
Sub-Saharan Africa 55·7 (55·0–56·3) 66·2 (65·4–67·0) 51·6 (51·0–52·3) 61·7 (60·8–62·4) 47·6 (45·2–49·7) 56·8 (54·1–59·3) 44·8 (42·8–46·7) 53·7 (51·3–55·9)
Central sub-Saharan 
Africa
54·6 (53·4–56·1) 64·4 (62·7–66·0) 50·1 (48·8–51·4) 60·3 (58·7–62·0) 46·0 (43·3–48·3) 54·7 (51·9–57·4) 43·1 (40·7–45·3) 52·1 (49·2–54·7)
Angola 50·6 (48·5–52·9) 66·7 (64·5–68·9) 45·5 (43·3–47·6) 61·7 (59·7–64·0) 43·0 (40·1–45·7) 56·8 (53·5–59·8) 39·4 (37·0–41·8) 53·3 (50·3–56·3)
Central African 
Republic
50·1 (48·4–51·8) 54·9 (52·0–58·0) 44·6 (42·9–46·3) 49·1 (46·5–51·7) 42·5 (39·9–44·7) 47·0 (43·7–50·2) 38·5 (36·3–40·8) 42·8 (40·1–45·6)
Congo (Brazzaville) 56·2 (54·2–58·1) 62·7 (60·2–65·6) 51·5 (49·4–53·5) 62·6 (60·4–64·8) 48·0 (45·2–50·7) 53·8 (50·7–56·9) 44·6 (42·2–47·2) 54·3 (51·5–57·3)
Democratic Republic of 
the Congo
56·0 (54·1–58·0) 64·3 (62·0–66·7) 51·8 (50·0–53·7) 60·4 (58·2–62·7) 46·9 (43·8–49·7) 54·6 (51·4–57·6) 44·4 (41·8–47·1) 52·0 (48·9–55·2)
Equatorial Guinea 50·8 (48·3–53·5) 66·4 (62·6–70·5) 45·6 (43·0–48·3) 64·3 (61·3–67·1) 43·2 (40·3–46·0) 56·9 (53·1–60·8) 39·5 (36·8–42·1) 55·6 (52·3–58·9)
Gabon 64·0 (62·3–65·7) 72·1 (69·8–74·4) 56·4 (54·8–58·0) 65·1 (63·3–66·7) 54·3 (51·3–57·2) 61·2 (57·7–64·4) 49·0 (46·5–51·4) 56·6 (53·8–59·1)
Eastern sub-Saharan 
Africa
52·8 (52·3–53·4) 67·4 (66·8–68·1) 48·8 (48·0–49·5) 62·5 (61·7–63·3) 45·7 (43·5–47·5) 58·3 (55·6–60·7) 42·6 (40·8–44·4) 54·9 (52·6–57·0)
(Table 1 continues on next page)
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Life expectancy at birth HALE at birth
Females Males Females Males
1990 2017 1990 2017 1990 2017 1990 2017
(Continued from previous page)
Burundi 50·5 (48·7–52·4) 63·6 (61·3–65·9) 46·9 (45·0–48·8) 59·7 (57·3–62·2) 44·2 (41·8–46·5) 55·5 (52·7–58·3) 41·7 (39·6–43·9) 52·3 (49·3–55·4)
Comoros 59·4 (57·5–61·6) 70·0 (67·8–72·3) 56·9 (54·9–58·8) 67·1 (65·0–69·2) 51·4 (48·6–54·1) 61·0 (58·0–63·9) 49·6 (47·0–52·0) 58·9 (56·1–61·6)
Djibouti 61·4 (58·8–64·1) 68·9 (65·3–72·0) 58·9 (56·3–61·5) 66·0 (63·1–68·8) 53·7 (50·7–56·7) 60·3 (56·9–63·8) 52·2 (49·2–54·9) 58·5 (55·5–61·5)
Eritrea 43·6 (42·4–44·7) 65·9 (63·4–69·0) 30·6 (29·9–31·4) 59·2 (56·4–61·9) 37·0 (34·8–39·0) 57·0 (53·8–60·4) 26·2 (24·7–27·5) 51·6 (48·7–54·4)
Ethiopia 48·8 (47·8–49·9) 70·4 (69·3–71·5) 45·6 (44·4–46·8) 66·7 (65·6–67·7) 42·2 (40·0–44·1) 60·8 (57·9–63·4) 39·9 (37·8–41·7) 58·5 (55·9–60·8)
Kenya 63·2 (62·4–63·9) 68·8 (67·9–69·5) 60·6 (59·9–61·3) 63·2 (62·4–63·9) 55·0 (52·6–57·3) 59·7 (57·0–62·1) 53·4 (51·1–55·4) 55·7 (53·4–57·7)
Madagascar 57·0 (55·8–58·2) 64·8 (62·3–67·5) 53·9 (52·7–55·1) 62·2 (59·7–64·8) 49·3 (46·9–51·5) 56·3 (53·3–59·3) 47·0 (44·7–48·9) 54·6 (51·7–57·7)
Malawi 50·5 (48·9–52·0) 66·9 (64·9–69·0) 46·7 (44·9–48·4) 59·6 (57·9–61·5) 43·8 (41·4–45·9) 57·8 (54·7–60·6) 40·8 (38·4–43·0) 52·4 (50·0–54·8)
Mozambique 52·6 (51·3–54·1) 62·0 (59·4–64·5) 48·0 (46·7–49·4) 54·8 (52·7–57·0) 45·3 (42·8–47·5) 53·4 (50·2–56·6) 41·6 (39·4–43·6) 47·9 (45·2–50·4)
Rwanda 51·4 (50·1–52·7) 70·8 (69·1–72·7) 47·4 (46·1–48·7) 65·8 (64·0–67·6) 45·0 (42·9–47·0) 61·3 (58·3–64·2) 42·1 (40·2–44·0) 57·7 (55·1–60·4)
Somalia 52·4 (49·9–55·0) 60·6 (57·7–63·3) 48·0 (45·5–50·5) 56·5 (53·7–59·3) 45·3 (42·5–48·2) 52·7 (49·5–55·6) 42·4 (39·8–45·1) 49·9 (46·7–52·9)
South Sudan 53·5 (50·8–56·3) 61·8 (58·6–65·1) 49·3 (46·6–52·0) 56·9 (53·9–60·0) 44·9 (41·7–47·8) 52·3 (48·5–55·8) 42·4 (39·5–45·2) 49·2 (45·9–52·3)
Tanzania 56·5 (54·9–58·0) 68·9 (67·2–70·6) 53·2 (51·2–55·1) 64·6 (62·9–66·3) 48·8 (46·3–51·1) 59·7 (56·8–62·5) 46·6 (44·1–48·9) 56·8 (54·1–59·3)
Uganda 51·1 (48·8–53·4) 69·2 (67·2–71·1) 44·3 (40·3–48·4) 62·3 (60·5–64·2) 43·7 (40·9–46·6) 59·5 (56·5–62·4) 38·0 (34·4–41·8) 54·5 (52·0–57·0)
Zambia 52·1 (50·2–53·7) 66·3 (64·5–68·3) 49·3 (46·6–51·5) 60·4 (58·5–62·3) 45·3 (42·9–47·6) 57·4 (54·3–60·1) 43·6 (40·8–46·1) 53·1 (50·7–55·4)
Southern sub-Saharan 
Africa
67·9 (67·1–68·6) 68·5 (67·6–69·3) 60·3 (59·3–61·1) 61·5 (60·7–62·2) 57·8 (55·0–60·3) 58·3 (55·4–60·8) 52·6 (50·2–54·6) 53·6 (51·4–55·6)
Botswana 68·8 (66·3–71·3) 71·0 (68·8–72·5) 58·6 (55·2–61·3) 67·0 (64·1–69·2) 58·4 (55·2–61·5) 60·0 (56·8–63·0) 51·0 (47·8–54·0) 57·7 (54·4–60·7)
Lesotho 65·2 (63·5–67·0) 59·3 (56·3–62·7) 56·0 (54·3–57·6) 50·3 (48·1–52·7) 55·3 (52·2–58·1) 50·3 (46·8–53·6) 49·0 (46·6–51·1) 43·9 (41·3–46·4)
Namibia 65·4 (63·9–66·7) 70·7 (67·5–73·5) 58·2 (56·0–59·6) 62·3 (60·3–64·3) 55·8 (53·0–58·4) 60·1 (56·5–63·6) 50·5 (47·9–52·8) 54·2 (51·4–56·8)
South Africa 68·7 (68·1–69·4) 69·7 (68·6–70·6) 61·5 (60·8–62·1) 62·8 (62·0–63·6) 58·4 (55·7–60·9) 59·3 (56·3–61·9) 53·5 (51·3–55·5) 54·7 (52·5–56·8)
Swaziland (eSwatini) 66·5 (64·9–68·2) 65·1 (62·1–68·4) 57·9 (56·1–59·7) 54·9 (52·6–57·6) 56·7 (53·9–59·6) 55·1 (51·5–58·5) 50·7 (48·4–53·0) 47·8 (45·1–50·4)
Zimbabwe 64·7 (61·2–67·3) 64·4 (62·1–66·6) 57·5 (52·7–60·7) 58·1 (56·3–60·1) 55·4 (51·9–58·6) 55·1 (52·1–58·1) 50·4 (46·4–53·8) 51·1 (48·6–53·4)
Western sub-Saharan 
Africa
56·2 (55·0–57·4) 65·3 (63·6–66·9) 53·3 (52·0–54·5) 61·7 (60·2–62·9) 47·8 (45·1–50·1) 56·0 (53·0–58·7) 45·9 (43·5–48·1) 53·5 (50·9–56·0)
Benin 57·5 (56·0–58·9) 66·6 (64·2–69·1) 53·0 (51·4–54·4) 62·6 (60·1–65·0) 48·4 (45·5–51·2) 57·2 (54·1–60·5) 45·3 (42·6–47·8) 54·5 (51·5–57·5)
Burkina Faso 52·4 (51·0–53·8) 64·4 (62·6–66·3) 49·1 (47·5–50·8) 58·9 (56·9–61·0) 44·4 (41·8–46·8) 55·4 (52·5–58·2) 41·5 (38·8–44·0) 51·5 (48·8–54·1)
Cameroon 59·2 (58·0–60·4) 65·1 (62·7–67·8) 56·2 (55·0–57·4) 61·0 (58·6–63·5) 50·1 (47·4–52·6) 56·0 (52·6–59·0) 48·1 (45·6–50·3) 53·2 (50·2–56·1)
Cape Verde 73·5 (73·0–74·0) 79·0 (78·2–80·1) 66·4 (66·0–66·9) 72·5 (71·3–73·7) 63·0 (60·0–65·6) 68·1 (65·0–70·9) 58·2 (55·8–60·3) 63·6 (60·9–66·1)
Chad 54·7 (53·3–56·2) 61·6 (59·2–64·2) 52·0 (50·4–53·6) 58·6 (56·4–60·8) 46·2 (43·6–48·7) 52·5 (49·1–55·6) 44·8 (42·5–47·2) 50·7 (47·8–53·4)
Côte d’Ivoire 58·0 (55·5–59·9) 65·3 (62·8–67·7) 52·1 (48·7–54·4) 60·1 (57·8–62·3) 48·9 (45·7–51·7) 56·1 (52·8–59·1) 45·1 (41·5–47·7) 52·6 (49·9–55·3)
The Gambia 62·5 (60·4–64·8) 67·9 (65·6–70·2) 57·8 (55·5–60·2) 63·8 (62·0–65·8) 53·1 (49·9–56·2) 57·9 (54·6–61·0) 50·0 (47·1–53·0) 55·6 (52·9–58·2)
Ghana 60·7 (58·8–62·6) 68·4 (66·7–70·3) 57·8 (55·9–59·8) 62·6 (61·0–64·3) 52·1 (49·2–54·7) 59·3 (56·4–62·1) 50·3 (47·7–52·8) 54·8 (52·0–57·3)
Guinea 52·3 (50·8–53·8) 62·2 (60·3–64·2) 51·6 (50·1–53·0) 59·3 (57·2–61·4) 44·7 (42·2–47·1) 53·8 (50·9–56·4) 44·8 (42·6–46·9) 51·9 (49·1–54·5)
Guinea-Bissau 52·1 (49·9–54·5) 62·6 (60·3–64·9) 45·5 (43·3–47·6) 57·4 (55·1–59·7) 44·6 (41·7–47·4) 53·9 (50·8–56·8) 39·8 (37·5–42·2) 50·2 (47·4–52·8)
Liberia 51·3 (49·5–53·1) 65·1 (63·1–67·4) 46·8 (45·3–48·4) 63·7 (61·5–65·8) 43·4 (40·6–45·8) 54·7 (51·3–57·8) 39·9 (37·6–42·3) 54·0 (50·9–57·3)
Mali 49·5 (48·3–50·6) 63·0 (61·1–64·9) 49·2 (48·0–50·5) 61·0 (58·7–63·2) 42·0 (39·6–44·2) 53·9 (50·9–56·8) 42·1 (39·6–44·2) 52·5 (49·4–55·3)
Mauritania 60·2 (58·7–61·7) 71·0 (68·9–73·0) 59·0 (57·6–60·5) 70·0 (68·0–72·3) 51·8 (49·0–54·0) 61·2 (58·2–64·1) 51·4 (48·9–53·8) 60·7 (57·5–63·7)
Niger 47·4 (45·8–49·0) 63·6 (61·4–66·0) 45·8 (44·3–47·3) 61·1 (58·8–63·5) 40·7 (38·4–43·0) 54·9 (52·2–57·8) 40·0 (37·9–42·1) 53·5 (50·6–56·5)
Nigeria 57·1 (54·5–59·5) 65·8 (62·3–69·1) 54·0 (51·5–56·4) 62·8 (59·7–65·2) 48·5 (45·3–51·6) 56·2 (52·3–59·6) 46·5 (43·6–49·4) 54·0 (50·6–57·2)
São Tomé and Príncipe 65·6 (64·3–67·0) 71·8 (70·1–73·8) 62·5 (61·3–63·7) 68·1 (66·5–69·8) 56·5 (53·7–59·0) 62·3 (59·2–65·1) 54·4 (52·0–56·6) 59·6 (56·9–62·3)
Senegal 60·4 (59·0–61·8) 70·0 (68·3–71·9) 56·6 (55·4–57·8) 66·1 (64·5–67·9) 51·5 (48·7–54·1) 60·1 (57·2–62·9) 49·1 (46·6–51·3) 57·7 (54·9–60·3)
Sierra Leone 52·3 (50·4–54·3) 61·4 (59·4–63·7) 48·1 (46·3–50·0) 59·5 (57·2–61·7) 44·7 (41·9–47·2) 52·7 (49·9–55·5) 41·6 (39·3–43·7) 51·5 (48·5–54·3)
Togo 59·3 (57·7–60·9) 67·2 (65·0–69·6) 56·0 (54·3–57·7) 61·4 (59·1–63·8) 50·5 (47·7–53·2) 57·8 (54·6–60·9) 48·6 (46·1–51·0) 53·8 (51·0–56·7)
Data in parentheses are 95% uncertainty intervals. Super-regions, regions, and countries are listed alphabetically. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. HALE=healthy life expectancy. 
SDI=Socio-demographic Index.
Table 1: Life expectancy and HALE at birth for 21 GBD regions and 195 countries and territories, by sex in 1990 and 2017
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birth was 7·3 years (6·9–7·7) for males (from 63·2 years 
[62·9–63·4] in 1990 to 70·5 years [70·1–70·8] in 2017) and 
7·5 years (7·2–7·9) for females (from 68·0 years 
[67·8–68·3] in 1990 to 75·6 years [75·3–75·9] in 2017; 
table 1). During the same period, global HALE at birth 
for both sexes combined increased by 6·3 years (5·9–6·7), 
from 57·0 years (54·6–59·1) in 1990 to 63·3 years 
(60·5–65·7) in 2017 (appendix 2). The increase in HALE 
at birth was 6·2 years (5·8–6·7) for males (from 
55·6 years [53·5–57·5] in 1990 to 61·8 years [59·4–64·0] 
in 2017) and 6·4 years (6·0–6·8) for females (from 
58·4 years [55·7–60·8] in 1990 to 64·8 years [61·7–67·4] 
in 2017; table 1). The number of years lived in poor health 
from birth increased globally by 1·1 years (95% UI 
0·9–1·4), in the low SDI countries by 1·5 years (1·2–1·9), 
and in the high SDI countries by 1·3 years (1·0–1·7; 
appendix 2). 
The increases from 1990 to 2017 in life expectancy and 
HALE varied across SDI quintiles and countries, with the 
greatest increases in life expectancy and HALE seen in 
the low SDI quintile and the smallest increases seen in 
the high SDI quintile. The increase in life expectancy 
varied from 5·1 years (5·0–5·3) in high SDI countries to 
12·0 years (11·3–12·8) in low SDI countries. HALE 
increased for both sexes in low SDI countries by 
10·5 years (95% UI 9·8–11·2; by 10·1 years [9·3–10·9] for 
males and by 10·9 years [10·1–11·7] for females), and in 
high SDI countries by 3·8 years (3·4–4·1; by 4·4 years 
[4·0–4·8] for males and by 3·2 years [2·9–3·5] for 
females; table 1, figure 1; appendix 2). Increases in HALE 
in the middle SDI quintiles for both sexes follow a 
gradient, with increases of 6·8 years (6·3–7·4) for 
low-middle SDI, 5·7 years (5·3–6·2) for middle SDI, and 
5·5 years (5·1–5·8) for high-middle SDI (figure 1; 
appendix 2).
Increases in HALE at birth between 1990 and 2017 
were smaller than increases in life expectancy over the 
same period in all SDI quintiles, resulting in an increase 
in years lived in poor health. Of the additional years of 
life expected at birth, 26·3% (20·1–33·1) were spent in 
poor health in high SDI countries compared with 11·7% 
(8·8–15·1) in low-middle SDI countries (figure 2). The 
largest increase in years lived in poor health was for 
females in low SDI quintile countries, by 1·6 years 
(1·2–2·1), and the smallest increase was for males in 
middle SDI quintile countries, by 0·8 years (0·6–1·0; 
figure 1). Although males and females in all SDI quintiles 
had increases in HALE at birth, the increase was 
disparate between the sexes. In 1990, high SDI quintile 
countries had the largest gap in HALE between males 
and females, at 4·1 years (3·4–4·8; figure 3); this gap 
decreased to 2·9 years (2·3–3·5) by 2017. In 2017, the 
high-middle SDI quintile countries had the largest gap in 
HALE between males and females (3·8 years [3·1–4·5]); 
this gap had increased from 1990 to peak in 1995 at 
4·8 years (4·5–5·2) and then decreased gradually 
thereafter. Low SDI quintile countries had the smallest 
gap in HALE between males and females in 2017 
(figure 3). The difference in HALE at birth between the 
sexes during the period 1990–2017 increased in countries 
in the low SDI, low-middle SDI, and middle SDI 
quintiles. South Asia was the only region where males 
had higher HALE at birth than females did in 1990, and 
this trend lasted until 2000, after which point females 
Figure 1: Trends of HALE at birth and years in poor health from birth by SDI quintile and sex, 1990–2017
HALE=healthy life expectancy. SDI=Socio-demographic Index.
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Figure 3: Difference in HALE at birth between males and females by SDI quintile, 1990–2017
HALE=healthy life expectancy. SDI=Socio-demographic Index.
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Figure 2: Years of life gained at birth by sex and functional health status for five SDI quintiles, 21 GBD regions, and 28 countries with the largest and smallest 
proportions of years spent in poor health between 1990 and 2017
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDI=Socio-demographic Index.
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Life expectancy at age 65 years HALE at age 65 years
Females Males Females Males
1990 2017 1990 2017 1990 2017 1990 2017
Global 16·2 (16·1–16·2) 18·7 (18·6–18·8) 13·6 (13·5–13·6) 15·9 (15·8–16·0) 11·9 (10·8–12·9) 13·7 (12·4–14·9) 10·3 (9·4–11·0) 12·0 (10·9–12·9)
Low SDI 12·2 (12·0–12·5) 14·7 (14·5–15·0) 11·4 (11·1–11·6) 13·7 (13·4–13·9) 8·6 (7·7–9·5) 10·5 (9·5–11·5) 8·3 (7·5–9·1) 10·0 (9·1–10·9)
Low-middle SDI 13·8 (13·6–14·0) 15·8 (15·6–16·1) 12·6 (12·4–12·8) 14·1 (13·9–14·3) 9·9 (8·9–10·7) 11·4 (10·3–12·5) 9·3 (8·4–10·1) 10·5 (9·5–11·4)
Middle SDI 15·4 (15·3–15·6) 18·2 (18·0–18·4) 13·8 (13·7–13·9) 15·4 (15·2–15·6) 11·5 (10·5–12·4) 13·5 (12·3–14·6) 10·6 (9·8–11·4) 11·8 (10·8–12·7)
High-middle SDI 15·8 (15·6–15·9) 18·5 (18·3–18·8) 13·2 (13·0–13·3) 15·6 (15·4–15·9) 11·6 (10·5–12·5) 13·7 (12·4–14·8) 10·0 (9·2–10·8) 11·8 (10·8–12·8)
High SDI 18·7 (18·6–18·7) 21·9 (21·8–22·0) 14·9 (14·9–14·9) 18·6 (18·5–18·7) 13·9 (12·7–15·1) 16·2 (14·6–17·6) 11·3 (10·3–12·1) 13·8 (12·6–15·0)
Central Europe, eastern 
Europe, and central Asia
15·9 (15·9–15·9) 18 (17·9–18·1) 12·5 (12·5–12·5) 14·0 (14·0–14·1) 11·4 (10·2–12·5) 12·9 (11·6–14·1) 9·0 (8·1–9·9) 10·1 (9·1–11·1)
Central Asia 16·4 (16·3–16·5) 16·5 (16·2–16·8) 13·2 (13·1–13·2) 12·8 (12·5–13·0) 12·0 (10·8–13·1) 12·2 (10·9–13·2) 9·8 (8·9–10·6) 9·5 (8·6–10·4)
Armenia 15·7 (15·4–15·9) 17·3 (17·0–17·6) 13·2 (12·9–13·4) 14·6 (14·4–14·9) 11·4 (10·3–12·5) 12·7 (11·4–13·9) 9·7 (8·7–10·6) 10·8 (9·8–11·8)
Azerbaijan 16·9 (16·6–17·3) 16·4 (15·8–17·1) 13·6 (13·2–13·9) 11·9 (11·4–12·4) 12·5 (11·4–13·6) 12·1 (10·9–13·4) 10·2 (9·1–11·1) 8·9 (8·0–9·8)
Georgia 16·2 (15·9–16·5) 16·7 (16·5–17·0) 13·2 (12·9–13·6) 13·1 (12·9–13·3) 12·1 (11·0–13·2) 12·3 (11·1–13·4) 10·0 (9·0–10·8) 9·8 (8·8–10·6)
Kazakhstan 16·5 (16·4–16·5) 17·0 (16·6–17·4) 12·3 (12·2–12·3) 13·2 (12·9–13·6) 11·8 (10·6–12·9) 12·4 (11·2–13·5) 8·9 (8·0–9·7) 9·7 (8·7–10·6)
Kyrgyzstan 16·0 (15·6–16·4) 17·0 (16·8–17·3) 12·5 (12·1–12·8) 13·7 (13·5–13·9) 11·7 (10·5–12·8) 12·6 (11·4–13·7) 9·2 (8·3–10·1) 10·3 (9·4–11·2)
Mongolia 13·1 (12·8–13·4) 16·1 (15·4–16·9) 11·1 (10·8–11·4) 12·1 (11·5–12·8) 9·8 (8·9–10·7) 12·0 (10·7–13·1) 8·4 (7·6–9·1) 9·0 (8·1–9·9)
Tajikistan 16·9 (16·6–17·1) 17·1 (16·3–17·9) 14·4 (14·3–14·6) 13·9 (13·2–14·6) 12·4 (11·2–13·5) 12·7 (11·4–13·8) 10·8 (9·7–11·7) 10·5 (9·4–11·6)
Turkmenistan 15·4 (15·4–15·5) 16·4 (15·7–17·1) 12·7 (12·6–12·7) 13·3 (12·8–13·9) 11·5 (10·4–12·5) 12·3 (11·0–13·4) 9·6 (8·7–10·3) 10·1 (9·1–11·0)
Uzbekistan 17·0 (16·9–17·0) 15·8 (14·8–16·9) 14·2 (14·1–14·2) 12·0 (11·2–12·8) 12·5 (11·3–13·6) 11·7 (10·4–13·0) 10·7 (9·7–11·5) 9·1 (8·1–10·1)
Central Europe 15·9 (15·8–15·9) 19·0 (18·8–19·2) 12·6 (12·6–12·6) 15·3 (15·2–15·5) 11·2 (10·0–12·3) 13·5 (12·1–14·8) 8·9 (8·0–9·8) 10·8 (9·6–11·9)
Albania 19·3 (19·2–19·5) 20·6 (18·9–22·4) 13·7 (13·6–13·8) 15·6 (14·4–17·1) 14·1 (12·7–15·4) 15·1 (13·4–17·0) 10·0 (9·1–10·9) 11·4 (10·0–13·0)
Bosnia and Herzegovina 16·4 (16·3–16·6) 17·4 (16·9–17·9) 13·6 (13·6–13·7) 15·1 (14·6–15·5) 11·8 (10·6–12·9) 12·4 (11·1–13·6) 9·8 (8·8–10·7) 10·6 (9·4–11·7)
Bulgaria 16·0 (15·9–16·1) 18·0 (17·5–18·5) 12·8 (12·7–12·8) 14·2 (13·8–14·7) 11·6 (10·4–12·6) 13·0 (11·7–14·3) 9·2 (8·3–10·1) 10·2 (9·1–11·2)
Croatia 15·9 (15·8–16·0) 19·3 (18·8–19·8) 12·6 (12·6–12·7) 15·7 (15·3–16·2) 11·4 (10·1–12·5) 13·7 (12·2–15·1) 9·0 (8·0–9·8) 11·1 (9·8–12·2)
Czech Republic 15·3 (15·2–15·4) 19·8 (19·3–20·3) 11·6 (11·5–11·6) 16·3 (15·9–16·8) 10·6 (9·3–11·7) 13·9 (12·2–15·3) 8·1 (7·2–8·9) 11·2 (9·9–12·5)
Hungary 15·5 (15·4–15·5) 19·1 (18·6–19·5) 12·1 (12·1–12·1) 15·0 (14·6–15·5) 10·5 (9·3–11·7) 13·4 (11·9–14·8) 8·4 (7·4–9·2) 10·5 (9·3–11·6)
Macedonia 16·3 (16·2–16·5) 18·8 (18·5–19·2) 13·6 (13·5–13·7) 14·8 (14·3–15·2) 11·7 (10·5–12·8) 13·6 (12·2–14·9) 9·8 (8·8–10·7) 10·6 (9·4–11·6)
Montenegro 17·6 (17·4–17·7) 17·4 (16·8–18·0) 14·5 (14·4–14·7) 14·8 (14·0–15·5) 12·7 (11·5–14·0) 12·5 (11·2–13·8) 10·5 (9·4–11·5) 10·6 (9·4–11·7)
Poland 16·3 (16·3–16·4) 20·2 (19·7–20·7) 12·6 (12·6–12·6) 16·0 (15·5–16·4) 11·6 (10·3–12·7) 14·4 (12·8–15·8) 9·0 (8·0–9·8) 11·2 (10–12·5)
Romania 15·2 (15·2–15·2) 18·2 (17·8–18·7) 13·1 (13·0–13·1) 14·7 (14·3–15·1) 10·8 (9·7–11·9) 13·1 (11·7–14·4) 9·2 (8·2–10·2) 10·4 (9·3–11·5)
Serbia 15·9 (15·8–16·0) 16·5 (16·0–17·0) 12·4 (12·4–12·5) 14·6 (14·2–15·0) 11·4 (10·2–12·4) 11·8 (10·5–12·9) 8·9 (8·0–9·7) 10·4 (9·3–11·5)
Slovakia 15·8 (15·7–15·9) 19·0 (18·5–19·5) 12·2 (12·2–12·3) 15·4 (14·9–15·8) 11·2 (10·0–12·3) 13·5 (12·0–14·8) 8·6 (7·6–9·5) 10·7 (9·4–11·8)
Slovenia 17·2 (17·0–17·3) 21·6 (21·0–22·2) 13·4 (13·3–13·5) 17·5 (17·0–18·0) 12·0 (10·6–13·2) 15·1 (13·3–16·7) 9·3 (8·2–10·3) 12·1 (10·6–13·5)
Eastern Europe 15·9 (15·9–15·9) 17·7 (17·5–17·8) 12·3 (12·2–12·3) 13·4 (13·2–13·5) 11·4 (10·2–12·4) 12·7 (11·3–13·8) 9·0 (8·1–9·8) 9·8 (8·8–10·6)
Belarus 16·7 (16·6–16·8) 17·9 (17·5–18·4) 13·2 (13·2–13·2) 13·0 (12·7–13·4) 12·1 (10·9–13·2) 13·0 (11·7–14·2) 9·7 (8·7–10·6) 9·6 (8·6–10·5)
Estonia 15·8 (15·7–16·0) 20·4 (19·4–21·4) 12·1 (12·0–12·2) 15·9 (15·0–16·9) 11·5 (10·4–12·5) 14·9 (13·3–16·5) 8·8 (7·9–9·6) 11·6 (10·3–12·9)
Latvia 15·9 (15·8–16·0) 19·0 (18·0–20·0) 12·3 (12·2–12·3) 14·2 (13·4–15·1) 11·4 (10·2–12·5) 13·7 (12·2–15·1) 8·9 (8·0–9·7) 10·3 (9·1–11·4)
Lithuania 16·9 (16·8–17·0) 19·3 (18·8–19·8) 13·4 (13·3–13·4) 14·3 (13·8–14·7) 12·2 (11·0–13·3) 13·8 (12·3–15·2) 9·8 (8·8–10·6) 10·2 (9·1–11·3)
Moldova 14·9 (14·8–14·9) 17·9 (17·6–18·2) 12·6 (12·6–12·7) 13·6 (13·4–13·8) 10·8 (9·7–11·7) 13·1 (11·9–14·3) 9·3 (8·3–10·1) 10·1 (9·1–11·0)
Russia 15·9 (15·9–15·9) 17·7 (17·7–17·8) 12·0 (12·0–12·0) 13·6 (13·6–13·7) 11·3 (10·2–12·4) 12·6 (11·3–13·8) 8·8 (7·9–9·6) 9·9 (8·9–10·8)
Ukraine 15·8 (15·7–15·9) 17·2 (16·7–17·6) 12·5 (12·4–12·6) 12·5 (12·2–12·9) 11·3 (10·1–12·3) 12·5 (11·2–13·6) 9·2 (8·3–10·0) 9·2 (8·3–10·1)
High income 18·8 (18·8–18·8) 21·9 (21·8–22·0) 15·0 (15·0–15·0) 18·6 (18·5–18·7) 14·1 (12·8–15·2) 16·3 (14·7–17·6) 11·4 (10·4–12·3) 13·9 (12·6–15·0)
Australasia 18·9 (18·8–18·9) 22·2 (21·4–22·9) 15·1 (15·0–15·1) 19·4 (18·7–20·2) 14·0 (12·7–15·2) 16·3 (14·6–17·8) 11·3 (10·2–12·2) 14·3 (12·8–15·7)
Australia 19·0 (18·9–19·1) 22·3 (21·4–23·2) 15·1 (15·1–15·2) 19·4 (18·6–20·3) 14·2 (12·8–15·3) 16·4 (14·7–17·9) 11·3 (10·3–12·2) 14·4 (12·8–15·7)
New Zealand 18·2 (18·1–18·3) 21·7 (21·2–22·1) 14·8 (14·6–14·9) 19·2 (18·8–19·7) 13·4 (12·0–14·6) 15·5 (13·8–17·0) 11·0 (9·9–11·9) 13·9 (12·4–15·2)
High-income Asia Pacific 19·7 (19·7–19·8) 24·1 (24·0–24·3) 15·8 (15·8–15·9) 19·5 (19·4–19·7) 15·1 (13·8–16·2) 18·2 (16·6–19·7) 12·3 (11·3–13·1) 14·9 (13·6–16·0)
Brunei 13·8 (13·4–14·2) 17·8 (17·2–18·4) 12·5 (12·1–12·8) 15·3 (14·4–16·2) 10·3 (9·3–11·2) 13·5 (12·2–14·6) 9·4 (8·5–10·2) 11·6 (10·5–12·8)
Japan 20·3 (20·3–20·3) 24·4 (24·2–24·6) 16·4 (16·4–16·4) 19·7 (19·5–19·9) 15·6 (14·2–16·7) 18·5 (16·8–19·9) 12·8 (11·8–13·6) 15·1 (13·8–16·2)
Singapore 18·1 (18·0–18·3) 24·6 (24·1–25·0) 14·7 (14·6–14·8) 20·2 (19·7–20·7) 13·8 (12·6–14·9) 18·8 (17·1–20·2) 11·4 (10·5–12·2) 15·7 (14·4–16·9)
South Korea 16·6 (16·6–16·7) 22·6 (22·2–23·1) 12·4 (12·4–12·4) 18·5 (18·0–19·0) 12·5 (11·3–13·5) 17·0 (15·4–18·5) 9·4 (8·5–10·1) 13·9 (12·6–15·0)
(Table 2 continues on next page)
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Life expectancy at age 65 years HALE at age 65 years
Females Males Females Males
1990 2017 1990 2017 1990 2017 1990 2017
(Continued from previous page)
High-income North 
America
19·2 (19·2–19·2) 20·8 (20·6–20·9) 15·3 (15·3–15·3) 18·2 (18·0–18·4) 14·1 (12·8–15·3) 14·9 (13·4–16·3) 11·3 (10·2–12·2) 13·1 (11·7–14·3)
Canada 19·6 (19·6–19·7) 22·1 (21·7–22·6) 15·5 (15·4–15·5) 19·5 (19·0–19·9) 14·8 (13·4–15·9) 16·5 (14·9–17·9) 11·8 (10·7–12·7) 14·6 (13·3–15·9)
Greenland 14·3 (14·0–14·6) 18·3 (17·6–18·9) 11·6 (11·4–11·8) 14·2 (14·0–15·0) 10·4 (9·4–11·3) 13·4 (12·1–14·6) 8·5 (7·7–9·3) 10·5 (9·5–11·5)
USA 19·1 (19·1–19·1) 20·6 (20·4–20·8) 15·3 (15·3–15·3) 18·1 (17·9–18·3) 14·1 (12·7–15·3) 14·7 (13·2–16·1) 11·2 (10·2–12·2) 12·9 (11·6–14·1)
Southern Latin America 17·5 (17·5–17·6) 19·7 (18·9–20·3) 14·0 (14·0–14·0) 16·3 (15·6–16·9) 13·3 (12·1–14·3) 14·9 (13·5–16·2) 10·7 (9·7–11·5) 12·3 (11·1–13·5)
Argentina 17·6 (17·5–17·6) 19·3 (18·4–20·2) 13·9 (13·9–13·9) 15·7 (14·8–16·5) 13·4 (12·2–14·4) 14·7 (13·3–16·1) 10·6 (9·7–11·4) 11·9 (10·7–13·2)
Chile 17·2 (17·1–17·3) 20·6 (19·7–21·6) 14·4 (14·4–14·5) 17·9 (17·0–18·9) 12·9 (11·8–14·0) 15·4 (13·9–16·9) 10·9 (9·9–11·8) 13·4 (12·1–14·8)
Uruguay 17·9 (17·8–18·0) 19·8 (18·9–20·8) 13·9 (13·8–14·0) 15·8 (14·9–16·7) 13·5 (12·3–14·6) 15·0 (13·5–16·4) 10·5 (9·6–11·4) 11·9 (10·7–13·1)
Western Europe 18·5 (18·5–18·5) 21·9 (21·6–22·1) 14·7 (14·7–14·7) 18·7 (18·5–18·9) 13·9 (12·7–15·0) 16·4 (14·9–17·7) 11·2 (10·3–12·1) 14·1 (12·9–15·2)
Andorra 20·7 (19·4–22·3) 22·4 (21·3–23·8) 16·6 (15·8–17·2) 19·4 (18·8–20·1) 15·5 (13·8–17·3) 16·8 (15·0–18·5) 12·7 (11·5–13·8) 14·7 (13·4–15·9)
Austria 17·9 (17·8–18·0) 21·6 (21·1–22·0) 14·5 (14·4–14·6) 18·5 (18·0–18·9) 13·5 (12·3–14·6) 16·1 (14·6–17·5) 11·1 (10·1–11·9) 13·9 (12·6–15·1)
Belgium 18·5 (18·4–18·6) 21·7 (21·2–22·2) 14·3 (14·2–14·3) 18·3 (17·8–18·7) 13·7 (12·5–14·9) 15·9 (14·4–17·4) 10·8 (9·8–11·6) 13·5 (12·1–14·7)
Cyprus 17·3 (17·2–17·5) 22·5 (21·8–23·1) 15·0 (14·9–15·1) 17·5 (16·8–18·2) 13·0 (11·8–14·0) 16·8 (15·2–18·3) 11·5 (10·5–12·3) 13·3 (12·0–14·5)
Denmark 17·8 (17·7–17·9) 20·7 (20·1–21·2) 14·1 (14·0–14·2) 18·0 (17·5–18·4) 13·3 (12·1–14·4) 15·5 (14·0–16·7) 10·8 (9·8–11·6) 13·6 (12·3–14·7)
Finland 17·9 (17·7–18·0) 21·8 (21·2–22·3) 13·9 (13·8–13·9) 18·2 (17·7–18·7) 13·4 (12·2–14·5) 16·2 (14·7–17·7) 10·5 (9·5–11·3) 13·6 (12·2–14·8)
France 19·9 (19·8–19·9) 23·5 (23·0–23·9) 15·5 (15·4–15·5) 19·5 (19·1–19·9) 15·1 (13·7–16·3) 17·8 (16·1–19·2) 11·9 (10·9–12·8) 14·9 (13·6–16·1)
Germany 17·7 (17·7–17·8) 20·8 (19·9–21·7) 14·1 (14·1–14·1) 17·8 (16·9–18·7) 13·3 (12·0–14·3) 15·5 (13·9–17·0) 10·7 (9·7–11·5) 13·4 (12·0–14·6)
Greece 18·9 (18·8–18·9) 21·3 (20·8–21·8) 15·7 (15·6–15·7) 18·3 (17·9–18·8) 14·2 (13·0–15·3) 16·0 (14·5–17·3) 12·0 (11·0–12·9) 13·8 (12·6–15·0)
Iceland 19·0 (18·8–19·3) 23·1 (22·7–23·5) 16·1 (15·9–16·3) 18·4 (18·1–18·7) 14·2 (12·9–15·4) 17·2 (15·6–18·6) 12·2 (11·1–13·1) 13·9 (12·5–15·0)
Ireland 16·8 (16·7–17·0) 21·2 (20·6–21·7) 13·4 (13·3–13·5) 18·7 (18·2–19·2) 12·7 (11·6–13·7) 15·8 (14·3–17·1) 10·2 (9·3–11·0) 14·0 (12·6–15·2)
Israel 18·0 (17·9–18·1) 21·9 (21·4–22·4) 16·4 (16·3–16·5) 19·9 (19·4–20·4) 13·3 (12·0–14·5) 16·2 (14·6–17·6) 12·3 (11·2–13·3) 14·9 (13·4–16·2)
Italy 19·0 (18·9–19·0) 22·5 (22·1–23·0) 15·2 (15·2–15·2) 19·2 (18·8–19·6) 14·3 (13·0–15·4) 17·0 (15·5–18·4) 11·6 (10·6–12·5) 14·6 (13·2–15·8)
Luxembourg 18·1 (17·9–18·2) 20·9 (20·2–21·6) 13·9 (13·8–14·1) 18·8 (18·0–19·6) 13·2 (11·9–14·4) 15·3 (13·8–16·8) 10·4 (9·4–11·2) 13·8 (12·4–15·2)
Malta 17·4 (17·2–17·6) 20·6 (20·1–21·1) 14·7 (14·5–14·8) 17·9 (17·6–18·3) 13·1 (11·8–14·2) 15·4 (13·9–16·7) 11·1 (10·1–12·0) 13·4 (12·1–14·6)
Netherlands 19·0 (18·9–19·1) 20·9 (20·5–21·4) 14·4 (14·3–14·4) 18·3 (17·9–18·8) 14·2 (12·9–15·4) 15·6 (14·1–17·0) 10·9 (10·0–11·8) 13·8 (12·5–15·0)
Norway 18·8 (18·7–18·8) 21·6 (21·4–21·7) 14·7 (14·6–14·7) 19·0 (18·8–19·1) 14·1 (12·7–15·2) 16·0 (14·4–17·3) 11·0 (10·0–11·9) 13·9 (12·6–15·2)
Portugal 17·2 (17·2–17·3) 21·7 (21·2–22·1) 14·1 (14·0–14·1) 18·3 (17·9–18·8) 12·8 (11·5–13·8) 16·1 (14·5–17·5) 10·6 (9·6–11·4) 13·8 (12·5–15·0)
Spain 19·1 (19·1–19·2) 23·0 (22·6–23·4) 15·5 (15·5–15·5) 19·1 (18·7–19·5) 14·5 (13·3–15·6) 17·6 (16·0–18·9) 11·9 (10·9–12·8) 14·6 (13·4–15·7)
Sweden 19·1 (19·1–19·2) 21·5 (21·1–21·9) 15·4 (15·4–15·5) 19·2 (18·8–19·6) 14·4 (13·2–15·6) 16·1 (14·6–17·4) 11·9 (10·8–12·7) 14·5 (13·2–15·7)
Switzerland 19·8 (19·7–19·9) 22·8 (22·4–23·3) 15·6 (15·5–15·7) 20·2 (19·8–20·7) 14·7 (13·2–15·9) 17·0 (15·4–18·5) 11·8 (10·7–12·7) 15·2 (13·8–16·5)
UK 17·8 (17·7–17·8) 20·8 (20·7–20·9) 14·1 (14·0–14·1) 18·5 (18·4–18·6) 13·4 (12·3–14·5) 15·4 (14·0–16·7) 10·8 (9·9–11·6) 13·9 (12·6–15·0)
England 17·9 (17·9–17·9) 20·9 (20·8–21·0) 14·2 (14·2–14·2) 18·6 (18·6–18·7) 13·6 (12·4–14·6) 15·4 (14·0–16·8) 10·9 (10·0–11·7) 13·9 (12·7–15·1)
Northern Ireland 16·9 (16·7–17·1) 20·7 (19·9–21·4) 13·3 (13·2–13·4) 18·3 (17·7–19·0) 12·8 (11·7–13·8) 15·6 (14·2–16·9) 10·2 (9·3–10·9) 13·8 (12·5–15·1)
Scotland 16·7 (16·6–16·8) 19·8 (19·2–20·5) 13·2 (13·1–13·2) 17·4 (16·8–18·1) 12·6 (11·5–13·5) 14·9 (13·5–16·2) 10·0 (9·2–10·8) 13·2 (12·0–14·4)
Wales 17·8 (17·7–17·9) 20·7 (20·1–21·2) 13·9 (13·8–14·0) 18·1 (17·6–18·6) 13·4 (12·2–14·5) 15·6 (14·0–16·9) 10·6 (9·7–11·4) 13·7 (12·4–14·9)
Latin America and 
Caribbean
17·3 (17·2–17·3) 19·7 (19·6–19·9) 15·3 (15·3–15·4) 17·4 (17·2–17·5) 13·0 (11·8–14·0) 14·9 (13·6–16·1) 11·7 (10·7–12·6) 13·3 (12·2–14·3)
Andean Latin America 17·8 (17·5–18·1) 20·2 (19·4–20·9) 16·2 (15·9–16·5) 18·8 (18·0–19·5) 13·5 (12·4–14·6) 15·4 (14·0–16·8) 12·4 (11·3–13·4) 14·4 (13·1–15·7)
Bolivia 13·6 (13·0–14·2) 16·6 (15·4–18·3) 12·9 (12·4–13·5) 14·9 (13·2–16·7) 10·3 (9·3–11·2) 12·6 (11·2–14·2) 9·7 (8·7–10·7) 11·4 (9·8–13·0)
Ecuador 18·1 (18·0–18·1) 19·5 (18·7–20·3) 16·4 (16·4–16·5) 18·4 (17·7–19·1) 13·8 (12·6–14·9) 14·9 (13·5–16·3) 12·5 (11·4–13·4) 14·0 (12·6–15·2)
Peru 19·2 (18·6–19·7) 21·7 (20·4–23·0) 17·2 (16·7–17·8) 20·2 (19·0–21·5) 14·6 (13·3–15·8) 16·7 (15·1–18·4) 13·3 (12·1–14·3) 15·6 (14·0–17·2)
Caribbean 17·1 (16·9–17·2) 18·9 (18·3–19·4) 15·4 (15·2–15·5) 16·4 (15·9–16·9) 13·1 (12·0–14·1) 14·4 (13·2–15·6) 12·0 (11·0–12·8) 12·7 (11·7–13·8)
Antigua and Barbuda 19·0 (18·6–19·5) 18·5 (18·1–19·1) 14·7 (14·4–15·1) 17·3 (16·8–17·8) 14·6 (13·2–15·8) 14·2 (12·8–15·3) 11·5 (10·5–12·4) 13·4 (12·1–14·4)
The Bahamas 17·9 (17·7–18·1) 18·5 (17·7–19·3) 14·5 (14·4–14·7) 16·3 (15·7–17·0) 13·8 (12·6–14·8) 14·2 (12·9–15·5) 11·4 (10·5–12·2) 12·8 (11·6–13·9)
Barbados 17·5 (17·3–17·7) 19·2 (18·6–19·9) 15·0 (14·8–15·1) 17·5 (16·9–18·2) 13·6 (12·5–14·6) 14·8 (13·5–16·0) 11·8 (10·9–12·7) 13·7 (12·5–14·8)
Belize 17·0 (16·6–17·5) 19·2 (18·9–19·5) 16·3 (15·9–16·7) 17·4 (17·2–17·7) 13·0 (11·8–14·1) 14·6 (13·2–15·7) 12·8 (11·7–13·7) 13·5 (12·4–14·5)
Bermuda 18·3 (18·0–18·6) 23·1 (22·5–23·8) 13·7 (13·4–14·0) 17·3 (16·8–17·6) 14·1 (12·9–15·2) 17·7 (16·2–19·2) 10·8 (9·9–11·6) 13·4 (12·4–14·5)
Cuba 17·8 (17·7–17·9) 19·7 (18·7–20·7) 15·9 (15·8–15·9) 17·2 (16·2–18·1) 13·7 (12·5–14·7) 15·1 (13·7–16·5) 12·5 (11·5–13·3) 13·5 (12·3–14·7)
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Females Males Females Males
1990 2017 1990 2017 1990 2017 1990 2017
(Continued from previous page)
Dominica 17·0 (16·7–17·2) 17·7 (17·1–18·4) 14·8 (14·6–15·0) 15·4 (15·0–15·9) 13·1 (12·0–14·1) 13·7 (12·5–14·9) 11·6 (10·7–12·4) 12·0 (11·1–13·0)
Dominican Republic 19·6 (19·0–20·2) 19·3 (18·4–20·3) 18·0 (17·4–18·6) 16·2 (15·2–17·4) 15·0 (13·7–16·2) 14·8 (13·4–16·1) 14 (12·8–15·1) 12·6 (11·4–13·9)
Grenada 15·0 (14·7–15·3) 16·7 (16·2–17·3) 12·6 (12·4–12·8) 16·9 (16·5–17·3) 11·5 (10·5–12·4) 12·8 (11·7–13·9) 9·9 (9·1–10·7) 13·1 (12·0–14·2)
Guyana 15·1 (15·0–15·3) 16·2 (15·2–17·2) 12·7 (12·6–12·8) 14·1 (13·2–15·0) 11·5 (10·5–12·4) 12·3 (11·0–13·5) 9·8 (8·9–10·5) 10·9 (9·8–11·9)
Haiti 11·4 (10·6–12·0) 13·7 (12·3–15·4) 11·6 (10·9–12·3) 13·0 (12·2–14·3) 8·6 (7·7–9·5) 10·4 (9·0–11·8) 8·9 (8·0–9·7) 10·0 (8·9–11·3)
Jamaica 18·1 (17·7–18·6) 18·5 (17·1–19·8) 16·0 (15·7–16·4) 15·6 (14·5–16·8) 14·0 (12·7–15·1) 14·2 (12·7–15·6) 12·6 (11·6–13·5) 12·2 (10·9–13·5)
Puerto Rico 18·7 (18·6–18·9) 21·6 (21·1–22·1) 15·9 (15·8–16·0) 18·7 (18·2–19·2) 14·5 (13·3–15·5) 16·5 (15·0–17·8) 12·4 (11·4–13·3) 14·4 (13·1–15·5)
Saint Lucia 16·1 (15·9–16·3) 18·8 (18·2–19·3) 13·4 (13·2–13·5) 17·0 (16·6–17·5) 12·3 (11·3–13·3) 14·4 (13·1–15·6) 10·5 (9·6–11·2) 13·2 (12·1–14·2)
Saint Vincent and the 
Grenadines
16·2 (15·9–16·5) 17·4 (16·9–17·9) 14·7 (14·5–14·9) 14·6 (14·3–15·0) 12·4 (11·3–13·4) 13·3 (12·1–14·4) 11·5 (10·5–12·3) 11·3 (10·3–12·2)
Suriname 16·4 (15·9–16·8) 18·2 (17·4–19·0) 14·7 (14·2–15·1) 15·1 (14·2–16·0) 12·6 (11·5–13·6) 13·8 (12·4–15·1) 11·5 (10·5–12·4) 11·7 (10·5–12·8)
Trinidad and Tobago 15·8 (15·6–15·9) 19·0 (17·3–20·9) 13·4 (13·3–13·5) 15·7 (14·3–17·3) 11·9 (10·9–12·9) 14·4 (12·6–16·2) 10·3 (9·5–11·1) 12·1 (10·6–13·6)
Virgin Islands 17·3 (16·5–17·9) 18·8 (17·7–19·6) 13·7 (13·4–14·0) 13·5 (12·8–15·4) 13·5 (12·3–14·6) 14·5 (13·1–15·8) 10·8 (10·0–11·6) 10·6 (9·5–12·2)
Central Latin America 17·6 (17·5–17·6) 19·9 (19·6–20·1) 16·0 (16·0–16·1) 17·8 (17·6–18·1) 13·2 (12·0–14·2) 15·0 (13·7–16·2) 12·3 (11·2–13·2) 13·6 (12·5–14·7)
Colombia 17·5 (17·4–17·5) 22·1 (21·1–23·0) 16·4 (16·4–16·5) 20·1 (19·2–21·0) 13·2 (12·1–14·3) 16·9 (15·3–18·4) 12·6 (11·6–13·6) 15·5 (14·2–17·0)
Costa Rica 18·8 (18·7–19·0) 21·5 (20·9–22·0) 16·8 (16·7–16·9) 18·1 (17·6–18·5) 14·2 (12·9–15·4) 16·3 (14·8–17·5) 13·0 (12·0–14·0) 14·0 (12·8–15·0)
El Salvador 18·5 (18·4–18·6) 19·0 (17·5–20·5) 16·4 (16·4–16·5) 16·6 (15·4–17·8) 14·0 (12·7–15·0) 14·5 (12·8–16·0) 12·6 (11·5–13·5) 12·7 (11·3–14·0)
Guatemala 15·0 (14·9–15·0) 18·4 (17·5–19·3) 13·8 (13·8–13·9) 16·1 (15·3–16·8) 11·2 (10·2–12·1) 13·8 (12·5–15·2) 10·6 (9·7–11·4) 12·3 (11·2–13·4)
Honduras 18·2 (17·3–19·1) 17·0 (15·7–19·3) 17·4 (16·4–18·4) 17·0 (15·7–18·4) 13·6 (12·2–14·9) 12·9 (11·3–14·8) 13·3 (12·1–14·6) 13·0 (11·6–14·5)
Mexico 17·6 (17·6–17·6) 19·1 (18·9–19·2) 16·0 (16·0–16·0) 17·3 (17·1–17·4) 13·2 (12·0–14·2) 14·3 (13·0–15·4) 12·3 (11·2–13·2) 13·1 (12·0–14·2)
Nicaragua 19·1 (18·6–19·6) 20·6 (19·7–21·5) 18·0 (17·4–18·6) 19·9 (18·9–20·7) 14·2 (12·8–15·4) 15·4 (13·8–16·9) 13·7 (12·4–14·8) 15·2 (13·8–16·6)
Panama 19·3 (19·2–19·5) 21·6 (21·1–22·2) 17·3 (17·2–17·5) 19·7 (19·2–20·2) 14·6 (13·3–15·8) 16·4 (14·9–17·7) 13·4 (12·2–14·4) 15·1 (13·7–16·3)
Venezuela 17·6 (17·6–17·7) 20·0 (18·7–21·3) 15·4 (15·4–15·5) 16·9 (15·7–18·1) 13·2 (12·1–14·3) 15·1 (13·5–16·6) 11·9 (10·9–12·7) 13·0 (11·6–14·4)
Tropical Latin America 17·0 (16·9–17·0) 19·7 (19·6–19·8) 14·5 (14·5–14·5) 16·9 (16·8–16·9) 12·6 (11·4–13·6) 14·8 (13·5–16·0) 11·0 (10·0–11·9) 12·8 (11·7–13·8)
Brazil 16·9 (16·9–17·0) 19·7 (19·7–19·8) 14·4 (14·4–14·5) 16·9 (16·8–16·9) 12·5 (11·4–13·6) 14·8 (13·5–16·0) 11·0 (10·0–11·8) 12·8 (11·7–13·8)
Paraguay 18·5 (18–19·0) 19·3 (17·8–20·8) 16·3 (15·8–16·7) 16·5 (15·1–18·0) 13·9 (12·6–15·1) 14·5 (12·9–16·1) 12·4 (11·2–13·4) 12·5 (11·0–14·0)
North Africa and Middle 
East
15·4 (15·3–15·6) 18·6 (18·3–18·9) 13·8 (13·6–14·0) 15·8 (15·5–16·1) 11·0 (9·9–12·1) 13·4 (12·0–14·7) 10·3 (9·3–11·1) 11·7 (10·6–12·7)
Afghanistan 10·4 (9·5–11·3) 12·1 (11·3–13·2) 10·7 (10·0–11·7) 12·5 (12·0–13·2) 7·2 (6·2–8·3) 8·4 (7·3–9·6) 7·8 (6·8–8·8) 9·0 (7·9–10·0)
Algeria 16·9 (16·3–17·4) 18·9 (18·5–19·3) 15·8 (15·3–16·3) 18·5 (18·1–18·9) 12·1 (10·7–13·3) 13·7 (12·2–15·0) 11·7 (10·5–12·8) 13·6 (12·3–14·9)
Bahrain 13·7 (13·4–14·0) 18·7 (17·9–19·4) 12·2 (12·0–12·6) 17·7 (17·0–18·4) 9·7 (8·6–10·7) 13·3 (11·8–14·7) 9·0 (8·1–9·8) 12·9 (11·5–14·2)
Egypt 14·7 (14·7–14·7) 16·2 (15·3–17·2) 11·8 (11·8–11·9) 12·0 (11·3–12·7) 10·5 (9·4–11·5) 11·6 (10·2–12·9) 8·8 (8·0–9·6) 8·9 (8·0–9·8)
Iran 16·3 (16·0–16·6) 18·6 (18·5–18·6) 15·1 (14·8–15·4) 17·4 (17·3–17·4) 11·9 (10·6–13·0) 13·4 (12·0–14·7) 11·5 (10·5–12·4) 13·0 (11·8–14·1)
Iraq 14·1 (13·1–15·1) 20·3 (19·8–20·9) 13·2 (12·3–14·2) 20·0 (19·4–20·5) 9·9 (8·7–11·1) 14·3 (12·7–15·8) 9·6 (8·4–10·7) 14·3 (12·7–15·8)
Jordan 15·2 (14·3–16·1) 19·9 (19·0–20·8) 15·6 (14·7–16·5) 18·2 (17·1–19·2) 11·0 (9·8–12·2) 14·4 (12·8–15·9) 11·6 (10·4–12·9) 13·5 (12·0–14·9)
Kuwait 18·7 (18·5–18·8) 24·7 (24·3–25·1) 17·9 (17·7–18·0) 20·2 (19·8–20·7) 13·5 (12·0–14·8) 17·7 (15·7–19·4) 13·2 (11·9–14·4) 14·8 (13·3–16·2)
Lebanon 16·6 (15·9–17·6) 19·0 (18·6–19·5) 13·3 (12·8–14·3) 16·7 (16·1–17·2) 12·0 (10·6–13·3) 13·7 (12·2–15·0) 9·9 (8·9–11·0) 12·3 (11·0–13·4)
Libya 16·8 (15·7–17·9) 16·6 (15·5–17·9) 15·9 (14·8–16·9) 15·4 (14·4–16·6) 12·0 (10·6–13·4) 11·8 (10·4–13·3) 11·6 (10·2–12·9) 11·2 (9·9–12·7)
Morocco 14·1 (13·6–14·6) 16·4 (15·1–17·7) 15·4 (14·9–16·0) 15·9 (14·5–17·4) 10·2 (9·0–11·2) 11·9 (10·5–13·5) 11·4 (10·3–12·5) 11·8 (10·2–13·3)
Oman 16·1 (14·8–17·4) 18·8 (18·2–20·0) 13·2 (11·9–14·7) 16·4 (15·0–18·1) 11·0 (9·4–12·5) 13·1 (11·5–14·7) 9·4 (8·1–10·9) 11·8 (10·3–13·6)
Palestine 16·0 (14·7–17·3) 17·4 (16·9–18·0) 14·0 (12·9–15·4) 16·6 (15·9–17·3) 11·4 (10·0–13·0) 12·4 (11·0–13·7) 10·4 (9·1–11·9) 12·2 (10·9–13·4)
Qatar 14·2 (13·2–15·3) 19·9 (18·5–21·4) 13·3 (12·3–14·3) 18·8 (17·5–20·2) 9·9 (8·6–11·1) 14·1 (12·2–15·9) 9·4 (8·1–10·7) 13·5 (11·8–15·2)
Saudi Arabia 17·3 (16·0–18·6) 19·1 (18·3–19·7) 15·4 (14·1–16·8) 16·6 (15·7–17·1) 12·3 (10·9–13·9) 13·9 (12·5–15·2) 11·4 (10–12·9) 12·3 (11·0–13·5)
Sudan 13·5 (12·6–14·5) 16·4 (14·9–18·0) 13·0 (12·1–13·8) 14·8 (13·3–16·5) 9·7 (8·4–10·9) 11·8 (10·3–13·4) 9·5 (8·5–10·6) 10·9 (9·4–12·5)
Syria 16·0 (15·4–16·4) 18·5 (18·0–19·2) 14·2 (13·5–15·0) 15·3 (14·0–16·6) 11·5 (10·4–12·7) 13·4 (11·9–14·7) 10·7 (9·6–11·8) 11·4 (10·1–12·8)
Tunisia 17·0 (16·7–17·3) 19·4 (17·8–21·2) 15·6 (15·3–15·9) 16·7 (15·2–18·4) 12·4 (11·2–13·5) 14·3 (12·5–16·0) 11·5 (10·4–12·5) 12·4 (10·8–14·0)
Turkey 17·2 (16·7–17·6) 21·9 (21·2–22·7) 13·9 (13·5–14·3) 16·3 (15·6–17·0) 12·3 (11·0–13·6) 16·0 (14·4–17·6) 10·5 (9·5–11·4) 12·2 (11·0–13·4)
United Arab Emirates 14·8 (13·6–16·2) 16·9 (15·4–18·5) 13·6 (12·5–15·0) 13·8 (12·4–15·3) 10·5 (9·1–12·0) 12·1 (10·6–13·8) 10·0 (8·7–11·3) 10·1 (8·7–11·5)
Yemen 13·2 (11·8–14·7) 15·6 (14·0–17·0) 12·1 (10·8–13·4) 13·6 (12·5–15·0) 8·8 (7·4–10·2) 10·7 (9·2–12·3) 8·5 (7·3–9·9) 9·7 (8·5–11·1)
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Females Males Females Males
1990 2017 1990 2017 1990 2017 1990 2017
(Continued from previous page)
South Asia 13·1 (12·9–13·3) 15·2 (15·0–15·4) 12·1 (11·9–12·3) 14·2 (14·0–14·4) 9·2 (8·2–10·1) 10·8 (9·7–11·8) 8·9 (8·0–9·6) 10·4 (9·4–11·3)
Bangladesh 14·3 (13·9–14·9) 17·5 (16·6–18·5) 12·5 (12·0–12·9) 16·2 (15·3–17·1) 10·3 (9·2–11·4) 12·5 (11·1–13·9) 9·4 (8·5–10·2) 12·1 (10·9–13·2)
Bhutan 13·5 (12·4–14·5) 17·9 (16·5–19·3) 13·5 (12·5–14·5) 15·5 (13·7–17·0) 9·7 (8·5–10·9) 13·3 (11·8–14·7) 10·1 (8·9–11·3) 11·8 (10·2–13·3)
India 12·9 (12·6–13·1) 15·0 (14·8–15·2) 11·7 (11·5–12·0) 13·9 (13·7–14·1) 9·0 (8·0–9·9) 10·6 (9·5–11·6) 8·6 (7·7–9·3) 10·2 (9·3–11·1)
Nepal 12·9 (12·0–13·9) 16·3 (15·3–17·4) 12·4 (11·6–13·4) 13·3 (12·9–14·5) 9·1 (8·0–10·2) 11·6 (10·5–12·9) 9·1 (8·0–10·1) 9·9 (8·9–11·0)
Pakistan 14·1 (13·7–14·5) 14·9 (13·5–16·4) 14·1 (13·7–14·6) 14·5 (13·1–15·9) 10·1 (9·0–11·0) 10·6 (9·2–12·2) 10·5 (9·5–11·4) 10·8 (9·5–12·2)
Southeast Asia, 
east Asia, and Oceania
15·0 (14·9–15·2) 18·4 (18·1–18·6) 13·3 (13·1–13·4) 15·4 (15·2–15·7) 11·3 (10·3–12·1) 13·7 (12·5–14·8) 10·3 (9·6–11·0) 11·9 (11·0–12·8)
East Asia 15·0 (14·8–15·2) 18·6 (18·3–18·9) 13·3 (13·2–13·5) 15·7 (15·4–16·0) 11·3 (10·4–12·2) 14·0 (12·7–15·1) 10·5 (9·8–11·2) 12·2 (11·3–13·1)
China 15·0 (14·8–15·1) 18·6 (18·3–18·9) 13·3 (13·2–13·5) 15·7 (15·4–16·0) 11·3 (10·4–12·1) 14·0 (12·7–15·0) 10·5 (9·7–11·2) 12·2 (11·3–13·1)
North Korea 16·5 (15·4–18·0) 16·7 (15·4–18·1) 13·2 (12·8–14·4) 13·3 (12·9–13·8) 12·3 (11·1–13·7) 12·3 (11·1–13·7) 10·3 (9·5–11·4) 10·3 (9·4–11·1)
Taiwan (province of 
China)
17·0 (16·9–17·1) 21·3 (20·8–21·8) 15·3 (15·2–15·3) 18·0 (17·6–18·4) 12·7 (11·6–13·7) 15·7 (14·3–17·0) 11·9 (11·0–12·7) 13·6 (12·6–14·7)
Oceania 11·8 (11·4–12·3) 12·7 (12·1–13·3) 10·4 (10·1–10·8) 11·0 (10·5–11·6) 8·5 (7·6–9·4) 9·0 (8·0–10·0) 7·7 (6·9–8·4) 8·0 (7·2–8·8)
American Samoa 16·4 (15·9–17·1) 15·9 (15·6–16·4) 13·0 (12·7–13·5) 13·9 (12·9–15·3) 11·8 (10·6–13·0) 11·4 (10·1–12·5) 9·6 (8·7–10·6) 10·2 (9·0–11·6)
Federated States of 
Micronesia
12·7 (12·1–13·6) 14·3 (13·2–15·0) 11·7 (10·8–12·7) 12·3 (11·8–12·8) 9·3 (8·2–10·3) 10·2 (8·9–11·3) 8·8 (7·7–9·9) 9·1 (8·1–10·0)
Fiji 14·5 (13·6–15·4) 14·4 (13·3–15·7) 12·6 (11·9–13·3) 12·1 (11·3–13·1) 10·6 (9·4–11·7) 10·4 (9·0–11·8) 9·4 (8·4–10·4) 8·9 (7·9–10·0)
Guam 18·0 (17·6–18·3) 17·8 (17·1–18·5) 14·3 (14·1–14·6) 15·6 (15·1–16·2) 13·3 (12·0–14·4) 12·9 (11·5–14·2) 11·0 (10·0–11·8) 11·7 (10·5–12·7)
Kiribati 12·0 (11·5–12·5) 13·0 (12·2–14·3) 10·4 (10·0–10·7) 10·7 (10·1–11·4) 8·7 (7·8–9·6) 9·2 (8·1–10·5) 7·7 (7·0–8·4) 7·8 (6·9–8·7)
Marshall Islands 13·0 (12·8–13·2) 13·2 (12·3–14·0) 10·3 (10·0–10·6) 11·1 (10·4–12·0) 9·6 (8·7–10·4) 9·6 (8·4–10·7) 7·8 (7·1–8·5) 8·3 (7·4–9·3)
Northern Mariana 
Islands
17·0 (16·2–18·2) 19·0 (18·2–19·7) 15·6 (14·0–16·4) 15·9 (14·8–16·8) 12·5 (11·2–13·8) 13·8 (12·3–15·2) 11·8 (10·4–13·0) 11·9 (10·5–12·9)
Papua New Guinea 10·5 (10·0–11·2) 11·6 (10·8–12·3) 9·4 (9·0–10·0) 10·2 (9·6–11·1) 7·5 (6·6–8·3) 8·1 (7·1–9·1) 6·9 (6·2–7·7) 7·5 (6·6–8·3)
Samoa 17·0 (15·9–18·4) 16·2 (15·3–17·7) 14·3 (13·3–15·2) 14·1 (13·8–14·7) 12·5 (11·0–14·0) 11·7 (10·4–13·2) 10·8 (9·7–11·9) 10·5 (9·5–11·5)
Solomon Islands 12·1 (11·4–12·8) 13·4 (12·7–14·0) 11·2 (10·4–12·2) 12·1 (11·4–12·8) 8·9 (8·0–9·9) 9·7 (8·6–10·7) 8·5 (7·6–9·5) 9·1 (8·1–10·0)
Tonga 15·0 (14·6–15·5) 16·6 (15·5–18·0) 13·1 (12·9–13·4) 13·5 (12·7–14·0) 10·9 (9·7–11·9) 11·9 (10·4–13·4) 9·9 (9·0–10·7) 10·1 (9·0–11·0)
Vanuatu 12·8 (12·0–13·6) 13·4 (12·6–14·4) 10·9 (10·2–11·8) 11·5 (10·6–12·4) 9·3 (8·2–10·3) 9·5 (8·4–10·6) 8·3 (7·4–9·2) 8·6 (7·6–9·5)
Southeast Asia 15·1 (14·8–15·3) 17·5 (17·2–17·9) 13·0 (12·8–13·2) 14·3 (14·0–14·6) 11·0 (9·9–12·0) 12·9 (11·6–14·0) 9·8 (8·9–10·6) 10·7 (9·8–11·6)
Cambodia 12·4 (11·8–13·1) 15·9 (14·7–16·8) 11·0 (10·5–11·6) 13·0 (12·7–13·2) 8·8 (7·7–9·8) 11·4 (10·1–12·7) 8·1 (7·2–8·9) 9·6 (8·6–10·4)
Indonesia 14·2 (13·8–14·5) 16·1 (15·6–16·6) 13·2 (12·9–13·5) 13·4 (13·0–14·0) 10·2 (9·2–11·2) 11·6 (10·5–12·7) 9·8 (8·9–10·7) 10·0 (9·1–11·0)
Laos 11·8 (10·9–13·0) 15·7 (14·5–16·8) 10·5 (9·7–11·5) 13·2 (12·4–14·3) 8·8 (7·8–10·0) 11·7 (10·4–13·0) 8·1 (7·2–9·0) 10·0 (9·0–11·2)
Malaysia 15·1 (15·0–15·1) 16·9 (16·2–17·6) 13·3 (13·3–13·3) 14·8 (14·1–15·5) 11·3 (10·3–12·2) 12·6 (11·4–13·8) 10·2 (9·3–11·0) 11·3 (10·3–12·4)
Maldives 12·4 (12·2–12·5) 21·6 (21·0–22·2) 13·3 (13·2–13·5) 19·2 (18·7–19·7) 8·9 (8·0–9·7) 15·9 (14·3–17·4) 10·0 (9·1–10·8) 14·6 (13·3–15·8)
Mauritius 15·8 (15·6–16·0) 18·4 (17·8–19·0) 12·3 (12·2–12·4) 15·3 (14·8–15·8) 11·7 (10·6–12·8) 13·4 (12·0–14·7) 9·2 (8·4–10·0) 11·3 (10·2–12·3)
Myanmar 12·5 (11·4–13·7) 16·3 (15·2–17·6) 10·5 (9·8–11·6) 12·8 (12·5–13·5) 8·8 (7·7–10·1) 11·7 (10·4–13·1) 7·7 (6·7–8·7) 9·5 (8·6–10·3)
Philippines 16·3 (15·9–16·8) 15·8 (14·6–16·9) 14·3 (13·8–14·7) 12·8 (11·8–13·9) 11·9 (10·7–12·9) 11·5 (10·2–12·8) 10·5 (9·5–11·5) 9·4 (8·3–10·6)
Sri Lanka 17·0 (16·8–17·3) 19·7 (18·8–21·5) 13·2 (13·0–13·3) 15·8 (14·7–17·0) 12·8 (11·6–13·8) 14·8 (13·2–16·7) 10·0 (9·2–10·8) 12·0 (10·7–13·3)
Seychelles 17·4 (17·0–17·7) 18·1 (17·7–18·6) 12·6 (12·4–12·8) 14·2 (13·9–14·5) 13·0 (11·8–14·2) 13·5 (12·2–14·7) 9·7 (8·8–10·4) 10·8 (9·8–11·7)
Thailand 17·1 (16·8–17·4) 21·7 (20·9–22·5) 14·6 (14·3–14·9) 18·5 (17·7–19·4) 12·8 (11·6–13·8) 16·3 (14·8–17·7) 11·0 (10·1–11·9) 14·1 (12·8–15·4)
Timor-Leste 13·4 (12·3–14·5) 16·3 (15·3–17·3) 13·7 (12·9–14·6) 13·8 (13·0–15·0) 9·5 (8·3–10·8) 11·7 (10·3–13·0) 9·9 (8·8–11·1) 10 ·0 (9·0–11·3)
Vietnam 16·4 (15·7–17·4) 18·8 (18·0–19·9) 12·7 (12·3–13·3) 13·9 (13·0–14·6) 12·2 (11·0–13·4) 14·0 (12·6–15·5) 9·7 (8·8–10·6) 10·6 (9·6–11·5)
Sub-Saharan Africa 13·2 (12·9–13·6) 15·4 (15·1–15·8) 12·1 (11·8–12·4) 13·4 (13·1–13·7) 9·6 (8·6–10·4) 11·3 (10·2–12·4) 8·8 (7·9–9·6) 9·9 (8·9–10·8)
Central sub-Saharan Africa 12·2 (11·5–12·8) 13·9 (12·9–14·8) 10·7 (10·1–11·2) 12·1 (11·6–12·9) 8·5 (7·5–9·5) 9·9 (8·7–11·0) 7·6 (6·7–8·5) 8·7 (7·7–9·8)
Angola 11·6 (10·6–12·8) 15·0 (13·7–16·3) 10·0 (9·3–11·0) 12·3 (11·7–13·4) 8·4 (7·3–9·5) 10·8 (9·4–12·2) 7·3 (6·4–8·2) 8·9 (7·9–10·1)
Central African Republic 10·4 (9·8–11·1) 11·4 (10·2–13·2) 8·9 (8·6–9·3) 9·7 (9·0–10·6) 7·4 (6·5–8·2) 8·2 (7·0–9·7) 6·3 (5·6–7·0) 7·0 (6·2–7·9)
Congo (Brazzaville) 11·0 (10·4–11·7) 12·8 (11·9–14·4) 9·9 (9·4–10·4) 12·7 (12·1–13·7) 7·8 (6·9–8·7) 9·3 (8·1–10·6) 7·1 (6·3–7·8) 9·2 (8·2–10·3)
Democratic Republic of 
the Congo
12·5 (11·6–13·5) 13·7 (12·4–15·0) 11·0 (10·2–12·0) 12·1 (11·4–13·3) 8·7 (7·6–9·8) 9·7 (8·5–11·0) 7·8 (6·8–8·9) 8·7 (7·5–10·0)
Equatorial Guinea 10·6 (9·5–11·8) 15·9 (13·3–18·8) 9·1 (8·5–10·0) 13·7 (12·3–15·3) 7·6 (6·6–8·7) 11·5 (9·5–13·7) 6·6 (5·9–7·5) 9·9 (8·6–11·3)
(Table 2 continues on next page)
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Life expectancy at age 65 years HALE at age 65 years
Females Males Females Males
1990 2017 1990 2017 1990 2017 1990 2017
(Continued from previous page)
Gabon 13·5 (12·5–14·4) 16·3 (14·9–17·8) 10·8 (10·3–11·2) 12·9 (12·5–13·1) 9·6 (8·5–10·8) 11·7 (10·2–13·3) 7·8 (7·0–8·7) 9·4 (8·4–10·2)
Eastern sub-Saharan 
Africa
11·6 (11·4–11·8) 15·3 (15·0–15·6) 11·1 (10·9–11·3) 13·0 (12·8–13·3) 8·6 (7·7–9·3) 11·4 (10·3–12·3) 8·2 (7·4–8·9) 9·7 (8·8–10·6)
Burundi 10·2 (9·5–11·1) 13·2 (12·0–14·6) 9·3 (8·8–9·9) 12·0 (11·2–13·2) 7·8 (6·9–8·6) 10·0 (8·8–11·3) 7·0 (6·2–7·7) 9·0 (8·0–10·2)
Comoros 12·4 (11·4–13·5) 15·2 (13·9–16·5) 11·7 (10·8–12·7) 13·5 (12·6–14·6) 9·2 (8·1–10·3) 11·5 (10·1–12·8) 8·6 (7·5–9·6) 10·1 (8·9–11·3)
Djibouti 13·1 (11·7–14·6) 15·3 (13·3–17·3) 12·7 (11·4–14·0) 13·4 (12·2–15·0) 9·8 (8·5–11·2) 11·6 (9·9–13·4) 9·6 (8·3–10·9) 10·1 (8·9–11·6)
Eritrea 10·0 (9·4–10·6) 13·2 (12·2–14·7) 8·0 (7·8–8·3) 11·0 (10·3–12·1) 7·2 (6·4–8·0) 9·8 (8·6–11·2) 5·7 (5·0–6·3) 8·0 (7·1–9·1)
Ethiopia 10·0 (9·6–10·4) 16·0 (15·4–16·6) 9·5 (9·2–9·8) 14·1 (13·6–14·6) 7·3 (6·5–8·0) 11·9 (10·7–13) 6·9 (6·2–7·6) 10·5 (9·5–11·5)
Kenya 13·9 (13·5–14·2) 15·9 (15·5–16·3) 13·2 (13·0–13·5) 12·8 (12·5–13·0) 10·4 (9·4–11·2) 11·9 (10·8–12·9) 9·9 (8·9–10·8) 9·5 (8·6–10·3)
Madagascar 12·1 (11·6–12·6) 13·5 (12·1–15·0) 12·9 (12·3–13·4) 12·6 (11·6–14·0) 9·0 (8·1–9·8) 10·1 (8·8–11·5) 9·6 (8·6–10·5) 9·5 (8·4–10·8)
Malawi 12·1 (11·5–12·7) 15·8 (14·5–17·0) 11·2 (10·7–11·8) 12·3 (11·8–13·0) 9·0 (8·1–9·9) 11·8 (10·4–13·2) 8·3 (7·4–9·1) 9·1 (8·2–10·0)
Mozambique 12·4 (11·7–13·0) 14·0 (12·6–15·5) 11·0 (10·5–11·5) 11·2 (10·5–12·0) 9·1 (8·2–10·0) 10·4 (9·0–11·8) 8·0 (7·2–8·9) 8·2 (7·3–9·2)
Rwanda 10·4 (9·8–11·0) 16·0 (14·9–17·1) 9·5 (9·1–9·9) 13·1 (12·5–14·1) 7·8 (7·0–8·6) 12·1 (10·7–13·4) 7·2 (6·5–7·9) 9·9 (8·9–11·0)
Somalia 10·8 (9·7–12·0) 12·3 (10·9–13·8) 10·2 (9·2–11·3) 11·4 (10·4–12·7) 8·0 (7·0–9·2) 9·2 (8·0–10·6) 7·6 (6·6–8·7) 8·5 (7·5–9·7)
South Sudan 12·0 (10·8–13·4) 13·7 (11·9–15·3) 11·0 (9·9–12·2) 12·1 (10·8–13·4) 8·4 (7·2–9·6) 9·5 (8·0–11·0) 7·9 (6·8–9·0) 8·6 (7·3–9·9)
Tanzania 13·1 (12·5–13·9) 16·0 (15·0–16·8) 12·5 (11·8–13·1) 13·9 (13·0–14·6) 9·8 (8·8–10·7) 12·0 (10·8–13·2) 9·3 (8·3–10·2) 10·4 (9·3–11·5)
Uganda 12·0 (11·3–12·8) 16·1 (14·9–17·1) 12·1 (11·1–13·4) 12·7 (12·1–13·9) 8·7 (7·7–9·7) 12·0 (10·6–13·3) 8·7 (7·6–10·0) 9·4 (8·5–10·5)
Zambia 11·5 (11·0–12·0) 14·9 (13·8–16·2) 11·3 (10·8–12·0) 12·4 (12·0–13·2) 8·6 (7·8–9·4) 11·2 (9·8–12·5) 8·5 (7·6–9·4) 9·3 (8·4–10·2)
Southern sub-Saharan 
Africa
17·8 (17·6–18·1) 17·5 (17·2–17·7) 14·5 (14·3–14·8) 14·0 (13·8–14·2) 12·6 (11·4–13·8) 12·4 (11·2–13·5) 10·5 (9·5–11·5) 10·1 (9·0–11·0)
Botswana 15·8 (14·8–17·0) 16·3 (15·3–17·1) 11·9 (11·2–12·4) 14·8 (13·5–15·4) 11·2 (10·0–12·5) 11·5 (10·3–12·8) 8·5 (7·6–9·4) 10·5 (9·1–11·8)
Lesotho 14·4 (13·5–15·3) 13·5 (11·9–15·7) 10·8 (10·3–11·3) 10·0 (9·4–10·7) 10·1 (8·9–11·3) 9·4 (7·9–11·1) 7·8 (6·9–8·5) 7·0 (6·2–7·9)
Namibia 13·9 (13·2–14·7) 17·7 (16·1–19·2) 11·4 (11·0–11·7) 12·8 (12·4–13·1) 9·8 (8·8–10·9) 12·6 (11·0–14·3) 8·1 (7·2–8·9) 9·1 (8·1–10·0)
South Africa 18·9 (18·6–19·1) 18·3 (18·1–18·4) 15·7 (15·4–15·9) 14·6 (14·5–14·8) 13·3 (12–14·6) 13·0 (11·7–14·2) 11·3 (10·2–12·4) 10·5 (9·4–11·5)
Swaziland (eSwatini) 14·0 (13·1–15·0) 15·1 (13·2–17·2) 10·9 (10·3–11·5) 10·8 (10·1–11·8) 9·9 (8·7–11·1) 10·6 (8·9–12·3) 7·8 (6·9–8·6) 7·6 (6·6–8·5)
Zimbabwe 15·3 (14·5–16·0) 13·7 (12·5–15·1) 12·3 (11·6–13·3) 11·6 (10·7–12·3) 10·9 (9·8–12·1) 9·8 (8·5–11·1) 9·0 (8·0–10·1) 8·4 (7·4–9·3)
Western sub-Saharan 
Africa
13·6 (12·9–14·4) 15·3 (14·4–16·2) 12·8 (12·1–13·5) 13·9 (13·2–14·5) 9·8 (8·7–10·8) 11·2 (9·9–12·4) 9·3 (8·2–10·2) 10·2 (9·1–11·2)
Benin 13·5 (12·8–14·3) 14·9 (13·5–16·3) 12·0 (11·4–12·6) 13·3 (12·1–14·4) 9·6 (8·5–10·7) 10·9 (9·5–12·4) 8·7 (7·6–9·7) 9·8 (8·5–11·1)
Burkina Faso 12·5 (11·9–13·1) 14·3 (13·4–15·3) 11·7 (11·1–12·3) 12·5 (11·7–13·3) 8·9 (7·9–9·9) 10·6 (9·4–11·7) 8·3 (7·2–9·2) 9·2 (8·2–10·3)
Cameroon 12·9 (12·3–13·6) 14·8 (13·2–16·3) 12·1 (11·6–12·7) 12·8 (11·7–14·1) 9·2 (8·2–10·2) 10·9 (9·4–12·3) 8·8 (7·8–9·6) 9·5 (8·2–10·7)
Cape Verde 18·8 (18·5–19·1) 19·7 (19·4–20·4) 16·1 (15·9–16·3) 17·4 (16·8–18·1) 14·0 (12·6–15·1) 14·8 (13·4–16·1) 12·2 (11·1–13·1) 13·2 (11·9–14·4)
Chad 13·0 (12·4–13·7) 13·8 (12·6–15·0) 12·2 (11·6–12·9) 12·8 (11·8–13·7) 9·3 (8·3–10·4) 9·9 (8·6–11·2) 8·8 (7·8–9·8) 9·3 (8·2–10·4)
Côte d’Ivoire 13·4 (12·6–14·2) 14·7 (13·4–16·0) 11·7 (11·0–12·5) 12·9 (11·8–13·9) 9·3 (8·1–10·4) 10·7 (9·4–12·2) 8·3 (7·3–9·3) 9·5 (8·3–10·6)
The Gambia 13·6 (12·5–14·9) 14·5 (13·2–15·8) 12·0 (10·9–13·2) 12·7 (12·3–13·3) 9·9 (8·7–11·2) 10·6 (9·2–12·0) 8·9 (7·8–10·1) 9·5 (8·5–10·4)
Ghana 13·3 (12·3–14·4) 15·2 (14·1–16·3) 12·6 (11·7–13·6) 12·4 (12·0–13·1) 9·8 (8·7–11·0) 11·3 (10·1–12·6) 9·3 (8·2–10·4) 9·3 (8·3–10·2)
Guinea 12·4 (11·8–13·0) 13·1 (12·1–14·2) 12·8 (12·2–13·4) 12·2 (11·4–13·2) 9·0 (8·1–10·0) 9·7 (8·6–10·8) 9·4 (8·6–10·3) 9·1 (8·0–10·2)
Guinea-Bissau 11·3 (10·4–12·5) 13·0 (11·8–14·5) 9·6 (8·9–10·5) 11·4 (10·6–12·1) 8·2 (7·1–9·3) 9·5 (8·2–10·7) 7·0 (6·1–7·9) 8·4 (7·4–9·3)
Liberia 12·6 (11·7–13·5) 14·1 (12·8–15·5) 12·5 (11·7–13·3) 13·7 (12·6–14·6) 8·7 (7·6–9·8) 10·0 (8·6–11·3) 8·9 (7·7–10) 9·8 (8·6–11·1)
Mali 11·5 (11·0–12·0) 14·5 (13·4–15·6) 11·8 (11·3–12·3) 14·1 (13·3–15·2) 8·2 (7·2–9·0) 10·5 (9·2–11·8) 8·4 (7·5–9·3) 10·3 (9·0–11·4)
Mauritania 12·2 (11·5–13·0) 15·5 (14·3–16·7) 12·4 (11·8–13·2) 15·1 (14·1–16·6) 8·8 (7·8–9·7) 11·3 (9·9–12·7) 9·0 (8·1–10·0) 11·0 (9·6–12·5)
Niger 12·6 (11·9–13·3) 14·2 (13·1–15·5) 12·0 (11·4–12·6) 13·4 (12·5–14·4) 9·3 (8·2–10·2) 10·5 (9·4–11·8) 8·8 (7·9–9·8) 10·0 (8·8–11·1)
Nigeria 14·3 (12·8–15·9) 16·4 (14·3–18·8) 13·5 (12·1–15·0) 15·2 (13·5–16·4) 10·3 (8·9–11·8) 12·0 (10·0–13·8) 9·8 (8·5–11·3) 11·1 (9·5–12·5)
São Tomé and Príncipe 15·9 (15·2–16·6) 15·3 (14·3–16·6) 14·3 (13·7–14·9) 13·6 (13·0–14·4) 11·7 (10·5–12·8) 11·4 (10·2–12·8) 10·6 (9·6–11·6) 10·1 (9·1–11·2)
Senegal 13·5 (12·9–14·2) 15·3 (14·2–16·3) 12·3 (11·7–12·9) 13·3 (12·5–14·2) 9·8 (8·7–10·9) 11·2 (9·9–12·4) 9·0 (8·0–9·9) 9·8 (8·6–10·9)
Sierra Leone 13·2 (12·2–14·2) 13·3 (12·2–14·5) 11·6 (10·8–12·4) 13·0 (12·1–13·9) 9·6 (8·5–10·7) 9·7 (8·5–10·9) 8·4 (7·5–9·3) 9·5 (8·2–10·6)
Togo 13·2 (12·4–14·1) 15·1 (13·7–16·5) 12·2 (11·5–13·0) 12·5 (11·7–13·6) 9·6 (8·5–10·7) 11·1 (9·7–12·6) 9·0 (8·0–10·0) 9·3 (8·2–10·4)
Data in parentheses are 95% uncertainty intervals. Super-regions, regions, and countries are listed alphabetically. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. HALE=healthy life expectancy. 
SDI=Socio-demographic Index.
Table 2: Life expectancy and HALE at age 65 years for 21 GBD regions and 195 countries and territories, by sex, in 1990 and 2017
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had higher HALE at birth (appendix 2). In all other 
regions, females had higher HALE at birth than males 
did in all study years. Eastern Europe had the biggest 
difference in HALE at birth between females and males 
throughout the period 1990–2017, with a difference of 
7·7 years (6·8–8·4) in 2017. North Africa and the Middle 
East had the smallest difference in HALE at birth 
between females and males in 1990, and south Asia had 
the lowest difference in 2017 (appendix 2).
At the country level, countries that had the largest 
increases in HALE at birth for both sexes combined 
between 1990 and 2017 were Eritrea (23·7 years [95% UI 
21·9–25·6], Ethiopia (18·5 years [17·2–19·9], and Uganda 
(16·3 years [13·5–19·0]). The smallest increases were seen 
in Saint Vincent and the Grenadines (1·0 years [0·4–1·7]), 
South Africa (1·1 years [0·3–1·8]), and Uzbekistan 
(1·4 years [0·4–2·4]). Decreases in HALE at birth for both 
sexes combined occurred in Lesotho (5·0 years [3·1–6·8]), 
Swaziland (eSwatini; 2·3 years  [0·4–4·3]), and Guam 
(1·2 years [0·5–1·9]). In 2017, the highest HALE at birth 
was estimated to be in Singapore for both females 
(75·8 years [72·4–78·7]) and males (72·6 years [69·8–75·0]; 
table 1). The lowest HALE at birth in 2017 for both males 
and females was estimated to be in the Central African 
Republic, at 47·0 years (43·7–50·2) for females and 
42·8 years (40·1–45·6) for males. The largest differences 
in HALE at birth in 2017 between males and females were 
in Ukraine [8·7 years (7·5–9·8), Lithuania (7·8 years 
[6·6–8·9]), and Russia (7·4 years [6·6–8·1]).
Trends in HALE for males and females at age 65 years
Globally, HALE at age 65 years for females was 11·9 years 
(95% UI 10·8–12·9) in 1990 and 13·7 years (12·4–14·9) 
in 2017, an increase of 1·8 years (1·6–2·0; table 2). For 
males, HALE at age 65 years increased by 1·7 years 
(1·5–1·9), from 10·3 years (9·4–11·1) to 12·0 years 
(10·9–12·9). At the SDI level, both males and females in 
the high SDI quintile had the largest increases in HALE 
at age 65, increasing from 13·9 years (12·7–15·1) in 1990 
to 16·2 years (14·6–17·6) in 2017 for females, and 
increasing from 11·3 years (10·3–12·1) in 1990 to 
13·8 years (12·6–15·0) in 2017 for males. The countries 
with the largest increases in HALE for females at age 65 
years from 1990 to 2017 were the Maldives (by 7·0 years 
[6·3–7·8]), Singapore (by 4·9 years [4·4–5·5]), and 
Ethiopia (by 4·6 years [4·0–5·3]). For males, the largest 
increases were in Iraq (by 4·7 years [3·8–5·6]), the 
Maldives (by 4·5 years [4·0–5·1]), and South Korea (by 
4·5 years [4·0–5·0]). In 2017, the largest difference 
between HALE at age 65 years between females and 
males was in Bermuda (17·7 years [16·2–19·2] for 
females, and 13·4 years [12·4–14·5] for males).
Decomposition of years of life gained at birth and at age 
65 years
Although life expectancy at birth increased for both 
males and females globally during the period 1990–2017, 
the proportion of additional years spent in poor health 
was 15·3% (95% UI 11·8–19·2) of the additional 7·5 years 
(7·2–7·9) for females and 14·9% (11·3–19·0) of the 
additional 7·3 years (6·9–7·7) for males, with substantial 
variations across SDI quintiles, regions, and countries 
(figure 2). The proportion of additional years spent in 
poor health varied from 11·1% (8·3–14·3) of the 
additional 8·2 years (7·5–8·8) among females in low-
middle SDI countries, to 27·3% (20·8–34·4) of the 
additional 4·4 years (4·2–4·6) among females in high 
SDI countries. From 1990 to 2017, life expectancy at birth 
increased the most for both males and females in eastern 
sub-Saharan Africa compared with other regions (table 1), 
but of the additional years gained, 11·1% (8·3–14·3) of 
13·8 years (12·8–14·8) for males and 13·1% (10·0–16·7) 
of 14·6 years (13·7–15·5) for females were spent in poor 
health. At the country level, 179 countries gained 
additional years of life from 1990 to 2017, and 16 did not 
(appendix 2). The most additional years of life were 
gained by males in Eritrea (28·6 years [25·7–31·4]), 
Ethiopia (21·1 years [19·5–22·8]), and Equatorial Guinea 
(18·6 years [15·1–21·8]). Of these years gained, the 
proportion spent in poor health was 11·3% (8·0–14·9) for 
Eritrea, 12·1% (9·2–15·6) for Ethiopia, and 13·7% 
(9·4–18·7) for Equatorial Guinea. Females gained the 
most additional years of life in Eritrea (22·4 years 
[19·7–25·4]), Ethiopia (21·5 years [20·0–23·2]), and 
Rwanda (19·5 years [17·1–22·1]). Of these years gained, 
the proportion spent in poor health was 10·4% (7·1–14·6) 
for Eritrea, 13·6% (10·2–17·4) for Ethiopia, and 16·1% 
(11·8–21·1) for Rwanda. Males spent over a third of the 
years of life gained in poor health in Belize (45·9% 
[5·5–155·6]), Ukraine (39·3% [14·1–128·7]), the 
Federated States of Micronesia (34·2% [7·0–55·9]), and 
the USA (33·6% [25·1–42·2]). Similarly, females spent 
over a third of their years of life gained in poor health in 
the USA (47·9% [35·2–61·6]), Northern Mariana Islands 
(40·7% [25·9–70·7]), and the UK (34·3% [25·8–43·6]; 
appendix 2).
Globally, between 1990 and 2017, life expectancy for 
females at age 65 years increased by 2·5 years (95% UI 
2·4–2·6) and they spent 27·6% (21·2–35·0) of those 
years in poor health (appendix 2). Similarly, males at age 
65 years gained 2·4 years (2·2–2·5) of life and spent 
26·6% (20·1–34·0) of those years in poor health. 
Between 1990 and 2017, at the SDI quintile level, females 
in the high SDI quintile spent the largest proportion 
of years gained in poor health (29·9% [22·9–37·5] 
of 3·2 years [3·1–3·4] gained), and females in the 
low-middle SDI quintile spent the smallest proportion 
of years gained in poor health (23·8% [17·1–31·6] of 
2·0 years [1·7–2·3] gained; appendix 2). Similarly, males 
in the high SDI quintile spent the largest proportion of 
additional years in poor health in the same period 
(30·0% [22·9–37·8] of 3·7 years [3·6–3·8] gained), and 
males in the low-middle SDI quintile spent the smallest 
proportion of additional years in poor health (23·7% 
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[17·2–30·9] of 1·5 years [1·2–1·8] gained). At the country 
level, life expectancy between 1990 and 2017 for females 
at age 65 years increased the most in the Maldives 
(9·3 years [8·6–9·9]), Singapore (6·4 years [5·9–6·8]), 
and Iraq (6·2 years [5·0–7·4]), with the proportion of 
years spent in poor health being 24·4% (18·2–31·3) for 
those in the Maldives, 23·2% (17·4–29·7) for those in 
Singapore, and 28·5% (21·3–36·3) for those in Iraq 
(appendix 2). For males at age 65 years, life expectancy 
increased the most for Iraq (6·8 years [5·6–7·9]), South 
Korea (6·1 years [5·6–6·6]), and the Maldives (5·9 years 
[5·3–6·4]), with the proportion of those years spent in 
poor health being 30·3% (22·9–38·2) for Iraq, 26·1% 
(19·6–33·1) for South Korea, and 22·5% (16·6–29·4) for 
the Maldives (appendix 2).
Decomposition of extra years lived by females 
compared with males in 2017
In 2017, females had longer life expectancy than males in 
180 of 195 countries (appendix 2). Of these countries, the 
largest differences (>10 years) between female and male 
life expectancy at birth were in Ukraine (76·5 years 
[95% UI 75·8–77·2] for females and 64·7 years 
[63·9–65·4] for males), Lithuania (80·2 years [79·4–81·0] 
for females and 69·6 years [68·7–70·5] for males), Russia 
(77·2 years [77·1–77·4] for females and 66·8 years 
[66·6–66·9] for males), and Swaziland (eSwatini; 
65·1 years [62·1–68·4] for females and 54·9 years 
[52·6–57·6] for males). For the other 15 countries, life 
expectancy was not significantly different between the 
sexes.
Globally, in 2017, females lived an additional 5·1 years 
(95% UI 4·9–5·3) compared with males, and of those 
extra years 57·5% (46·2–67·4) were spent in good health 
and 42·5% (32·6–53·8) in poor health (figure 4). The 
proportion of additional years spent in poor health varied 
a lot across SDI quintiles, regions, and countries. 
Compared with all other SDI quintiles, females in the 
high-middle SDI quintile lived the most extra years of life 
compared with males, living longer than males by 
6·1 years; however, 37·8% (29·1–47·6) of those extra 
years were lived in poor health. At the regional level, the 
proportion of extra years lived in poor health among 
females in 2017 ranged from 21·9% (16·2–28·4) in central 
Europe to 92·2% (87·2–96·2) in south Asia (figure 4). 
Extra years lived by females varied from 11·9 years 
(10·9–12·9) in Ukraine to 1·4 years (0·6–2·3) in Algeria 
(appendix 2). Of the extra years lived, the proportion 
Figure 4: Extra years of life expected at birth in females compared with males by functional health status for five SDI quintiles, 21 GBD regions, and 
28 countries with the largest and smallest percentages of years spent in poor health, 2017
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDI=Socio-demographic Index.
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All-age DALYs (thousands) Age-standardised DALY rate (per 100 000)
2017 Percentage change, 2007–17 2017 Percentage change, 2007–17
Males Females Both Males Females Both Males Females Both Males Females Both
All causes 1 340 000 
(1 240 000 to 
1 460 000)
1 160 000 
(1 040 000 to 
1 290 000)
2 500 000 
(2 290 000 to 
2 740 000)
–1·4% 
(–3·0 to 
0·1)
–1·6% 
(–3·5 to 
0·2)
–1·5% 
(–3·1 to 
0·1)
35 834·3 
(33 218·6 
to 
38 740·3)
29 934·6 
(26 981·7 
to 
33 211·3)
32 796·9 
(30 041·9 
to 
35 849·3)
–15·9% 
(–17·2 to 
–14·6)*
–16·7% 
(–18·3 to 
–15·1)*
–16·2% 
(–17·6 to 
–14·8)*
Communicable, 
maternal, neonatal, and 
nutritional diseases
362 000 
(345 000 to 
384 000)
334 000 
(314 000 to 
357 000)
696 000 
(660 000 to 
740 000)
–25·8% 
(–27·9 to 
–23·6)*
–27·0% 
(–29·1 to 
–24·8)*
–26·4% 
(–28·4 to 
–24·3)*
10 106·6 
(9630·6 
to 
10 695·2)
9601·9 
(9073·8 
to 
10 240·7)
9853·3 
(9349·7 to 
10 459·3)
–31·5% 
(–33·4 to 
–29·4)*
–32·9% 
(–34·8 to 
–30·9)*
–32·2% 
(–34·0 
to 
–30·3)*
HIV/AIDS and sexually 
transmitted 
infections
35 100 
(30 900 to 
40 400)
30 800 
(27 700 to 
34 400)
65 900 
(58 700 to 
74 700)
–40·4% 
(–43·4 to 
–37·0)*
–50·0% 
(–52·7 to 
–46·9)*
–45·3% 
(–48·0 to 
–42·0)*
918·3 
(799·5 to 
1074·4)
828·2 
(735·9 to 
937·9)
874·1 
(767·5 to 
1006·2)
–46·1% 
(–49·3 to 
–42·5)*
–54·7% 
(–57·4 to 
–51·6)*
–50·5% 
(–53·4 to 
–47·1)*
HIV/AIDS 28 300 
(26 700 to 
30 200)
26 100 
(24 300 to 
28 000)
54 400 
(51 200 to 
57 700)
–44·8% 
(–46·6 to 
–42·5)*
–53·9% 
(–55·8 to 
–51·6)*
–49·6% 
(–51·3 to 
–47·4)*
724·0 
(683·0 to 
771·1)
686·1 
(638·2 to 
735·8)
704·8 
(662·6 to 
747·9)
–51·1% 
(–52·6 to 
–49·0)*
–58·8% 
(–60·6 to 
–56·8)*
–55·2% 
(–56·8 to 
–53·3)*
HIV/AIDS and 
drug-susceptible 
tuberculosis 
co-infection
5810 
(4180 to 
7430)
5260 
(3760 to 
6760)
11 100 
(7940 to 
14 200)
–51·9% 
(–55·0 to 
–48·0)*
–57·8% 
(–60·8 to 
–53·9)*
–54·9% 
(–57·9 to 
–51·0)*
150·0 
(108·3 to 
191·6)
140·2 
(100·6 to 
179·4)
145·1 
(104·4 to 
185·3)
–57·2% 
(–59·9 to 
–53·7)*
–62·3% 
(–65·0 to 
–58·9)*
–59·8% 
(–62·5 to 
–56·3)*
HIV/AIDS and 
multidrug-resistant 
tuberculosis without 
extensive drug 
resistance 
co-infection
674 
(405 to 1020)
589 
(347 to 905)
1260 
(755 to 1920)
–48·9% 
(–62·9 to 
–29·4)*
–54·2% 
(–68·1 to 
–36·0)*
–51·5% 
(–65·6 to 
–32·9)*
17·4 
(10·5 to 
26·5)
15·8 
(9·3 to 
24·2)
16·6 
(9·9 to 
25·3)
–54·4% 
(–67·0 to 
–37·1)*
–58·9% 
(–71·4 to 
–42·4)*
–56·6% 
(–69·1 to 
–40·1)*
HIV/AIDS and 
extensively 
drug-resistant 
tuberculosis 
co-infection
39·3 
(23·8 to 58·0)
23·9 
(14·9 to 35·3)
63·3 
(38·8 to 93·3)
–8·1% 
(–25·0 to 
13·5)
–13·5% 
(–32·8 to 
10·9)
–10·2% 
(–28·3 to 
11·9)
1·0 
(0·6 to 
1·5)
0·6 
(0·4 to 
0·9)
0·8 
(0·5 to 1·2)
–19·0% 
(–33·9 to 
–0·1)*
–23·3% 
(–40·4 to 
–1·7)*
–20·7% 
(–36·7 to 
–1·1)*
HIV/AIDS resulting in 
other diseases
21 800 
(19 500 to 
24 300)
20 200 
(18 000 to 
22 600)
42 100 
(37 800 to 
46 700)
–42·4% 
(–45·1 to 
–39·2)*
–52·8% 
(–55·5 to 
–49·8)*
–47·9% 
(–50·5 to 
–44·9)*
555·5 
(497·5 to 
618·1)
529·5 
(469·3 to 
591·4)
542·3 
(487·0 to 
603·1)
–49·0% 
(–51·3 to 
–46·1)*
–57·8% 
(–60·2 to 
–55·2)*
–53·7% 
(–56·1 to 
–51·1)*
Sexually transmitted 
infections excluding 
HIV
6740 
(2970 to 
12 200)
4730 
(2350 to 8070)
11 500 
(5320 to 
20 200)
–10·4% 
(–18·2 to 
–1·8)*
–6·8% 
(–14·2 to 
1·2)
–8·9% 
(–16·1 to 
–1·0)*
194·3 
(84·5 to 
355)
142·1 
(67·7 to 
246·7)
169·3 
(76·7 to 
300·4)
–13·8% 
(–21·2 to 
–5·7)*
–11·7% 
(–18·4 to 
–4·7)*
–13·0% 
(–20·1 to 
–5·5)*
Syphilis 6160 
(2430 to 
11 600)
3750 
(1460 to 
7060)
9910 
(3930 to 
18 700)
–11·9% 
(–19·7 to 
–2·9)*
–10·4% 
(–18·5 to 
–1·7)*
–11·3% 
(–19·1 to 
–2·9)*
179·6 
(70·8 to 
339)
117·3 
(45·6 to 
221·1)
149·5 
(59·1 to 
283·2)
–14·8% 
(–22·3 to 
–6·1)*
–13·4% 
(–21·2 to 
–5·0)*
–14·3% 
(–21·8 to 
–6·2)*
Chlamydial infection 192 
(112 to 336)
163 
(107 to 266)
355 
(219 to 606)
7·9% 
(4·0 to 
11·6)*
8·3% 
(4·8 to 
11·3)*
8·1% 
(5·1 to 
10·5)*
4·8 
(2·8 to 
8·5)
4·1 
(2·7 to 
6·8)
4·5 
(2·8 to 7·7)
–2·6% 
(–5·9 to 
0·7)
–3·5% 
(–7·0 to 
–0·9)*
–3·0% 
(–5·9 to 
–0·8)*
Gonococcal infection 135 
(77·5 to 244)
168 
(132 to 229)
303 
(216 to 468)
11·2% 
(7·2 to 
16·0)*
–0·3% 
(–5·7 to 
5·5)
4·5% 
(0·1 to 
8·6)*
3·5 
(2·0 to 
6·2)
4·2 
(3·3 to 
5·8)
3·9 
(2·7 to 6·0)
2·2% 
(–1·5 to 
6·5)
–12·0% 
(–17·4 to 
–6·2)*
–6·1% 
(–10·7 to 
–2·1)*
Trichomoniasis 7·04 
(2·77 to 14·8)
236 
(94·7 to 508)
243 
(97·6 to 524)
16·2% 
(12·8 to 
19·5)*
16·0% 
(14·2 to 
17·7)*
16·0% 
(14·2 to 
17·7)*
0·2 
(0·1 to 
0·4)
6·0 
(2·4 to 
12·9)
3·1 
(1·2 to 6·6)
1·7% 
(–1·0 to 
4·3)
2·3% 
(1·2 to 
3·4)*
2·2% 
(1·1 to 
3·2)*
Genital herpes 98·4 
(32·0 to 235)
149 
(48·0 to 357)
247 
(79·8 to 594)
21·2% 
(19·3 to 
22·5)*
18·9% 
(17·0 to 
20·4)*
19·8% 
(18·1 to 
21·0)*
2·5 
(0·8 to 
5·9)
3·7 
(1·2 to 
8·8)
3·1 
(1·0 to 7·4)
2·6% 
(1·7 to 
3·5)*
0·9% 
(–0·1 to 
1·9)
1·5% 
(0·9 to 
2·3)*
Other sexually 
transmitted 
infections
147 
(86·7 to 258)
269 
(189 to 399)
416 
(276 to 659)
8·0% 
(5·3 to 
11·1)*
8·2% 
(5·2 to 
11·0)*
8·1% 
(5·9 to 
10·1)*
3·7 
(2·2 to 
6·6)
6·8 
(4·8 to 
10·2)
5·3 
(3·5 to 8·4)
–1·0% 
(–3·5 to 
1·7)
–3·5% 
(–6·6 to 
–0·8)*
–2·6% 
(–5·0 to 
–0·7)*
Respiratory infections 
and tuberculosis
88 800 
(84 000 to 
94 100)
71 100 
(66 900 to 
75 600)
160 000 
(152 000 to 
168 000)
–22·1% 
(–25·2 to 
–18·5)*
–24·0% 
(–27·4 to 
–20·4)*
–22·9% 
(–25·6 to 
–19·9)*
2434·0 
(2298·0 
to 
2579·8)
2002·9 
(1881·7 
to 
2134·1)
2209·6 
(2095·9 to 
2327·9)
–30·7% 
(–33·5 to 
–27·5)*
–32·1% 
(–35·3 to 
–28·8)*
–31·4% 
(–33·9 to 
–28·6)*
Tuberculosis 28 000 
(26 400 to 
29 700)
17 000 
(16 100 to 
18 200)
45 000 
(42 800 to 
47 300)
–19·1% 
(–23·4 to 
–15·2)*
–20·6% 
(–24·6 to 
–13·1)*
–19·7% 
(–22·7 to 
–16·0)*
714·5 
(672·6 to 
759·4)
437·3 
(412·6 to 
467·3)
572·8 
(544·0 to 
602·4)
–32·0% 
(–35·5 to 
–28·7)*
–32·2% 
(–35·5 to 
–25·8)*
–32·0% 
(–34·5 to 
–28·9)*
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All-age DALYs (thousands) Age-standardised DALY rate (per 100 000)
2017 Percentage change, 2007–17 2017 Percentage change, 2007–17
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(Continued from previous page)
Latent tuberculosis 
infection
0 
(0 to 0)
0 
(0 to 0)
0 
(0 to 0)
·· ·· ·· 0 
(0 to 0)
0 
(0 to 0)
0 
(0 to 0)
·· ·· ··
Drug-susceptible 
tuberculosis
24 800 
(22 600 to 
26 900)
15 100 
(13 700 to 
16 500)
39 900 
(36 400 to 
43 100)
–19·4% 
(–25·7 to 
–13·5)*
–21·4% 
(–28·2 to 
–13·0)*
–20·2% 
(–26·0 to 
–14·4)*
632·9 
(576·3 to 
686·5)
389·1 
(354·0 to 
424·5)
508·2 
(463·4 to 
548·7)
–32·2% 
(–37·4 to 
–27·4)*
–32·9% 
(–38·4 to 
–25·6)*
–32·4% 
(–37·2 to 
–27·6)*
Multidrug-resistant 
tuberculosis without 
extensive drug 
resistance
2910 
(1710 to 4530)
1740 
(971 to 2780)
4650 
(2660 to 
7220)
–18·3% 
(–49·4 to 
25·3)
–15·0% 
(–49·6 to 
33·5)
–17·1% 
(–49·1 to 
27·5)
74·0 
(43·5 to 
115·1)
44·6 
(25·3 to 
70·5)
59·0 
(34·0 to 
91·4)
–31·3% 
(–57·4 to 
4·8)
–27·3% 
(–56·5 to 
13·6)
–29·8% 
(–56·6 to 
7·6)
Extensively 
drug-resistant 
tuberculosis
304 
(219 to 416)
143 
(92·7 to 211)
447 
(311 to 626)
2·0% 
(–23·9 to 
38·3)
15·8% 
(–20·7 to 
69·3)
6·0% 
(–22·7 to 
45·8)
7·7 
(5·5 to 
10·5)
3·6 
(2·3 to 
5·3)
5·6 
(3·9 to 7·8)
–14·4% 
(–36·2 to 
16·1)
–1·6% 
(–32·3 to 
43·4)
–10·7% 
(–34·8 to 
22·8)
Lower respiratory 
infections
56 600 
(52 800 to 
60 400)
49 900 
(46 600 to 
53 000)
106 000 
(100 000 to 
112 000)
–24·9% 
(–29·1 to 
–20·4)*
–26·8% 
(–30·7 to 
–22·6)*
–25·8% 
(–29·1 to 
–22·1)*
1605·9 
(1498·2 to 
1716·6)
1453·6 
(1354·5 
to 
1547·7)
1523·9 
(1433 to 
1610·4)
–31·4% 
(–35·3 to 
–27·4)*
–33·6% 
(–37·3 to 
–29·7)*
–32·5% 
(–35·6 to 
–29·1)*
Upper respiratory 
infections
3200 
(1930 to 
4960)
3140 
(1910 to 
4880)
6340 
(3870 to 
9820)
5·5% 
(–1·7 to 
10·4)
6·8% 
(0·7 to 
10·7)*
6·1% 
(0·7 to 
9·9)*
84·5 
(51·1 to 
131·1)
84·7 
(51·4 to 
131·0)
84·6 
(51·7 to 
130·7)
–5·2% 
(–11·5 to 
–0·8)*
–4·2% 
(–9·5 to 
–0·5)*
–4·7% 
(–9·7 to 
–1·4)*
Otitis media 1090 
(668 to 1730)
992 
(608 to 1560)
2080 
(1280 to 
3290)
1·7% 
(–2·9 to 
5·5)
2·3% 
(–2·2 to 
5·9)
2·0% 
(–1·6 to 
4·8)
29·1 
(17·8 to 
46·2)
27·3 
(16·7 to 
43·2)
28·2 
(17·3 to 
44·7)
–6·9% 
(–11·1 to 
–3·5)*
–6·8% 
(–10·9 to 
–3·6)*
–6·8% 
(–10·2 to 
–4·4)*
Enteric infections 49 100 
(41 400 to 
61 500)
46 100 
(38 700 to 
57 600)
95 200 
(83 900 to 
112 000)
–27·0% 
(–35·6 to 
–16·6)*
–27·0% 
(–33·1 to 
–18·7)*
–27·0% 
(–32·5 to 
–20·5)*
1377·7 
(1165·5 to 
1708·6)
1319·4 
(1127·4 
to 
1605·6)
1350·2 
(1195·2 to 
1579·1)
–33·2% 
(–40·8 to 
–23·6)*
–34·3% 
(–39·8 to 
–27·0)*
–33·6% 
(–38·7 to 
–27·9)*
Diarrhoeal diseases 41 400 
(33 900 to 
53 400)
39 600 
(32 100 to 
50 200)
81 000 
(70 100 to 
97 200)
–27·7% 
(–37·5 to 
–15·6)*
–27·8% 
(–35·0 to 
–18·1)*
–27·8% 
(–33·8 to 
–20·3)*
1166·8 
(958·5 to 
1491·2)
1128·4 
(932·6 to 
1406·7)
1149 
(1005·2 to 
1359·9)
–34·0% 
(–42·8 to 
–22·8)*
–35·5% 
(–41·8 to 
–27·1)*
–34·7% 
(–40·1 to 
–28·1)*
Typhoid and 
paratyphoid
5350 
(3070 to 
8560)
4450 
(2530 to 7300)
9800 
(5580 to 
15 800)
–25·4% 
(–30·4 to 
–20·8)*
–21·9% 
(–27·7 to 
–17·0)*
–23·8% 
(–29·3 to 
–19·4)*
146·6 
(84·1 to 
235·4)
128·8 
(72·5 to 
211·4)
137·9 
(78·4 to 
223·3)
–30·0% 
(–35·0 to 
–25·6)*
–27·0% 
(–32·6 to 
–22·3)*
–28·7% 
(–33·9 to 
–24·4)*
Typhoid fever 4620 
(2590 to 
7330)
3820 
(2140 to 6220)
8440 
(4730 to 
13 500)
–26·6% 
(–32·2 to 
–21·9)*
–23·7% 
(–30·4 to 
–18·7)*
–25·3% 
(–31·0 to 
–20·8)*
126·6 
(71·2 to 
202·5)
110·5 
(61·9 to 
180·5)
118·8 
(66·9 to 
190·4)
–31·2% 
(–36·6 to 
–26·5)*
–28·7% 
(–35·0 to 
–23·9)*
–30·1% 
(–35·6 to 
–25·8)*
Paratyphoid fever 730 
(336 to 1400)
633 
(287 to 1220)
1360 
(633 to 2630)
–16·3% 
(–25·7 to 
–5·7)*
–9·3% 
(–20·3 to 
2·5)
–13·2% 
(–21·2 to 
–3·8)*
20·0 
(9·1 to 
38·3)
18·3 
(8·3 to 
35·2)
19·1 
(8·9 to 
36·7)
–21·5% 
(–30·4 to 
–11·6)*
–15·1% 
(–25·6 to 
–3·8)*
–18·7% 
(–26·5 to 
–9·8)*
Invasive non-typhoidal 
salmonella disease
2240 
(1240 to 
3850)
2020 
(1150 to 3500)
4260 
(2380 to 
7380)
–16·0% 
(–25·9 to 
–3·1)*
–18·5% 
(–27·7 to 
–8·1)*
–17·2% 
(–25·7 to 
–6·8)*
63·0 
(34·9 to 
108·8)
60·3 
(34·0 to 
104·8)
61·7 
(34·7 to 
107·6)
–21·4% 
(–31·0 to 
–9·1)*
–23·8% 
(–32·6 to 
–13·9)*
–22·6% 
(–30·7 to 
–12·5)*
Other intestinal 
infectious diseases
45·5 
(26·6 to 87·5)
59·9 
(33·5 to 120)
105 
(68·7 to 172)
–43·0% 
(–75·3 to 
37·9)
–44% 
(–77·7 to 
38·8)
–43·6% 
(–71·4 to 
11·5)
1·3 
(0·7 to 
2·5)
1·8 
(1·0 to 
3·7)
1·5 
(1·0 to 2·5)
–46·4% 
(–76·8 to 
30·8)
–47·3% 
(–79·2 to 
32·5)
–46·9% 
(–73·5 to 
5·7)
Neglected tropical 
diseases and malaria
33 300 
(25 900 to 
43 000)
29 000 
(22 300 to 
36 900)
62 300 
(48 600 to 
79 900)
–29·5% 
(–37·2 to 
–21·1)*
–30·0% 
(–38·0 to 
–21·3)*
–29·7% 
(–37·2 to 
–21·2)*
917·6 
(710·8 to 
1192·3)
836·2 
(636·3 to 
1073·7)
877·6 
(679·5 to 
1129·2)
–35·2% 
(–42·5 to 
–27·4)*
–36·2% 
(–43·7 to 
–28·0)*
–35·7% 
(–42·7 to 
–27·7)*
Malaria 24 000 
(16 800 to 
32 800)
21 100 
(14 800 to 
28 400)
45 000 
(31 700 to 
61 000)
–33·0% 
(–42·5 to 
–22·3)*
–35·4% 
(–44·9 to 
–25·4)*
–34·2% 
(–43·1 to 
–23·5)*
672·3 
(468·6 to 
924·1)
626·4 
(437·9 to 
848·8)
649·8 
(457·1 to 
878·7)
–37·7% 
(–46·8 to 
–27·6)*
–40·2% 
(–49·2 to 
–30·7)*
–38·9% 
(–47·4 to 
–28·8)*
Chagas disease 138 
(125 to 156)
94 
(84·1 to 107)
232 
(210 to 261)
–3·6% 
(–8·8 to 
4·6)
–1·4% 
(–5·9 to 
4·6)
–2·8% 
(–6·8 to 
4·1)
3·6 
(3·2 to 
4·0)
2·2 
(2·0 to 
2·6)
2·9 
(2·6 to 3·2)
–24·0% 
(–28·1 to 
–17·7)*
–22·7% 
(–26·2 to 
–18·0)*
–23·4% 
(–26·6 to 
–18·0)*
Leishmaniasis 442 
(89·4 to 1700)
332 
(109 to 1030)
774 
(199 to 2720)
–55·4% 
(–68·9 to 
28·3)
–46·5% 
(–67·3 to 
36·1)
–52% 
(–68·2 to 
32·5)
11·9 
(2·3 to 
46·7)
9·2 
(2·8 to 
29·6)
10·6 
(2·6 to 
38·2)
–59·0% 
(–71·0 to 
12·7)
–52·1% 
(–69·9 to 
20·1)
–56·3% 
(–70·6 to 
16·5)
(Table 3 continues on next page)
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(Continued from previous page)
Visceral leishmaniasis 326 
(0·657 to 
1570)
184 
(0·355 to 878)
511 
(1·02 to 2440)
–63·9% 
(–85·7 to 
–41·3)*
–63·8% 
(–81·6 to 
–36·5)*
–63·9% 
(–84·5 to 
–40·0)*
8·9 
(0 to 43·3)
5·4 
(0 to 
25·8)
7·2 
(0 to 34·7)
–66·3% 
(–87·4 to 
–46·2)*
–66·1% 
(–83·1 to 
–41·3)*
–66·2% 
(–86·0 to 
–44·3)*
Cutaneous and 
mucocutaneous 
leishmaniasis
116 
(74·8 to 171)
148 
(96·6 to 216)
264 
(172 to 389)
30·5% 
(20·3 to 
43·1)*
32·3% 
(22·0 to 
45·5)*
31·5% 
(21·2 to 
44·2)*
3·0 
(1·9 to 
4·4)
3·8 
(2·5 to 
5·5)
3·4 
(2·2 to 5·0)
14·4% 
(4·6 to 
26·4)*
15·8% 
(5·8 to 
28·1)*
15·3% 
(5·2 to 
27·4)*
African 
trypanosomiasis
41·5 
(7·46 to 160)
37·5 
(7·06 to 142)
79·0 
(15·4 to 287)
–80·7% 
(–95·9 to 
–22·4)*
–80·8% 
(–95·8 to 
–30·1)*
–80·7% 
(–95·6 to 
–27·3)*
1·1 
(0·2 to 
4·2)
1·0 
(0·2 to 
3·8)
1·1 
(0·2 to 3·9)
–82·3% 
(–96·3 to 
–30·8)*
–82·3% 
(–96·2 to 
–33·5)*
–82·3% 
(–95·9 to 
–33·4)*
Schistosomiasis 693 
(427 to 1180)
738 
(447 to 1250)
1430 
(876 to 2440)
–19·3% 
(–21·9 to 
–15·7)*
–19·8% 
(–22·5 to 
–17·1)*
–19·6% 
(–21·6 to 
–17·3)*
17·7 
(10·9 to 
30·0)
18·9 
(11·5 to 
31·9)
18·3 
(11·2 to 
30·9)
–29·3% 
(–31·8 to 
–26·2)*
–29·5% 
(–32·1 to 
–27·1)*
–29·4% 
(–31·4 to 
–27·4)*
Cysticercosis 671 
(440 to 928)
937 
(618 to 1300)
1610 
(1050 to 2230)
3·7% 
(–1·7 to 
8·8)
10·5% 
(5·5 to 
15·1)*
7·6% 
(2·4 to 
12·0)*
17·1 
(11·2 to 
23·5)
23·1 
(15·2 to 
32·1)
20·1 
(13·2 to 
27·8)
–13·0% 
(–17·5 to 
–8·9)*
–7·3% 
(–11·7 to 
–3·5)*
–9·8% 
(–14·0 to 
–6·1)*
Cystic echinococcosis 46·8 
(32·0 to 65·0)
53·4 
(37·2 to 73·4)
100 
(72·8 to 139)
–22·7% 
(–46·2 to 
7·7)
–17·7% 
(–39 to 
7·2)
–20·1% 
(–36·7 to 
0·6)
1·2 
(0·8 to 
1·7)
1·4 
(1·0 to 
1·9)
1·3 
(1·0 to 1·8)
–32·5% 
(–53·1 to 
–6·3)*
–29·4% 
(–48·1 to 
–7·5)*
–30·8% 
(–45·2 to 
–13·2)*
Lymphatic filariasis 1110 
(569 to 1830)
258 
(151 to 394)
1360 
(752 to 2160)
–40·8% 
(–52·3 to 
–30·0)*
–13·2% 
(–16·7 to 
–9·8)*
–37·0% 
(–48·7 to 
–26·4)*
28·1 
(14·4 to 
46·4)
6·6 
(3·9 to 
10·0)
17·4 
(9·6 to 
27·5)
–48·1% 
(–58·2 to 
–38·6)*
–24·2% 
(–27·5 to 
–21·2)*
–44·8% 
(–54·7 to 
–35·5)*
Onchocerciasis 719 
(346 to 1270)
624 
(299 to 1130)
1340 
(639 to 2370)
3·2% 
(–15·4 to 
19·2)
4·7% 
(–16·0 to 
21·7)
3·9% 
(–15·1 to 
19·9)
18·5 
(8·9 to 
32·7)
16·2 
(7·6 to 
29·3)
17·3 
(8·2 to 
30·5)
–8·6% 
(–26·0 to 
6·0)
–7·3% 
(–26·6 to 
8·3)
–8·0% 
(–25·8 to 
6·7)
Trachoma 122 
(80·3 to 174)
181 
(120 to 253)
303 
(202 to 425)
–0·7% 
(–11·7 to 
10·5)
–8·5% 
(–16·5 to 
–0·8)*
–5·5% 
(–13·1 to 
2·0)
3·4 
(2·2 to 
4·8)
4·2 
(2·8 to 
5·9)
3·8 
(2·6 to 5·4)
–25·6% 
(–33·6 to 
–17·3)*
–30·1% 
(–35·9 to 
–24·1)*
–28·2% 
(–33·8 to 
–22·5)*
Dengue 1530 
(754 to 2110)
1390 
(651 to 1930)
2920 
(1630 to 3970)
39·9% 
(4·2 to 
73·1)*
42·1% 
(4 to 
79·5)*
40·9% 
(13·9 to 
67·9)*
41·1 
(20·2 to 
56·2)
38 
(17·6 to 
52·8)
39·6 
(22·0 to 
53·3)
26·1% 
(–6·1 to 
56·2)
26·3% 
(–8·0 to 
60·3)
26·2% 
(2·2 to 
49·5)*
Yellow fever 222 
(45·9 to 632)
92·3 
(18·7 to 267)
314 
(67·2 to 900)
–16·9% 
(–33·2 to 
4·4)
–13·5% 
(–31·2 to 
8·6)
–16·0% 
(–28·9 to 
0)*
6·0 
(1·2 to 
17·0)
2·6 
(0·5 to 
7·6)
4·3 
(0·9 to 
12·4)
–22·3% 
(–37·9 to 
–1·8)*
–19·1% 
(–35·6 to 
2·3)
–21·3% 
(–33·6 to 
–5·9)*
Rabies 441 
(356 to 598)
193 
(98·0 to 287)
634 
(504 to 836)
–49·9% 
(–60·1 to 
–33·9)*
–54·8% 
(–70·4 to 
–34·7)*
–51·5% 
(–61·3 to 
–38·9)*
11·7 
(9·4 to 
16·1)
5·3 
(2·7 to 
8·1)
8·6 
(6·8 to 
11·5)
–54·4% 
(–63·8 to 
–39·4)*
–59·5% 
(–73·7 to 
–40·8)*
–56·2% 
(–65·1 to 
–44·3)*
Intestinal nematode 
infections
907 
(569 to 1410)
1010 
(632 to 1560)
1920 
(1200 to 
2980)
–32·4% 
(–38·3 to 
–27·2)*
–32·2% 
(–37·8 to 
–26·9)*
–32·3% 
(–37·1 to 
–27·7)*
24·2 
(15·3 to 
37·5)
27·8 
(17·5 to 
42·6)
25·9 
(16·4 to 
40·1)
–38·3% 
(–43·7 to 
–33·3)*
–38·2% 
(–43·6 to 
–33·2)*
–38·3% 
(–42·7 to 
–33·9)*
Ascariasis 427 
(284 to 641)
434 
(284 to 661)
861 
(569 to 1290)
–37·8% 
(–46·7 to 
–28·4)*
–37·2% 
(–46·2 to 
–27·1)*
–37·5% 
(–45·0 to 
–29·7)*
11·6 
(7·7 to 
17·3)
12·3 
(8·1 to 
18·6)
12·0 
(8·0 to 
17·8)
–42·7% 
(–51·0 to 
–33·7)*
–42·4% 
(–50·9 to 
–32·6)*
–42·6% 
(–49·5 to 
–35·3)*
Trichuriasis 107 
(59·8 to 178)
106 
(59·6 to 177)
213 
(120 to 354)
–23·1% 
(–29·4 to 
–16·0)*
–23·0% 
(–29·3 to 
–15·7)*
–23·1% 
(–29·3 to 
–15·8)*
2·8 
(1·6 to 4·6)
2·8 
(1·6 to 
4·7)
2·8 
(1·6 to 4·7)
–29·3% 
(–35·1 to 
–22·7)*
–29·2% 
(–35·0 to 
–22·5)*
–29·3% 
(–35·0 to 
–22·5)*
Hookworm disease 373 
(218 to 603)
472 
(289 to 740)
845 
(510 to 1340)
–27·8% 
(–33·3 to 
–22·0)*
–28·9% 
(–34·6 to 
–23·2)*
–28·5% 
(–34·0 to 
–22·7)*
9·8 
(5·7 to 
15·8)
12·6 
(7·7 to 
19·8)
11·2 
(6·7 to 
17·8)
–34·7% 
(–39·7 to 
–29·3)*
–35·5% 
(–40·6 to 
–30·3)*
–35·2% 
(–40·2 to 
–30·0)*
Food-borne 
trematodiases
1110 
(627 to 1890)
763 
(432 to 1280)
1870 
(1070 to 3150)
4·3% 
(0·9 to 
8·0)*
15·0% 
(9·8 to 
20·2)*
8·5% 
(4·8 to 
12·0)*
27·7 
(15·7 to 
47·1)
19 
(10·7 to 
31·9)
23·4 
(13·4 to 
39·3)
–9·4% 
(–12·4 to 
–6·5)*
–1·0% 
(–5·3 to 
3·2)
–6·2% 
(–9·1 to 
–3·5)*
Leprosy 22·1 
(15·0 to 31·0)
9·46 
(6·35 to 13·3)
31·5 
(21·5 to 44·6)
–2·2% 
(–5·2 to 
0·8)
1·0% 
(–2·7 to 
4·8)
–1·3% 
(–3·7 to 
1·1)
0·6 
(0·4 to 
0·8)
0·2 
(0·2 to 
0·3)
0·4 
(0·3 to 0·6)
–21·2% 
(–23·6 to 
–18·9)*
–18·8% 
(–21·9 to 
–15·9)*
–20·4% 
(–22·4 to 
–18·5)*
Ebola virus disease 0·319 
(0·238 to 
0·361)
0·184 
(0·161 to 
0·210)
0·503 
(0·459 to 
0·552)
–97·5% 
(–97·8 to 
–97·2)*
–98·6% 
(–98·8 to 
–98·4)*
–98·1% 
(–98·3 to 
–97·9)*
0 
(0 to 0)
0 
(0 to 0)
0 
(0 to 0)
–97·7% 
(–98·0 to 
–97·4)*
–98·7% 
(–98·9 to 
–98·5)*
–98·2% 
(–98·4 to 
–98·0)*
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Zika virus disease 1·13 
(0·657 to 2·09)
1·12 
(0·529 to 2·71)
2·24 
(1·27 to 4·66)
·· ·· ·· 0 
(0 to 0·1)
0 
(0 to 0·1)
0 
(0 to 0·1)
·· ·· ··
Guinea worm disease 0·000249 
(0·000133 to 
0·000398)
0·000301 
(0·000161 to 
0·000482)
0·000550 
(0·000294 to 
0·000883)
–99·5% 
(–99·7 to 
–99·3)*
–99·5% 
(–99·6 to 
–99·2)*
–99·5% 
(–99·6 to 
–99·3)*
0 
(0 to 0)
0 
(0 to 0)
0 
(0 to 0)
–99·6% 
(–99·7 to 
–99·4)*
–99·5% 
(–99·7 to 
–99·3)*
–99·5% 
(–99·7 to 
–99·3)*
Other neglected 
tropical diseases
1130 
(743 to 2330)
1200 
(794 to 2070)
2340 
(1560 to 
4190)
–2·6% 
(–13·5 to 
9·7)
–2·6% 
(–8·6 to 
4·8)
–2·6% 
(–9·5 to 
5·6)
31·6 
(20·7 to 
65·7)
34·0 
(22·5 to 
60·8)
32·8 
(21·8 to 
60·1)
–9·7% 
(–20·1 to 
1·9)
–10·5% 
(–16·5 to 
–2·9)*
–10·1% 
(–16·7 to 
–2·3)*
Other infectious 
diseases
29 500 
(25 200 to 
34 700)
27 500 
(23 200 to 
32 600)
57 100 
(48 800 to 
67 300)
–30·8% 
(–37·5 to 
–23·1)*
–32·1% 
(–38·7 to 
–24·3)*
–31·4% 
(–37·8 to 
–23·8)*
824·0 
(703·3 to 
971·5)
810·9 
(677·3 to 
966·3)
816·8 
(693·8 to 
970·0)
–35·9% 
(–42·2 to 
–28·7)*
–37·3% 
(–43·5 to 
–29·9)*
–36·6% 
(–42·6 
to 
–29·5)*
Meningitis 10 900 
(9460 to 
12 700)
9430 
(7810 to 
11 100)
20 400 
(17 800 to 
23 400)
–23·3% 
(–31·0 to 
–12·2)*
–25·6% 
(–32·7 to 
–15·3)*
–24·4% 
(–30·6 to 
–15·3)*
306·8 
(264·8 to 
356·4)
278·6 
(232·0 to 
327·4)
293 
(254·3 to 
337·3)
–28·4% 
(–35·6 to 
–17·9)*
–30·8% 
(–37·7 to 
–21·0)*
–29·6% 
(–35·5 to 
–21·1)*
Pneumococcal 
meningitis
1770 
(1480 to 
2130)
1310 
(1080 to 
1560)
3080 
(2640 to 
3600)
–18·5% 
(–27·9 to 
–4·6)*
–20·3% 
(–27·8 to 
–10·3)*
–19·2% 
(–26·5 to 
–8·9)*
49·4 
(41·1 to 
59·6)
38·0 
(31·3 to 
45·3)
43·9 
(37·5 to 
51·4)
–24·2% 
(–33·1 to 
–11·3)*
–26·3% 
(–33·5 to 
–16·7)*
–25·1% 
(–32·1 to 
–15·1)*
H influenzae type B 
meningitis
2530 
(2110 to 3140)
2460 
(2070 to 3010)
4990 
(4310 to 
5890)
–39·5% 
(–46·2 to 
–31·0)*
–41·6% 
(–48 to 
–33·1)*
–40·6% 
(–46·1 to 
–33·3)*
70·9 
(59·0 to 
88·1)
72·6 
(60·7 to 
88·6)
71·6 
(61·6 to 
85)
–43·8% 
(–50·0 to 
–35·6)*
–45·9% 
(–52·0 to 
–37·8)*
–44·9% 
(–50·1 to 
–38·0)*
Meningococcal 
infection
1280 
(1050 to 1550)
1000 
(819 to 1200)
2280 
(1920 to 2720)
–33·5% 
(–41·4 to 
–22·0)*
–34·7% 
(–41·7 to 
–24·7)*
–34·0% 
(–40·3 to 
–25·6)*
36·2 
(29·6 to 
44·2)
30·1 
(24·3 to 
36·1)
33·2 
(27·8 to 
39·7)
–37·5% 
(–45·0 to 
–26·4)*
–38·9% 
(–45·5 to 
–29·4)*
–38·1% 
(–44·1 to 
–30·0)*
Other meningitis 5360 
(4570 to 6270)
4660 
(3810 to 
5480)
10 000 
(8600 to 
11 500)
–10·5% 
(–19·7 to 
3·3)
–11·9% 
(–20·8 to 
0·8)
–11·1% 
(–18·5 to 
0·6)
150·4 
(128·2 to 
175·7)
137·9 
(112·6 to 
162·9)
144·2 
(123·6 to 
166·2)
–16·3% 
(–25·1 to 
–3·1)*
–17·8% 
(–26·3 to 
–5·6)*
–17·0% 
(–24·2 to 
–5·9)*
Encephalitis 2620 
(2310 to 3030)
2490 
(2220 to 2810)
5110 
(4540 to 
5760)
–12·4% 
(–27·6 to 
4·5)
–8·4% 
(–24·1 to 
8·3)
–10·5% 
(–25·5 to 
4·7)
71·6 
(63·0 to 
82·3)
70·2 
(62·0 to 
79·2)
70·8 
(62·8 to 
79·3)
–20·4% 
(–34·4 to 
–5·1)*
–17·5% 
(–32·3 to 
–2·3)*
–18·9% 
(–32·9 to 
–5·2)*
Diphtheria 155 
(80·2 to 331)
143 
(74·1 to 291)
299 
(182 to 510)
–21·9% 
(–63·8 to 
75·5)
–26·1% 
(–65·7 to 
71·5)
–23·9% 
(–56·7 to 
38·7)
4·4 
(2·3 to 
9·5)
4·4 
(2·3 to 
8·9)
4·4 
(2·7 to 7·6)
–26·3% 
(–66·2 to 
66·6)
–30·4% 
(–67·9 to 
62·6)
–28·3% 
(–59·5 to 
31·4)
Whooping cough 3540 
(1790 to 6340)
4440 
(2250 to 7740)
7980 
(4020 to 
14 100)
–24·1% 
(–54·8 to 
33·4)
–22·5% 
(–54·3 to 
35·1)
–23·2% 
(–54·5 to 
35·0)
102·5 
(51·9 to 
183·6)
137·4 
(69·6 to 
239·7)
119·3 
(60·1 to 
210·7)
–27·7% 
(–56·9 to 
27·1)
–26·4% 
(–56·6 to 
28·3)
–27·0% 
(–56·8 to 
28·4)
Tetanus 1400 
(955 to 1930)
1050 
(753 to 1410)
2450 
(1740 to 3200)
–58·1% 
(–70·2 to 
–37·9)*
–60·9% 
(–72·2 to 
–42·0)*
–59·3% 
(–69·9 to 
–43·5)*
38·9 
(26·6 to 
54·3)
31·3 
(22·5 to 
42·2)
35·2 
(25 to 
46·4)
–61·0% 
(–72·2 to 
–42)*
–63·4% 
(–74·1 to 
–45·6)*
–62·1% 
(–72·1 to 
–47)*
Measles 4080 
(1460 to 
8860)
4080 
(1480 to 8710)
8160 
(2950 to 
17 600)
–56·5% 
(–61·9 to 
–50·6)*
–57·2% 
(–62·6 to 
–51·6)*
–56·8% 
(–61·8 to 
–51·7)*
117·7 
(42·1 to 
255·6)
125·6 
(45·7 to 
268·5)
121·5 
(44·0 to 
261·7)
–58·8% 
(–63·9 to 
–53·2)*
–59·5% 
(–64·7 to 
–54·2)*
–59·1% 
(–63·8 to 
–54·3)*
Varicella and herpes 
zoster
559 
(476 to 656)
586 
(495 to 690)
1140 
(985 to 1320)
–15·8% 
(–25·9 to 
–4·3)*
–12·3% 
(–23·2 to 
–1·6)*
–14·0% 
(–22·4 to 
–5·6)*
15·5 
(13·3 to 
18·1)
16·5 
(14·0 to 
19·3)
16·0 
(13·9 to 
18·4)
–24·1% 
(–33·0 to 
–13·7)*
–21·6% 
(–31·6 to 
–11·5)*
–22·8% 
(–30·2 to 
–15·5)*
Acute hepatitis 3240 
(2150 to 3940)
2750 
(1970 to 3390)
5990 
(4580 to 
6900)
–18·9% 
(–25·9 to 
–5·0)*
–21·0% 
(–29·2 to 
–12·3)*
–19·8% 
(–25·6 to 
–12·7)*
84·2 
(55·8 to 
102·9)
74·2 
(52·5 to 
92·2)
78·9 
(60·1 to 
91·2)
–29·0% 
(–35·1 to 
–16)*
–30·1% 
(–37·5 to 
–22·4)*
–29·5% 
(–34·8 to 
–23·1)*
Acute hepatitis A 697 
(465 to 949)
801 
(565 to 1050)
1500 
(1130 to 1870)
–31·6% 
(–42·8 to 
–10·4)*
–32·7% 
(–44·1 to 
–19·5)*
–32·2% 
(–40·9 to 
–21·1)*
18·8 
(12·6 to 
25·4)
23·1 
(16·3 to 
30·4)
20·9 
(15·7 to 
26·2)
–36·9% 
(–47·4 to 
–16·2)*
–37·5% 
(–48·6 to 
–24·5)*
–37·2% 
(–45·5 to 
–26·3)*
Acute hepatitis B 2050 
(1370 to 2460)
1470 
(1040 to 1810)
3530 
(2620 to 
4120)
–11·2% 
(–20·0 to 
1·6)
–10·5% 
(–21·0 to 
1·4)
–10·9% 
(–18·2 to 
–2·0)*
52·4 
(34·8 to 
63·0)
38·0 
(26·7 to 
46·7)
45·1 
(33·3 to 
53·0)
–24·7% 
(–32·1 to 
–13·9)*
–24·0% 
(–33·0 to 
–13·7)*
–24·5% 
(–30·4 to 
–17·0)*
Acute hepatitis C 106 
(54 to 187)
122 
(64·9 to 207)
228 
(124 to 383)
–30·5% 
(–44·8 to 
–1·8)*
–29·9% 
(–44·3 to 
–9·9)*
–30·2% 
(–42·2 to 
–14·7)*
3·0 
(1·5 to 5·3)
3·7 
(1·9 to 
6·2)
3·3 
(1·8 to 5·6)
–35·1% 
(–48·3 to 
–7·0)*
–34·6% 
(–48·4 to 
–15·3)*
–34·8% 
(–46·4 to 
–20·3)*
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Acute hepatitis E 382 
(226 to 507)
356 
(247 to 459)
739 
(517 to 935)
–24·5% 
(–36·5 to 
–10·1)*
–24·6% 
(–38·9 to 
–9·6)*
–24·6% 
(–34·1 to 
–13·6)*
9·9 
(5·9 to 
13·1)
9·5 
(6·6 to 
12·3)
9·7 
(6·8 to 
12·2)
–31·2% 
(–41·6 to 
–18·4)*
–30·9% 
(–43·9 to 
–17·5)*
–31·1% 
(–39·5 to 
–21·2)*
Other unspecified 
infectious diseases
2990 
(2240 to 
3420)
2580 
(1980 to 
3060)
5570 
(4300 to 
6430)
–6·3% 
(–13·2 to 
4·5)
–10·5% 
(–15·7 to 
–5·8)*
–8·3% 
(–13·2 to 
–2·7)*
82·5 
(61·4 to 
94·3)
72·7 
(55·3 to 
85·8)
77·6 
(59·3 to 
89·5)
–14·1% 
(–20·6 to 
–4·3)*
–18·8% 
(–23·7 to 
–14·4)*
–16·4% 
(–21 to 
–11·2)*
Maternal and 
neonatal disorders
103 000 
(97 100 to 
109 000)
94 500 
(89 300 to 
100 000)
198 000 
(187 000 to 
209 000)
–20·1% 
(–23·3 to 
–16·5)*
–19·0% 
(–22·1 to 
–15·9)*
–19·6% 
(–22·5 to 
–16·5)*
2979·1 
(2808·2 
to 3151·8)
2839·4 
(2691·4 
to 
3000·0)
2916·4 
(2761·0 to 
3077·1)
–22·9% 
(–26·1 to 
–19·4)*
–22·9% 
(–25·8 to 
–19·8)*
–22·9% 
(–25·8 to 
–19·9)*
Maternal disorders ·· 11 800 
(11 000 to 
12 800)
11 800 
(11 000 to 
12 800)
·· –24·1% 
(–28·3 to 
–19·9)*
–24·1% 
(–28·3 to 
–19·9)*
·· 305·5 
(284·3 to 
330·6)
151·2 
(140·7 to 
163·6)
·· –30·3% 
(–34·1 to 
–26·3)*
–30·5% 
(–34·3 to 
–26·5)*
Maternal 
haemorrhage
·· 2230 
(1910 to 2610)
2230 
(1910 to 2610)
·· –52·4% 
(–59·5 to 
–44·3)*
–52·4% 
(–59·5 to 
–44·3)*
·· 57·8 
(49·6 to 
67·4)
28·6 
(24·5 to 
33·4)
·· –56·3% 
(–62·8 to 
–48·9)*
–56·4% 
(–62·8 to 
–49·1)*
Maternal sepsis and 
other pregnancy-
related infections
·· 1250 
(1080 to 
1480)
1250 
(1080 to 
1480)
·· –27·8% 
(–39·6 to 
–15·1)*
–27·8% 
(–39·6 to 
–15·1)*
·· 32·5 
(27·8 to 
38·4)
16·1 
(13·8 to 
19·0)
·· –33·4% 
(–43·7 to 
–21·8)*
–33·6% 
(–43·9 to 
–21·9)*
Maternal 
hypertensive 
disorders
·· 1870 
(1620 to 2190)
1870 
(1620 to 2190)
·· –6·2% 
(–21·4 to 
9·8)
–6·2% 
(–21·4 to 
9·8)
·· 48·9 
(42·2 to 
57·1)
24·2 
(20·9 to 
28·2)
·· –13·0% 
(–27·2 to 
1·9)
–13·3% 
(–27·5 to 
1·6)
Maternal obstructed 
labour and uterine 
rupture
·· 1120 
(901 to 1380)
1120 
(901 to 1380)
·· –16·1% 
(–29·9 to 
–2·6)*
–16·1% 
(–29·9 to 
–2·6)*
·· 28·8 
(23·2 to 
35·6)
14·3 
(11·5 to 
17·6)
·· –23·7% 
(–36·1 to 
–11·2)*
–23·9% 
(–36·3 to 
–11·5)*
Maternal abortive 
outcome
·· 982 
(827 to 1180)
982 
(827 to 1180)
·· –8·7% 
(–23·9 to 
8·8)
–8·7% 
(–23·9 to 
8·8)
·· 25·3 
(21·3 to 
30·5)
12·5 
(10·5 to 
15·1)
·· –16·4% 
(–30·2 to 
–0·5)*
–16·6% 
(–30·3 to 
–0·7)*
Ectopic pregnancy ·· 606 
(424 to 896)
606 
(424 to 896)
·· –12·8% 
(–42·8 to 
26·4)
–12·8% 
(–42·8 to 
26·4)
·· 15·7 
(11·0 to 
23·4)
7·8 
(5·4 to 
11·6)
·· –19·6% 
(–46·9 to 
17·3)
–19·8% 
(–47·1 to 
16·9)
Indirect maternal 
deaths
·· 1930 
(1690 to 
2220)
1930 
(1690 to 
2220)
·· –6·1% 
(–19·2 to 
6·8)
–6·1% 
(–19·2 to 
6·8)
·· 50·1 
(43·9 to 
57·5)
24·8 
(21·7 to 
28·5)
·· –13·6% 
(–25·5 to 
–2·0)*
–13·9% 
(–25·8 to 
–2·3)*
Late maternal deaths ·· 195 
(152 to 251)
195 
(152 to 251)
·· –2·0% 
(–8·2 to 
4·1)
–2·0% 
(–8·2 to 
4·1)
·· 5·1 
(4·0 to 
6·5)
2·5 
(2·0 to 3·2)
·· –9·8% 
(–15·1 to 
–4·3)*
–10·1% 
(–15·4 to 
–4·5)*
Maternal deaths 
aggravated by 
HIV/AIDS
·· 84·4 
(53·0 to 114)
84·4 
(53·0 to 114)
·· –26·7% 
(–33·6 to 
–19·2)*
–26·7% 
(–33·6 to 
–19·2)*
·· 2·2 
(1·4 to 
2·9)
1·1 
(0·7 to 1·4)
·· –34·1% 
(–40·4 to 
–27·3)*
–34·2% 
(–40·6 to 
–27·5)*
Other maternal 
disorders
·· 1520 
(1280 to 1810)
1520 
(1280 to 1810)
·· –8·0% 
(–24·7 to 
10·9)
–8·0% 
(–24·7 to 
10·9)
·· 39·2 
(33·0 to 
46·7)
19·4 
(16·4 to 
23·1)
·· –15·5% 
(–30·5 to 
1·5)
–15·7% 
(–30·7 to 
1·3)
Neonatal disorders 103 000 
(97 100 to 
109 000)
82 700 
(77 800 to 
88 200)
186 000 
(175 000 to 
197 000)
–20·1% 
(–23·3 to 
–16·5)*
–18·2% 
(–21·7 to 
–14·6)*
–19·3% 
(–22·4 to 
–15·9)*
2979·1 
(2808·2 to 
3151·8)
2533·9 
(2389·9 
to 
2691·1)
2765·2 
(2611·8 to 
2922·7)
–22·9% 
(–26·1 to 
–19·4)*
–21·9% 
(–25·2 to 
–18·4)*
–22·5% 
(–25·5 to 
–19·2)*
Neonatal preterm 
birth
38 400 
(35 200 to 
42 800)
31 800 
(28 500 to 
36 000)
70 200 
(64 400 to 
77 200)
–20·9% 
(–26·6 to 
–15·1)*
–18·7% 
(–24·7 to 
–12·4)*
–19·9% 
(–25·3 to 
–14·4)*
1109·6 
(1019·0 to 
1236·1)
966·4 
(871·4 to 
1090·2)
1041·2 
(958·9 to 
1138·5)
–23·8% 
(–29·2 to 
–18·3)*
–22·7% 
(–28·4 to 
–17·0)*
–23·3% 
(–28·4 to 
–18·3)*
Neonatal 
encephalopathy due 
to birth asphyxia and 
trauma
32 200 
(28 300 to 
36 200)
24 300 
(21 200 to 
27 700)
56 500 
(50 200 to 
63 100)
–19·7% 
(–27·1 to 
–11·6)*
–18·4% 
(–25·6 to 
–11·3)*
–19·1% 
(–25·0 to 
–12·4)*
928·1 
(817·0 to 
1038·6)
742·9 
(644·7 to 
836·9)
838·9 
(746·3 to 
930·9)
–22·7% 
(–29·8 to 
–14·9)*
–22·2% 
(–29·0 to 
–15·4)*
–22·5% 
(–28·0 to 
–16·4)*
Neonatal sepsis and 
other neonatal 
infections
11 900 
(10 100 to 
14 600)
10 100 
(7820 to 
13 700)
22 000 
(18 900 to 
28 000)
–10·5% 
(–20·2 to 
0·8)
–3·2% 
(–14·6 to 
7·0)
–7·3% 
(–15·3 to 
1·5)
343·3 
(291·8 to 
416·1)
306·1 
(241·7 to 
420·6)
325·4 
(281·2 to 
417·5)
–14·1% 
(–23·4 to 
–3·1)*
–7·8% 
(–18·9 to 
1·8)
–11·3% 
(–19·0 to 
–2·7)*
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Haemolytic disease 
and other neonatal 
jaundice
2890 
(2480 to 
3300)
2300 
(1970 to 
2660)
5190 
(4610 to 
5790)
–31·9% 
(–41·3 to 
–21·1)*
–32·1% 
(–42·3 to 
–18·4)*
–32·0% 
(–39·7 to 
–22·9)*
83·3 
(71·5 to 
95·2)
70·4 
(60·1 to 
81·8)
77·1 
(68·4 to 
86·0)
–34·5% 
(–43·6 to 
–24·2)*
–35·3% 
(–45·1 to 
–21·8)*
–34·9% 
(–42·3 to 
–26·0)*
Other neonatal 
disorders
17 600 
(13 900 to 
19 800)
14 300 
(12 200 to 
16 000)
31 800 
(27 100 to 
34 800)
–22·3% 
(–30·3 to 
–12·3)*
–23·0% 
(–31·3 to 
–13·2)*
–22·6% 
(–28·7 to 
–14·7)*
514·8 
(407·8 to 
579·1)
448·2 
(384·7 to 
503·4)
482·6 
(410·4 to 
527·5)
–24·4% 
(–32·2 to 
–14·7)*
–25·3% 
(–33·3 to 
–15·8)*
–24·8% 
(–30·6 to 
–17·1)*
Nutritional 
deficiencies
23 600 
(17 900 to 
30 700)
34 400 
(26 000 to 
45 600)
58 000 
(44 300 to 
76 900)
–21·1% 
(–27·5 to 
–14·0)*
–14·0% 
(–17·6 to 
–10·5)*
–17·0% 
(–21·4 to 
–12·6)*
655·9 
(499·1 to 
849·1)
964·9 
(731·6 to 
1268·5)
808·7 
(619·2 to 
1065·8)
–27·3% 
(–33·2 to 
–20·8)*
–22·0% 
(–25·4 to 
–18·7)*
–24·3% 
(–28·3 to 
–20·3)*
Protein-energy 
malnutrition
7770 
(6790 to 
9010)
8430 
(7490 to 9310)
16 200 
(14 500 to 
18 000)
–36·5% 
(–43·9 to 
–22·8)*
–28·6% 
(–34·8 to 
–22·5)*
–32·7% 
(–38·3 to 
–24·7)*
222·6 
(194·7 to 
258·2)
254·9 
(225·6 to 
281·7)
238·0 
(212·7 to 
264·8)
–40·7% 
(–47·6 to 
–27·8)*
–33·5% 
(–39·3 to 
–27·7)*
–37·2% 
(–42·5 to 
–29·7)*
Iodine deficiency 886 
(542 to 1370)
1170 
(705 to 1870)
2060 
(1250 to 3260)
–6·9% 
(–10·6 to 
–4·0)*
–7·0% 
(–10·1 to 
–4·0)*
–6·9% 
(–10·1 to 
–4·3)*
22·8 
(14·0 to 
35·4)
30·8 
(18·5 to 
48·9)
26·7 
(16·2 to 
42·3)
–17·6% 
(–20·8 to 
–14·9)*
–17·2% 
(–20·2 to 
–14·3)*
–17·4% 
(–20·1 to 
–14·9)*
Dietary iron deficiency 10 700 
(7040 to 
15 800)
19 300 
(13 000 to 
27 800)
30 000 
(20 300 to 
43 600)
–5·6% 
(–11·3 to 
0·3)
–5·0% 
(–8·0 to 
–2·1)*
–5·2% 
(–8·3 to 
–1·9)*
291·9 
(191·3 to 
428·4)
514·3 
(345·7 to 
740·8)
403·0 
(272·4 to 
586·6)
–13·7% 
(–18·8 to 
–8·1)*
–14·6% 
(–17·3 to 
–12·0)*
–14·3% 
(–17·2 to 
–11·4)*
Other nutritional 
deficiencies
561 
(479 to 693)
885 
(751 to 1020)
1450 
(1250 to 1640)
–32·3% 
(–40·1 to 
–14·3)*
–21·7% 
(–30·7 to 
–12·7)*
–26·2% 
(–33·4 to 
–17·7)*
15·3 
(13·1 to 
18·9)
23·8 
(20·0 to 
27·7)
19·5 
(16·8 to 
22·3)
–40·7% 
(–47·5 to 
–25·0)*
–32·7% 
(–40·8 to 
–24·8)*
–35·9% 
(–42·3 to 
–28·5)*
Non-communicable 
diseases
811 000 
(732 000 to 
902 000)
740 000 
(649 000 to 
844 000)
1 550 000 
(1 380 000 to 
1 750 000)
15·7% 
(14·5 to 
16·9)*
16·4% 
(15·3 to 
17·4)*
16·0% 
(15·1 to 
16·9)*
21 329·9 
(19 298·6 
to 
23 679·8)
18 204·5 
(15 923·1 
to 
20 796·3)
19 676·5 
(17 509·8 
to 
22 177·9)
–6·2% 
(–7·4 to 
–5·2)*
–5·0% 
(–6·1 to 
–4·1)*
–5·6% 
(–6·6 to 
–4·8)*
Neoplasms 131 000 
(128 000 to 
135 000)
102 000 
(99 300 to 
105 000)
234 000 
(229 000 to 
238 000)
20·2% 
(17·8 to 
22·6)*
20·2% 
(17·2 to 
23·1)*
20·2% 
(18·3 to 
22·0)*
3417·7 
(3337·7 to 
3497·3)
2454·6 
(2386·7 
to 
2517·4)
2900·9 
(2842·8 to 
2957)
–5·7% 
(–7·6 to 
–3·9)*
–4·5% 
(–7·0 to 
–2·3)*
–5·1% 
(–6·6 to 
–3·7)*
Lip and oral cavity 
cancer
3490 
(3240 to 
3680)
1770 
(1660 to 
1880)
5250 
(4980 to 
5500)
27·3% 
(18·3 to 
34·2)*
38·4% 
(30·6 to 
47·1)*
30·8% 
(24·1 to 
36·6)*
87·6 
(81·5 to 
92·4)
42·2 
(39·6 to 
45·0)
64·2 
(60·9 to 
67·2)
0·4% 
(–6·6 to 
5·8)
9·5% 
(3·3 to 
16·5)*
3·2% 
(–2·0 to 
7·7)
Nasopharynx cancer 1520 
(1440 to 
1610)
563 
(539 to 589)
2090 
(2000 to 2170)
19·0% 
(13·2 to 
25·4)*
16·9% 
(11·2 to 
23·7)*
18·4% 
(14·0 to 
23·1)*
38·0 
(36·0 to 
40·1)
13·6 
(13·0 to 
14·2)
25·4 
(24·4 to 
26·5)
–4·7% 
(–9·2 to 
0·4)
–5·5% 
(–10·1 to 
–0·2)*
–4·9% 
(–8·5 to 
–1·2)*
Other pharynx cancer 2340 
(1940 to 
2540)
927 
(859 to 990)
3260 
(2820 to 
3460)
34·5% 
(20·6 to 
47·1)*
40·2% 
(30·1 to 
49·4)*
36·1% 
(25·6 to 
44·3)*
58·2 
(48·3 to 
63·4)
22·1 
(20·4 to 
23·6)
39·6 
(34·3 to 
42·0)
5·4% 
(–5·6 to 
15·1)
10·5% 
(2·4 to 
17·8)*
6·6% 
(–1·6 to 
12·9)
Oesophageal cancer 7190 
(6960 to 
7420)
2590 
(2480 to 
2690)
9780 
(9530 to 
10 000)
11·2% 
(7·2 to 
15·2)*
3·4% 
(–1·7 to 
8·3)
9·0% 
(5·9 to 
12·2)*
184·3 
(178·3 to 
190·1)
61·0 
(58·5 to 
63·4)
119·9 
(116·9 to 
123·0)
–14·5% 
(–17·5 to 
–11·4)*
–20·3% 
(–24·2 to 
–16·6)*
–16·2% 
(–18·5 to 
–13·7)*
Stomach cancer 12 200 
(11 900 to 
12 600)
6880 
(6680 to 
7080)
19 100 
(18 700 to 
19 600)
5·6% 
(2·4 to 
9·2)*
4·5% 
(0·8 to 
8·0)*
5·2% 
(2·8 to 
7·8)*
317·8 
(308·7 to 
327·9)
163·0 
(158·3 to 
167·8)
235·9 
(231·1 to 
241·3)
–18·5% 
(–20·9 to 
–15·8)*
–18·1% 
(–21·1 to 
–15·4)*
–18·4% 
(–20·2 to 
–16·3)*
Colon and rectum 
cancer
10 700 
(10 200 to 
11 000)
8330 
(8060 to 
8580)
19 000 
(18 500 to 
19 500)
26·9% 
(20·9 to 
31·5)*
21·6% 
(15·9 to 
26·0)*
24·5% 
(20·0 to 
28·3)*
280·3 
(269 to 
290·5)
196·3 
(189·9 to 
202·2)
235·7 
(229·7 to 
242·0)
–2·6% 
(–7·1 to 
0·8)
–6·0% 
(–10·4 to 
–2·6)*
–4·1% 
(–7·5 to 
–1·2)*
Liver cancer 15 200 
(14 300 to 
16 300)
5530 
(5320 to 5750)
20 800 
(19 900 to 
21 800)
22·9% 
(16·8 to 
31·8)*
17·6% 
(12·0 to 
25·0)*
21·4% 
(17·3 to 
27·5)*
382·9 
(360·9 to 
408·8)
130·9 
(125·9 to 
136·2)
253·6 
(243·2 to 
266·2)
–3·0% 
(–7·7 to 
4·0)
–8·2% 
(–12·5 to 
–2·5)*
–4·5% 
(–7·8 to 
0·2)
Liver cancer due to 
hepatitis B
7580 
(7030 to 
8270)
1970 
(1840 to 2110)
9550 
(8920 to 
10 300)
16·4% 
(10·2 to 
26·6)*
9·2% 
(2·6 to 
17·3)*
14·9% 
(9·9 to 
22·1)*
187·3 
(173·8 to 
204·4)
47·0 
(43·8 to 
50·4)
115·8 
(108·3 to 
124·4)
–6·7% 
(–11·6 to 
1·3)
–13·1% 
(–18·4 to 
–6·7)*
–8·2% 
(–12·1 to 
–2·5)*
Liver cancer due to 
hepatitis C
3160 
(2880 to 
3450)
1800 
(1690 to 1910)
4960 
(4600 to 
5330)
29·5% 
(23·6 to 
36·8)*
23·0% 
(18·0 to 
29·5)*
27·1% 
(23·4 to 
31·7)*
81·5 
(74·7 to 
88·7)
42·1 
(39·6 to 
44·7)
61·1 
(56·9 to 
65·6)
–1·0% 
(–5·4 to 
4·6)
–6·1% 
(–9·9 to 
–1·1)*
–2·9% 
(–5·7 to 
0·6)
Liver cancer due to 
alcohol use
2490 
(2160 to 
2910)
589 
(514 to 688)
3080 
(2680 to 
3590)
29·0% 
(22·0 to 
36·7)*
23·6% 
(18·4 to 
30·0)*
27·9% 
(22·5 to 
34·0)*
63·2 
(55·2 to 
73·3)
13·9 
(12·1 to 
16·2)
37·6 
(32·9 to 
43·8)
0·4% 
(–4·6 to 
6·0)
–4·2% 
(–8·2 to 
0·7)
–0·5% 
(–4·4 to 
4·0)
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Liver cancer due to 
NASH
956 
(842 to 1070)
505 
(451 to 560)
1460 
(1300 to 1620)
40·7% 
(33·5 to 
49·8)*
31·6% 
(25·4 to 
39·2)*
37·4% 
(32·8 to 
42·9)*
24·6 
(21·8 to 
27·6)
11·9 
(10·6 to 
13·2)
18·0 
(16·1 to 
20·0)
9·1% 
(3·7 to 
16·1)*
1·6% 
(–3·1 to 
7·3)
6·4% 
(3·0 to 
10·6)*
Liver cancer due to 
other causes
1050 
(930 to 1200)
670 
(607 to 743)
1720 
(1540 to 1920)
24·9% 
(17·6 to 
34)*
16·0% 
(9·6 to 
24·5)*
21·3% 
(16·2 to 
27·7)*
26·3 
(23·3 to 
29·7)
16·0 
(14·5 to 
17·7)
21·1 
(19·0 to 
23·5)
0·1% 
(–5·3 to 
7·2)
–8·1% 
(–13 to 
–1·5)*
–3·3% 
(–7·0 to 
1·5)
Gallbladder and biliary 
tract cancer
1460 
(1220 to 1620)
2020 
(1710 to 2160)
3480 
(3040 to 3710)
21·9% 
(15·8 to 
27·9)*
22·0% 
(16·7 to 
27·2)*
22·0% 
(18·0 to 
26·4)*
38·7 
(32·2 to 
42·9)
47·5 
(40·2 to 
50·7)
43·2 
(37·7 to 
46·1)
–6·9% 
(–11·4 to 
–2·5)*
–6·4% 
(–10·5 to 
–2·4)*
–6·7% 
(–9·8 to 
–3·4)*
Pancreatic cancer 4990 
(4830 to 5140)
4090 
(4000 to 
4190)
9080 
(8890 to 
9260)
33·6% 
(28·1 to 
38·1)*
38·6% 
(35·7 to 
41·4)*
35·8% 
(32·5 to 
38·6)*
129·4 
(125·4 to 
133·2)
96·1 
(94·0 to 
98·4)
112·2 
(110·0 to 
114·4)
2·6% 
(–1·5 to 
6·0)
6·0% 
(3·8 to 
8·1)*
4·0% 
(1·5 to 
6·1)*
Larynx cancer 2730 
(2650 to 2820)
547 
(523 to 570)
3280 
(3190 to 
3380)
16·9% 
(13·2 to 
20·8)*
22·5% 
(17·1 to 
28·0)*
17·8% 
(14·4 to 
21·4)*
69·0 
(66·9 to 
71·1)
13·0 
(12·4 to 
13·5)
39·9 
(38·8 to 
41·0)
–9·6% 
(–12·3 to 
–6·6)*
–4·0% 
(–8·2 to 
0·3)
–8·8% 
(–11·3 to 
–6)*
Tracheal, bronchus, and 
lung cancer
28 400 
(27 500 to 
29 200)
12 600 
(12 200 to 
13 000)
40 900 
(40 000 to 
41 900)
22·3% 
(18·0 to 
26·0)*
31·7% 
(27·5 to 
35·9)*
25·0% 
(21·9 to 
27·8)*
734·1 
(712 to 
754·8)
295·7 
(286·6 to 
305·2)
503·1 
(491·9 to 
514·3)
–6·4% 
(–9·6 to 
–3·5)*
1·4% 
(–1·8 to 
4·6)
–4·0% 
(–6·4 to 
–1·9)*
Malignant skin 
melanoma
905 
(603 to 1130)
749 
(584 to 966)
1650 
(1330 to 1940)
17·3% 
(9·6 to 
22·9)*
17·3% 
(11·1 to 
25·5)*
17·3% 
(14·0 to 
21·0)*
23·3 
(15·4 to 
28·9)
17·9 
(14·0 to 
23·1)
20·5 
(16·5 to 
24·0)
–6·2% 
(–12·0 to 
–1·6)*
–6·2% 
(–11·0 to 
0·8)
–6·3% 
(–8·9 to 
–3)*
Non-melanoma skin 
cancer
929 
(883 to 976)
400 
(380 to 426)
1330 
(1270 to 1400)
28·4% 
(25·3 to 
30·9)*
34·4% 
(27·7 to 
40·1)*
30·1% 
(26·5 to 
32·8)*
24·9 
(23·6 to 
26·2)
9·4 
(9·0 to 
10·0)
16·6 
(15·9 to 
17·5)
–1·5% 
(–3·8 to 
0·4)
3·7% 
(–1·4 to 
8·1)
0·3% 
(–2·3 to 
2·4)
Non-melanoma skin 
cancer (squamous-cell 
carcinoma) 
928 
(883 to 975)
399 
(379 to 424)
1330 
(1270 to 1390)
28·4% 
(25·3 to 
30·9)*
34·5% 
(27·7 to 
40·2)*
30·1% 
(26·5 to 
32·8)*
24·8 
(23·6 to 
26·1)
9·4 
(8·9 to 
10·0)
16·6 
(15·9 to 
17·5)
–1·5% 
(–3·8 to 
0·4)
3·7% 
(–1·4 to 
8·1)
0·3% 
(–2·3 to 
2·4)
Non-melanoma skin 
cancer (basal-cell 
carcinoma)
1·35 
(0·512 to 2·86)
1·12 
(0·433 to 2·33)
2·47 
(0·945 to 5·20)
32·6% 
(24·7 to 
39·4)*
28·6% 
(20·0 to 
35·8)*
30·8% 
(23·1 to 
37·0)*
0 
(0 to 0·1)
0 
(0 to 0·1)
0 
(0 to 0·1)
–1·5% 
(–7·3 to 
3·4)
–1·5% 
(–7·6 to 
3·5)
–1·0% 
(–6·4 to 
3·2)
Breast cancer 285 
(273 to 299)
17 400 
(16 600 to 
18 400)
17 700 
(16 900 to 
18 700)
39·0% 
(31·5 to 
46·1)*
24·4% 
(17·8 to 
29·1)*
24·6% 
(18·1 to 
29·3)*
7·3 
(7·0 to 
7·6)
414·7 
(395·5 to 
437·6)
216·3 
(206·4 to 
228·1)
7·9% 
(2·3 to 
13·2)*
–1·4% 
(–6·5 to 
2·4)
–1·2% 
(–6·3 to 
2·5)
Cervical cancer ·· 8060 
(7530 to 8400)
8060 
(7530 to 8400)
·· 15·2% 
(9·5 to 
19·2)*
15·2% 
(9·5 to 
19·2)*
·· 193·0 
(180·2 to 
201·2)
98·2 
(91·7 to 
102·4)
·· –7·1% 
(–11·8 to 
–3·9)*
–7·0% 
(–11·6 to 
–3·8)*
Uterine cancer ·· 2140 
(2060 to 2230)
2140 
(2060 to 2230)
·· 16·6% 
(13·3 to 
20·8)*
16·6% 
(13·3 to 
20·8)*
·· 50·5 
(48·5 to 
52·5)
26·3 
(25·2 to 
27·3)
·· –9·8% 
(–12·4 to 
–6·7)*
–9·8% 
(–12·4 to 
–6·7)*
Ovarian cancer ·· 4670 
(4530 to 4830)
4670 
(4530 to 4830)
·· 29% 
(24·7 to 
33·1)*
29·0% 
(24·7 to 
33·1)*
·· 110·9 
(107·5 to 
114·6)
57·1 
(55·4 to 
59·0)
·· 1·3% 
(–2·0 to 
4·5)
1·2% 
(–2·1 to 
4·3)
Prostate cancer 7060 
(6050 to 8350)
·· 7060 
(6050 to 8350)
29·7% 
(26·3 to 
36·3)*
·· 29·7% 
(26·3 to 
36·3)*
201·3 
(171·7 to 
237·1)
·· 90·0 
(77·2 to 
106·6)
–4·4% 
(–6·8 to 
0·6)
·· –2·6% 
(–5·1 to 
2·4)
Testicular cancer 375 
(356 to 398)
·· 375 
(356 to 398)
2·7% 
(–1·4 to 
8·0)
·· 2·7% 
(–1·4 to 
8·0)
9·5 
(9·0 to 
10·1)
·· 4·7 
(4·5 to 5·0)
–9·4% 
(–13·0 to 
–4·7)*
·· –9·2% 
(–12·9 to 
–4·5)*
Kidney cancer 2170 
(2030 to 2240)
1120 
(1030 to 1160)
3280 
(3090 to 
3390)
25·3% 
(20·3 to 
29·6)*
19·2% 
(11·8 to 
25·7)*
23·2% 
(18·5 to 
27·3)*
56·5 
(53·0 to 
58·5)
27·2 
(25·0 to 
28·3)
41·1 
(38·7 to 
42·5)
–1·9% 
(–5·7 to 
1·4)
–5·7% 
(–11·5 to 
–0·3)*
–3·2% 
(–6·9 to 
0·1)
Bladder cancer 2710 
(2600 to 2870)
889 
(854 to 924)
3600 
(3480 to 3770)
24·2% 
(21·1 to 
27·3)*
20·6% 
(14·3 to 
26·1)*
23·3% 
(20·6 to 
26·0)*
74·2 
(71·2 to 
78·7)
20·9 
(20·1 to 
21·7)
45·3 
(43·7 to 
47·4)
–6·5% 
(–8·8 to 
–4·2)*
–7·7% 
(–12·5 to 
–3·4)*
–6·4% 
(–8·4 to 
–4·3)*
Brain and nervous 
system cancer
5030 
(4200 to 5740)
3720 
(2690 to 4210)
8740 
(7650 to 9550)
24·2% 
(16·8 to 
33·9)*
12·4% 
(–3·8 to 
31·5)
18·9% 
(12·3 to 
25·1)*
129·4 
(108·3 to 
147·9)
95·0 
(68·6 to 
107·9)
111·9 
(97·8 to 
122·5)
5·0% 
(–1·2 to 
13·3)
–5·3% 
(–19·1 to 
11·1)
0·4% 
(–5·3 to 
5·7)
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Thyroid cancer 468 
(444 to 493)
665 
(618 to 747)
1130 
(1070 to 1230)
30·3% 
(21·6 to 
36·6)*
19·6% 
(12·6 to 
27·0)*
23·8% 
(18·6 to 
29·6)*
12·1 
(11·5 to 
12·7)
16·0 
(14·9 to 
18·0)
14·1 
(13·3 to 
15·3)
3·7% 
(–3·1 to 
8·6)
–3·8% 
(–9·6 to 
2·4)
–0·9% 
(–5·1 to 
3·8)
Mesothelioma 478 
(462 to 494)
193 
(181 to 208)
671 
(648 to 693)
23·0% 
(15·9 to 
29·0)*
16·7% 
(7·0 to 
25·5)*
21·1% 
(13·9 to 
27·4)*
12·5 
(12·1 to 
12·9)
4·6 
(4·3 to 
5·0)
8·3 
(8·0 to 
8·6)
–4·9% 
(–10·2 to 
–0·4)*
–7·0% 
(–14·2 to 
–0·6)*
–5·3% 
(–10·7 to 
–0·7)*
Hodgkin lymphoma 871 
(705 to 1090)
508 
(400 to 606)
1380 
(1160 to 1620)
–6·0% 
(–9·6 to 
–2·3)*
–1·8% 
(–7·7 to 
4·4)
–4·5% 
(–8·0 to 
–1·1)*
22·5 
(18·1 to 
28·2)
13·1 
(10·3 to 
15·6)
17·8 
(14·9 to 
20·9)
–18·3% 
(–21·5 to 
–15·1)*
–13·1% 
(–18·4 to 
–7·1)*
–16·6% 
(–19·5 to 
–13·4)*
Non-Hodgkin 
lymphoma
4260 
(4070 to 4420)
2760 
(2670 to 2860)
7020 
(6790 to 7230)
23·2% 
(12·7 to 
28·8)*
21·5% 
(14·5 to 
27·8)*
22·5% 
(16·2 to 
27·3)*
111·1 
(106·2 to 
115·4)
68·5 
(66·1 to 
71·2)
89·3 
(86·1 to 
92·2)
1·2% 
(–7·2 to 
5·8)
–0·7% 
(–6·6 to 
4·7)
0·4% 
(–4·9 to 
4·6)
Multiple myeloma 1240 
(1090 to 1460)
1080 
(1030 to 1240)
2330 
(2180 to 2610)
32·4% 
(23·6 to 
38·6)*
29·3% 
(23·9 to 
34·6)*
30·9% 
(26·1 to 
35·0)*
32·4 
(28·2 to 
37·9)
25·5 
(24·3 to 
29·2)
28·8 
(26·9 to 
32·2)
1·7% 
(–4·8 to 
6·3)
–0·5% 
(–4·5 to 
3·6)
0·7% 
(–2·9 to 
3·8)
Leukaemia 6820 
(6010 to 7300)
5150 
(4420 to 5630)
12 000 
(10 700 to 
12 800)
4·3% 
(0·4 to 
9·0)*
0·6% 
(–8·4 to 
6·0)
2·7% 
(–3·3 to 
6·6)
181·0 
(159·4 to 
194·1)
134·2 
(115·0 to 
147·3)
156·8 
(140·8 to 
168·1)
–10·4% 
(–13·9 to 
–6·5)*
–13·5% 
(–21·6 to 
–8·5)*
–11·7% 
(–17 to 
–8·3)*
Acute lymphoid 
leukaemia
1580 
(1360 to 1740)
1130 
(923 to 1310)
2700 
(2380 to 2990)
4·2% 
(–6·1 to 
19·1)
7·8% 
(–13·8 to 
18·0)
5·6% 
(–8·2 to 
15·9)
42·2 
(36·2 to 
46·7)
31·1 
(25·5 to 
36·4)
36·7 
(32·2 to 
40·7)
–5·7% 
(–15·3 to 
7·9)
–2·3% 
(–22·5 to 
7·4)
–4·4% 
(–17·4 to 
5·0)
Chronic lymphoid 
leukaemia
436 
(401 to 473)
273 
(245 to 296)
709 
(667 to 755)
20·5% 
(15·0 to 
26·7)*
20·4% 
(15·9 to 
24·7)*
20·5% 
(16·4 to 
24·5)*
11·8 
(10·9 to 
12·8)
6·5 
(5·8 to 
7·0)
8·9 
(8·4 to 
9·5)
–8·4% 
(–12·5 to 
–3·7)*
–7·1% 
(–10·6 to 
–3·7)*
–7·7% 
(–10·8 to 
–4·6)*
Acute myeloid 
leukaemia
1870 
(1590 to 2020)
1350 
(1180 to 1520)
3220 
(2890 to 3440)
20·5% 
(11·1 to 
29·1)*
10·9% 
(–6·1 to 
19·9)
16·3% 
(4·5 to 
24·6)*
49·2 
(41·7 to 
53·1)
34·5 
(30·0 to 
39·1)
41·7 
(37·3 to 
44·5)
1·9% 
(–5·8 to 
9·1)
–5·9% 
(–20·6 to 
2·1)
–1·4% 
(–11·2 to 
5·8)
Chronic myeloid 
leukaemia
347 
(309 to 383)
308 
(259 to 358)
655 
(595 to 713)
–1·8% 
(–6·1 to 
3·1)
–1·4% 
(–7·5 to 
3·6)
–1·6% 
(–5·0 to 
1·7)
9·0 
(8·0 to 
9·9)
7·5 
(6·3 to 
8·7)
8·2 
(7·4 to 8·9)
–20·3% 
(–23·7 to 
–16·4)*
–19·0% 
(–23·9 to 
–14·8)*
–19·6% 
(–22·4 to 
–17·0)*
Other leukaemia 2590 
(2190 to 2920)
2090 
(1700 to 2320)
4690 
(4040 to 5120)
–6·0% 
(–11·4 to 
1·5)
–9·7% 
(–19·9 to 
–2·4)*
–7·7% 
(–14·2 to 
–1·4)*
68·8 
(58·1 to 
77·3)
54·6 
(44·1 to 
60·7)
61·4 
(53·0 to 
67·0)
–18·9% 
(–23·4 to 
–12·6)*
–22·3% 
(–31·4 to 
–15·8)*
–20·5% 
(–26·1 to 
–15·1)*
Other malignant 
cancers
6300 
(5620 to 6650)
5570 
(5090 to 5960)
11 900 
(11 000 to 
12 400)
21·1% 
(14·3 to 
27·3)*
23·1% 
(17·0 to 
28·8)*
22·0% 
(15·8 to 
27·0)*
165·0 
(147·5 to 
174·4)
142·4 
(129·9 to 
152·7)
153·2 
(142·0 to 
160·8)
2·0% 
(–3·7 to 
7·1)
3·7% 
(–1·8 to 
9·0)
2·7% 
(–2·5 to 
7·0)
Other neoplasms 1290 
(963 to 1690)
1190 
(926 to 1540)
2480 
(2080 to 2980)
35·6% 
(23·6 to 
50·5)*
30·2% 
(20·3 to 
43·3)*
33·0% 
(26·1 to 
42·4)*
34·5 
(25·4 to 
45·1)
29·4 
(23·1 to 
38·1)
31·8 
(26·6 to 
38·2)
9·5% 
(–0·4 to 
21·8)
6·0% 
(–2·3 to 
17·3)
7·9% 
(2·1 to 
16·2)*
Myelodysplastic, 
myeloproliferative, 
and other 
haemopoietic 
neoplasms
1180 
(876 to 1550)
1060 
(823 to 1380)
2240 
(1880 to 2720)
36·2% 
(23·8 to 
51·8)*
31·3% 
(22·3 to 
44·4)*
33·9% 
(26·8 to 
43·1)*
31·6 
(23·2 to 
41·4)
26·0 
(20·3 to 
33·8)
28·6 
(23·9 to 
34·6)
8·7% 
(–1·4 to 
21·4)
5·4% 
(–2·4 to 
16·6)
7·2% 
(1·4 to 
15·3)*
Benign and in-situ 
intestinal neoplasms
0 
(0 to 0)
0 
(0 to 0)
0 
(0 to 0)
- - - 0 
(0 to 0)
0 
(0 to 0)
0 
(0 to 0)
- - -
Benign and in-situ 
cervical and uterine 
neoplasms
- 0 
(0 to 0)
0 
(0 to 0)
- - - - 0 
(0 to 0)
0 
(0 to 0)
- - -
Other benign and in-
situ neoplasms
111 
(77·4 to 148)
126 
(89·7 to 150)
237 
(186 to 278)
29·1% 
(18·4 to 
45·4)*
21·5% 
(5·6 to 
39·3)*
25·0% 
(12·7 to 
38·6)*
2·9 
(2·0 to 
3·9)
3·4 
(2·4 to 
4·1)
3·2 
(2·5 to 3·7)
18·7% 
(8·9 to 
33·9)*
10·6% 
(–4·1 to 
26·8)
14·3% 
(3·0 to 
27·0)*
Cardiovascular 
diseases
210 000 
(204 000 to 
216 000)
156 000 
(150 000 to 
162 000)
366 000 
(355 000 to 
377 000)
17·1% 
(15·3 to 
19·0)*
15·4% 
(13·5 to 
17·5)*
16·4% 
(15·0 to 
17·8)*
5588·6 
(5428·4 
to 5743·1)
3680·1 
(3541·4 
to 
3821·0)
4597·9 
(4463·7 to 
4734·2)
–9·3% 
(–10·7 to 
–7·8)*
–10·8% 
(–12·4 to 
–9·3)*
–9·9% 
(–11·0 to 
–8·8)*
Rheumatic heart 
disease
4110 
(3710 to 
4630)
5280 
(4710 to 5950)
9390 
(8580 to 
10 300)
–9·2% 
(–14·6 to 
–4·0)*
–3·1% 
(–8·6 to 
2·4)
–5·9% 
(–10·6 to 
–2·2)*
106·9 
(96·7 to 
120·0)
130·3 
(116·1 to 
147·3)
118·7 
(108·5 to 
130·7)
–23·8% 
(–28·3 to 
–19·5)*
–19·6% 
(–24·3 to 
–14·9)*
–21·5% 
(–25·4 to 
–18·2)*
(Table 3 continues on next page)
Global Health Metrics
1886 www.thelancet.com   Vol 392   November 10, 2018
All-age DALYs (thousands) Age-standardised DALY rate (per 100 000)
2017 Percentage change, 2007–17 2017 Percentage change, 2007–17
Males Females Both Males Females Both Males Females Both Males Females Both
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Ischaemic heart disease 105 000 
(103 000 to 
108 000)
65 300 
(63 300 to 
67 200)
170 000 
(167 000 to 
174 000)
17·8% 
(15·7 to 
20·0)*
17·0% 
(14·6 to 
19·4)*
17·5% 
(15·7 to 
19·2)*
2776 
(2715·3 to 
2843·4)
1534·3 
(1487·3 
to 
1580·5)
2132·1 
(2093·7 to 
2179·8)
–9·2% 
(–10·8 to 
–7·6)*
–10·4% 
(–12·3 to 
–8·6)*
–9·7% 
(–11·0 to 
–8·4)*
Stroke 72 200 
(69 400 to 
75 000)
59 900 
(56 700 to 
63 000)
132 000 
(126 000 to 
137 000)
17·4% 
(14·6 to 
20·1)*
13·6% 
(10·9 to 
16·4)*
15·7% 
(13·5 to 
17·7)*
1924·7 
(1848·8 to 
1998·4)
1412·1 
(1336·8 
to 
1485·8)
1657·2 
(1587·4 to 
1723·8)
–9·9% 
(–11·9 to 
–7·9)*
–12·5% 
(–14·6 to 
–10·4)*
–11·0% 
(–12·6 to 
–9·4)*
Ischaemic stroke 28 500 
(26 400 to 
30 600)
26 700 
(24 400 to 
29 000)
55 100 
(50 900 to 
59 400)
28·6% 
(25·0 to 
32·2)*
20·8% 
(17·3 to 
24·2)*
24·7% 
(21·8 to 
27·5)*
790·0 
(732·7 to 
846·5)
625·2 
(570·9 to 
679·3)
702·8 
(649·5 to 
756·5)
–3·7% 
(–6·3 to 
–1·0)*
–8·1% 
(–10·8 to 
–5·6)*
–5·8% 
(–8·0 to 
–3·7)*
Intracerebral 
haemorrhage
37 400 
(35 900 to 
38 900)
27 200 
(25 900 to 
28 500)
64 500 
(62 300 to 
66 600)
10·7% 
(7·5 to 
14·2)*
7·9% 
(4·4 to 
11·6)*
9·5% 
(6·7 to 
12·0)*
971·6 
(933·9 to 
1011·4)
641·7 
(611·1 to 
673·3)
800·3 
(773·3 to 
826·1)
–14·5% 
(–16·9 to 
–11·8)*
–16·4% 
(–19·1 to 
–13·6)*
–15·2% 
(–17·4 to 
–13·3)*
Subarachnoid 
haemorrhage
6350 
(5680 to 7240)
6060 
(5610 to 6780)
12 400 
(11 600 to 
13 700)
13·4% 
(7·6 to 
24·3)*
10·9% 
(7·1 to 
14·7)*
12·2% 
(8·5 to 
17·3)*
163·1 
(145·8 to 
185·9)
145·2 
(134·5 to 
162·8)
154·1 
(143·7 to 
170·1)
–8·8% 
(–13·7 to 
–0·5)*
–12·0% 
(–15·0 to 
–9·0)*
–10·4% 
(–13·3 to 
–6·4)*
Hypertensive heart 
disease
7880 
(5500 to 
8620)
8660 
(6730 to 9560)
16 500 
(12 700 to 
17 900)
39·5% 
(19·4 to 
51·3)*
32·2% 
(19·7 to 
45·7)*
35·6% 
(20·5 to 
46·6)*
214·6 
(149·8 to 
234·1)
203·2 
(158·1 to 
224·5)
209·4 
(160·5 to 
226·3)
7·0% 
(–8·7 to 
15·5)
0·9% 
(–8·4 to 
10·8)
3·7% 
(–7·9 to 
11·8)
Non-rheumatic valvular 
heart disease
1270 
(1130 to 1400)
1260 
(1100 to 1420)
2530 
(2290 to 2770)
23·6% 
(19·2 to 
27·7)*
23·7% 
(19·3 to 
28)*
23·6% 
(20·6 to 
26·5)*
36·0 
(31·6 to 
39·7)
29·6 
(26·0 to 
33·5)
32·7 
(29·5 to 
36·0)
–5·0% 
(–8·2 to 
–1·8)*
–5·6% 
(–8·4 to 
–2·2)*
–5·5% 
(–7·5 to 
–3·2)*
Non-rheumatic 
calcific aortic valve 
disease
793 
(682 to 873)
720 
(595 to 818)
1510 
(1340 to 1650)
32·1% 
(26·1 to 
36·8)*
30·5% 
(23·7 to 
36·1)*
31·3% 
(26·4 to 
35·6)*
22·9 
(19·5 to 
25·1)
16·8 
(14·0 to 
19·1)
19·8 
(17·5 to 
21·5)
–0·3% 
(–4·3 to 
3·2)
–2·5% 
(–6·7 to 
1·2)
–1·5% 
(–4·7 to 
1·4)
Non-rheumatic 
degenerative mitral 
valve disease
408 
(340 to 480)
466 
(381 to 577)
874 
(748 to 1010)
12·5% 
(7·0 to 
19·9)*
16·4% 
(10·8 to 
22·3)*
14·6% 
(9·8 to 
19·8)*
11·2 
(9·4 to 
13·2)
11·1 
(9·1 to 
13·7)
11·2 
(9·5 to 
12·9)
–12·1% 
(–16·1 to 
–6·3)*
–9·1% 
(–13·0 to 
–4·7)*
–10·7% 
(–14·3 to 
–6·7)*
Other non-rheumatic 
valve diseases
71·5 
(46·3 to 103)
70·6 
(48·9 to 102)
142 
(109 to 190)
7·2% 
(–4·1 to 
29·7)
9·7% 
(–1·3 to 
32·3)
8·5% 
(–1·8 to 
27·8)
1·9 
(1·2 to 
2·8)
1·7 
(1·2 to 
2·5)
1·8 
(1·4 to 2·4)
–13·3% 
(–23·3 to 
7·0)
–11·0% 
(–20·1 to 
7·4)
–12·2% 
(–21·0 to 
4·7)
Cardiomyopathy and 
myocarditis
6530 
(5880 to 7020)
3720 
(3490 to 4010)
10 200 
(9500 to 
10 900)
–3·6% 
(–9·6 to 
12·4)
–4·2% 
(–7·1 to 
–0·2)*
–3·8% 
(–8·1 to 
6·4)
168·8 
(152·5 to 
181·2)
92·8 
(86·9 to 
100·2)
130·3 
(121·0 to 
138·8)
–19·9% 
(–24·7 to 
–6·8)*
–21·5% 
(–23·8 to 
–18·4)*
–20·6% 
(–24·1 to 
–12·5)*
Myocarditis 745 
(625 to 894)
646 
(561 to 723)
1390 
(1220 to 1560)
6·2% 
(–2·2 to 
17·6)
–4·3% 
(–10·6 to 
5·0)
1·0% 
(–5·3 to 
8·3)
19·9 
(16·7 to 
23·7)
16·7 
(14·5 to 
18·7)
18·3 
(16·1 to 
20·4)
–9·3% 
(–16·7 to 
0·6)
–19·1% 
(–24·5 to 
–11·2)*
–14·2% 
(–19·6 to 
–7·2)*
Alcoholic 
cardiomyopathy
2330 
(1990 to 2530)
660 
(610 to 750)
2990 
(2720 to 3210)
–26·9% 
(–32 to 
–0·2)*
–37·1% 
(–40 to 
–31·7)*
–29·4% 
(–33·5 to 
–11·1)*
57·6 
(49·2 to 
62·7)
15·9 
(14·6 to 
18·0)
36·4 
(33·2 to 
39·1)
–39·7% 
(–43·9 to 
–18·2)*
–49·0% 
(–51·3 to 
–44·6)*
–42·2% 
(–45·5 to 
–27·5)*
Other 
cardiomyopathy
3450 
(3050 to 3800)
2420 
(2160 to 2640)
5870 
(5290 to 6390)
19·7% 
(12·7 to 
25·7)*
11·7% 
(7·6 to 
17·6)*
16·3% 
(11·6 to 
20·3)*
91·4 
(81·2 to 
100·1)
60·3 
(53·8 to 
65·9)
75·6 
(68·3 to 
82·1)
–2·2% 
(–7·6 to 
2·7)
–9·5% 
(–12·7 to 
–5·2)*
–5·3% 
(–8·9 to 
–2·1)*
Atrial fibrillation and 
flutter
2850 
(2360 to 3460)
3120 
(2690 to 3640)
5980 
(5040 to 7090)
36·0% 
(33·1 to 
38·5)*
35·8% 
(34·1 to 
37·9)*
35·9% 
(34·3 to 
37·8)*
84·0 
(70·0 to 
101·4)
72·7 
(62·6 to 
84·9)
78·0 
(66·1 to 
92·0)
–0·1% 
(–2·2 to 
1·6)
1·1% 
(–0·1 to 
2·6)
0·5% 
(–0·5 to 
1·7)
Aortic aneurysm 2090 
(1950 to 2250)
949 
(907 to 1050)
3040 
(2880 to 
3190)
17·9% 
(12·9 to 
23·6)*
21·6% 
(16·2 to 
25·9)*
19·0% 
(14·5 to 
23·6)*
56·0 
(52·3 to 
60·2)
22·3 
(21·4 to 
24·7)
38·2 
(36·2 to 
40·0)
–9·9% 
(–13·6 to 
–5·7)*
–6·6% 
(–10·6 to 
–3·2)*
–8·5% 
(–11·9 to 
–5·1)*
Peripheral vascular 
disease
759 
(513 to 1190)
674 
(395 to 1150)
1430 
(970 to 2130)
40·6% 
(22·7 to 
52·9)*
39·8% 
(23·3 to 
55·6)*
40·2% 
(25·9 to 
53·5)*
21·4 
(14·4 to 
33·9)
15·7 
(9·2 to 
26·7)
18·4 
(12·5 to 
27·6)
4·1% 
(–9·0 to 
13·4)
4·1% 
(–8·1 to 
15·4)
4·1% 
(–6·5 to 
13·9)
Endocarditis 1160 
(1090 to 1230)
1070 
(920 to 1220)
2230 
(2080 to 2420)
20·6% 
(11·0 to 
26·2)*
13·6% 
(5·9 to 
20·5)*
17·1% 
(9·3 to 
22·3)*
30·8 
(28·9 to 
32·7)
27·3 
(23·5 to 
31·1)
29·0 
(27·1 to 
31·7)
0·8% 
(–6·7 to 
5·2)
–5·2% 
(–11·4 to 
0·6)
–2·3% 
(–8·6 to 
2·0)
Other cardiovascular 
and circulatory diseases
6420 
(5620 to 7410)
5730 
(4950 to 6750)
12 200 
(10 600 to 
14 000)
15·3% 
(12·3 to 
18·4)*
17·1% 
(14·2 to 
21·3)*
16·2% 
(13·6 to 
18·6)*
169·4 
(148·6 to 
195·5)
139·8 
(120·4 to 
163·9)
153·8 
(134·7 to 
176·5)
–7·5% 
(–9·9 to 
–5·2)*
–5·8% 
(–8·2 to 
–2·6)*
–6·7% 
(–8·7 to 
–5·0)*
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(Continued from previous page)
Chronic respiratory 
diseases
58 600 
(54 900 to 
62 300)
53 700 
(49 000 to 
57 900)
112 000 
(105 000 to 
120 000)
10·7% 
(8·5 to 
13·3)*
18·9% 
(14·8 to 
23·6)*
14·5% 
(12·3 to 
17·2)*
1586·3 
(1489·1 
to 
1681·7)
1293·2 
(1178·8 
to 
1399·0)
1422·9 
(1326·6 to 
1517·2)
–14·2% 
(–16·1 to 
–12·1)*
–6·0% 
(–9·2 to 
–2·4)*
–10·2% 
(–12·0 to 
–8·1)*
Chronic obstructive 
pulmonary disease
43 300 
(40 100 to 
46 100)
38 300 
(34 900 to 
41 400)
81 600 
(76 000 to 
86 800)
13·5% 
(10·3 to 
16·9)*
21·2% 
(14·9 to 
26·5)*
17·0% 
(13·7 to 
20·0)*
1181·3 
(1097·1 to 
1255·3)
906·4 
(824·1 to 
979·9)
1028·8 
(960·4 to 
1092·5)
–14·1% 
(–16·4 to 
–11·5)*
–6·3% 
(–11·1 to 
–2·3)*
–10·3% 
(–12·9 to 
–8·0)*
Pneumoconiosis 453 
(421 to 489)
54·1 
(45·7 to 63·1)
507 
(472 to 548)
10·4% 
(4·3 to 
17·1)*
11·8% 
(0·1 to 
22·4)*
10·6% 
(5·2 to 
16·6)*
12·1 
(11·2 to 
13·0)
1·3 
(1·1 to 
1·5)
6·3 
(5·9 to 
6·8)
–15·6% 
(–20·1 to 
–10·7)*
–12·3% 
(–21·5 to 
–4·1)*
–14·4% 
(–18·6 to 
–9·8)*
Silicosis 247 
(220 to 272)
13·3 
(8·66 to 17·0)
261 
(233 to 286)
13·0% 
(0·3 to 
24·2)*
17·8% 
(6·0 to 
31·2)*
13·2% 
(1·2 to 
24·1)*
6·5 
(5·8 to 
7·2)
0·3 
(0·2 to 
0·4)
3·2 
(2·9 to 3·5)
–13·6% 
(–23·1 to 
–5·1)*
–7·6% 
(–17·0 to 
3·0)
–12·3% 
(–21·6 to 
–3·9)*
Asbestosis 57·3 
(41·7 to 67·9)
11·7 
(8·38 to 15·0)
69·1 
(52·2 to 81·4)
20·2% 
(12·3 to 
31·3)*
14·7% 
(0·8 to 
32·0)*
19·2% 
(11·8 to 
30·4)*
1·6 
(1·2 to 
1·9)
0·3 
(0·2 to 
0·4)
0·9 
(0·7 to 1·0)
–9·1% 
(–14·9 to 
–0·7)*
–10·5% 
(–21·3 to 
3·4)
–8·5% 
(–14·1 to 
0·3)
Coal worker 
pneumoconiosis
74·6 
(63 to 92·9)
6·24 
(4·00 to 8·12)
80·8 
(69·0 to 100)
–0·6% 
(–10·0 to 
12·9)
9·0% 
(–2·8 to 
27·2)
0·1% 
(–8·8 to 
12·9)
2·0 
(1·7 to 2·5)
0·1 
(0·1 to 
0·2)
1·0 
(0·9 to 1·3)
–24·3% 
(–31·2 to 
–14·5)*
–14·8% 
(–24·0 to 
–0·6)*
–23% 
(–29·8 to 
–13·3)*
Other 
pneumoconiosis
74·1 
(61·6 to 94·6)
22·8 
(17·6 to 28·8)
96·9 
(81·8 to 117)
7·4% 
(–1·2 to 
22·6)
8·1% 
(–3·9 to 
19·7)
7·6% 
(0·6 to 
20·5)*
2·0 
(1·6 to 
2·5)
0·5 
(0·4 to 
0·7)
1·2 
(1·0 to 1·5)
–16·6% 
(–23·4 to 
–4·8)*
–15·0% 
(–24·6 to 
–5·9)*
–15·9% 
(–21·4 to 
–5·5)*
Asthma 11 000 
(8470 to 
14 100)
11 700 
(9050 to 
14 800)
22 800 
(18 100 to 
28 300)
–2·7% 
(–8·9 to 
4·8)
9·7% 
(4·3 to 
17·0)*
3·3% 
(–1·1 to 
9·0)
290·1 
(223·0 to 
371·5)
297·4 
(229·0 to 
376·2)
293·3 
(232·4 to 
365·2)
–19·3% 
(–25·5 to 
–10·8)*
–8·2% 
(–13·6 to 
–0·9)*
–13·7% 
(–18·2 to 
–7·9)*
Interstitial lung disease 
and pulmonary 
sarcoidosis
1840 
(1490 to 2390)
1530 
(1160 to 2000)
3360 
(2770 to 4080)
40·6% 
(25·8 to 
49·7)*
39·5% 
(25·2 to 
53·3)*
40·1% 
(31·5 to 
47·8)*
49·8 
(40·1 to 
64·4)
36·2 
(27·5 to 
47·5)
42·3 
(34·8 to 
51·4)
7·9% 
(–3·0 to 
14·7)
8·3% 
(–2·6 to 
19·1)
8·3% 
(1·8 to 
14·3)*
Other chronic 
respiratory diseases
2070 
(1820 to 2360)
2010 
(1740 to 2280)
4080 
(3600 to 4560)
14·8% 
(9·5 to 
22·0)*
21·3% 
(14·8 to 
29·3)*
17·9% 
(13·2 to 
24·5)*
53·0 
(46·6 to 
60·4)
51·9 
(44·7 to 
58·9)
52·1 
(46·1 to 
58·2)
–1·7% 
(–6·3 to 
4·3)
6·0% 
(0·1 to 
13·5)*
2·0% 
(–2·2 to 
7·8)
Digestive diseases 52 800 
(48 500 to 
58 200)
32 500 
(29 100 to 
36 800)
85 300 
(78 000 to 
94 500)
9·9% 
(6·7 to 
16·1)*
10·9% 
(8·1 to 
14·4)*
10·3% 
(7·5 to 
14·3)*
1346·7 
(1237·4 to 
1486·3)
803·1 
(717·1 to 
911·3)
1070·8 
(979·3 to 
1187·9)
–9·6% 
(–12·2 to 
–4·5)*
–8·9% 
(–11·5 to 
–6·0)*
–9·4% 
(–11·7 to 
–6·0)*
Cirrhosis and other 
chronic liver diseases
28 800 
(27 300 to 
31 400)
12 600 
(11 900 to 
14 700)
41 400 
(39 600 to 
45 100)
9·9% 
(4·3 to 
16·4)*
9·4% 
(2·9 to 
15·5)*
9·8% 
(4·5 to 
15·2)*
719·3 
(683·0 to 
784·9)
307·6 
(288·5 to 
359·6)
510·7 
(487·6 to 
557·1)
–10·2% 
(–14·8 to 
–4·9)*
–11·2% 
(–16·5 to 
–6·3)*
–10·6% 
(–14·9 to 
–6·3)*
Cirrhosis and other 
chronic liver diseases 
due to hepatitis B
9190 
(8310 to 
10 500)
3020 
(2700 to 
3600)
12 200 
(11 100 to 
13 900)
4·5% 
(–2·3 to 
11·9)
3·9% 
(–4·3 to 
13·3)
4·3% 
(–2·2 to 
11·4)
229·5 
(208·0 to 
261·6)
72·9 
(65·0 to 
86·8)
150·1 
(136·2 to 
170·3)
–14·3% 
(–20 to 
–8·2)*
–15·8% 
(–22·4 to 
–8·4)*
–14·7% 
(–20·0 to 
–8·9)*
Cirrhosis and other 
chronic liver diseases 
due to hepatitis C
7160 
(6450 to 
8000)
3250 
(2950 to 3700)
10 400 
(9470 to 
11 600)
13·0% 
(7·5 to 
19·1)*
13·1% 
(6·0 to 
20·0)*
13·0% 
(7·7 to 
18·1)*
178·1 
(160·8 to 
198·8)
77·8 
(70·7 to 
88·4)
127·2 
(115·9 to 
141·8)
–8·5% 
(–12·9 to 
–3·7)*
–9·6% 
(–15·2 to 
–4·4)*
–8·9% 
(–13·1 to 
–4·9)*
Cirrhosis and other 
chronic liver diseases 
due to alcohol use
7660 
(6980 to 
8450)
2530 
(2290 to 
2980)
10 200 
(9310 to 
11 300)
13·0% 
(7·8 to 
19·0)*
13·3% 
(7·2 to 
22·4)*
13·1% 
(8·1 to 
18·9)*
189·6 
(173·1 to 
209·1)
60·2 
(54·5 to 
70·8)
123·9 
(113·2 to 
138·1)
–8·8% 
(–13·2 to 
–4)*
–10·3% 
(–15·2 to 
–3·3)*
–9·3% 
(–13·4 to 
–4·8)*
Cirrhosis due to 
NASH
2110 
(1920 to 2310)
1330 
(1220 to 1470)
3430 
(3150 to 3740)
24·3% 
(18·4 to 
30·1)*
21·9% 
(15·4 to 
27·6)*
23·4% 
(17·8 to 
28·3)*
52·2 
(47·8 to 
57·3)
31·6 
(29·0 to 
35·0)
41·8 
(38·5 to 
45·5)
–0·6% 
(–5·2 to 
4·2)
–4·1% 
(–9·2 to 
0·3)
–2·0% 
(–6·4 to 
1·9)
Cirrhosis and other 
chronic liver diseases 
due to other causes
2660 
(2370 to 3000)
2500 
(2220 to 2960)
5160 
(4650 to 5760)
3·6% 
(–3·7 to 
13·8)
2·5% 
(–4·5 to 
11·5)
3·1% 
(–3·0 to 
11·2)
70·0 
(62·7 to 
78·6)
65·2 
(57·7 to 
77·8)
67·7 
(61·1 to 
75·4)
–10·5% 
(–16·8 to 
–1·6)*
–11·8% 
(–18·2 to 
–3·9)*
–11·1% 
(–16·5 to 
–3·9)*
Upper digestive system 
diseases
10 200 
(7880 to 
13 400)
9640 
(7080 to 
13 200)
19 800 
(15 100 to 
26 600)
7·4% 
(2·3 to 
12·3)*
12·7% 
(9·4 to 
15·7)*
9·9% 
(6·0 to 
13·4)*
261·0 
(202·6 to 
342·2)
237·4 
(173·6 to 
324·9)
248·7 
(189·1 to 
333·3)
–11·5% 
(–16·1 to 
–7·2)*
–6·6% 
(–9·7 to 
–3·8)*
–9·1% 
(–12·7 to 
–5·9)*
Peptic ulcer disease 3740 
(3440 to 
4200)
2610 
(2270 to 2910)
6350 
(5900 to 
6870)
–7·2% 
(–12·8 to 
–1·0)*
0·7% 
(–4·3 to 
6·9)
–4·1% 
(–8·5 to 
0·9)
96·9 
(89·1 to 
108·9)
63·2 
(55·0 to 
70·7)
79·6 
(73·9 to 
86·2)
–25·4% 
(–29·9 to 
–20·5)*
–19·1% 
(–23·2 to 
–14·1)*
–22·9% 
(–26·5 to 
–18·9)*
(Table 3 continues on next page)
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(Continued from previous page)
Gastritis and 
duodenitis
3470 
(2500 to 
4700)
4000 
(2750 to 5550)
7470 
(5240 to 
10 200)
16·4% 
(11·8 to 
21·0)*
15·7% 
(12·8 to 
18·7)*
16·1% 
(13·0 to 
19·1)*
89·1 
(64·1 to 
120·1)
99·7 
(68·4 to 
138·5)
94·3 
(66·4 to 
129·1)
–2·0% 
(–6·0 to 
1·9)
–2·7% 
(–5·3 to 
–0·3)*
–2·3% 
(–5·1 to 
0·4)
Gastro-oesophageal 
reflux disease 
2980 
(1590 to 
5020)
3040 
(1630 to 5150)
6010 
(3220 to 
10 200)
20·3% 
(18·6 to 
22·2)*
21·0% 
(19·3 to 
22·8)*
20·7% 
(19·1 to 
22·3)*
75·1 
(40·1 to 
126·9)
74·5 
(40·1 to 
126·9)
74·8 
(40·1 to 
126·9)
1·2% 
(0·1 to 
2·3)*
1·4% 
(0·4 to 
2·4)*
1·3% 
(0·6 to 
2·0)*
Appendicitis 910 
(813 to 1030)
947 
(799 to 1050)
1860 
(1680 to 
2020)
–7·3% 
(–16·6 to 
3·8)
–6·2% 
(–14·3 to 
2·8)
–6·7% 
(–14·1 to 
1·6)
23·9 
(21·4 to 
27)
25·0 
(21·1 to 
27·7)
24·4 
(22·0 to 
26·5)
–19% 
(–27·1 to 
–9·5)*
–17·3% 
(–24·8 to 
–9·0)*
–18·1% 
(–24·7 to 
–10·6)*
Paralytic ileus and 
intestinal obstruction
4080 
(3230 to 
4700)
3210 
(2350 to 3650)
7290 
(5910 to 
8030)
5·9% 
(–4·9 to 
17·8)
7·4% 
(–3·2 to 
18·7)
6·6% 
(–2·9 to 
15·5)
110·7 
(88·4 to 
127·2)
84·9 
(62·3 to 
96·2)
97·6 
(79·4 to 
107·4)
–8·9% 
(–18·0 to 
1·0)
–8·2% 
(–17·1 to 
1·5)
–8·6% 
(–16·7 to 
–0·8)*
Inguinal, femoral, and 
abdominal hernia
2490 
(1860 to 
3230)
989 
(753 to 1250)
3480 
(2610 to 
4480)
13·3% 
(10·1 to 
16·7)*
15·2% 
(11·9 to 
19·7)*
13·9% 
(11·0 to 
16·8)*
65·5 
(49·1 to 
84·6)
25·0 
(18·9 to 
31·8)
44·8 
(33·6 to 
57·5)
–5·3% 
(–8·0 to 
–2·6)*
–4·4% 
(–7·2 to 
–1·1)*
–5·0% 
(–7·3 to 
–2·7)*
Inflammatory bowel 
disease
885 
(741 to 1050)
964 
(751 to 1180)
1850 
(1510 to 2230)
16·8% 
(8·4 to 
23·2)*
15·8% 
(8·3 to 
21·0)*
16·3% 
(8·8 to 
21·4)*
23·0 
(19·3 to 
27·2)
23·5 
(18·3 to 
28·6)
23·2 
(19·1 to 
27·8)
–5·0% 
(–11·5 to 
0·1)
–6·2% 
(–12·2 to 
–2·1)*
–5·6% 
(–11·5 to 
–1·9)*
Vascular intestinal 
disorders
806 
(742 to 866)
791 
(688 to 869)
1600 
(1460 to 1700)
16·9% 
(9·5 to 
28·2)*
18·6% 
(12·1 to 
24·5)*
17·7% 
(11·0 to 
24·8)*
21·9 
(20·2 to 
23·6)
18·6 
(16·1 to 
20·5)
20·4 
(18·7 to 
21·6)
–10·1% 
(–15·6 to 
–2·3)*
–9·4% 
(–14·4 to 
–4·9)*
–9·9% 
(–15·0 to 
–4·9)*
Gallbladder and biliary 
diseases
940 
(882 to 1040)
1070 
(933 to 1140)
2010 
(1890 to 2130)
22·5% 
(15·6 to 
31·7)*
15·3% 
(9·9 to 
23·9)*
18·6% 
(13·6 to 
25·3)*
25·7 
(24·2 to 
28·4)
25·8 
(22·4 to 
27·7)
25·7 
(24·1 to 
27·2)
–3·8% 
(–8·9 to 
3·0)
–9·2% 
(–13·6 to 
–2·3)*
–6·8% 
(–10·8 to 
–1·7)*
Pancreatitis 2210 
(1950 to 
2470)
1050 
(831 to 1210)
3250 
(2890 to 
3610)
14·7% 
(7·4 to 
21·7)*
15·9% 
(8·8 to 
22·6)*
15·1% 
(10·6 to 
20·5)*
55·6 
(49·2 to 
62·2)
25·3 
(20·0 to 
29·3)
40·3 
(35·9 to 
44·7)
–5·2% 
(–11 to 
0·5)
–6·9% 
(–12·5 to 
–1·5)*
–5·9% 
(–9·5 to 
–1·6)*
Other digestive 
diseases
1510 
(1300 to 1750)
1210 
(1050 to 1380)
2720 
(2380 to 3110)
22·3% 
(11·7 to 
34·6)*
18·8% 
(12·2 to 
26·9)*
20·7% 
(12·9 to 
28·4)*
40·2 
(34·7 to 
46·3)
30·0 
(26·0 to 
34·4)
35·0 
(30·7 to 
40·0)
–0·4% 
(–8·3 to 
9·2)
–3·7% 
(–9·2 to 
3·1)
–1·9% 
(–8·2 to 
4·1)
Neurological disorders 46 300 
(37 200 to 
57 200)
64 900 
(51 100 to 
81 400)
111 000 
(88 500 to 
139 000)
20·5% 
(18·4 to 
23·3)*
20·6% 
(18·9 to 
22·4)*
20·5% 
(18·8 to 
22·6)*
1275·1 
(1036·4 
to 
1554·8)
1606·9 
(1256·7 
to 
2030·1)
1444·4 
(1154 to 
1792·7)
–0·1% 
(–1·9 to 
2·0)
–0·2% 
(–1·5 to 
1·2)
–0·2% 
(–1·6 to 
1·4)
Alzheimer’s disease and 
other dementias
11 700 
(10 900 to 
12 500)
18 900 
(17 600 to 
20 200)
30 500 
(28 500 to 
32 600)
41·8% 
(38·0 to 
44·4)*
36·1% 
(32·8 to 
38·2)*
38·3% 
(36·0 to 
40·1)*
376·8 
(352·1 to 
404·4)
436·2 
(407·7 to 
466·2)
412·6 
(385·7 to 
440·3)
0·5% 
(–2·0 to 
2·1)
–0·9% 
(–3·2 to 
0·6)
–0·6% 
(–2·2 to 
0·6)
Parkinson’s disease 3190 
(2940 to 
3500)
2390 
(2200 to 
2630)
5580 
(5150 to 
6080)
36·1% 
(31·2 to 
39·3)*
31·0% 
(26·5 to 
34·0)*
33·9% 
(29·7 to 
36·4)*
94·0 
(86·7 to 
103·1)
55·9 
(51·3 to 
61·3)
72·5 
(66·9 to 
79·0)
0·2% 
(–3·4 to 
2·5)
–0·7% 
(–4·0 to 
1·6)
0·4% 
(–2·7 to 
2·3)
Epilepsy 7910 
(6200 to 
10 100)
6880 
(5220 to 
8960)
14 800 
(11 400 to 
19 000)
4·3% 
(–3·3 to 
15·0)
7·7% 
(–1 to 
18·2)
5·8% 
(–2·0 to 
15·9)
208·1 
(162·8 to 
266·7)
183·5 
(139·3 to 
239·7)
195·8 
(151·4 to 
251·8)
–6·4% 
(–13·2 to 
3·2)
–3·8% 
(–11·4 to 
5·4)
–5·2% 
(–12·2 to 
3·7)
Multiple sclerosis 408 
(354 to 459)
677 
(579 to 781)
1080 
(943 to 1240)
17·9% 
(9·3 to 
21·6)*
17·4% 
(11·1 to 
22·3)*
17·6% 
(10·2 to 
21·9)*
10·1 
(8·8 to 
11·4)
16·3 
(14·0 to 
18·9)
13·3 
(11·5 to 
15·2)
–3·8% 
(–10·3 to 
–0·8)*
–4·5% 
(–9·1 to 
–0·4)*
–4·2% 
(–9·8 to 
–0·6)*
Motor neuron disease 508 
(481 to 556)
371 
(345 to 407)
879 
(841 to 966)
27·9% 
(21 to 
31·9)*
26·1% 
(20·0 to 
31·1)*
27·2% 
(22·9 to 
30·9)*
13·1 
(12·4 to 
14·3)
9·0 
(8·3 to 
9·8)
11·0 
(10·5 to 
12·0)
1·4% 
(–3·8 to 
4·5)
–1·0% 
(–5·8 to 
2·9)
0·3% 
(–3·1 to 
3·3)
Headache disorders 20 500 
(13 400 to 
29 300)
33 900 
(22 200 to 
48 100)
54 300 
(35 600 to 
76 800)
15·5% 
(14·5 to 
16·5)*
15·3% 
(14·4 to 
16·2)*
15·4% 
(14·6 to 
16·2)*
516·5 
(338 to 
738·7)
857·0 
(561·5 to 
1217·0)
686·5 
(448·7 to 
970·5)
1·5% 
(0·8 to 
2·3)*
0·7% 
(0·1 to 
1·3)*
1·0% 
(0·5 to 
1·5)*
Migraine 17 300 
(10 900 to 
25 500)
29 900 
(19 000 to 
42 900)
47 200 
(30 000 to 
68 700)
15·5% 
(14·4 to 
16·7)*
15·2% 
(14·2 to 
16·2)*
15·3% 
(14·5 to 
16·2)*
437·7 
(273·7 to 
645·5)
756·5 
(480·9 to 
1088·1)
596·8 
(378·2 to 
866)
1·7% 
(0·9 to 
2·6)*
0·8% 
(0·1 to 
1·5)*
1·1% 
(0·6 to 
1·7)*
Tension-type 
headache
3110 
(1740 to 
5000)
3990 
(2270 to 6230)
7100 
(4040 to 
11 200)
15·3% 
(14·1 to 
16·7)*
15·8% 
(14·6 to 
17·2)*
15·6% 
(14·5 to 
16·9)*
78·8 
(44·4 to 
126·9)
100·5 
(57·2 to 
157·6)
89·7 
(51·0 to 
142·2)
0·5% 
(0 to 1·0)
0·1% 
(–0·4 to 
0·6)
0·3% 
(–0·1 to 
0·6)
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(Continued from previous page)
Other neurological 
disorders
2130 
(1780 to 2570)
1830 
(1480 to 
2300)
3970 
(3270 to 
4850)
19·1% 
(10·1 to 
28·5)*
22·4% 
(11·4 to 
32·8)*
20·6% 
(12·5 to 
29·7)*
56·4 
(47·3 to 
68)
49·1 
(39·2 to 
61·9)
52·7 
(43·3 to 
64·7)
6·3% 
(–1·9 to 
14·6)
8·2% 
(–1·6 to 
17·6)
7·2% 
(–0·3 to 
15·3)
Mental disorders 56 200 
(41 800 to 
72 700)
66 500 
(49 700 to 
85 700)
123 000 
(91 600 to 
158 000)
13·4% 
(12·7 to 
14·0)*
13·6% 
(12·9 to 
14·4)*
13·5% 
(12·9 to 
14·1)*
1435·0 
(1065·8 
to 
1856·2)
1681·8 
(1255·2 
to 
2169·0)
1560·4 
(1165·1 to 
2010·5)
–0·6% 
(–1·1 to 
–0·2)*
–1·5% 
(–2·1 to 
–1·0)*
–1·1% 
(–1·5 to 
–0·7)*
Schizophrenia 6510 
(4860 to 
8020)
6140 
(4610 to 
7540)
12 700 
(9480 to 
15 600)
16·7% 
(15·4 to 
18·2)*
17·7% 
(16·3 to 
19·2)*
17·2% 
(16·1 to 
18·3)*
161·6 
(120·5 to 
198·9)
151·3 
(113·2 to 
185·8)
156·4 
(117·1 to 
192·3)
–0·4% 
(–1·4 to 
0·6)
–0·2% 
(–1·3 to 
0·9)
–0·3% 
(–1·1 to 
0·4)
Depressive disorders 16 800 
(11 900 to 
22 900)
26 300 
(18 700 to 
35 900)
43 100 
(30 500 to 
58 900)
14·8% 
(13·5 to 
16·2)*
14·1% 
(12·8 to 
15·5)*
14·3% 
(13·1 to 
15·6)*
425·1 
(300·8 to 
579·9)
653·5 
(462·2 to 
892·4)
540·5 
(382·4 to 
737·8)
–1·9% 
(–2·8 to 
–1·0)*
–3·1% 
(–4·1 to 
–2·1)*
–2·6% 
(–3·5 to 
–1·8)*
Major depressive 
disorder
12 700 
(8910 to 
17 300)
20 100 
(14 200 to 
27 000)
32 800 
(23 100 to 
44 300)
13·2% 
(11·8 to 
14·6)*
12·2% 
(10·7 to 
13·7)*
12·6% 
(11·3 to 
14·0)*
323·6 
(225·9 to 
439·5)
500·9 
(352·5 to 
676·7)
413·0 
(289·8 to 
558·9)
–2·7% 
(–3·8 to 
–1·8)*
–4·2% 
(–5·3 to 
–3·1)*
–3·6% 
(–4·6 to 
–2·7)*
Dysthymia 4030 
(2690 to 
5880)
6220 
(4180 to 
9090)
10 300 
(6880 to 
15 000)
20·2% 
(17·4 to 
23·2)*
20·6% 
(17·7 to 
23·5)*
20·4% 
(18·2 to 
22·6)*
101·5 
(67·9 to 
148·0)
152·7 
(102·4 to 
222·6)
127·4 
(85·4 to 
185·6)
1·0% 
(–1·0 to 
3·0)
0·6% 
(–1·4 to 
2·8)
0·8% 
(–0·8 to 
2·3)
Bipolar disorder 4490 
(2820 to 
6630)
4810 
(3030 to 7100)
9290 
(5870 to 
13 700)
15·3% 
(14·0 to 
16·8)*
15·2% 
(13·8 to 
16·7)*
15·2% 
(14·0 to 
16·6)*
113·4 
(71·3 to 
167·4)
121·6 
(76·8 to 
179·5)
117·5 
(74·1 to 
173·5)
1·5% 
(0·7 to 
2·3)*
0·9% 
(0·1 to 
1·8)*
1·2% 
(0·6 to 
1·8)*
Anxiety disorders 10 200 
(7200 to 
13 500)
17 000 
(12 000 to 
22 500)
27 100 
(19 200 to 
36 100)
13·6% 
(12·2 to 
15·1)*
12·4% 
(11·0 to 
13·8)*
12·8% 
(11·7 to 
14·0)*
259·2 
(183·1 to 
343·3)
431·9 
(306·8 to 
575·5)
345·7 
(245·6 to 
459·7)
0% 
(–1·1 to 
1·1)
–1·9% 
(–2·9 to 
–0·7)*
–1·2% 
(–2·0 to 
–0·4)*
Eating disorders 1050 
(662 to 1530)
2320 
(1500 to 3370)
3370 
(2170 to 
4890)
20·7% 
(18·4 to 
22·9)*
18·2% 
(16·4 to 
19·8)*
18·9% 
(17·3 to 
20·5)*
26·7 
(16·8 to 
39·1)
60·5 
(39·2 to 
87·6)
43·4 
(27·9 to 
62·9)
10·7% 
(8·8 to 
12·4)*
8·9% 
(7·6 to 
10·3)*
9·4% 
(8·2 to 
10·5)*
Anorexia nervosa 143 
(87·8 to 215)
585 
(365 to 864)
728 
(454 to 1080)
13·8% 
(9·4 to 
18·2)*
13·4% 
(10·8 to 
16·0)*
13·5% 
(11·1 to 
15·7)*
3·7 
(2·3 to 
5·6)
15·5 
(9·6 to 
22·8)
9·5 
(5·9 to 
14·1)
6·7% 
(3·0 to 
10·6)*
6·2% 
(3·9 to 
8·5)*
6·1% 
(4·2 to 
8·1)*
Bulimia nervosa 904 
(559 to 1340)
1740 
(1100 to 2620)
2640 
(1660 to 
3940)
21·9% 
(19·3 to 
24·3)*
19·8% 
(17·8 to 
21·9)*
20·5% 
(18·7 to 
22·1)*
22·9 
(14·2 to 
33·9)
45·0 
(28·6 to 
67·8)
33·8 
(21·3 to 
50·5)
11·4% 
(9·3 to 
13·2)*
9·9% 
(8·4 to 
11·4)*
10·3% 
(9·0 to 
11·6)*
Autism spectrum 
disorders
3590 
(2460 to 
4940)
1140 
(771 to 1570)
4730 
(3240 to 
6520)
11·1% 
(10·4 to 
11·9)*
12·4% 
(11·3 to 
13·6)*
11·4% 
(10·8 to 
12·1)*
94 
(64·4 to 
129·2)
30·4 
(20·5 to 
41·9)
62·4 
(42·7 to 
86·0)
–0·6% 
(–1·2 to 
0·1)
0·5% 
(–0·5 to 
1·6)
–0·3% 
(–0·8 to 
0·3)
Attention-deficit/
hyperactivity disorder
627 
(383 to 996)
262 
(158 to 416)
889 
(543 to 1410)
6·6% 
(4·4 to 
8·6)*
7·7% 
(5·3 to 
10·0)*
6·9% 
(5·2 to 
8·5)*
16·5 
(10·0 to 
26·2)
7·1 
(4·3 to 
11·3)
11·9 
(7·3 to 
18·9)
–0·8% 
(–2·9 to 
1·1)
0% 
(–2·2 to 
2·2)
–0·6% 
(–2·1 to 
0·8)
Conduct disorder 4190 
(2520 to 
6630)
2250 
(1330 to 3650)
6450 
(3870 to 
10 300)
4·1% 
(1·9 to 
6·1)*
6·3% 
(4·0 to 
8·7)*
4·8% 
(3·1 to 
6·5)*
113·8 
(68·5 to 
179·9)
64·9 
(38·2 to 
105·5)
90·0 
(54·0 to 
143·9)
1·7% 
(–0·4 to 
3·6)
3·7% 
(1·4 to 
5·8)*
2·4% 
(0·9 to 
3·8)*
Idiopathic 
developmental 
intellectual disability
2200 
(1060 to 
3740)
1840 
(901 to 3080)
4050 
(1940 to 
6860)
0·6% 
(–2·0 to 
2·0)
–0·6% 
(–3·9 to 
1·3)
0% 
(–2·8 to 
1·5)
58·0 
(28·0 to 
98·6)
50·4 
(24·7 to 
84·1)
54·2 
(26·1 to 
91·9)
–8·4% 
(–10·6 to 
–7·1)*
–9·1% 
(–12·0 to 
–7·5)*
–8·7% 
(–11·1 to 
–7·5)*
Other mental disorders 6640 
(4330 to 
9180)
4470 
(3010 to 6140)
11 100 
(7360 to 
15 300)
17·2% 
(16·5 to 
18·0)*
18·2% 
(17·3 to 
19·1)*
17·6% 
(17·0 to 
18·3)*
166·8 
(108·9 to 
230·4)
110·3 
(74·2 to 
151·5)
138·4 
(91·6 to 
191)
–0·1% 
(–0·7 to 
0·5)
0·1% 
(–0·6 to 
0·8)
0% 
(–0·4 to 
0·5)
Substance use 
disorders
31 900 
(25 900 to 
38 400)
12 800 
(9930 to 
15 700)
44 700 
(35 900 to 
54 100)
15·9% 
(13·5 to 
18·1)*
20·8% 
(18·9 to 
23·3)*
17·3% 
(15·2 to 
19·3)*
797·5 
(645·9 to 
960·9)
320·9 
(248·9 to 
395·7)
559·2 
(448·2 to 
677·9)
0·9% 
(–1·3 to 
2·9)
5·8% 
(4·2 to 
8·0)*
2·3% 
(0·5 to 
4·0)*
Alcohol use disorders 13 300 
(10 900 to 
16 200)
4170 
(3140 to 5420)
17 500 
(14 100 to 
21 600)
3·8% 
(0·8 to 
6·1)*
9·4% 
(6·0 to 
15·3)*
5·0% 
(2·4 to 
7·4)*
329·7 
(269·2 to 
401·9)
104·0 
(78·1 to 
134·8)
216·4 
(174·1 to 
268·5)
–11·4% 
(–14·1 to 
–9·3)*
–5·9% 
(–9·1 to 
–0·8)*
–10·2% 
(–12·7 to 
–8·1)*
Drug use disorders 18 600 
(14 500 to 
22 900)
8590 
(6660 to 
10 700)
27 200 
(21 100 to 
33 600)
26·6% 
(23·5 to 
29·9)*
27·3% 
(24·3 to 
30·7)*
26·8% 
(24·2 to 
29·6)*
467·7 
(364·7 to 
576·6)
217·0 
(168·1 to 
270·9)
342·8 
(266·4 to 
424·1)
11·9% 
(9·3 to 
14·7)*
12·4% 
(10·1 to 
15·2)*
12·1% 
(9·9 to 
14·5)*
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(Continued from previous page)
Opioid use disorders 14 800 
(11 300 to 
18 700)
6640 
(4960 to 
8460)
21 500 
(16 300 to 
27 100)
31·2% 
(27·6 to 
34·9)*
29·8% 
(25·3 to 
35·0)*
30·8% 
(27·5 to 
34·4)*
372·9 
(282·9 to 
468·1)
167·4 
(124·8 to 
214·1)
270·5 
(204·4 to 
342·2)
15·6% 
(12·3 to 
18·9)*
14·4% 
(10·7 to 
18·5)*
15·3% 
(12·4 to 
18·3)*
Cocaine use disorders 698 
(531 to 900)
293 
(215 to 391)
992 
(747 to 1290)
17·2% 
(13·2 to 
21·2)*
23·4% 
(14·9 to 
35·6)*
19·0% 
(15·5 to 
24·2)*
17·6 
(13·3 to 
22·7)
7·4 
(5·4 to 
9·9)
12·5 
(9·4 to 
16·3)
3·3% 
(–0·2 to 
6·7)
8·7% 
(1·4 to 
19·3)*
4·9% 
(1·9 to 
9·3)*
Amphetamine use 
disorders
785 
(501 to 1150)
399 
(253 to 593)
1180 
(757 to 1740)
4·0% 
(–0·4 to 
8·4)
8·5% 
(2·7 to 
16·7)*
5·5% 
(1·5 to 
9·4)*
20·1 
(12·7 to 
29·5)
10·4 
(6·5 to 
15·5)
15·3 
(9·7 to 
22·6)
–4·1% 
(–8·2 to 
–0·5)*
0·6% 
(–4·4 to 
7·4)
–2·5% 
(–6·2 to 
0·4)
Cannabis use 
disorders
343 
(217 to 510)
174 
(110 to 257)
518 
(329 to 766)
5·4% 
(2·7 to 
8·3)*
2·6% 
(–0·1 to 
5·4)
4·4% 
(2·2 to 
6·6)*
8·8 
(5·6 to 
13·1)
4·5 
(2·9 to 
6·7)
6·7 
(4·2 to 
9·9)
–2·8% 
(–5·4 to 
–0·2)*
–5·6% 
(–8·0 to 
–3·3)*
–3·7% 
(–5·7 to 
–1·7)*
Other drug use 
disorders
1920 
(1630 to 2260)
1090 
(908 to 1300)
3010 
(2550 to 3540)
12·9% 
(8·1 to 
17·1)*
26·5% 
(14·5 to 
41·6)*
17·5% 
(10·9 to 
24·1)*
48·5 
(41·0 to 
57·2)
27·2 
(22·6 to 
32·6)
37·9 
(32·1 to 
44·7)
–0·1% 
(–4·5 to 
3·3)
10·4% 
(0·1 to 
22·9)*
3·5% 
(–2·2 to 
8·9)
Diabetes and kidney 
diseases
54 000 
(46 900 to 
62 700)
50 000 
(43 100 to 
58 000)
104 000 
(90 100 to 
121 000)
27·1% 
(24·6 to 
29·7)*
26·6% 
(24·1 to 
29·2)*
26·9% 
(24·7 to 
29·2)*
1399·8 
(1218·1 to 
1617·7)
1197·7 
(1033·3 
to 
1390·8)
1294·2 
(1122·0 to 
1496·7)
1·0% 
(–0·9 to 
3·0)
0·3% 
(–1·7 to 
2·4)
0·8% 
(–1·0 to 
2·6)
Diabetes mellitus 35 000 
(28 500 to 
42 700)
32 900 
(26 800 to 
39 900)
67 900 
(55 400 to 
82 600)
30·4% 
(27·1 to 
34·1)*
29·5% 
(26·4 to 
32·9)*
30·0% 
(26·9 to 
33·3)*
898·7 
(733·5 to 
1095·5)
782·9 
(638·0 to 
951·0)
839 
(685·1 to 
1020·0)
2·9% 
(0·2 to 
5·7)*
1·9% 
(–0·7 to 
4·6)
2·5% 
(0 to 
5·1)*
Type 1 diabetes 
mellitus
5270 
(4760 to 
5820)
5180 
(4640 to 
5700)
10 400 
(9790 to 
11 100)
13·7% 
(9·5 to 
18·3)*
9·3% 
(4·0 to 
14)*
11·5% 
(7·9 to 
14·5)*
133·6 
(120·6 to 
147·8)
125·3 
(112·6 to 
138·1)
129·4 
(121·3 to 
137·6)
–7·7% 
(–11·4 to 
–4·0)*
–11·9% 
(–16·2 to 
–7·9)*
–9·8% 
(–12·8 to 
–7·2)*
Type 2 diabetes 
mellitus
29 700 
(23 200 to 
37 200)
27 700 
(21 900 to 
34 500)
57 400 
(45 000 to 
71 900)
33·9% 
(30·0 to 
38·2)*
34·2% 
(30·3 to 
38·4)*
34·0% 
(30·3 to 
38·1)*
765·2 
(599·9 to 
955·7)
657·5 
(518·1 to 
820·8)
709·6 
(557·2 to 
888·3)
5·0% 
(1·9 to 
8·2)*
5·0% 
(2·1 to 
8·3)*
5·1% 
(2·3 to 
8·1)*
Chronic kidney disease 18 900 
(17 700 to 
20 000)
16 900 
(15 800 to 
18 100)
35 800 
(33 700 to 
38 000)
21·9% 
(18·6 to 
24·7)*
21·5% 
(18·7 to 
24·1)*
21·7% 
(19·2 to 
23·9)*
496·3 
(465·5 to 
524·8)
411·5 
(384·8 to 
439·6)
451·3 
(424·9 to 
478·3)
–2·0% 
(–4·6 to 
0·2)
–2·4% 
(–4·6 to 
–0·3)*
–2·1% 
(–4·0 to 
–0·4)*
Chronic kidney 
disease due to type 1 
diabetes mellitus
1590 
(1280 to 1950)
1300 
(1060 to 1560)
2890 
(2370 to 3500)
18·5% 
(13·4 to 
23·2)*
17·7% 
(13·3 to 
22·2)*
18·2% 
(14·3 to 
22·3)*
39·1 
(31·6 to 
48·0)
31·3 
(25·7 to 
37·7)
35·2 
(28·9 to 
42·6)
–1·9% 
(–5·5 to 
1·4)
–3·4% 
(–6·3 to 
–0·4)*
–2·6% 
(–5·1 to 
–0·3)*
Chronic kidney 
disease due to type 2 
diabetes mellitus
4280 
(3700 to 4900)
3840 
(3380 to 4340)
8120 
(7120 to 9250)
34·2% 
(29·0 to 
38·1)*
34·4% 
(31·2 to 
37·6)*
34·3% 
(30·9 to 
37·2)*
112·7 
(97·7 to 
128·8)
90·2 
(79·2 to 
102·0)
100·9 
(88·4 to 
114·8)
2·0% 
(–1·9 to 
4·6)
2·4% 
(0·1 to 
4·8)*
2·3% 
(–0·2 to 
4·2)
Chronic kidney 
disease due to 
hypertension
4050 
(3520 to 4550)
3300 
(2900 to 3710)
7350 
(6450 to 8220)
32·4% 
(27·5 to 
36·2)*
32·3% 
(29·1 to 
35·2)*
32·3% 
(29·0 to 
35·0)*
110·2 
(96·2 to 
123·3)
78·0 
(68·6 to 
87·7)
92·7 
(81·7 to 
103·7)
1·4% 
(–2·1 to 
4·0)
2·3% 
(–0·1 to 
4·5)
2·1% 
(–0·3 to 
4·1)
Chronic kidney 
disease due to 
glomerulonephritis
3570 
(3160 to 4020)
3040 
(2680 to 3420)
6600 
(5860 to 7420)
14·7% 
(11·3 to 
18·0)*
12·9% 
(9·4 to 
16·4)*
13·8% 
(11·0 to 
17·0)*
92·3 
(81·9 to 
103·7)
75·9 
(67·1 to 
84·9)
83·7 
(74·4 to 
93·7)
–3·6% 
(–5·9 to 
–1·4)*
–5·4% 
(–7·9 to 
–3)*
–4·4% 
(–6·3 to 
–2·4)*
Chronic kidney 
disease due to other 
and unspecified 
causes
5390 
(4780 to 
6060)
5470 
(4800 to 6270)
10 900 
(9660 to 
12 200)
12·6% 
(9·2 to 
16·1)*
14·0% 
(10·7 to 
17·3)*
13·3% 
(10·4 to 
16·2)*
142·1 
(126·4 to 
159·3)
136·1 
(119·7 to 
155·0)
138·8 
(123·7 to 
155·9)
–6·3% 
(–8·5 to 
–3·8)*
–5·9% 
(–8·4 to 
–3·4)*
–6·0% 
(–8·0 to 
–4·1)*
Acute 
glomerulonephritis
180 
(165 to 201)
130 
(117 to 145)
311 
(285 to 339)
–3·9% 
(–10·5 to 
7·0)
–7·6% 
(–13·0 to 
0·5)
–5·5% 
(–10·3 to 
2·2)
4·7 
(4·3 to 
5·3)
3·3 
(2·9 to 
3·7)
4·0 
(3·6 to 4·3)
–19·2% 
(–24·8 to 
–10·5)*
–23·0% 
(–27·5 to 
–16·3)*
–20·9% 
(–25·0 to 
–15·0)*
Skin and 
subcutaneous diseases
20 900 
(14 200 to 
30 700)
23 200 
(15 800 to 
33 500)
44 100 
(29 900 to 
64 200)
13·7% 
(12·9 to 
15·1)*
13·7% 
(13·0 to 
14·9)*
13·7% 
(13·0 to 
14·7)*
553·3 
(375·4 to 
812·0)
618·0 
(418·6 to 
893·5)
585 
(396·2 to 
851·8)
0·9% 
(0·2 to 
2·1)*
0·7% 
(0·1 to 
1·5)*
0·8% 
(0·2 to 
1·6)*
Dermatitis 5100 
(2980 to 8140)
6020 
(3510 to 9590)
11 100 
(6480 to 
17 700)
12·3% 
(11·3 to 
13·3)*
11·9% 
(11·1 to 
12·8)*
12·1% 
(11·3 to 
12·8)*
136·5 
(79·3 to 
217·8)
164·7 
(94·8 to 
263·5)
150·3 
(87·0 to 
240·3)
1·4% 
(0·5 to 
2·4)*
0·9% 
(0 to 
1·7)*
1·1% 
(0·4 to 
1·8)*
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(Continued from previous page)
Atopic dermatitis 4100 
(2220 to 6820)
4900 
(2670 to 8160)
9000 
(4890 to 
15 000)
11·9% 
(10·8 to 
13·0)*
11·4% 
(10·4 to 
12·4)*
11·6% 
(10·8 to 
12·5)*
110·7 
(59·8 to 
184·4)
136·4 
(74·0 to 
227·2)
123·3 
(66·8 to 
205·2)
2·0% 
(0·9 to 
3·2)*
1·4% 
(0·5 to 
2·4)*
1·7% 
(0·9 to 
2·6)*
Contact dermatitis 937 
(618 to 1390)
1050 
(692 to 1560)
1990 
(1300 to 2950)
14·4% 
(12·3 to 
16·4)*
14·4% 
(12·5 to 
16·3)*
14·4% 
(12·6 to 
16·2)*
24·0 
(15·8 to 
35·6)
26·6 
(17·4 to 
39·4)
25·3 
(16·6 to 
37·4)
–0·8% 
(–1·7 to 
0·1)
–1·3% 
(–2·2 to 
–0·5)*
–1·1% 
(–1·7 to 
–0·5)*
Seborrhoeic 
dermatitis
69·0 
(39·8 to 110)
66·6 
(38·3 to 105)
136 
(78·1 to 215)
8·9% 
(6·7 to 
11·2)*
7·8% 
(5·6 to 
10·1)*
8·4% 
(6·6 to 
10·3)*
1·8 
(1·0 to 
2·8)
1·7 
(1·0 to 
2·7)
1·7 
(1·0 to 2·7)
–6·7% 
(–8·3 to 
–5·1)*
–7·5% 
(–9·0 to 
–5·9)*
–7·1% 
(–8·3 to 
–5·8)*
Psoriasis 2710 
(1920 to 3590)
2860 
(2030 to 3770)
5570 
(3960 to 7350)
21·2% 
(20·2 to 
22·4)*
20·9% 
(19·8 to 
22·0)*
21·1% 
(20·3 to 
21·9)*
68·7 
(48·7 to 
90·9)
71·4 
(50·7 to 
94·2)
70·0 
(49·7 to 
92·5)
2·5% 
(1·7 to 
3·4)*
2·1% 
(1·2 to 
3·0)*
2·3% 
(1·6 to 
2·9)*
Bacterial skin diseases 1160 
(700 to 1590)
1110 
(636 to 1540)
2270 
(1560 to 2900)
24·2% 
(13·4 to 
39·3)*
26·9% 
(17·9 to 
42·0)*
25·5% 
(17·8 to 
34·9)*
31·1 
(18·7 to 
42·9)
29·1 
(16·6 to 
40·7)
30·0 
(20·6 to 
38·2)
4·6% 
(–4·5 to 
18·1)
7·2% 
(–1·0 to 
20·4)
6·0% 
(–0·5 to 
14·5)
Cellulitis 321 
(178 to 465)
278 
(155 to 393)
598 
(377 to 760)
34·4% 
(22·9 to 
48·1)*
30·1% 
(15·8 to 
46·6)*
32·4% 
(26·4 to 
41·1)*
8·4 
(4·7 to 
12·3)
7·0 
(3·9 to 
9·8)
7·7 
(4·9 to 
9·8)
12·4% 
(2·7 to 
24·4)*
7·5% 
(–3·7 to 
21·6)
10·0% 
(5·1 to 
17·4)*
Pyoderma 843 
(489 to 1170)
833 
(441 to 1190)
1680 
(1110 to 2200)
20·6% 
(9·4 to 
37·5)*
25·9% 
(16·3 to 
41·7)*
23·2% 
(14·5 to 
34·3)*
22·7 
(13·1 to 
31·5)
22·1 
(11·7 to 
31·9)
22·3 
(14·8 to 
29·4)
2·0% 
(–7·5 to 
17·2)
7·1% 
(–1·8 to 
21·3)
4·7% 
(–2·7 to 
14·7)
Scabies 2260 
(1250 to 3700)
2270 
(1260 to 3700)
4530 
(2510 to 7410)
6·4% 
(5·0 to 
7·9)*
6·7% 
(5·3 to 
8·2)*
6·6% 
(5·3 to 
8·0)*
59·4 
(32·9 to 
96·8)
60·6 
(33·5 to 
98·8)
60·0 
(33·2 to 
97·8)
–3·2% 
(–3·8 to 
–2·5)*
–3·1% 
(–3·7 to 
–2·5)*
–3·1% 
(–3·6 to 
–2·6)*
Fungal skin diseases 2100 
(832 to 4370)
2050 
(819 to 4260)
4150 
(1650 to 
8630)
9·8% 
(8·1 to 
11·5)*
12·1% 
(10·4 to 
13·7)*
10·9% 
(9·2 to 
12·5)*
56·5 
(22·4 to 
117·4)
53·2 
(21·2 to 
110·5)
54·9 
(21·8 to 
114·2)
–4·6% 
(–5·6 to 
–3·6)*
–4·1% 
(–5·1 to 
–3·1)*
–4·4% 
(–5·4 to 
–3·4)*
Viral skin diseases 1940 
(1250 to 2880)
2090 
(1350 to 3110)
4030 
(2600 to 
6000)
7·1% 
(6·4 to 
7·7)*
5·9% 
(5·3 to 
6·4)*
6·4% 
(6·0 to 
6·9)*
52·9 
(33·9 to 
78·5)
59·0 
(38·0 to 
87·7)
56·0 
(36·0 to 
83·2)
–1·0% 
(–1·5 to 
–0·4)*
–2·5% 
(–3·0 to 
–2·0)*
–1·8% 
(–2·2 to 
–1·4)*
Acne vulgaris 1150 
(677 to 1830)
1400 
(841 to 2230)
2550 
(1520 to 4060)
17·3% 
(15·8 to 
18·9)*
15·3% 
(14·1 to 
16·6)*
16·2% 
(15·2 to 
17·2)*
30·0 
(17·7 to 
47·9)
37·9 
(22·7 to 
60·5)
33·9 
(20·2 to 
54·1)
12·8% 
(11·3 to 
14·6)*
10·2% 
(9·0 to 
11·6)*
11·4% 
(10·3 to 
12·5)*
Alopecia areata 241 
(154 to 358)
282 
(181 to 418)
523 
(335 to 775)
12·8% 
(11·3 to 
14·2)*
12·7% 
(11·4 to 
14·0)*
12·7% 
(11·8 to 
13·8)*
6·1 
(3·9 to 
9·1)
7·1 
(4·6 to 
10·6)
6·6 
(4·2 to 
9·8)
–0·6% 
(–1·9 to 
0·7)
–2·2% 
(–3·3 to 
–1·2)*
–1·5% 
(–2·3 to 
–0·6)*
Pruritus 331 
(156 to 632)
424 
(200 to 801)
756 
(356 to 1430)
19·3% 
(17·7 to 
20·9)*
18·6% 
(17·1 to 
20·2)*
18·9% 
(17·5 to 
20·4)*
8·6 
(4·0 to 
16·1)
10·7 
(5·0 to 
20·2)
9·7 
(4·5 to 
18·2)
2·2% 
(1·6 to 
2·8)*
1·2% 
(0·6 to 
1·7)*
1·6% 
(1·2 to 
2·0)*
Urticaria 2190 
(1450 to 3090)
2830 
(1880 to 3970)
5010 
(3320 to 7050)
10·8% 
(9·6 to 
12·1)*
10·8% 
(9·6 to 
12·0)*
10·8% 
(9·8 to 
11·9)*
58·4 
(38·6 to 
82·5)
77·2 
(51·1 to 
109·0)
67·7 
(44·8 to 
95·4)
0·6% 
(–0·2 to 
1·5)
0·1% 
(–0·5 to 
0·8)
0·3% 
(–0·2 to 
0·8)
Decubitus ulcer 238 
(169 to 357)
265 
(184 to 371)
503 
(379 to 661)
26·2% 
(18·8 to 
41·0)*
28·1% 
(21·7 to 
35·5)*
27·2% 
(21·5 to 
37·7)*
6·7 
(4·7 to 
10·1)
6·3 
(4·4 to 
8·9)
6·5 
(4·9 to 
8·6)
–2·3% 
(–8·2 to 
9·4)
–0·8% 
(–5·9 to 
5·6)
–1·6% 
(–6·0 to 
7·1)
Other skin and 
subcutaneous diseases
1470 
(736 to 2680)
1640 
(819 to 2970)
3110 
(1560 to 
5650)
25·8% 
(25·0 to 
26·5)*
25·0% 
(24·2 to 
26·0)*
25·4% 
(24·8 to 
26·0)*
38·4 
(19·3 to 
69·9)
40·7 
(20·4 to 
73·9)
39·5 
(19·8 to 
71·9)
4·5% 
(3·9 to 
5·0)*
3·9% 
(3·3 to 
4·7)*
4·2% 
(3·8 to 
4·7)*
Sense organ diseases 31 700 
(21 300 to 
45 700)
34 800 
(23 500 to 
49 900)
66 600 
(44 700 to 
95 700)
23·9% 
(23·1 to 
24·9)*
24·2% 
(23·4 to 
25·0)*
24·1% 
(23·4 to 
24·8)*
843·1 
(568·7 to 
1205·8)
841·0 
(567·7 to 
1206·4)
842·2 
(566·6 to 
1206·5)
–0·9% 
(–1·7 to 
–0·3)*
–0·9% 
(–1·6 to 
–0·2)*
–0·9% 
(–1·5 to 
–0·3)*
Blindness and vision 
impairment
13 500 
(9060 to 
20 000)
16 400 
(11 100 to 
24 100)
29 900 
(20 300 to 
44 000)
23·6% 
(22·4 to 
24·8)*
22·6% 
(21·6 to 
23·5)*
23·1% 
(22·0 to 
24)*
356·2 
(240·0 to 
523·0)
395·7 
(267·6 to 
583·1)
376·6 
(255·6 to 
555)
–1·5% 
(–2·4 to 
–0·6)*
–2·1% 
(–3 to 
–1·2)*
–1·8% 
(–2·7 to 
–0·9)*
Glaucoma 342 
(230 to 474)
344 
(233 to 478)
686 
(463 to 949)
28·8% 
(27·0 to 
30·8)*
27·1% 
(25·1 to 
28·9)*
27·9% 
(26·4 to 
29·4)*
9·4 
(6·3 to 
12·9)
8·0 
(5·4 to 
11·2)
8·6 
(5·8 to 
12·0)
–4·7% 
(–6·1 to 
–3·4)*
–4·8% 
(–6·3 to 
–3·3)*
–4·7% 
(–5·8 to 
–3·6)*
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(Continued from previous page)
Cataract 3350 
(2340 to 4540)
4650 
(3250 to 6270)
8010 
(5580 to 
10 800)
31·3% 
(28·5 to 
34·1)*
28·4% 
(26·5 to 
30·2)*
29·6% 
(27·4 to 
31·7)*
93·2 
(65·1 to 
126·4)
109·0 
(76 to 
147)
101·8 
(70·9 to 
137·7)
–1·7% 
(–3·7 to 
0·2)
–2·3% 
(–3·7 to 
–0·9)*
–2·0% 
(–3·6 to 
–0·5)*
Age-related macular 
degeneration
223 
(153 to 307)
308 
(210 to 422)
531 
(364 to 729)
34·1% 
(31·3 to 
37·1)*
28·3% 
(26·2 to 
30·6)*
30·7% 
(28·6 to 
32·9)*
6·3 
(4·3 to 
8·6)
7·2 
(4·9 to 
9·8)
6·8 
(4·6 to 
9·3)
–1·4% 
(–3·2 to 
0·6)
–4·8% 
(–6·5 to 
–3·1)*
–3·7% 
(–5·3 to 
–2·1)*
Refraction disorders 3980 
(2650 to 5780)
4000 
(2700 to 5720)
7980 
(5350 to 
11 500)
17·0% 
(15·0 to 
19·0)*
13·7% 
(12·0 to 
15·2)*
15·3% 
(13·6 to 
17·0)*
103·8 
(68·9 to 
150·7)
100·7 
(67·6 to 
144·2)
102·2 
(68·2 to 
147·3)
–1·5% 
(–2·9 to 
–0·1)*
–4·6% 
(–5·7 to 
–3·6)*
–3·1% 
(–4·2 to 
–1·9)*
Near vision loss 4260 
(2030 to 7790)
5540 
(2640 to 
10 100)
9800 
(4670 to 
17 900)
23·7% 
(22·9 to 
24·5)*
25·4% 
(24·6 to 
26·1)*
24·6% 
(24 to 
25·2)*
108·3 
(51·7 to 
198·2)
133·7 
(63·6 to 
244·5)
121·0 
(57·7 to 
221·3)
–0·7% 
(–1·2 to 
–0·2)*
1·4% 
(0·9 to 
1·9)*
0·5% 
(0·1 to 
0·9)*
Other vision loss 1350 
(941 to 1810)
1540 
(1070 to 2070)
2890 
(2010 to 3880)
22·9% 
(20·9 to 
24·7)*
19·5% 
(17·8 to 
21·1)*
21·0% 
(19·4 to 
22·6)*
35·3 
(24·6 to 
47·5)
37·1 
(25·8 to 
49·9)
36·3 
(25·3 to 
48·9)
–2·1% 
(–3·5 to 
–0·8)*
–5·0% 
(–6·1 to 
–3·9)*
–3·7% 
(–4·8 to 
–2·6)*
Age-related and other 
hearing loss
17 200 
(11 500 to 
24 500)
17 100 
(11 600 to 
24 200)
34 200 
(23 200 to 
48 700)
24·2% 
(22·8 to 
25·6)*
25·7% 
(24·4 to 
27·1)*
24·9% 
(23·9 to 
26·0)*
458·7 
(311·5 to 
650·0)
411·6 
(279·5 to 
583·7)
434·6 
(295·4 to 
616·1)
–0·7% 
(–1·8 to 
0·4)
0·2% 
(–0·9 to 
1·2)
–0·2% 
(–1·0 to 
0·5)
Other sense organ 
diseases
1070 
(665 to 1570)
1380 
(854 to 2010)
2450 
(1520 to 3570)
24·9% 
(23·9 to 
26·0)*
25·0% 
(24·1 to 
26)*
25·0% 
(24·2 to 
25·8)*
28·1 
(17·5 to 
41·2)
33·7 
(20·9 to 
49·0)
31·0 
(19·2 to 
45·2)
1·1% 
(0·4 to 
1·8)*
0·8% 
(0·1 to 
1·5)*
0·9% 
(0·4 to 
1·4)*
Musculoskeletal 
disorders
60 800 
(44 700 to 
80 400)
77 900 
(57 500 to 
103 000)
139 000 
(102 000 to 
183 000)
19·5% 
(18·3 to 
20·7)*
20·2% 
(19 to 
21·6)*
19·9% 
(18·8 to 
21·2)*
1538·9 
(1134·0 
to 
2023·2)
1894·7 
(1398·6 
to 
2491·4)
1720·5 
(1264·4 to 
2259·2)
–1% 
(–1·7 to 
–0·4)*
–1·2% 
(–1·9 to 
–0·5)*
–1·1% 
(–1·7 to 
–0·5)*
Rheumatoid arthritis 977 
(750 to 1220)
2510 
(1910 to 3180)
3490 
(2660 to 
4410)
26·1% 
(22·9 to 
28·9)*
30·6% 
(26·3 to 
34·1)*
29·3% 
(26·0 to 
32·1)*
25·4 
(19·6 to 
31·5)
60·1 
(45·5 to 
76·0)
43·3 
(33·0 to 
54·5)
–0·6% 
(–3·5 to 
1·7)
3·4% 
(0·1 to 
6·2)*
2·3% 
(–0·5 to 
4·6)
Osteoarthritis 3840 
(1930 to 
7680)
5760 
(2880 to 
11 500)
9600 
(4810 to 
19 100)
32·0% 
(31·0 to 
33·0)*
31·0% 
(30·3 to 
31·8)*
31·4% 
(30·7 to 
32·1)*
100·0 
(50·3 to 
199·1)
135·6 
(67·7 to 
269·7)
118·8 
(59·5 to 
236·2)
1·6% 
(0·9 to 
2·3)*
0·8% 
(0·2 to 
1·4)*
1·0% 
(0·5 to 
1·6)*
Low back pain 29 500 
(21 000 to 
40 000)
35 500 
(25 400 to 
47 700)
64 900 
(46 500 to 
87 400)
17·8% 
(16·5 to 
19·3)*
17·3% 
(15·8 to 
18·8)*
17·5% 
(16·2 to 
19·0)*
748·2 
(537·6 to 
1008·5)
869·1 
(624·5 to 
1164·5)
810·3 
(582·4 to 
1089·1)
–1·3% 
(–1·9 to 
–0·7)*
–2·7% 
(–3·3 to 
–2·2)*
–2·1% 
(–2·6 to 
–1·6)*
Neck pain 12 200 
(8540 to 
17 200)
16 400 
(11 400 to 
22 900)
28 600 
(20 000 to 
40 200)
22·3% 
(20·1 to 
24·3)*
20·8% 
(18·4 to 
23·7)*
21·4% 
(19·5 to 
23·6)*
307·4 
(215·7 to 
430·8)
395·1 
(275·9 to 
551·8)
352·0 
(245·6 to 
493·3)
0·4% 
(–0·8 to 
1·5)
–1·5% 
(–3·0 to 
0·2)
–0·7% 
(–1·6 to 
0·5)
Gout 953 
(641 to 1300)
332 
(226 to 451)
1280 
(867 to 1770)
30·2% 
(28·2 to 
32·2)*
32·9% 
(30·5 to 
35·3)*
30·9% 
(29·2 to 
32·6)*
24·6 
(16·6 to 
33·8)
7·8 
(5·3 to 
10·7)
15·9 
(10·7 to 
21·8)
2·4% 
(1·1 to 
3·7)*
3·1% 
(1·3 to 
4·9)*
2·7% 
(1·6 to 
3·7)*
Other musculoskeletal 
disorders
13 300 
(9130 to 
18 400)
17 500 
(12 400 to 
23 600)
30 800 
(21 500 to 
42 000)
16·6% 
(13·2 to 
19·8)*
21·0% 
(17·7 to 
24·4)*
19·1% 
(15·8 to 
22·3)*
333·3 
(229·5 to 
459·1)
427·0 
(303·1 to 
577·3)
380·2 
(266·2 to 
520·3)
–2·7% 
(–5·2 to 
–0·4)*
0·9% 
(–1·6 to 
3·2)
–0·7% 
(–3·0 to 
1·4)
Other 
non-communicable 
diseases
56 000 
(48 900 to 
64 900)
65 900 
(54 700 to 
79 500)
122 000 
(104 000 to 
144 000)
–3·8% 
(–10·8 to 
0·6)
0·3% 
(–3·7 to 
3·3)
–1·6% 
(–6·1 to 
1·6)
1547·8 
(1362·6 
to 1778·5)
1812·4 
(1524·5 
to 
2156·7)
1678·1 
(1450·0 to 
1961·2)
–12·8% 
(–18·8 to 
–9·3)*
–10·3% 
(–13·4 to 
–7·9)*
–11·5% 
(–15·4 to 
–8·9)*
Congenital anomalies 32 300 
(29 800 to 
35 300)
28 600 
(26 400 to 
30 700)
60 900 
(56 400 to 
65 400)
–12·1% 
(–21·3 to 
–7·0)*
–9·6% 
(–14·8 to 
–5·7)*
–10·9% 
(–17·3 to 
–7·1)*
917·1 
(847·3 to 
999·7)
859·6 
(795·0 to 
920·4)
889·0 
(827·6 to 
951·5)
–16·7% 
(–25·3 to 
–12)*
–14·8% 
(–19·6 to 
–11)*
–15·8% 
(–21·8 to 
–12·3)*
Neural tube defects 3140 
(2380 to 4350)
3030 
(2280 to 4150)
6170 
(4840 to 8170)
–11·2% 
(–27·1 to 
1·4)
–9·0% 
(–22·0 to 
4·9)
–10·2% 
(–21·3 to 
0·9)
90·1 
(68·3 to 
125·1)
92·7 
(69·7 to 
127·2)
91·3 
(71·7 to 
121·2)
–15·3% 
(–30·4 to 
–3·2)*
–13·6% 
(–26·0 to 
–0·2)*
–14·5% 
(–25·1 to 
–4·0)*
Congenital heart 
anomalies
11 500 
(9480 to 
14 000)
10 700 
(8260 to 
12 600)
22 200 
(18 400 to 
26 300)
–19·1% 
(–27·9 to 
–9·6)*
–17·6% 
(–23·4 to 
–10·1)*
–18·4% 
(–24·8 to 
–10·3)*
332·1 
(272·0 to 
404·0)
328·0 
(253·0 to 
388·2)
330·0 
(272·3 to 
390·8)
–22·5% 
(–30·9 to 
–13·4)*
–21·3% 
(–26·9 to 
–14·2)*
–21·9% 
(–28·1 to 
–14·3)*
Orofacial clefts 352 
(194 to 657)
300 
(187 to 599)
652 
(411 to 
1110)
–21·9% 
(–37·7 to 
–4·3)*
–21·8% 
(–38·2 to 
–5·6)*
–21·9% 
(–35·2 to 
–8·1)*
9·8 
(5·3 to 
18·7)
8·7 
(5·3 to 
18·2)
9·3 
(5·8 to 
16·2)
–27·2% 
(–41·8 to 
–10·0)*
–28·3% 
(–42·6 to 
–13·9)*
–27·7% 
(–39·9 to 
–15·4)*
(Table 3 continues on next page)
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(Continued from previous page)
Down syndrome 1240 
(963 to 1790)
989 
(755 to 1520)
2230 
(1760 to 3040)
–1·5% 
(–12·1 to 
14·2)
2·6% 
(–9·0 to 
16·7)
0·3% 
(–9·2 to 
13·6)
34·8 
(26·7 to 
50·5)
29·0 
(21·9 to 
45·3)
32·0 
(24·9 to 
43·9)
–7·8% 
(–17·4 to 
6·7)
–4·6% 
(–15·3 to 
8·3)
–6·4% 
(–15·1 to 
5·9)
Turner syndrome ·· 10·1 
(5·02 to 16·5)
10·1 
(5·02 to 16·5)
·· 9·1% 
(7·3 to 
10·9)*
9·1% 
(7·3 to 
10·9)*
·· 0·3 
(0·1 to 
0·5)
0·1 
(0·1 to 0·2)
·· 1·0% 
(–0·6 to 
2·6)
0·9% 
(–0·7 to 
2·5)
Klinefelter syndrome 5·16 
(2·43 to 9·74)
·· 5·16 
(2·43 to 9·74)
7·4% 
(4·3 to 
10·7)*
·· 7·4% 
(4·3 to 
10·7)*
0·1 
(0·1 to 
0·3)
·· 0·1 
(0 to 0·1)
–1·9% 
(–4·7 to 
1·0)
·· –1·7% 
(–4·5 to 
1·1)
Other chromosomal 
abnormalities
928 
(654 to 1380)
1170 
(769 to 2010)
2100 
(1510 to 2840)
10·2% 
(–2·8 to 
22·0)
6·1% 
(–7·2 to 
19·3)
7·9% 
(–1·9 to 
18·2)
26·0 
(18·3 to 
38·8)
35·2 
(22·6 to 
61·2)
30·4 
(21·8 to 
41·3)
3·7% 
(–8·1 to 
14·5)
0·2% 
(–11·8 to 
12·6)
1·7% 
(–7·2 to 
11·4)
Congenital 
musculoskeletal and 
limb anomalies
2890 
(2030 to 3790)
2650 
(1850 to 3510)
5530 
(3880 to 7270)
8·6% 
(4·1 to 
11·8)*
9·0% 
(4·2 to 
12·8)*
8·8% 
(4·8 to 
11·1)*
76·8 
(54·5 to 
100·5)
71·6 
(50·4 to 
94·3)
74·2 
(52·6 to 
97·2)
–2·3% 
(–5·9 to 
0·3)
–2·7% 
(–6·7 to 
0·4)
–2·5% 
(–5·6 to 
–0·5)*
Urogenital 
congenital anomalies
687 
(459 to 879)
560 
(411 to 698)
1250 
(926 to 1500)
–4·9% 
(–15·5 to 
8·5)
–3·9% 
(–13·3 to 
7·3)
–4·5% 
(–13·2 to 
6·1)
19·7 
(13·0 to 
25·3)
16·9 
(12·3 to 
21·0)
18·3 
(13·6 to 
22·1)
–9·1% 
(–19·1 to 
3·5)
–9·1% 
(–18·1 to 
1·8)
–9·1% 
(–17·2 to 
0·8)
Digestive congenital 
anomalies
2970 
(2190 to 3960)
2220 
(1440 to 3300)
5190 
(3990 to 
7050)
–16·1% 
(–30·4 to 
–4·8)*
–9·5% 
(–17·8 to 
1·3)
–13·4% 
(–24·5 to 
–4·0)*
85·3 
(62·6 to 
113·9)
67·5 
(43·1 to 
101·0)
76·7 
(58·7 to 
104·6)
–20·0% 
(–33·4 to 
–9·1)*
–14·1% 
(–21·9 to 
–4·1)*
–17·6% 
(–28·1 to 
–8·9)*
Other congenital 
anomalies
8570 
(6620 to 
10 500)
6980 
(5170 to 
8960)
15 500 
(12 000 to 
19 200)
–9·7% 
(–17·9 to 
1·5)
–5·8% 
(–14·8 to 
5·0)
–8·0% 
(–15·8 to 
2·7)
242·4 
(186·3 to 
297·7)
209·8 
(155·1 to 
270·2)
226·5 
(174·1 to 
279·7)
–14·5% 
(–22·1 to 
–4·1)*
–11·0% 
(–19·4 to 
–1·0)*
–13·0% 
(–20·4 to 
–3·3)*
Urinary diseases and 
male infertility
6080 
(5080 to 7320)
3310 
(3140 to 3480)
9390 
(8260 to 
10 700)
21·8% 
(18·1 to 
25·1)*
24·5% 
(18 to 
28·2)*
22·8% 
(18·9 to 
25·6)*
162·2 
(136 to 
194·8)
82·7 
(78·4 to 
87·1)
119·9 
(105·9 to 
136·8)
–2·7% 
(–5·3 to 
–0·2)*
2·3% 
(–3·3 to 
5·4)
–0·8% 
(–3·9 to 
1·6)
Urinary tract 
infections
2120 
(1970 to 2410)
2570 
(2410 to 2830)
4700 
(4430 to 
5190)
24·5% 
(17·7 to 
31·7)*
36·4% 
(28·5 to 
44·1)*
30·8% 
(24·2 to 
37·8)*
57·8 
(53·8 to 
65·4)
63·8 
(59·5 to 
70·5)
60·7 
(57·2 to 
67·2)
2·3% 
(–3·0 to 
7·9)
11·3% 
(4·8 to 
17·6)*
7·0% 
(1·6 to 
12·6)*
Urolithiasis 281 
(227 to 346)
205 
(165 to 252)
486 
(397 to 591)
15·9% 
(9·5 to 
25·0)*
23·7% 
(18·2 to 
34·5)*
19·1% 
(13·6 to 
28)*
7·3 
(5·9 to 
8·9)
4·9 
(4·0 to 
6·1)
6·0 
(4·9 to 7·3)
–7·0% 
(–12·3 to 
0·3)
–0·2% 
(–4·6 to 
8·2)
–4·1% 
(–8·5 to 
3·0)
Benign prostatic 
hyperplasia
2430 
(1560 to 3460)
·· 2430 
(1560 to 3460)
32·0% 
(30·7 to 
33·3)*
·· 32·0% 
(30·7 to 
33·3)*
63·7 
(40·9 to 
90·7)
·· 29·9 
(19·2 to 
42·5)
–0·7% 
(–1·6 to 
0·3)
·· –0·2% 
(–1·1 to 
0·8)
Male infertility 181 
(74·8 to 374)
·· 181 
(74·8 to 374)
17·0% 
(13·7 to 
20·1)*
·· 17·0% 
(13·7 to 
20·1)*
4·6 
(1·9 to 
9·5)
·· 2·3 
(1·0 to 4·8)
6·7% 
(3·9 to 
9·4)*
·· 6·9% 
(4·1 to 
9·7)*
Other urinary 
diseases
1080 
(903 to 1240)
526 
(346 to 654)
1600 
(1290 to 1790)
1·7% 
(–6·3 to 
11·6)
–12·4% 
(–23·3 to 
–3·3)*
–3·4% 
(–9·4 to 
5·1)
28·9 
(24·3 to 
33·4)
13·9 
(9·2 to 
17·4)
21·0 
(16·9 to 
23·6)
–15·0% 
(–21·4 to 
–7·3)*
–24·8% 
(–33·4 to 
–17·3)*
–18·4% 
(–23·1 to 
–11·5)*
Gynaecological diseases ·· 11 900 
(8210 to 
16 600)
11 900 
(8210 to 
16 600)
·· 10·2% 
(9·0 to 
11·6)*
10·2% 
(9·0 to 
11·6)*
·· 299·4 
(206·4 to 
415·8)
148·8 
(102·6 to 
206·6)
·· –2·4% 
(–3·3 to 
–1·4)*
–2·5% 
(–3·4 to 
–1·4)*
Uterine fibroids ·· 1550 
(947 to 2460)
1550 
(947 to 2460)
·· 8·3% 
(4·5 to 
11·9)*
8·3% 
(4·5 to 
11·9)*
·· 37·7 
(23·1 to 
59·9)
18·9 
(11·5 to 
30·0)
·· –8·2% 
(–11·4 to 
–5·2)*
–7·9% 
(–11·1 to 
–5·0)*
Polycystic ovarian 
syndrome
·· 460 
(204 to 886)
460 
(204 to 886)
·· 13·1% 
(12·1 to 
14·0)*
13·1% 
(12·1 to 
14·0)*
·· 11·7 
(5·2 to 
22·7)
5·8 
(2·6 to 
11·2)
·· 2·0% 
(1·1 to 
2·8)*
1·8% 
(1·0 to 
2·7)*
Female infertility ·· 343 
(129 to 723)
343 
(129 to 723)
·· 27·5% 
(22·2 to 
32·7)*
27·5% 
(22·2 to 
32·7)*
·· 8·8 
(3·3 to 
18·5)
4·4 
(1·7 to 9·2)
·· 16·7% 
(12·2 to 
21·1)*
16·5% 
(12·0 to 
20·8)*
Endometriosis ·· 4130 
(2760 to 5950)
4130 
(2760 to 5950)
·· 9·2% 
(7·9 to 
10·5)*
9·2% 
(7·9 to 
10·5)*
·· 103·9 
(69·5 to 
149·1)
51·6 
(34·5 to 
74)
·· –2·9% 
(–3·8 to 
–1·9)*
–3·0% 
(–3·9 to 
–2·0)*
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Genital prolapse ·· 352 
(173 to 652)
352 
(173 to 652)
·· 18·6% 
(16·0 to 
20·4)*
18·6% 
(16·0 to 
20·4)*
·· 8·4 
(4·1 to 
15·6)
4·3 
(2·1 to 8·0)
·· –4·5% 
(–6·7 to 
–3·4)*
–4·7% 
(–6·9 to 
–3·5)*
Premenstrual 
syndrome
·· 3930 
(2530 to 5900)
3930 
(2530 to 5900)
·· 8·8% 
(7·2 to 
10·1)*
8·8% 
(7·2 to 
10·1)*
·· 100·0 
(64·5 to 
150·1)
49·5 
(31·9 to 
74·3)
·· –2·1% 
(–3·5 to 
–0·9)*
–2·2% 
(–3·6 to 
–1·0)*
Other gynaecological 
diseases
·· 1150 
(830 to 1580)
1150 
(830 to 1580)
·· 13·5% 
(10·1 to 
16·6)*
13·5% 
(10·1 to 
16·6)*
·· 28·9 
(20·8 to 
39·6)
14·4 
(10·3 to 
19·7)
·· 0·2% 
(–2·8 to 
3·0)
0·2% 
(–2·8 to 
3·0)
Haemoglobinopathies 
and haemolytic 
anaemias
4350 
(3040 to 6130)
5800 
(4510 to 7370)
10 100 
(7740 to 
13 300)
–1·0% 
(–9·7 to 
7·3)
–5·6% 
(–10·3 to 
0·2)
–3·7% 
(–9·3 to 
2·3)
117·9 
(82·4 to 
165·8)
156·6 
(122·3 to 
198·9)
137·1 
(104·6 to 
179·3)
–10·5% 
(–18·6 to 
–2·8)*
–15·3% 
(–19·8 to 
–9·8)*
–13·2% 
(–18·5 to 
–7·6)*
Thalassaemias 308 
(239 to 367)
274 
(221 to 338)
582 
(491 to 683)
–21·1% 
(–33·6 to 
–6·2)*
–28·0% 
(–36·5 to 
–13·4)*
–24·5% 
(–33·5 to 
–13·4)*
8·7 
(6·8 to 
10·4)
8·2 
(6·6 to 
10·1)
8·4 
(7·1 to 9·9)
–25% 
(–37·2 to 
–10·7)*
–32·0% 
(–40·2 to 
–18·0)*
–28·5% 
(–37·2 to 
–17·8)*
Thalassaemias trait 477 
(306 to 722)
1430 
(968 to 2070)
1910 
(1280 to 2780)
–13·8% 
(–20·0 to 
–7·0)*
–11·5% 
(–16 to 
–6·8)*
–12·1% 
(–16·1 to 
–7·7)*
12·8 
(8·2 to 
19·3)
37·2 
(25·1 to 
53·8)
25 
(16·8 to 
36·4)
–22·6% 
(–28·1 to 
–16·8)*
–21·4% 
(–25·4 to 
–17·3)*
–21·6% 
(–25·1 to 
–18·0)*
Sickle cell disorders 1580 
(865 to 2640)
1470 
(1050 to 2090)
3050 
(2000 to 4200)
8·2% 
(–11·4 to 
23·1)
–1·9% 
(–15·7 to 
19·2)
3·1% 
(–11·6 to 
16·9)
43·5 
(23·8 to 
72·8)
42·9 
(30·6 to 
61·2)
43·2 
(28·3 to 
59·4)
2·2% 
(–16·6 to 
16·6)
–8·1% 
(–21·4 to 
12·7)
–3·0% 
(–16·9 to 
10·6)
Sickle cell trait 362 
(237 to 534)
841 
(567 to 1200)
1200 
(812 to 1730)
–5·1% 
(–13·0 to 
3·5)
0·4% 
(–3·4 to 
4·4)
–1·3% 
(–5·1 to 
2·9)
9·8 
(6·4 to 
14·6)
22·8 
(15·4 to 
32·5)
16·3 
(11·0 to 
23·4)
–13·4% 
(–20·4 to 
–5·4)*
–8·8% 
(–12·3 to 
–5·2)*
–10·3% 
(–13·9 to 
–6·4)*
G6PD deficiency 485 
(330 to 655)
232 
(187 to 289)
717 
(546 to 920)
6·6% 
(–2·1 to 
16·1)
–0·3% 
(–5·6 to 
8·2)
4·3% 
(–2·2 to 
11·9)
12·3 
(8·4 to 
16·6)
5·9 
(4·8 to 
7·4)
9·1 
(7·0 to 
11·7)
–7·8% 
(–14·3 to 
–0·5)*
–13·0% 
(–17·7 to 
–5·4)*
–9·6% 
(–14·7 to 
–3·5)*
G6PD trait 0 
(0 to 0)
0·416 
(0·281 to 
0·580)
0·416 
(0·281 to 
0·580)
·· 3·0% 
(–1·7 to 
7·8)
3·0% 
(–1·7 to 
7·8)
0 
(0 to 0)
0 
(0 to 0)
0 
(0 to 0)
·· –8·1% 
(–12·1 to 
–3·9)*
–8·1% 
(–12·2 to 
–3·9)*
Other 
haemoglobinopathies 
and haemolytic 
anaemias
1140 
(845 to 1550)
1550 
(1180 to 2060)
2680 
(2030 to 3580)
–1·2% 
(–5·5 to 
3·8)
–1·6% 
(–4·1 to 
1·0)
–1·4% 
(–3·8 to 
1·4)
30·7 
(22·9 to 
41·6)
39·4 
(29·9 to 
52·8)
35·0 
(26·4 to 
46·7)
–15·3% 
(–19·2 to 
–11)*
–15·9% 
(–18·4 to 
–13·6)*
–15·6% 
(–18·1 to 
–12·9)*
Endocrine, metabolic, 
blood, and immune 
disorders
3310 
(2750 to 3820)
4410 
(3610 to 5350)
7720 
(6500 to 
9080)
10·3% 
(3·9 to 
15·5)*
5·1% 
(1·6 to 
8·5)*
7·3% 
(3·0 to 
11·1)*
89·1 
(73·8 to 
102·7)
115·1 
(94·0 to 
140·0)
101·8 
(85·9 to 
120·0)
–4·7% 
(–9·8 to 
–0·5)*
–9·0% 
(–11·8 to 
–6·0)*
–7·2% 
(–10·7 to 
–4·1)*
Oral disorders 7860 
(4620 to 
12 300)
10 400 
(6390 to 
16 000)
18 300 
(11 000 to 
28 300)
20·5% 
(19·6 to 
21·4)*
22·1% 
(21·2 to 
23·0)*
21·4% 
(20·5 to 
22·3)*
202·1 
(119·1 to 
315·7)
253·7 
(154·8 to 
388·5)
228·8 
(137·5 to 
353·7)
–1·8% 
(–2·6 to 
–1·1)*
–0·9% 
(–1·6 to 
–0·2)*
–1·3% 
(–2·0 to 
–0·6)*
Caries of deciduous 
teeth
72·4 
(30·9 to 145)
66·5 
(28·5 to 133)
139 
(59·4 to 278)
4·6% 
(2·7 to 
6·3)*
5·1% 
(3·0 to 
6·9)*
4·9% 
(3·1 to 
6·3)*
2·1 
(0·9 to 
4·1)
2·0 
(0·9 to 
4·0)
2·0 
(0·9 to 4·1)
–2·2% 
(–3·9 to 
–0·6)*
–2·0% 
(–3·9 to 
–0·4)*
–2·1% 
(–3·7 to 
–0·8)*
Caries of permanent 
teeth
785 
(338 to 1490)
834 
(362 to 1590)
1620 
(698 to 3090)
9·4% 
(8·5 to 
10·4)*
9·5% 
(8·5 to 
10·5)*
9·4% 
(8·6 to 
10·3)*
20·0 
(8·6 to 
38·0)
21·3 
(9·2 to 
40·4)
20·7 
(8·9 to 
39·2)
–3·9% 
(–4·7 to 
–3·0)*
–4·1% 
(–5·0 to 
–3·3)*
–4·0% 
(–4·8 to 
–3·3)*
Periodontal diseases 2470 
(967 to 5070)
2720 
(1080 to 5580)
5190 
(2040 to 
10 700)
25·1% 
(23·5 to 
26·6)*
27·9% 
(26·3 to 
29·3)*
26·6% 
(25·1 to 
27·9)*
61·6 
(24·2 to 
127·0)
65·4 
(25·9 to 
134·2)
63·5 
(25·0 to 
130·3)
1·8% 
(1·3 to 
2·3)*
3·6% 
(3·0 to 
4·3)*
2·8% 
(2·3 to 
3·2)*
Edentulism and 
severe tooth loss
2770 
(1850 to 3940)
4580 
(3060 to 6480)
7350 
(4890 to 
10 400)
24·0% 
(23·1 to 
24·8)*
25·1% 
(24·0 to 
26·2)*
24·6% 
(23·7 to 
25·5)*
73·5 
(49·1 to 
104·2)
108·0 
(72·2 to 
153·1)
91·7 
(61·3 to 
129·9)
–5·1% 
(–5·8 to 
–4·4)*
–3·3% 
(–3·9 to 
–2·5)*
–4·1% 
(–4·7 to 
–3·4)*
Other oral disorders 1770 
(1100 to 
2620)
2250 
(1400 to 3310)
4020 
(2510 to 5900)
15·5% 
(14·7 to 
16·3)*
15·8% 
(15·0 to 
16·6)*
15·7% 
(15 to 
16·3)*
44·8 
(28·0 to 
66·7)
56·9 
(35·6 to 
83·8)
50·9 
(31·8 to 
74·7)
0·3% 
(–0·2 to 
0·7)
0·2% 
(–0·3 to 
0·6)
0·2% 
(–0·1 to 
0·5)
Sudden infant death 
syndrome
2040 
(816 to 3870)
1450 
(572 to 3230)
3490 
(1570 to 6730)
–18·1% 
(–32·9 to 
2·1)
–16·1% 
(–30·7 to 
6·4)
–17·3% 
(–28·6 to 
–1·4)*
59·4 
(23·8 to 
112·8)
45·4 
(17·8 to 
100·9)
52·7 
(23·7 to 
101·5)
–20·9% 
(–35·2 to 
–1·4)*
–19·2% 
(–33·2 to 
2·5)
–20·2% 
(–31·2 to 
–4·9)*
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All-age DALYs (thousands) Age-standardised DALY rate (per 100 000)
2017 Percentage change, 2007–17 2017 Percentage change, 2007–17
Males Females Both Males Females Both Males Females Both Males Females Both
(Continued from previous page)
Injuries 171 000 
(161 000 to 
182 000)
81 900 
(74 500 to 
90 000)
252 000 
(236 000 to 
271 000)
–1·8% 
(–3·6 to 
0·2)
0·7% 
(–1·9 to 
3·4)
–1·0% 
(–2·8 to 
1·0)
4397·9 
(4149·6 
to 
4678·6)
2128·2 
(1943·4 
to 
2330·6)
3267·0 
(3058·2 to 
3505·1)
–13·5% 
(–15·1 to 
–11·8)*
–12·7% 
(–14·7 to 
–10·6)*
–13·3% 
(–14·7 to 
–11·7)*
Transport injuries 54 900 
(52 000 to 
57 800)
20 400 
(18 700 to 
22 300)
75 300 
(71 000 to 
79 800)
–6·0% 
(–8·7 to 
–3·2)*
–3·3% 
(–6·1 to 
–0·3)*
–5·3% 
(–7·7 to 
–2·8)*
1403·5 
(1328·7 to 
1475·7)
528·6 
(484·5 to 
575·5)
967·6 
(914·2 to 
1023·9)
–16·8% 
(–19·1 to 
–14·5)*
–15·9% 
(–18·3 to 
–13·4)*
–16·6% 
(–18·5 to 
–14·6)*
Road injuries 49 800 
(47 300 to 
52 100)
18 000 
(16 600 to 
19 400)
67 800 
(64 300 to 
71 500)
–6·5% 
(–9·3 to 
–3·6)*
–4·8% 
(–7·8 to 
–1·9)*
–6·1% 
(–8·5 to 
–3·5)*
1272·2 
(1209·4 to 
1331·3)
467·2 
(431·8 to 
501·5)
871·1 
(827·9 to 
917·3)
–17·3% 
(–19·6 to 
–14·8)*
–17·2% 
(–19·7 to 
–14·7)*
–17·2% 
(–19·2 to 
–15·1)*
Pedestrian road 
injuries
16 500 
(15 200 to 
18 500)
7090 
(6430 to 7870)
23 600 
(22 000 to 
25 800)
–12·3% 
(–17·1 to 
–7·7)*
–11·2% 
(–15·0 to 
–6·8)*
–12·0% 
(–15·6 to 
–8·3)*
423·2 
(390·0 to 
474·3)
184·9 
(167·7 to 
204·9)
304·1 
(283·9 to 
332·1)
–23·0% 
(–27 to 
–19·1)*
–23·2% 
(–26·5 to 
–19·3)*
–23·1% 
(–26·1 to 
–20·0)*
Cyclist road injuries 3290 
(2740 to 3790)
1270 
(1050 to 1510)
4550 
(3860 to 
5270)
8·6% 
(2·2 to 
14·9)*
12·3% 
(6·8 to 
17·3)*
9·6% 
(4·2 to 
14·9)*
83·5 
(69·6 to 
96·5)
31·5 
(26·2 to 
37·6)
57·5 
(48·8 to 
66·3)
–6·4% 
(–11·8 to 
–0·9)*
–5·6% 
(–9·9 to 
–1·4)*
–6·3% 
(–10·8 to 
–1·7)*
Motorcyclist road 
injuries
11 700 
(10 300 to 
12 600)
2310 
(1960 to 
2610)
14 000 
(12 300 to 
15 100)
–1·8% 
(–8·5 to 
3·2)
–0·1% 
(–7·8 to 
10·0)
–1·6% 
(–7·6 to 
3·2)
295·8 
(259·7 to 
318·9)
59·0 
(50·2 to 
66·6)
177·9 
(157·3 to 
191·9)
–12·1% 
(–17·8 to 
–7·8)*
–12·8% 
(–19·4 to 
–4·4)*
–12·2% 
(–17·3 to 
–8·1)*
Motor vehicle road 
injuries
17 700 
(16 500 to 
19 000)
6850 
(6230 to 7410)
24 600 
(23 100 to 
26 000)
–6·5% 
(–9·8 to 
–1·7)*
–3·7% 
(–7·1 to 
1·9)
–5·7% 
(–8·4 to 
–1·3)*
453·4 
(423·2 to 
485·8)
179·5 
(162·8 to 
193·5)
317·2 
(297·9 to 
335·1)
–16·6% 
(–19·5 to 
–12·2)*
–15·0% 
(–18·1 to 
–9·9)*
–16·1% 
(–18·4 to 
–12·1)*
Other road injuries 640 
(540 to 761)
491 
(380 to 629)
1130 
(932 to 1380)
1·7% 
(–5·2 to 
17)
30·2% 
(22·0 to 
40·2)*
12·4% 
(5·3 to 
25·6)*
16·3 
(13·8 to 
19·4)
12·3 
(9·6 to 
15·6)
14·3 
(11·9 to 
17·4)
–11·8% 
(–17·3 to 
1·4)
10·1% 
(3·7 to 
18·4)*
–3·5% 
(–9·1 to 
7·7)
Other transport injuries 5130 
(4510 to 5920)
2400 
(1940 to 2960)
7530 
(6480 to 8760)
–0·2% 
(–4·6 to 
4·8)
10·0% 
(5·6 to 
14·3)*
2·9% 
(–1·0 to 
6·7)
131·3 
(115·3 to 
151·4)
61·3 
(49·7 to 
75·3)
96·5 
(83·0 to 
112·1)
–12·1% 
(–15·9 to 
–7·9)*
–5·3% 
(–9·1 to 
–1·6)*
–10·0% 
(–13·3 to 
–6·7)*
Unintentional injuries 65 300 
(58 800 to 
72 800)
40 700 
(35 400 to 
46 700)
106 000 
(94 200 to 
119 000)
–5·0% 
(–8·1 to 
–1·5)*
2·3% 
(–1·6 to 
6·3)
–2·3% 
(–5·4 to 
1·3)
1715·6 
(1548·7 
to 
1908·9)
1058·9 
(924·2 to 
1207·6)
1389·0 
(1241·3 to 
1560·2)
–17% 
(–19·5 to 
–14·3)*
–13% 
(–16·0 to 
–9·8)*
–15·6% 
(–18·0 to 
–12·7)*
Falls 21 000 
(17 600 to 
24 900)
15 000 
(12 300 to 
18 000)
35 900 
(30 200 to 
42 900)
15·3% 
(10·3 to 
20·3)*
24·4% 
(20·7 to 
27·5)*
18·9% 
(15·4 to 
22·7)*
549·9 
(462·2 to 
652·6)
367·2 
(304·1 to 
442·2)
459·4 
(387·1 to 
547·5)
–3·8% 
(–7·7 to 
0·4)
0·3% 
(–2·9 to 
2·8)
–2·3% 
(–5·0 to 
0·7)
Drowning 11 600 
(11 100 to 
12 100)
5110 
(4680 to 5510)
16 700 
(15 900 to 
17 500)
–25·0% 
(–28·0 to 
–21·8)*
–27·8% 
(–32·5 to 
–20·3)*
–25·9% 
(–28·8 to 
–22·2)*
311·4 
(298·2 to 
325·9)
145·9 
(133·3 to 
158·3)
229·9 
(219·0 to 
241·2)
–31·6% 
(–34·3 to 
–28·6)*
–34·6% 
(–39·0 to 
–27·5)*
–32·6% 
(–35·4 to 
–29·2)*
Fire, heat, and hot 
substances
4060 
(3380 to 4770)
4400 
(3560 to 5210)
8460 
(7030 to 9880)
–7·3% 
(–13·1 to 
4·9)
–5·2% 
(–11·2 to 
3·9)
–6·3% 
(–11·7 to 
1·2)
106·3 
(88·5 to 
124·6)
116·3 
(94·1 to 
136·7)
111·1 
(92·8 to 
129·3)
–18·8% 
(–23·6 to 
–8·4)*
–16·6% 
(–21·6 to 
–8·4)*
–17·7% 
(–22·4 to 
–11·0)*
Poisonings 2320 
(1740 to 2620)
1470 
(1090 to 1640)
3790 
(2930 to 4210)
–12·4% 
(–20·1 to 
–0·3)*
–8·2% 
(–14·8 to 
2·6)
–10·8% 
(–17·8 to 
–0·5)*
60·6 
(45·2 to 
68·5)
39·5 
(29·3 to 
43·9)
50·1 
(38·8 to 
55·6)
–22·4% 
(–29 to 
–11·3)*
–18·3% 
(–24·2 to 
–8·5)*
–20·9% 
(–26·9 to 
–11·7)*
Poisoning by carbon 
monoxide
1040 
(770 to 1150)
500 
(329 to 558)
1540 
(1150 to 1690)
–19·6% 
(–27·6 to 
–11·0)*
–12·8% 
(–20·8 to 
–5·4)*
–17·5% 
(–25·3 to 
–10·1)*
26·6 
(19·7 to 
29·4)
13·1 
(8·6 to 
14·7)
19·9 
(14·8 to 
21·9)
–29·5% 
(–36·4 to 
–21·9)*
–23·3% 
(–30·3 to 
–16·6)*
–27·6% 
(–34·5 to 
–21·0)*
Poisoning by other 
means
1290 
(948 to 1500)
966 
(737 to 1090)
2250 
(1780 to 2560)
–5·6% 
(–15·0 to 
12·3)
–5·6% 
(–13·5 to 
6·8)
–5·6% 
(–13·8 to 
7·5)
34·0 
(25·1 to 
39·7)
26·4 
(20·1 to 
29·8)
30·2 
(23·9 to 
34·3)
–15·7% 
(–24·1 to 
0·8)
–15·6% 
(–22·8 to 
–4·2)*
–15·7% 
(–23·2 to 
–3·7)*
Exposure to mechanical 
forces
8110 
(6970 to 
9480)
3240 
(2560 to 3980)
11 300 
(9620 to 
13 500)
–3·5% 
(–8·0 to 
1·4)
13·6% 
(7·7 to 
20·5)*
0·8% 
(–3·6 to 
5·5)
208·5 
(179·4 to 
243·3)
83·8 
(66·4 to 
102·5)
146·1 
(124·2 to 
172·6)
–15·8% 
(–19·2 to 
–12·2)*
–2·4% 
(–7·1 to 
2·8)
–12·5% 
(–15·8 to 
–8·9)*
Unintentional 
firearm injuries
1080 
(972 to 1250)
334 
(285 to 390)
1410 
(1270 to 1620)
–4·6% 
(–9·4 to 
2·8)
11·2% 
(3·5 to 
21·7)*
–1·3% 
(–5·8 to 
4·2)
28·0 
(25·1 to 
32·5)
8·7 
(7·4 to 
10·2)
18·4 
(16·6 to 
21·2)
–14·6% 
(–18·8 to 
–8·1)*
–2·9% 
(–9·7 to 
6·5)
–12·1% 
(–16·2 to 
–7·3)*
(Table 3 continues on next page)
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2017 Percentage change, 2007–17 2017 Percentage change, 2007–17
Males Females Both Males Females Both Males Females Both Males Females Both
(Continued from previous page)
Other exposure to 
mechanical forces
7030 
(5970 to 8340)
2900 
(2260 to 3600)
9930 
(8310 to 
11 900)
–3·4% 
(–8·2 to 
1·8)
13·9% 
(8·0 to 
21·4)*
1·1% 
(–3·6 to 
6·1)
180·5 
(153·2 to 
213·8)
75·1 
(58·4 to 
93)
127·6 
(107·2 to 
152·3)
–16·0%% 
(–19·7 to 
–12·1)*
–2·3% 
(–7·1 to 
3·3)
–12·5% 
(–16·1 to 
–8·9)*
Adverse effects of 
medical treatment
2490 
(2070 to 3100)
2230 
(1760 to 2660)
4720 
(3940 to 5600)
7·2% 
(1·0 to 
14·4)*
5·5% 
(0 to 
12·3)*
6·4% 
(1·2 to 
13·2)*
66·6 
(55·2 to 
83·7)
58·7 
(46·0 to 
70·8)
62·6 
(51·9 to 
75·2)
–6·7% 
(–11·9 to 
–0·8)*
–9·3% 
(–13·9 to 
–3·5)*
–7·9% 
(–12·3 to 
–2·2)*
Animal contact 2650 
(1630 to 3090)
2340 
(1180 to 2870)
4990 
(3180 to 5830)
–8·5% 
(–16·1 to 
5·5)
0% 
(–7·8 to 
9·9)
–4·7% 
(–10·7 to 
3·6)
69·3 
(42·6 to 
81·1)
63·2 
(31·6 to 
77·4)
66·1 
(42·1 to 
77·4)
–19·1% 
(–25·8 to 
–6·5)*
–11·3% 
(–18·0 to 
–2·9)*
–15·6% 
(–21·2 to 
–8·0)*
Venomous animal 
contact
2160 
(1250 to 2540)
1960 
(898 to 2450)
4120 
(2490 to 4910)
–10·3% 
(–18·2 to 
4·6)
–0·4% 
(–8·8 to 
9·3)
–5·8% 
(–11·7 to 
2·8)
56·6 
(32·7 to 
66·6)
53·1 
(23·8 to 
66·6)
54·7 
(32·8 to 
65·3)
–20·5% 
(–27·6 to 
–7·0)*
–11·3% 
(–18·5 to 
–3·2)*
–16·4% 
(–21·9 to 
–8·5)*
Non-venomous 
animal contact
484 
(343 to 612)
379 
(247 to 648)
863 
(640 to 1140)
0·3% 
(–8·5 to 
9·4)
2·0% 
(–24·8 to 
23·6)
1·1% 
(–16·0 to 
10·7)
12·7 
(9·0 to 
16·1)
10·1 
(6·5 to 
17·8)
11·4 
(8·4 to 
15·1)
–12·3% 
(–19·5 to 
–4·7)*
–11·1% 
(–33·7 to 
7·9)
–11·7% 
(–26·2 to 
–3·4)*
Foreign body 4140 
(3830 to 4500)
2710 
(2500 to 2910)
6860 
(6340 to 7350)
–9·0% 
(–13·1 to 
–4·5)*
–8·6% 
(–15 to 
–3·2)*
–8·8% 
(–12·6 to 
–5·0)*
113·7 
(104·7 to 
123·4)
77·0 
(70·8 to 
82·6)
95·4 
(88·2 to 
102·2)
–17·7% 
(–21·3 to 
–13·8)*
–17·7% 
(–23·5 to 
–12·8)*
–17·7% 
(–21·2 to 
–14·3)*
Pulmonary aspiration 
and foreign body in 
airway
3460 
(3250 to 3760)
2210 
(2050 to 2350)
5680 
(5350 to 6050)
–11·4% 
(–16 to 
–6·7)*
–11·7% 
(–18·8 to 
–5·9)*
–11·5% 
(–15·7 to 
–7·4)*
95·8 
(89·8 to 
104·1)
64·1 
(59·1 to 
68·3)
80·0 
(75·2 to 
85·5)
–19·3% 
(–23·4 to 
–15·0)*
–19·5% 
(–26·1 to 
–14·3)*
–19·4% 
(–23·3 to 
–15·6)*
Foreign body in eyes 149 
(76·1 to 250)
52·8 
(28·0 to 85·9)
202 
(105 to 334)
21·6% 
(20·0 to 
23·8)*
16·7% 
(15·4 to 
18·3)*
20·3% 
(18·8 to 
22·1)*
3·9 
(2·0 to 
6·5)
1·3 
(0·7 to 
2·2)
2·6 
(1·3 to 4·3)
3·9% 
(2·6 to 
4·7)*
–0·9% 
(–2·7 to 
0·4)
2·7% 
(1·3 to 
3·6)*
Foreign body in other 
body part
532 
(420 to 657)
446 
(357 to 547)
978 
(797 to 1180)
2·1% 
(–7·5 to 
9·6)
7·2% 
(–0·7 to 
14·1)
4·4% 
(–1·9 to 
10·2)
13·9 
(11·0 to 
17·3)
11·5 
(9·2 to 
14·1)
12·7 
(10·4 to 
15·4)
–11·0% 
(–18·7 to 
–5·1)*
–7·6% 
(–14·1 to 
–1·5)*
–9·6% 
(–14·7 to 
–4·7)*
Environmental heat 
and cold exposure
2240 
(1690 to 2650)
1120 
(817 to 1360)
3360 
(2550 to 4000)
–9·3% 
(–13·9 to 
–5·0)*
2·0% 
(–3·3 to 
6·6)
–5·8% 
(–10·6 to 
–1·7)*
57·5 
(43·2 to 
68·2)
28·4 
(20·5 to 
34·7)
42·8 
(32·4 to 
51·1)
–22·6% 
(–26·6 to 
–19)*
–13·7% 
(–18·4 to 
–9·7)*
–19·9% 
(–24·2 to 
–16·4)*
Exposure to forces of 
nature
749 
(624 to 920)
454 
(370 to 564)
1200 
(1000 to 1470)
–18·7% 
(–25·1 to 
–11·5)*
–15·6% 
(–22·6 to 
–7·8)*
–17·6% 
(–23·3 to 
–10·9)*
19·2 
(16·0 to 
23·5)
11·9 
(9·7 to 
14·8)
15·5 
(13·0 to 
18·9)
–27·5% 
(–33·2 to 
–21·2)*
–25·8% 
(–32·0 to 
–18·8)*
–26·9% 
(–32·0 to 
–21·1)*
Other unintentional 
injuries
5950 
(5220 to 6860)
2640 
(2110 to 3340)
8580 
(7380 to 
10 200)
–7·7% 
(–11·4 to 
–3·6)*
5·4% 
(–0·3 to 
10·8)
–4·0% 
(–8·2 to 
0·4)
152·7 
(134·1 to 
175·9)
67·0 
(54·1 to 
84·1)
110·0 
(94·9 to 
130·3)
–19% 
(–21·9 to 
–15·8)*
–10·9% 
(–15·2 to 
–6·8)*
–16·8% 
(–19·9 to 
–13·6)*
Self-harm and 
interpersonal violence
50 300 
(47 500 to 
52 300)
20 800 
(19 600 to 
21 900)
71 100 
(68 100 to 
73 700)
8·1% 
(4·7 to 
10·9)*
1·7% 
(–1·3 to 
4·1)
6·2% 
(3·8 to 
8·2)*
1278·8 
(1206·1 
to 1328·3)
540·8 
(510·6 to 
570·7)
910·5 
(871·7 to 
944·2)
–4·0% 
(–7·0 to 
–1·5)*
–8·6% 
(–11·2 to 
–6·3)*
–5·3% 
(–7·4 to 
–3·5)*
Self-harm 22 900 
(20 900 to 
24 000)
11 100 
(10 600 to 
11 500)
34 000 
(31 800 to 
35 100)
–0·8% 
(–6·2 to 
3·6)
–8·0% 
(–12·6 to 
–5·1)*
–3·3% 
(–6·9 to 
–0·8)*
577·3 
(525·5 to 
603·9)
282·2 
(268·3 to 
293)
429·0 
(401·6 to 
443·5)
–13·5% 
(–18·2 to 
–9·7)*
–18·3% 
(–22·4 to 
–15·7)*
–15·1% 
(–18·3 to 
–12·9)*
Self-harm by firearm 2250 
(1840 to 2880)
405 
(334 to 476)
2660 
(2250 to 3290)
2·3% 
(–3·7 to 
7·8)
–6·2% 
(–14·1 to 
3·1)
0·9% 
(–3·5 to 
5·5)
57·0 
(46·5 to 
72·8)
10·3 
(8·4 to 
12·1)
33·5 
(28·3 to 
41·7)
–10·6% 
(–15·5 to 
–6·1)*
–16·6% 
(–23·1 to 
–8·5)*
–11·5% 
(–15·2 to 
–7·6)*
Self-harm by other 
specified means
20 700 
(18 600 to 
21 700)
10 700 
(10 200 to 
11 100)
31 400 
(29 200 to 
32 600)
–1·1% 
(–6·8 to 
3·7)
–8·1% 
(–12·8 to 
–5·0)*
–3·6% 
(–7·4 to 
–1)*
520·3 
(467·5 to 
546·3)
271·9 
(258·6 to 
282·5)
395·4 
(368·6 to 
410·5)
–13·8% 
(–18·8 to 
–9·6)*
–18·4% 
(–22·5 to 
–15·7)*
–15·4% 
(–18·7 to 
–13·1)*
Interpersonal violence 19 800 
(17 800 to 
21 000)
6250 
(5370 to 7230)
26 000 
(23 700 to 
28 000)
2·0% 
(–0·7 to 
5·2)
–2·6% 
(–5·8 to 
2·7)
0·9% 
(–1·4 to 
3·6)
503·0 
(451·5 to 
534·9)
163·2 
(139·9 to 
188·5)
334·3 
(304·7 to 
360·5)
–8·3% 
(–10·6 to 
–5·5)*
–13·0% 
(–15·8 to 
–8·2)*
–9·4% 
(–11·5 to 
–6·9)*
Assault by firearm 8690 
(7330 to 9500)
968 
(804 to 1140)
9660 
(8230 to 
10 400)
6·8% 
(3·3 to 
10·8)*
–4·5% 
(–8·6 to 
1·3)
5·5% 
(2·4 to 
9·2)*
221·5 
(186·8 to 
242·3)
25·4 
(21·0 to 
30·0)
124·4 
(105·8 to 
134·0)
–2·7% 
(–5·8 to 
1·0)
–13·6% 
(–17·2 to 
–8·4)*
–3·7% 
(–6·6 to 
–0·4)*
Assault by sharp 
object
4150 
(3240 to 5180)
959 
(792 to 1100)
5110 
(4170 to 6160)
–11·8% 
(–15·8 to 
–6·2)*
–12·6% 
(–15·7 to 
–7·4)*
–11·9% 
(–15·5 to 
–7·1)*
105·1 
(81·7 to 
131·1)
24·8 
(20·4 to 
28·3)
65·2 
(53·2 to 
78·5)
–21·0% 
(–24·6 to 
–16·0)*
–22·1% 
(–25 to 
–17·5)*
–21·2% 
(–24·3 to 
–16·9)*
(Table 3 continues on next page)
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spent in poor health varied largely at the country level, 
with less than 20% of the additional years spent in poor 
health for females in Bosnia and Herzegovina, Burundi, 
and Slovakia, whereas females lived all extra years in poor 
health in Bahrain (1·6 years [0·2–3·1]; appendix 2).
Globally, at age 65 years, women lived an additional 
2·7 years (95% UI 2·6–2·9) compared with men, but 
63·9% (55·2–72·2) of those years were spent in good 
health and 36·1% (27·8–44·8) in poor health (appendix 2). 
Compared with other SDI quintiles, the difference in life 
expectancy was greatest between females and males in 
the high SDI quintile, with females living 3·3 years 
(3·1–3·5) longer than males, but 28·4% (21·3–36·1) of 
those years were spent in poor health. In the low SDI 
quintile, females are estimated to live the largest 
proportion of extra years in poor health compared with 
other SDI quintiles (58·0% [43·8–74·6] of 1·1 years 
[0·7–1·4]). For females aged 65 years in Iran and India, of 
the extra years lived compared with males, more than 
60% of extra years were spent in poor health, 70·1% 
(53·5–88·2) for those in Iran and 63·4% (49·0–79·6) for 
those in India (appendix 2).
Global levels and trends for DALYs
The global level of all-age all-cause DALYs in 2017 was 
2·50 billion (95% UI 2·29–2·74). The estimated DALY 
counts and age-standardised rate of DALYs, and changes 
in these metrics between 2007 and 2017, are in table 3. 
The largest contribution to global DALYs was from non-
communicable diseases, which, combined, accounted 
for 62·0% (60·3–63·8) of total DALYs, whereas com-
municable, maternal, neonatal, and nutritional (CMNN) 
causes accounted for 27·9% (26·4–29·4), and injuries 
10·1% (9·7–10·5) of total DALYs.
For non-communicable diseases, global DALYs 
increased by 40·1% (95% UI 36·8–43·0), although 
age-standardised DALY rates decreased by 18·1% 
(16·0–20·2).  Between 2007 and 2017, 12 causes at Level 2 
of the GBD cause hierarchy (diabetes and kidney diseases, 
sense organ diseases, neurological disorders, neoplasms, 
musculoskeletal disorders, substance use disorders, 
cardiovascular diseases, chronic respiratory diseases, skin 
and subcutaneous diseases, mental disorders, digestive 
diseases, and self-harm and interpersonal violence) had 
significant increases in DALY counts. The greatest 
number of DALYs among Level 3 non-communicable 
disease causes in 2017 were estimated for ischaemic heart 
disease (170 million [167–174]), stroke (132 million 
[126–137]), and chronic obstructive pulmonary disease 
(81·6 million [76·0–86·8]) which, combined, accounted 
for 15·4% (14·2–16·4) of all-cause DALYs (table 3). By 
contrast with the overall decrease in DALYs during 
2007–17 for many causes, total all-age DALYs from non-
communicable diseases increased from 1·11 billion 
(1·00–1·23) in 1990 to 1·34 billion (1·19–1·51) in 2007, 
and continued to increase to 1·55 billion (1·38–1·75) in 
2017 (appendix 2): a change of 20·7% (18·4–22·8) from 
1990 to 2007, and 16·0% (15·1–16·9) from 2007 to 2017. At 
Level 4 between 1990 and 2007, the largest significant 
increases in total DALYs were estimated for HIV/AIDS 
and multidrug-resistant tuberculosis co-infection without 
extensive drug resistance (5329·0% [3143·5–8492·9]), 
multidrug-resistant tuberculosis without extensive drug 
resistance (700·6% [335·0–1,431·6]), and HIV/AIDS 
resulting in other diseases (454·3% [389·5–529·2]; 
appendix 2. From 2007 to 2017, the largest significant 
increases in DALYs were for liver cancer due to NASH 
(37·4% [32·8–42·9]), chronic kidney disease due to type 2 
diabetes (34·3% [30·9–37·2]), and diabetes type 2 (34·0% 
[30·3–38·1]). Relative to changes in the population, 
the age-standardised DALY rate for non-communicable 
diseases decreased by 13·2% (11·7–14·7), from 
All-age DALYs (thousands) Age-standardised DALY rate (per 100 000)
2017 Percentage change, 2007–17 2017 Percentage change, 2007–17
Males Females Both Males Females Both Males Females Both Males Females Both
(Continued from previous page)
Sexual violence 370 
(248 to 540)
1770 
(1190 to 2570)
2140 
(1450 to 3110)
9·4% 
(7·7 to 
11·1)*
13·0% 
(10·7 to 
15·1)*
12·4% 
(10·2 to 
14·3)*
9·4 
(6·3 to 
13·8)
45·4 
(30·6 to 
66·1)
27·3 
(18·5 to 
39·7)
–1·7% 
(–2·3 to 
–1·0)*
1·0% 
(–0·2 to 
2·3)
0·6% 
(–0·6 to 
1·6)
Assault by other 
means
6540 
(5750 to 7730)
2550 
(2140 to 2990)
9090 
(8190 to 
10 400)
5·9% 
(0·6 to 
11·5)*
–6·9% 
(–11·3 to 
1·5)
1·9% 
(–1·9 to 
6·2)
167·0 
(147·0 to 
197·4)
67·6 
(56·2 to 
79·4)
117·4 
(105·7 to 
134·4)
–6·2% 
(–10·6 to 
–1·3)*
–17·0% 
(–20·9 to 
–9·2)*
–9·5% 
(–12·9 to 
–5·8)*
Conflict and terrorism 6840 
(6400 to 7830)
3270 
(2820 to 3870)
10 100 
(8980 to 
11 400)
81·9% 
(55·6 to 
112·4)*
70·8% 
(48·8 to 
99·3)*
78·1% 
(58·6 to 
101·2)*
177·1 
(155·8 to 
203·0)
90·6 
(78·2 to 
107·0)
134·1 
(119·3 to 
151·9)
66·2% 
(42·8 to 
94·5)*
58·4% 
(36·9 to 
86·4)*
63·7% 
(45·4 to 
85·1)*
Executions and police 
conflict
840 
(800 to 894)
179 
(170 to 190)
1020 
(972 to 1080)
140·7% 
(123·6 to 
160·4)*
280·6% 
(245·5 to 
309·1)*
157·3% 
(139·7 to 
178·0)*
21·4 
(20·4 to 
22·8)
4·8 
(4·5 to 
5·1)
13·1 
(12·6 to 
13·9)
117·3% 
(101·5 to 
135·6)*
242·7% 
(210·3 to 
269·5)*
133·1% 
(116·6 to 
152·4)*
DALY counts are quoted to three significant figures and percentage changes and rates to one decimal place. DALY=disability-adjusted life-year. G6PD=glucose-6-phosphate dehydrogenase. H influenzae=Haemophilus 
influenzae. NASH=non-alcoholic steatohepatitis. *Percentage changes that are statistically significant. ‡Incidence estimates for stroke represent first-ever stroke only.
Table 3: Global all-age DALYs and age-standardised DALY rates in 2017 with percentage changes between 2007 and 2017 for all causes, by sex
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Figure 5: DALYs by Level 2 causes by age and sex, for global (A), high SDI (B), high-middle SDI (C), middle SDI (D), low-middle SDI (E), and low SDI (F), 2017 
Scales in each panel are different. The early neonatal period is 0–6 days, the late neonatal period is 7–27 days, and the post neonatal period is 28–364 days. DALYs=disability-adjusted life-years. 
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDI=Socio-demographic Index.
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24 017·4 DALYs (21 861·4–26 509·6) per 100 000 in 1990 to 
20 852·2 DALYs (18 710·2–23 388·5) per 100 000 in 2007, 
and decreased by a further 5·6% (4·8–6·6) to 
19 676·5 DALYs (17 509·8–22 177·9) per 100 000 in 2017. 
From 1990 to 2017, the greatest significant decreases in 
age-standardised DALY rates were for visceral 
leishmaniasis (97·8% [97·0–99·2]), maternal haemor-
rhage (78·7% [73·4–83·0]), and ascariasis (70·8% 
[66·0–75·3]). Significant increases in age-standardised 
DALY rates from 1990 to 2017 were observed for 17 Level 4 
non-communicable diseases, with other benign and in-
situ neoplasms (35·1% [7·8–81·7]), type 2 diabetes 
(28·2% [24·1–32·3]), and opioid use disorders (24·8% 
[20·1–31·0]) having the most pronounced changes.
Among CMNNs, at Level 3 of the GBD cause hierarchy 
the greatest contributors to global DALYs in 2017 were 
neonatal disorders (186 million [95% UI 175–197] DALYs), 
lower respiratory infections (106 million [100–112] DALYs), 
and diarrhoeal diseases (81·0 million [70·1–97·2] DALYs). 
Globally, total DALYs from all CMNNs decreased from 
1·19 billion (1·14–1·23) in 1990 to 0·946 billion 
(0·910–0·987) in 2007, to 0·696 billion (0·660–0·740) in 
2017, a decrease of 41·3% (38·8–43·5) from 1990 to 2017. In 
parallel, the age-standardised DALY rate for all CMNN 
causes decreased by 49·8% (47·9–51·6) from 1990 to 2017. 
For 2007–17, the largest decreases were for visceral 
leishmaniasis (by 63·9% [40·0–84·5]), HIV/AIDS and 
drug-susceptible tuberculosis co-infection (by 54·9% 
[51·0–57·9]), and maternal haemorrhage (52·4% 
[44·3–59·5]; table 3). Significant decreases of more than 
50% in age-standardised DALY rates between 2007–17 
were estimated for five Level 4 CMNN causes, specifically, 
visceral leishmaniasis (66·2% [44·3–86·0]), HIV/AIDS 
and drug-susceptible tuberculosis co-infection (59·8% 
[56·3–62·5]), HIV/AIDS and multidrug-resistant tubercu-
losis without extensive drug resistance co-infection (56·6% 
[40·1–69·1]), maternal haemorrhage (56·4% [49·1–62·8]), 
and HIV/AIDS resulting in other diseases (53·7% 
[51·1–56·1]). Against this general decreasing trend, seven 
CMNN causes at Level 4 were estimated to have significant 
increases in age-standardised DALY rate between 1990 and 
2017, specifically, HIV/AIDS and multidrug-resistant 
tuberculosis without extensive drug resistance co-infection 
(1805·0% [1016·3–3049·2]), HIV/AIDS resulting in other 
diseases (103·1% [76·3–134·9]), and cutaneous and 
mucocutaneous leishmaniasis (40·5% [7·0–106·0]).
(Figure 6 continues on next page)
Females
Leading causes 1990 Leading causes 2007 Mean percentage 
change in number
of DALYs,
1990–2007
Mean percentage
change in
age-standardised
DALY rate,
1990–2007
Leading causes 2017
  1 Neonatal disorders
  2 Lower respiratory infections
  3 Diarrhoeal diseases
  4 Stroke
  5 Ischaemic heart disease
  6 Congenital defects
  7 COPD
  8 Measles
  9 Tuberculosis
10 Malaria
11 Low back pain
12 Headache disorders
13 Dietary iron deficiency
14 Maternal disorders
15 Protein-energy malnutrition
16 Road injuries
17 Depressive disorders 
18 Meningitis
19 Diabetes
20 Self-harm
21 Drowning
22 Asthma
23 Chronic kidney disease
24 Anxiety disorders
25 Tetanus
26 Breast cancer
27 Falls
28 Cirrhosis
29 Other musculoskeletal
30 Blindness & vision impairment
31 Age-related hearing loss
32 Neck pain
33 Alzheimer’s disease
34 Gynaecological diseases
36 HIV/AIDS
43 Lung cancer
  1 Neonatal disorders –18·2 –21·9
  2 Ischaemic heart disease 17·0 –10·4
  3 Stroke 13·6 –12·5
  4 Lower respiratory infections –26·8 –33·6
  5 Diarrhoeal diseases –27·8 –35·5
  6 COPD 21·2 –6·3
  7 Low back pain 17·3 –2·7
  8 Headache disorders 15·3 0·7
  9 Diabetes 29·5 1·9
10 Congenital defects –9·6 –14·8
11 Depressive disorders 14·1 –3·1
12 HIV/AIDS –53·9 –58·8
13 Malaria –35·4 –40·2
14 Dietary iron deficiency –5·0 –14·6
15 Alzheimer's disease 36·1 –0·9
16 Road injuries –4·8 –17·2
17 Other musculoskeletal 21·0 0·9
18 Breast cancer 24·4 –1·4
19 Age-related hearing loss 25·7 0·2
20 Tuberculosis –20·6 –32·2
21 Anxiety disorders 12·4 –1·9
22 Chronic kidney disease 21·5 –2·4
23 Neck pain 20·8 –1·5
24 Blindness & vision impairment 22·6 –2·1
25 Falls 24·4 0·3
26 Cirrhosis 9·4 –11·2
27 Lung cancer 31·7 1·4
28 Gynaecological diseases 10·2 –2·4
29 Maternal disorders –24·1 –30·3
30 Asthma 9·7 –8·2
31 Self-harm
34 Meningitis
37 Protein-energy malnutrition
52 Drowning
64 Measles
  1 Neonatal disorders  –17·3 –17·8
  2 Lower respiratory infect  –39·6  –42·0
  3 HIV/AIDS 610·7 483·0
  4 Ischaemic heart disease  14·9  –23·6
  5 Diarrhoeal diseases  –40·8  –44·2
  6 Stroke  8·4  –26·5
  7 Malaria  28·6 23·2
  8 COPD  –1·3 –32·7
  9 Congenital defects –12·8 –15·6
10 Low back pain 29·8 –7·6
11 Headache disorders 34·0 –0·1
12 Diabetes 60·3 10·4
13 Depressive disorders 32·2 –3·0
14 Tuberculosis –25·0 –40·9
15 Dietary iron deficiency 0·3 –18·8
16 Road injuries –1·6 –20·5
17 Maternal disorders –21·7 –38·7
18 Anxiety disorders 33·0 0·6
19 Other musculoskeletal 49·7 7·0
20 Breast cancer 35·9 –8·1
21 Chronic kidney disease 22·4 –11·0
22 Alzheimer's disease 52·1 –6·1
23 Age-related hearing loss 44·9 0·7
24 Neck pain 45·7 0·8 
25 Blindness & vision impairment 41·8 –0·6
26 Meningitis –23·0 –27·0 
27 Self-harm –21·9 –39·8
28 Falls 19·2 –12·9
29 Protein-energy malnutrition –39·8 –40·9
30 Cirrhosis 16·6 –16·6
31 Gynaecological diseases 
32 Asthma
33 Lung cancer
34 Measles
37 Drowning
74 Tetanus
Mean percentage 
change in number
of DALYs,
2007–17
Mean percentage
change in
age-standardised
DALY rate,
2007–17
Communicable, maternal,
neonatal, and nutritional diseases
Non-communicable diseases
Injuries118 Tetanus
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In 2017, the top five leading causes of DALYs were 
communicable diseases (lower respiratory infections, 
malaria, diarrhoeal diseases, HIV/AIDS, and tuberculosis) 
and neonatal disorders (table 3). For low-middle SDI 
countries, both communicable and non-communicable 
diseases ranked highly as leading causes of DALYs, and 
the top five causes were neonatal disorders, lower 
respiratory infections, ischaemic heart disease, diarrhoeal 
diseases, and stroke (figure 5). In high SDI countries, 
non-communicable diseases (ischaemic heart disease, 
low back pain, stroke, lung cancer, and chronic obstructive 
pulmonary disease) were the leading causes of DALYs 
(figure 5). Younger age groups contributed more to total 
DALY counts in low SDI countries than did older age 
groups, and mostly from communicable diseases. In low 
SDI countries in 2017, 136 million (95% UI 130–143) 
DALYs were estimated for neonatal age groups to be from 
communicable diseases, with a further 18·9 million 
(17·2–21·0) from non-communicable diseases, and 
2·95 million (2·60–3·26) from injuries. For low and 
low-middle SDI countries, the burden is more equal 
across age groups than in other SDI quintiles. The burden 
from DALYs in high-middle and high SDI countries 
occurs mostly from age 15 years and consists largely of 
non-communicable diseases (figure 5).
Leading causes of DALYs and changes during 1990–2017
Globally in 2017, the leading causes of DALYs were 
predominantly CMNN and non-communicable causes for 
both men and women (figure 6). Of the top 30 causes of 
DALYs for men, four were injuries: road injuries 
(49·8 million [95% UI 47·3–52·1] DALYs), self-harm 
(22·9 million [20·9–24·0] DALYs), falls (21·0 million 
[17·6–24·9] DALYs), and interpersonal violence 
(19·8 million [17·8–21·0] DALYs; table 3). By contrast, two 
of the top 30 causes of DALYs for women were injuries: 
road injuries (18·0 million [16·6–19·4] DALYs) and falls 
(15·0 million [12·3–18·0] DALYs). Our results showed 
disparities in disease burden between males and females. 
Females are more likely than males to have a higher 
Figure 6: Leading 30 Level 3 causes of global DALYs for 1990, 2007, and 2017 with percentage change in number of DALYs and age-standardised DALY rates by sex
Solid lines indicate increases and dashed lines indicate decreases in rank between periods. Significant changes are shown in bold. COPD=chronic obstructive pulmonary disease. DALYs=disability-adjusted 
life-years.
Males
Leading causes 1990 Leading causes 2007 Mean percentage
change in number
of DALYs,
1990–2007
Mean percentage
change in
age-standardised
DALY rate,
1990–2007
Leading causes 2017 Mean percentage 
change in number 
of DALYs,
2007–17
Mean percentage
change in
age-standardised
DALY rate,
2007–17
  1 Neonatal disorders
  2 Lower respiratory infections
  3 Diarrhoeal diseases
  4 Ischaemic heart disease 
  5 Stroke
  6 Road injuries
  7 Congenital defects
  8 Tuberculosis
  9 COPD
10 Measles
11 Malaria
12 Drowning 
13 Protein-energy malnutrition
14 Self-harm
15 Cirrhosis
16 Meningitis
17 Low back pain
18 Lung cancer
19 Interpersonal violence
20 Diabetes
21 Falls
22 Asthma
23 Tetanus
24 Headache disorders
25 HIV/AIDS
26 Stomach cancer
27 Dietary iron deficiency
28 Chronic kidney disease
29 Leishmaniasis
30 Depressive disorders
31 Drug use disorders
32 Age-related hearing loss
35 Liver cancer
36 Alcohol use disorders
38 Other musculoskeletal
39 Blindness & vision impairment
41 Neck pain
54 Alzheimer’s disease
  1 Ischaemic heart disease  17·8  –9·2
  2 Neonatal disorders  –20·1  –22·9
  3 Stroke  17·4  –9·9
  4 Lower respiratory infect  –24·9  –31·4
  5 Road injuries  –6·5  –17·3
  6 COPD  13·5  –14·1
  7 Diarrhoeal diseases  –27·7  –34·0
  8 Diabetes  30·4  2·9
  9 Congenital defects  –12·1  –16·7
10 Low back pain  17·8  –1·3
11 Cirrhosis  9·9  –10·2
12 Lung cancer  22·3  –6·4
13 HIV/AIDS  –44·8  –51·1
14 Tuberculosis  –19·1  –32·0
15 Malaria  –33·0  –37·7
16 Self-harm  –0·8  –13·5
17 Falls  15·3  –3·8
18 Headache disorders  15·5  1·5
19 Interpersonal violence  2·0  –8·3
20 Chronic kidney disease  21·9  –2·0
21 Drug use disorders  26·6  11·9
22 Age-related hearing loss  24·2  –0·7
23 Depressive disorders  14·8  –1·9
24 Liver cancer  22·9  –3·0
25 Blindness & vision impairment  23·6  –1·5
26 Other musculoskeletal  16·6  –2·7
27 Alcohol use disorders  3·8  –11·4
28 Stomach cancer  5·6  –18·5
29 Neck pain  22·3  0·4
30 Alzheimer's disease  41·8  0·5
31 Drowning
32 Asthma
33 Meningitis
34 Dietary iron deficiency
42 Protein-energy malnutrition
66 Measles
  1 Neonatal disorders –17·1 –17·6
  2 Ischaemic heart disease 25·7 –18·0
  3 Lower respiratory infections –37·4 –40·1
  4 Stroke  22·4  –18·3
  5 Diarrhoeal diseases –33·3 –37·5
  6 Road injuries 7·3 –14·7
  7 HIV/AIDS 297·3 212·9
  8 COPD 5·5 –29·9
  9 Congenital defects –14·5 –17·8
10 Malaria 30·5 23·6
11 Tuberculosis –12·7 –35·1
12 Diabetes 73·3 17·8
13 Cirrhosis 26·9 –11·3
14 Low back pain 30·2 –6·8
15 Lung cancer 22·9 –16·4
16 Self-harm 10·7 –16·8
17 Interpersonal violence 15·3 –9·6
18 Falls 18·7 –10·8 
19 Headache disorders 34·1 1·1 
20 Chronic kidney disease 34·5 –2·7 
21 Drowning –39·2 –45·5 
22 Drug use disorders 37·2 5·7 
23 Depressive disorders 35·5 –0·1 
24 Meningitis –26·2 –30·4 
25 Age-related hearing loss 44·0 –0·1 
26 Alcohol use disorders 47·1 7·0 
27 Liver cancer 33·0 –7·8 
28 Protein-energy malnutrition –44·1 –45·8 
29 Stomach cancer –1·4 –33·0 
30 Other musculoskeletal 40·5 0·3 
31 Dietary iron deficiency
32 Asthma
33 Blindness & vision impairment
34 Neck pain
36 Measles
40 Alzheimer’s disease
72 Tetanus
Communicable, maternal,
neonatal, and nutritional diseases
Non-communicable diseases
Injuries115 Leishmaniasis
108 Tetanus
145 Leishmaniasis
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burden from disabling conditions such as most musculo-
skeletal disorders except for gout, iron-deficiency anaemia, 
and major depressive disorder. Iron-deficiency aneaemia 
is common especially at reproductive ages for females, and 
for boys and girls (aged 5–14 years) equally (appendix 2). 
Males are more likely than females to be affected by fatal 
conditions including different types of cancer, injuries, 
and ischaemic heart disease. Globally, the all-age DALY 
count of HIV/AIDS for females increased sharply from 
1990 to 2007, rising from 36th to third leading cause of 
DALYs with an increase of 610·7% (548·5–680·6), then 
decreased from 2007 to 2017 by 53·9% (51·6–53·9), 
dropping to 12th leading cause of DALYs (figure 6). 
Similarly, the global age-standardised DALY rate for 
females increased from 1990 to 2007 by 483·0% 
(431·4–540·5), and then decreased from 2007 to 2017 by 
58·8% (56·8–60·6; appendix 2). Males had similar 
patterns in all-age DALY counts and age-standardised 
DALY rates for HIV/AIDS during the same period. The all-
age DALY count of HIV/AIDS for males increased by 
297·3 (259·8–338·4) from 1990 to 2007, rising from the 
25th leading cause of DALYs to seventh (figure 6; 
appendix 2). By 2017, all-age DALYs from HIV/AIDS for 
males dropped to 13th leading cause of DALYs, a decrease 
of 44·8% (42·8–46·6) between 2007 and 2017. Similarly, the 
age-standardised DALY rate of HIV/AIDS for males 
increased sharply from 1990 to 2007, with an increase of 
212·9% (182·8–246·4), and then decreasing by 51·1% 
(49·0–52·6) in 2017. The global all-age DALY count of 
malaria for females increased from 1990 to 2007 by 28·6% 
(11·7–51·2), rising from the tenth leading cause of DALYs 
to the seventh leading cause of DALYs. Malaria age-
standardised DALY rates for females also increased, with 
an increase of 23·2% (7·4–44·2) between 1990 and 2007, 
and then decreased from 2007 to 2017 by 40·2% 
(30·7–49·2). DALYs from malaria for males also increased 
from 1990 to 2007, increasing by 30·5% (12·9–55·7) from 
the 11th to the tenth leading cause of DALYs. Similarly, the 
age-standardised DALY rate for malaria in males increased 
between 1990 and 2007 by 23·6% (7·0–46·0), and then 
decreased by 37·7% (27·6–46·8) in 2017.
The leading 30 causes of DALYs for men and women 
varied between SDI quintiles (appendix 2). In the low SDI 
quintile countries, males and females had similar CMNN 
causes as the leading causes of DALYs in 2017, with 
the greatest total DALYs for both sexes being from neo-
natal disorders, lower respiratory infections, diarrhoeal 
diseases, and malaria for both sexes, and thereafter for 
females the fifth leading cause was congenital defects and 
for males was ischaemic heart disease. In the low SDI 
quintile, males had more injury sources of DALYs than 
females, whereas CMNN causes of DALYs were more 
common among the leading DALY causes for females 
than males. An epidemiological shift in sources of DALYs 
was evident in the leading causes for both men and 
women at middle to high SDI levels, which were 
dominated by non-communicable disease causes. In high 
SDI quintiles, two CMNN causes of DALYs were in the 
leading 30 causes for both men and women, lower 
respiratory infections and neonatal disorders, and the age-
standardised DALYs rate for these causes decreased 
between 1990 and 2017, by 36·2% (95% UI 33·9–38·6) for 
lower respiratory infections and 30·1% (25·1–36·7) for 
neonatal disorders for men, and by 37·8% (35·8–39·9) 
for lower respiratory infections and 27·5% (22·3–34·1) 
for neonatal disorders for women (appendix 2).
YLLs and YLDs composition by age, sex, and SDI
Globally in 2017, males had 1·34 billion (95% UI 
1·24–1·46) DALYs and females had 1·16 billion 
(1·04–1·29) DALYs. For males, 29·4% (23·8–34·9) of 
DALYs were from YLDs and 70·6% (65·1–76·2) were 
from YLLs. For females, 39·4% (33·0–45·6) of DALYs 
were from YLDs and 60·6% (54·4–67·0) were from YLLs. 
A greater proportion of DALYs were from YLDs for 
females than for males, particularly for those older than 
65 years (figure 7). Globally, among females YLDs were 
the larger fraction of DALYs for many age groups, 
whereas for males this was only the case for those aged 
10–14 years. Across SDI quintiles, the composition of 
DALYs varied. Females aged 1–69 years in the high SDI 
quintile had more DALYs from YLDs than from YLLs, 
whereas in the low SDI quintile all age groups except 
those aged 10–29 years had more DALYs from YLLs than 
from YLDs. In all quintiles, women older than 65 years 
had more DALYs from YLDs than men older than 
65 years did.
Observed and expected values of HALE and DALYs based 
on SDI level
Maps of observed minus expected HALE can highlight 
which countries have worse or better HALE than 
expected based on SDI quintile, as shown in figure 8. 
The three countries with the greatest difference 
between expected HALE at birth and observed HALE at 
birth for males, with observed HALE much lower than 
expected on the basis of their SDI value, were Lesotho, 
with a difference of 13·4 years, Swaziland (eSwatini), 
with a difference of 11·7 years, and Central African 
Republic, with a differences of 7·9 years. For females, 
the countries with the greatest differences were 
Lesotho, with a difference of 10·0 years, Congo 
(Brazzaville), with a difference of 9·3 years, and 
Swaziland (eSwatini), with a difference of 8·1 years. 
The three countries that had the greatest difference 
between observed and expected HALE at birth for 
Figure 7: Contribution of YLLs and YLDs to DALYs by age and sex for 
global (A), high SDI (B), high-middle SDI (C), middle SDI (D), 
low-middle SDI (E), and low SDI (F), 2017 
The early neonatal period is 0–6 days, the late neonatal period is 7–27 days, and 
the post neonatal period is 28–364 days. DALYs=disability-adjusted life-years. 
SDI=Socio-demographic Index. YLDs=years lived with disability. YYLs=years of 
life lost.
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males, where HALE was much better than expected, 
were Niger, Nicaragua, and the Maldives, with differ-
ences of 11·9 years for Niger, 9·5 years for Nicaragua, 
and 9·2 years for the Maldives. For females, these 
countries were Niger, Nicaragua, and Ethiopia, with 
differences between observed and expected HALE at 
birth of 11·5 years for Niger, 8·3 years for Nicaragua, 
and 8·2 years for the Maldives. We saw a similar trend 
in countries having differences in observed and 
expected HALE at age 65 years for both males and 
females (appendix 2). The greatest differences in 
observed and expected HALE at age 65 years for males, 
where HALE was worse than expected, were seen in 
Lesotho (3·1 years), Swaziland (eSwatini; 2·8 years), 
and Papua New Guinea (2·3 years), and for females 
were seen in Congo (Brazzaville; 2·7 years), Papua New 
Guinea (2·6 years), and Marshall Islands (2·2 years). 
HALE at age 65 years was better than expected on the 
basis of SDI level for males in Peru (by 5·0 years), 
Colombia (by 5·0 years), and Nicaragua (by 4·9 years), 
and for females in Colombia (by 4·5 years), Peru (by 
4·3 years), and Nicaragua (by 3·7 years).
Higher ratios of observed to expected age-standardised 
DALY rates indicate more DALYs experienced than 
expected on the basis of SDI (appendix 2). Males had the 
highest ratio of observed to expected age-standardised 
DALY rates in Lesotho (1·94), Swaziland (eSwatini; 1·86), 
and Central African Republic (1·60). Females had the 
highest ratio of observed to expected age-standardised 
DALY rates in Congo (Brazzaville; 1·67), Lesotho (1·62), 
and Equatorial Guinea (1·57). Alternatively, males in the 
Maldives, Niger, and Nicaragua experience DALYs at a 
much lower rate than expected, with observed to expected 
ratios of 0·54 in the Maldives, 0·56 in Niger, and 0·57 in 
Nicaragua. Females had low ratios of observed to 
expected age-standardised DALY rates in Niger, 
Nicaragua, and Ethiopia, with ratios of 0·57 in Niger, 
0·58 in Nicaragua, and 0·62 in Ethiopia.
Discussion
Main findings
Globally, HALE at birth increased by 6·3 years (95% UI 
5·9–6·7) and the number of years lived in poor health 
from birth increased by 1·1 years (0·9–1·4) during the 
period 1990–2017, with substantial variation across socio-
demographic quintiles and countries. People in low SDI 
countries gained an additional 10·5 years (9·8–11·2) of 
life in good health and 1·5 years (1·2–1·9) in poor health 
from birth, whereas people in high SDI countries gained 
an additional 3·8 years (3·4–4·1) in good health and 
1·3 years (1·0–1·7) in poor health from birth. Women are 
expected to live longer than men (both at birth and at age 
65 years) in most countries, but the number of extra 
years lived and the proportions of extra years spent in 
poor health vary greatly across countries. In 2017, the 
global leading causes of DALYs were neonatal disorders, 
ischaemic heart disease, stroke, lower respiratory 
infections, and chronic obstructive pulmonary disease. 
Communicable diseases and neonatal disorders were the 
leading causes of DALYs in low SDI countries in 2017. 
Non-communicable diseases were the leading causes of 
DALYs in the remaining SDI quintiles in the same year.
Sex disparities in health
Sex differences in HALE exist across SDI quintiles, with 
the smallest difference seen in low SDI countries. 
Although societal factors, biological factors, and men’s 
risk behaviours probably contribute to their shorter 
HALE,22,23 the smaller male–female gap in HALE in low 
SDI countries might be explained by the increased risk 
of mortality in both sexes due to the high occurrence of 
infectious diseases. Additionally, women are affected by 
pregnancy-related conditions, and maternal disorders 
were a leading cause of DALYs in low SDI countries in 
2017. In several high SDI countries, the difference 
between male and female HALE has decreased over 
time, which could partly be attributable to the decreasing 
gap between the sexes in the prevalence of specific risk 
factors—eg, smoking and alcohol use.24,25
Our results show increased life expectancy and more 
years lived in poor health for women than men in 
most countries. This finding could be attributable to 
sex differences in the patterns of disease burden. For 
example, women are more likely than men to have a 
higher burden from disabling conditions (eg, most 
musculoskeletal disorders except for gout, iron-deficiency 
anaemia, and major depressive disorder), whereas men 
are more likely than women to be affected by fatal 
conditions including different types of cancer (eg, liver 
cancer, lung cancer, leukaemia, colorectal cancer, and 
pancreatic cancer), injuries, and ischaemic heart disease. 
Various explanations have been suggested for the sex 
difference in disease risk, including social norms 
(eg, heavy drinking is socially acceptable for men in 
Russian tradition), health-related beliefs and behaviours, 
and biological factors (eg, sex hormones).22,26
In 2017, the widest difference between male and female 
HALE at birth was observed in the eastern European 
region (7·7 years [95% UI 6·8–8·4]), where the age-
standardised DALY rate from all causes among men was 
also 1·7 times higher than among women. A large 
proportion of DALYs in men in these countries was 
attributable to alcohol use and smoking, which led to 
high incidence and prevalence of cardiovascular disease 
and other leading causes of DALYs.27 Interventions 
aiming to reduce these risk factors could help decrease 
Figure 8: Difference in years between observed and expected HALE at birth 
on the basis of SDI for females and males, 2017
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. HALE=healthy 
life expectancy. Isl=Islands. LCA=Saint Lucia. SDI=Socio-demographic Index. 
TTO=Trinidad and Tobago. TLS=Timor-Leste. VCT=Saint Vincent and the 
Grenadines.
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the difference. Ukraine and Lithuania had the biggest sex 
difference in HALE at birth globally (8·7 years [7·5–9·8] 
for Ukraine and 7·8 years [6·6–8·9] for Lithuania) in 
2017. Age-standardised DALY rates due to cardiovascular 
diseases and alcohol use disorders were two times higher 
in both these countries for men than for women, whereas 
self-harm and drug use disorders were four or more 
times higher.
Longevity and functional health status
With increasing life expectancy in almost all locations 
worldwide, the question of whether the years of life 
gained are spent in good health or poor health is 
increasingly relevant because of the associated policy 
implications, ranging from health-care provisions to 
extending retirement ages.
In the context of improving longevity, the age of 
retirement versus extending working life has been much 
debated. Some key questions need to be considered in 
this debate, including whether the increase in life 
expectancy is accompanied by an equivalent increase in 
years in good health, and whether the common causes of 
early retirement,28,29 such as mental disorders and muscu-
lo skeletal disorders, have improved over time. Our 
results showed that the additional years of life were 
accompanied by poor health to some extent, but varied 
widely across countries, and the burden from musculo-
skeletal disorders and mental disorders has not improved 
over time. A lack of progress in reducing the burden of 
these causes and other conditions associated with ageing, 
such as sense organ disorders and Alzheimer’s disease, 
might restrict the ability of older workers to contribute to 
the workforce.30
Globally, 12 Level 2 causes have had significant 
increases in DALY counts since 2007. Causes with the 
largest increases in DALY counts include musculoskeletal 
disorders, sense organ diseases, neurological disorders, 
diabetes and kidney diseases, and neoplasms. The large 
and increasing number of people living with these 
diseases necessitates careful planning by governments 
and health-care providers to ensure adequate funding 
and staff for treatment and rehabilitation services. Some 
of these diseases are expensive to manage.31 Despite the 
large amount of spending on health in some countries, 
such as India and Nigeria, the spending is inefficient 
because most of it is through out-of-pocket expenditures 
(ie, direct payments by individuals to health-care 
providers); additional health services could be provided if 
the money was consolidated.32
Cross-national variation in health gains
Our results showed that substantial variations in health 
gains exist even between countries within the same SDI 
quintile. For example, between 1990 and 2017, the 
increase in HALE at birth among females in Singapore 
was more than six times greater than the increase among 
females in the USA (7·3 years [95% UI 6·6–7·9] vs 
1·1 years [0·8–1·4]), and the females in Singapore spent 
a smaller proportion of the extra years in poor 
health (17·7% [12·7–23·1] vs 33·6% [25·1–42·2]). The 
comparatively small increase in HALE in the USA is 
probably due to inequalities in access to health care.33 
The burden attributable to drug use disorders has also 
been increasing in the USA, with the age-standardised 
DALY rates due to drug use disorders almost three times 
higher in 2017 compared with 1990. This trend coincides 
with a sharp increase between 2015 and 2016 in the use 
of and deaths from synthetic opioids such as fentanyl, 
suggesting the need to improve harm-reduction efforts 
in the USA.34,35
Over the past 28 years, several countries in sub-Saharan 
Africa have had substantial increases in HALE. But at the 
same time, some countries in this region, especially 
those with major HIV epidemics, had a stagnation or 
reduction in HALE. Although HIV control efforts have 
resulted in a decrease in HIV-related mortality and an 
increase in life expectancy and HALE in the past decade, 
countries such as Lesotho and Swaziland (eSwatini) still 
have yet to catch up with the level of HALE in 1990.
In addition to examining improvements in health, we 
compared the observed HALE and disease burden with 
those expected based on development status to discern 
which countries are lagging behind and identify priority 
areas that need to be addressed to further improve HALE. 
In 2017, several countries, most of them from southern 
sub-Saharan Africa and eastern Europe, had higher 
disease burden and lower HALE than expected on the 
basis of their sociodemographic development. Our study 
also identified countries that outperformed expectations 
based on their development status (eg, in Niger and the 
Maldives, males had more than 9 years higher HALE at 
birth than expected based on the countries’ SDI). The 
approaches used in these countries to accelerate improve-
ments in health (eg, the child survival programme in 
Niger36) could inform successful programmatic strategies 
for countries with poor performance with similar levels 
of development.
Disease burden related to undernutrition and obesity
Although child and maternal undernutrition is the main 
risk factor for the leading causes of disease burden in low 
SDI countries (eg, lower respiratory infections, diarrhoea, 
and neonatal disorders), obesity remains a key driver of the 
leading causes of burden in high-middle and high SDI 
countries (eg, ischaemic heart disease, ischaemic stroke, 
diabetes, low back and neck pain).27 With changing diets 
and lifestyle over time, obesity-related diseases are emer-
ging, especially in low-middle and middle SDI countries 
where diseases related to both undernutrition and obesity 
contribute sub stantially to the total burden of disease. 
Evidence suggests that the disease burden asso ciated with 
undernutrition and obesity can potentially be reduced.37 
For example, nutritional counselling, food supple men-
tation, and conditional cash-transfer programmes have 
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been shown to substantially reduce stunting and associated 
burdens of disease in settings with food insecurity.37 
Randomised controlled trials have shown that a lifestyle 
intervention with a small amount of weight loss (5–7%) 
decreases the incidence of type 2 diabetes by 58% during a 
3-year follow-up and by 34% during a 10-year follow-up.38–40 
However, weight maintenance after weight loss is 
challenging and requires continuing support to help 
maintain diet, physical activity, and behavioural changes.41 
For countries with a dual burden of malnutrition, an 
integrated approach addressing both undernutrition and 
obesity to simultaneously reduce the burden associated 
with both risk factors has been recommended.42,43
Dietary iron deficiency was the fifth leading cause of 
DALYs among women of reproductive age and the top 
leading cause of DALYs among children of both sexes at 
ages 5–14 years in 2017. Age-standardised DALY rates 
due to dietary iron deficiency were similar between boys 
and girls aged 5–14 years, but for adult women the rates 
were almost double those for men. Despite its 
high burden, iron deficiency remains commonly under-
diagnosed and undertreated.44 Iron deficiency is not only 
a problem in low SDI countries, but also in high SDI 
countries, and reduction of iron deficiency among 
children and women of reproductive age, for example, 
is one of the objectives of the US Public Health Service’s 
Healthy People 2020 initiative.45 Various options are 
available to treat iron deficiency, ranging from iron 
supple men tation to biofortification of crops.46,47 Although 
iron supplementation has been shown to be efficacious, 
challenges exist in terms of distribution, cost and 
compliance, and inability to tolerate it because of 
potential adverse gastrointestinal effects.46 Food 
fortification is highly cost-effective but can be a challenge 
in rural populations with little access to marketed 
fortified food.47 Biofortification of crops is considered to 
be a sustainable strategy to prevent iron deficiency, 
especially in settings with few resources; this strategy 
has been shown to improve iron status in iron-deficient 
individuals, but the longer-term effects on functional 
outcomes has yet to be determined.48
Communicable diseases with increasing trends
A global shift has occurred from communicable to non-
communicable causes of disease burden with sociodemo-
graphic development. However, a few key exceptions 
exist among communicable diseases. In most tropical 
and subtropical countries, the burden of dengue has 
been increasing over time, in terms of both DALY counts 
and age-standardised DALY rates, with the highest 
number of DALYs occurring in south Asia. A dengue 
vaccine has been licensed for use in people aged 9–45 years 
living in several endemic settings;49 however, the vaccine 
efficacy varies from 76% in seropositive individuals to 
only 39% in seronegative individuals.50 In the absence of 
specific treatment for dengue, prevention and control 
measures are crucial. Top-down vector-control efforts 
have restricted effectiveness and sustainability, and 
innovative community-based vector-control strategies are 
being developed.51
All-age DALY counts and age-standardised DALY rates 
due to HIV/AIDS have been decreasing since 2007, but 
for adolescents (aged 15–19 years) age-specific DALY 
rates continued to increase after 2007. The HIV/AIDS 
YLL and YLD trends among adolescents also differ from 
the all-age trends. The all-age YLL rate increased after 
1990, peaked around 2005, and then declined steadily 
afterwards11 as antiretroviral treatment became more 
widely available. Among adolescents, the YLL rate 
continued to increase after 2005, reaching a plateau since 
2013. The all-age YLD rate due to HIV/AIDS has 
decreased slightly since 2007, but the adolescent YLDs 
rate has continued to increase.12 DALYs from HIV/AIDS 
are concentrated in sub-Saharan Africa. Adolescents 
have low rates of HIV testing and poor access to 
antiretroviral treatment, which might partly explain 
some of the increases in HIV/AIDS DALYs in this age 
group.52
Causes with sharp decreases in DALYs
Since 1990, we have seen exceptional progress in many 
countries in reducing the burden from communicable 
diseases, especially vaccine-preventable diseases such as 
tetanus and measles. Much of this burden came from 
premature mortality, which has sharply decreased in the 
past 28 years. However, despite these interventions, 
DALYs due to these causes remain unnecessarily high in 
several low, low-middle, and middle SDI countries. 
Immunisation efforts have been helpful, but progress in 
immunisation coverage has slowed in the past decade; 
about 20 million children younger than 1 year, most of 
them in sub-Saharan Africa and south Asia, did not 
receive the measles vaccine and the three recommended 
doses of the diphtheria, tetanus, and pertussis vaccine in 
2016.53 Conflict, inadequate investment in national 
immuni sation programmes, and vaccine stock outages 
were among the reasons for the stalled progress in 
immunisation coverage.53
Comparisons with GBD 2016
We have made substantial improvements in the 
estimation of mortality and life expectancy in GBD 2017 
across our publications, including an independent 
estimation of population, a comprehensive update on 
fertility, adding a substantial amount of new data (from 
censuses, Demographic Surveillance Sites, and other 
sources), improvements to the GBD model life-table 
system, and enhancements to the modelling framework.13 
We made changes to the GBD cause hierarchy, which can 
restrict comparisons to estimates from previous GBD 
iterations. For example, we have combined maternal and 
neonatal conditions at Level 2 of the cause hierarchy in 
GBD 2017 and reported these causes separately at Level 3 
(rather than Level 2). Because of these changes, neonatal 
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disorders now appear for the first time as the first leading 
cause of DALYs in both 1990 and 2017.
Estimates of DALYs due to congenital birth defects 
were higher in GBD 2017 than in GBD 2016 for two 
reasons.9 First, all data sources that captured only a small 
subset of congenital causes (eg, only congenital heart 
disease and neural tube defects) were excluded for GBD 
2017, leading to increased mortality estimates. Second, 
for GBD 2017 we implemented an algorithm to 
empirically identify data sources for registration of birth 
defects and for administrations (ie, hospital and claims) 
that had systematic under-reporting by age, sex, and 
defect. This change led to exclusion of several sources 
and, in many cases, higher prevalence estimates. The 
estimated DALYs due to malaria were lower in GBD 2017 
than in GBD 2016 because of newly included Plasmodium 
parasite rate survey data and updates to insecticide-
treated bednet coverage, which decreased incidence 
estimates, particularly in Nigeria. The decrease in 
incidence was in agreement with additional verbal 
autopsy data for Nigeria, which resulted in a decrease in 
estimated YLLs and DALYs.
The global age-standardised DALY rate for drug use 
disorders in GBD 2017 was higher for the most recent 
decade than in GBD 2016, because of a better fit to the 
most recent years of cause of death data in the USA 
and the use of more appropriate covariates, including 
the prevalence of injecting drug use and an estimate 
of consumption (measured by import and domestic 
manu facture of scheduled substances, including opioids, 
expressed as daily doses per 1000 people per day). 
Estimates of DALYs due to acute hepatitis overall are very 
similar to GBD 2016, but our assessments of the relative 
contribution of different viruses changed. We used clinical 
administrative data sources to calculate location-specific 
and age-specific case-fatality ratios for acute hepatitis 
infection, pairing these ratios with incidence estimates of 
each virus. Previously all locations were assu med to have 
identical case-fatality ratios. This resulted in higher 
estimates of DALYs for acute hepatitis A, and lower DALY 
estimates for acute hepatitis B, C, and E. Finally, estimated 
DALYs due to HIV/AIDS among children younger than 
5 years have increased in the GBD 2017 study because of 
methodo logical improvements. In countries with high-
quality vital registration data, incidence among children 
was adjusted to produce mortality estimates that better 
align with recorded HIV/AIDS deaths. Additionally, we 
produced the paediatric estimates of HIV/AIDS mortality 
using the CD4 progression and CD4-specific mortality 
rates developed by UNAIDS.54
Limitations
This study has several limitations. First, the GBD 2017 
YLL and YLD analyses had limitations as described in the 
GBD 2017 cause of death,11 disease and injury,12 and 
mortality papers.13 Second, we assumed that uncertainty 
is independent between YLLs and YLDs because little 
empirical evidence exists to establish this correlation; 
however, this assumption could result in an under-
estimation of the total uncertainty for DALYs. Third, 
HALE and DALY estimates are influenced by the 
availability of data for YLL and YLD estimations. Because 
of time lags in the reporting of health data by countries 
and their subsequent incorporation into the GBD 
estimation, recent changes in health states might not 
have been captured in our estimates. The scarcity of data 
for a particular location is reflected by wider uncertainty 
intervals. Fourth, although we have included several 
sources of uncertainty in our estimations, we have not 
been able to incorporate uncertainty into the covariates 
used by cause of death and non-fatal models. Fifth, SDI 
utility might be restricted in countries with high income 
inequality. The applicability of SDI could be enhanced in 
the future by taking into account social heterogeneity 
within countries. Finally, time trends for specific causes, 
such as cancer, might be influenced by changes in 
diagnostic technology, whereas in previous years under-
reporting might have occurred when diagnostic tests 
were done infrequently.
Conclusion
Understanding trends in the health status of the global 
population and changes in the leading causes of disease 
burden over time is needed to accurately inform policies 
and set priorities for action. Updating the GBD study on 
a regular basis provides an opportunity to assess the 
latest evidence and monitor these trends with time to 
understand where interventions are having an effect and 
how much they have affected the disease burden. Our 
results showed that, globally, enormous improvements 
in health have occurred over the past 28 years. 
Nevertheless, large inequalities in HALE, years lived 
in poor health, and disease burden exist across SDI 
quintiles and countries, and between sexes. Despite the 
progress made in reducing the total burden of disease, 
hundreds of millions of DALYs could still be averted and 
disparities could be minimised through targeted 
interventions ranging from the prevention of risk factors 
and extended vaccine coverage, to universal access to 
essential health services.
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Australia (J Jonnagaddala PhD); University of Social Welfare and 
Rehabilitation Sciences, Tehran, Iran (Z Jorjoran Shushtari MSc, 
M Noroozi PhD); Centre for Community Medicine (A Joshi MD, 
A P Pakhare MD), Department of Forensic Medicine and Toxicology 
(T Kanchan MD), Department of Psychiatry (Prof R Sagar MD), 
Department of Endocrinology, Metabolism, & Diabetes 
(Prof N Tandon PhD), All India Institute of Medical Sciences, New 
Delhi, India; Faculty of Medicine and Health Sciences (J J Jozwiak PhD), 
Department of Family Medicine and Public Health (J J Jozwiak PhD), 
University of Opole, Opole, Poland; School of Health Sciences, Savitribai 
Phule Pune University, Pune, India (S B Jungari MA); Institute of Family 
Medicine and Public Health, University of Tartu, Tartu, Estonia 
(M Jürisson PhD); School of Public Health, University College Cork, 
Cork, UK (Z Kabir PhD); Personal Social Services Research Unit, 
London School of Economics and Political Science, London, UK 
(R Kadel MPH); Department of Nephrology, Srirama Chandra Bhanja 
Medical College and Hospital, Cuttack, India (Prof C Kar MD); 
Department for Epidemiology, Helmholtz Centre for Infection Research, 
Braunschweig, Germany (A Karch MD); Quality and Equity Health Care, 
Kigali, Rwanda (C Karema MPH); School of Interdisciplinary Arts and 
Sciences, University of Washington Tacoma, Tacoma, WA, USA 
(S Karimi PhD); Department of Anesthesiology & Pain Medicine, Seattle 
Children’s Hospital, Seattle, WA, USA (N J Kassebaum MD); MRC/CSO 
Social and Public Health Sciences Unit, University of Glasgow, Glasgow, 
UK (S V Katikireddi PhD); School of Health Care Administration, 
Oklahoma State University, Tulsa, OK, USA (Prof A Kaul MD); Health 
Care Delivery Sciences, University of Tulsa, Tulsa, OK, USA 
(Prof A Kaul MD); ODeL Campus (Prof P N Keiyoro PhD), Department 
of Psychiatry (M Kumar PhD), University of Nairobi, Nairobi, Kenya; 
Department of Linguistics and Germanic, Slavic, Asian, and African 
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Languages, Michigan State University, East Lansing, MI, USA 
(G R Kemp BA); Non-Communicable Diseases Research Unit 
(Prof A P Kengne PhD), Alcohol, Tobacco, & Other Drug Use Research 
Unit (Prof C D H Parry PhD), Cochrane South Africa (A B Wiyeh MD, 
Prof C S Wiysonge MD), Medical Research Council South Africa, Cape 
Town, South Africa; Department of Medicine (Prof A P Kengne PhD, 
G A Mensah MD, J Noubiap MD, Prof K Sliwa MD, L J Zuhlke PhD), 
Department of Psychiatry and Mental Health (Prof D J Stein MD), 
Department of Paediatrics and Child Health (Prof H J Zar PhD, 
L J Zuhlke PhD), University of Cape Town, Cape Town, South Africa; 
Institute of Cardiology, Assuta Hospital, Tel Aviv Yaffo, Israel 
(Prof A Keren MD); Heart Failure and Cardiomyopathies Center, 
Hadassah Hebrew University Hospital, Jerusalem, Israel 
(Prof A Keren MD); Department of Public Health and Community 
Medicine, Jordan University of Science and Technology, Ramtha, Jordan 
(Prof Y S Khader PhD); Department of Statistics, Azad University, 
Omidiyeh Branch, Iran (B Khafaei PhD); School of Food and 
Agricultural Sciences, University of Management and Technology, 
Lahore, Pakistan (N Khalid PhD); Epidemiology and Biostatistics 
Department, Health Services Academy, Islamabad, Pakistan 
(E A Khan MPH); Department of Internal Medicine, John H Stroger Jr 
Hospital of Cook County, Chicago, IL, USA (M S Khan MD); 
Department of Internal Medicine, Dow University of Health Sciences, 
Karachi, Pakistan (M S Khan MD, T J Siddiqi MB, M S Usman MB); 
Department of Epidemiology (G Naik MPH, J A Singh MD), Department 
of Medicine (P Ranjan PhD, J A Singh MD), Department of Psychology 
(D C Schwebel PhD), University of Alabama at Birmingham, 
Birmingham, AL, USA (M Khan MD, A R Sawant MD); Department of 
Pediatrics (Prof J A Towbin MD), University of Tennessee, Knoxville, TN, 
USA (M Khan MD); Institute of Health Policy and Management 
(Prof Y Khang MD), Department of Health Policy and Management 
(Prof Y Khang MD), Seoul National University, Seoul, South Korea; 
International Otorhinolaryngology Research Association, Tehran, Iran 
(M Khosravi MD); Clinical Epidemiology Unit (A A Kiadaliri PhD), 
Department of Clinical Sciences (Prof B Norrving PhD), Lund 
University, Lund, Sweden; Research Department, Kenya Revenue 
Authority, Nairobi, Kenya (D N Kiirithio MSc); Research and Data 
Solutions, Synotech Consultant, Nairobi, Kenya (D N Kiirithio MSc); 
Korea Health Industry Development Institute, Cheongju-si, South Korea 
(C Kim PhD); Department of Health Sciences, Northeastern University, 
Boston, MA, USA (Prof D Kim DrPH); Department of Preventive 
Medicine, Korea University, Seoul, South Korea (Y Kim PhD, 
Prof S Yoon PhD); School of Medicine, Xiamen University Malaysia, 
Sepang, Malaysia (Y Kim PhD); Department of Nutrition, Simmons 
College, Boston, MA, USA (R W Kimokoti MD); Faculty of Health, 
University of Canberra, Canberra, ACT, Australia (Y Kinfu PhD); 
Murdoch Childrens Research Institute (Y Kinfu PhD), Neurology 
Department (M T Mackay PhD), Cardiology Department 
(R G Weintraub MB), Royal Children’s Hospital, Melbourne, VIC, 
Australia; Department of Global Community Health and Behavioral 
Sciences, Tulane University, New Orleans, LA, USA (Prof A Kisa PhD); 
Department of Health Economics and Social Security 
(K Kissimova-Skarbek PhD), Institute of Public Health 
(R Topor-Madry PhD), Jagiellonian University Medical College, Krakow, 
Poland; Centre for Disease Burden (A S Knudsen PhD), Division of 
Mental and Physical Health (Prof S Øverland PhD), Norwegian Institute 
of Public Health, Bergen, Norway (Prof V Skirbekk PhD, G Sulo PhD); 
Public Health Sciences Division, Fred Hutchinson Cancer Research 
Center, Seattle, WA, USA (J M Kocarnik PhD); Department of Preventive 
Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan 
(Prof Y Kokubo PhD); Arthritis Research Canada, Richmond, BC, 
Canada (J A Kopec PhD); Independent Consultant, Jakarta, Indonesia 
(S Kosen MD); Department of Internal and Pulmonary Medicine, 
Sheri Kashmir Institute of Medical Sciences, Srinagar, India 
(Prof P A Koul MD); Department of Anthropology, Panjab University, 
Chandigarh, India (K Krishan PhD); Department of Social and 
Preventive Medicine (Prof B Kuate Defo PhD), Department of 
Demography (Prof B Kuate Defo PhD), University of Montreal, 
Montreal, QC, Canada; Department of Public Health, Yuksek Ihtisas 
University, Ankara, Turkey (B Kucuk Bicer BEP); Department of Public 
Health, Hacettepe University, Ankara, Turkey (B Kucuk Bicer BEP); 
Department of Internal Medicine (D P Lad DM), Department of 
Pediatrics (S D Lad MD), Post Graduate Institute of Medical Education 
and Research, Chandigarh, India; Population and Work Ability Program 
(T Lallukka PhD), Finnish Institute of Occupational Health, Helsinki, 
Finland (R Shiri PhD); Department of Public Health (T Lallukka PhD), 
University of Helsinki, Helsinki, Finland (T J Meretoja MD); 
Department of Community and Family Medicine, Academy of Medical 
Science, Baghdad, Iraq (F H Lami PhD); Health Promotion and Chronic 
Disease Prevention Branch, Public Health Agency of Canada, Ottawa, 
ON, Canada (J J Lang PhD); HelpMeSee, New York, NY, USA 
(Prof V C Lansingh PhD); International Relations, Mexican Institute of 
Ophthalmology, Queretaro, Mexico (Prof V C Lansingh PhD); 
Department of Public Health (A Latifi PhD), Managerial Epidemiology 
Research Center (S Safiri PhD), Maragheh University of Medical 
Sciences, Maragheh, Iran; College of Optometry, Nova Southeastern 
University, Fort Lauderdale, FL, USA (J L Leasher OD); Regional Centre 
for the Analysis of Data on Occupational and Work-Related Injuries and 
Diseases, Local Health Unit Tuscany Centre, Florence, Italy 
(M Levi PhD); Department of Health Sciences, University of Florence, 
Florence, Italy (M Levi PhD); Oxford University Clinical Research Unit, 
Wellcome Trust Asia Programme, Hanoi, Vietnam (S Lewycka PhD); 
Department of Clinical Research and Epidemiology, Shenzhen Sun 
Yat-Sen Cardiovascular Hospital, Shenzhen, China (Y Li PhD); 
Noncommunicable Disease Control and Prevention Center 
(M Zhou PhD), Chinese Center for Disease Control and Prevention, 
Beijing, China (Prof X Liang MD); Alliance for Improving Health 
Outcomes, Inc, Quezon City, Philippines (Y Liao PhD); Department of 
Public Health, Samara University, Samara, Ethiopia (M L Liben MPH); 
Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia 
(L Lim MD); Department of Medicine and Therapeutics, The Chinese 
University of Hong Kong, Shatin, China (L Lim MD); School of Public 
Health, University of Haifa, Haifa, Israel (Prof S Linn DrPH); Centre for 
Chronic Disease Control, Beijing, China (Prof S Liu PhD); Population 
Health Sciences, Bristol Medical School, University of Bristol, Bristol, 
UK (K J Looker PhD); Department of Paediatrics (M T Mackay PhD, 
Prof G C Patton MD), School of Health Sciences (A Meretoja MD, 
Prof C E I Szoeke PhD), School of Population and Global Health 
(Prof H R Taylor MD), Department of Medicine (Prof T Wijeratne MD), 
University of Melbourne, Melbourne, QLD, Australia 
(Prof A D Lopez PhD); Institute of Nutrition, Friedrich Schiller 
University Jena, Jena, Germany (Prof S Lorkowski PhD); Competence 
Cluster for Nutrition and Cardiovascular Health (NUTRICARD), Jena, 
Germany (Prof S Lorkowski PhD); General Surgery Department, Aintree 
University Hospital National Health Service (NHS) Foundation Trust, 
Liverpool, UK (R Lunevicius PhD); Surgery Department, University of 
Liverpool, Liverpool, UK (R Lunevicius PhD); Health Data Research UK, 
Swansea University, Swansea, UK (Prof R A Lyons MD); Saw Swee Hock 
School of Public Health (S Ma PhD), Yong Loo Lin School of Medicine 
(Prof N Venketasubramanian MBBS), National University of Singapore, 
Singapore, Singapore; Department of Internal Medicine, Grant Medical 
College & Sir J J Group of Hospitals, Mumbai, India 
(D P Maghavani MBBS); Institute for Global Health Innovations, Duy 
Tan University, Hanoi, Vietnam (H T Mai MPH, H L T Nguyen MPH, 
H Q Pham MD); Department of Public Health, Trnava University, 
Trnava, Slovakia (M Majdan PhD); Non-Communicable Diseases 
Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 
(Prof R Malekzadeh MD, S G Sepanlou MD); Surgery Department, 
Emergency University Hospital Bucharest, Bucharest, Romania 
(A Manda MD); Campus Caucaia, Federal Institute of Education, Science 
and Technology of Ceará, Caucaia, Brazil (F R Martins-Melo PhD); 
Clinical Institute of Medical and Chemical Laboratory Diagnostics, 
Medical University of Graz, Graz, Austria (Prof W März MD); Graduate 
School, University of the East Ramon Magsaysay Memorial Medical 
Center, Quezon City, Philippines (M B Marzan MSc); Department of 
Neurology, Hospital Center of St John, Porto, Portugal (J Massano MD); 
Department of Biology and Biological Engineering, Chalmers University 
of Technology, Gothenburg, Sweden (M Mazidi PhD); Department of 
Ophthalmology, Hywel Dda University Health Board, Carmarthen, UK 
(C McAlinden PhD, E Skiadaresi MD); Liver Disease and Hepatitis 
Program, Alaska Native Medical Center, Anchorage, AK, USA 
(B J McMahon MD); Research, Monitoring and Evaluation, Ipas Nepal, 
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Kathmandu, Nepal (S Mehata PhD); Preventive Oncology, National 
Institute of Cancer Prevention and Research, Noida, India 
(Prof R Mehrotra PhD); Department of Epidemiology and Biostatistics, 
University of California San Francisco, San Francisco, CA, USA 
(K M Mehta DSc); Department of Internal Medicine, Sevenhills 
Hospital, Mumbai, India (V Mehta MD); College of Health Sciences, 
Debre Tabor University, Debre Tabor, Ethiopia (A Melese MSc); 
Department of Public Health, University of West Florida, Pensacola, FL, 
USA (P T N Memiah DrPH); Research Department Prince Mohammed 
Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia 
(Prof Z A Memish MD); Peru Country Office, United Nations Population 
Fund (UNFPA), Lima, Peru (W Mendoza MD); Department of 
Pharmacy, Wollo University, Dessie, Ethiopia (G Mengistu MSc); 
Neurocenter (A Meretoja MD), Breast Surgery Unit (T J Meretoja MD), 
Helsinki University Hospital, Helsinki, Finland; Clinical Microbiology 
and Parasitology Unit, Dr Zora ozic Polyclinic, Zagreb, Croatia 
(T Mestrovic PhD); University Centre Varazdin, University North, 
Varazdin, Croatia (T Mestrovic PhD); Department of Hypertension 
(Prof T Miazgowski MD), Zdroje Hospital (J Widecka PhD), Emergency 
Department (B Miazgowski MD), Pomeranian Medical University, 
Szczecin, Poland (B Miazgowski MD); Pacific Institute for Research & 
Evaluation, Calverton, MD, USA (T R Miller PhD); Nevada Division of 
Public and Behavioral Health, Carson City, NV, USA 
(M Mirarefin MPH); President’s Office, National Institute of Statistics, 
Bucharest, Romania (A Mirica PhD); Faculty of General Medicine, 
Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan 
(Prof E M Mirrakhimov MD); Department of Atherosclerosis and 
Coronary Heart Disease, National Center of Cardiology and Internal 
Disease, Bishkek, Kyrgyzstan (Prof E M Mirrakhimov MD); Institute of 
Addiction Research (ISFF), Frankfurt University of Applied Sciences, 
Frankfurt, Germany (B Moazen MSc); Department of Biology, 
Salahaddin University, Erbil, Iraq (K A Mohammad PhD); Ishik 
University, Erbil, Iraq (K A Mohammad PhD); Cardiovascular Research 
Institute, Isfahan University of Medical Sciences, Isfahan, Iran 
(N Mohammadifard PhD, Prof N Sarrafzadegan MD); Department of 
Public Health, Jigjiga University, Jigjiga, Ethiopia 
(M A Mohammed PhD); Health Systems and Policy Research Unit 
(S Mohammed PhD), Department of Community Medicine 
(M B Sufiyan MD), Ahmadu Bello University, Zaria, Nigeria; Clinical 
Epidemiology and Public Health Research Unit, Burlo Garofolo Institute 
for Maternal and Child Health, Trieste, Italy (L Monasta DSc, 
L Ronfani PhD); Health Systems Research Center, National Health 
Research Institutes, Cuernavaca, Mexico (Prof J C Montañez MSc); 
Department of Epidemiology and Biostatistics (G Moradi PhD), Social 
Determinants of Health Research Center (G Moradi PhD), Kurdistan 
University of Medical Sciences, Sanandaj, Iran; Lancaster University, 
Lancaster, UK (P Moraga PhD); International Laboratory for Air Quality 
and Health (Prof L Morawska PhD), Australian Centre for Health 
Services Innovation (R Pacella PhD), School of Exercise and Nutrition 
Sciences (Q G To PhD), Queensland University of Technology, Brisbane, 
QLD, Australia; Hospital de Sto António, Hospital Center of Porto, 
Porto, Portugal (J Morgado-Da-Costa MSc); 1st Department of 
Ophthalmology, University of Athens, Athens, Greece 
(M M Moschos PhD); Biomedical Research Foundation, Academy of 
Athens, Athens, Greece (M M Moschos PhD); Demographic Change and 
Ageing Research Area (A Werdecker PhD), Competence Center 
Mortality-Follow-Up (R Westerman PhD), Federal Institute for 
Population Research, Wiesbaden, Germany (Prof U O Mueller MD); 
Center for Population and Health, Wiesbaden, Germany 
(Prof U O Mueller MD); Department of Endocrinology & Metabolism, 
Institute of Post Graduate Medical Education & Research, Kolkata, India 
(Prof S Mukhopadhyay MD); School of Medical Sciences, Science 
University of Malaysia, Kubang Kerian, Malaysia (K Musa PhD); 
Pediatrics Department, Nishtar Medical University, Multan, Pakistan 
(Prof G Mustafa MD); Pediatrics & Pediatric Pulmonology, Institute of 
Mother & Child Care, Multan, Pakistan (Prof G Mustafa MD); 
Department of Obstetrics and Gynecology (Prof A F Nabhan PhD), 
Department of Entomology (A M Samy PhD), Ain Shams University, 
Cairo, Egypt; National Center for Child Health and Development, 
Setagaya, Japan (C Nagata PhD); Institute of Epidemiology and Medical 
Biometry, Ulm University, Ulm, Germany (Prof G Nagel PhD, 
Prof D Rothenbacher MD); Department of Preventive Medicine and 
Public Health, Chungnam National University School of Medicine, 
Daejeon, South Korea (Prof H Nam PhD); Daejeon Regional Cancer 
Center, Chungnam National University Hospital, Daejeon, South Korea 
(Prof H Nam PhD); Suraj Eye Institute, Nagpur, India (V Nangia MD); 
Department of Public Heath, University of Yaoundé I, Yaoundé, 
Cameroon (J Nansseu MD); Department of Cardiology, Cardio-Aid, 
Bucharest, Romania (R I Negoi PhD); Neurosciences, Kenya Medical 
Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya 
(Prof C R J Newton MD); Department off Biological Sciences, University 
of Embu, Embu, Kenya (J W Ngunjiri DrPH); Health Economics and 
Finance (A Q Nguyen PhD), Department of Health Economics 
(H T Nguyen MSc), Hanoi School of Public Health, Hanoi, Vietnam 
(H T Nguyen PhD); Public Health Science Department, State University 
of Semarang, Kota Semarang, Indonesia (D N A Ningrum MPH); 
Graduate Institute of Biomedical Informatics, Taipei Medical University, 
Taipei City, Taiwan (D N A Ningrum MPH); Institute for Global Health 
Policy Research, National Center for Global Health and Medicine, 
Shinjuku-ku, Japan (S Nomura MSc); Independent Consultant, Accra, 
Ghana (R Ofori-Asenso MSc); Department of Preventive Medicine, 
Kyung Hee University, Dongdaemun-gu, South Korea (I Oh PhD); 
Department of HIV/AIDS, STIs & TB, Human Sciences Research 
Council, Durban, South Africa (O Oladimeji MD); School of Public 
Health, University of Namibia, Oshakati Campus, Namibia 
(O Oladimeji MD); Department of Psychiatry, University of Lagos, 
Lagos, Nigeria (A T Olagunju MD); Centre for Healthy Start Initiative, 
Ikoyi, Nigeria (B O Olusanya PhD, J O Olusanya MBA); NCD Prevention 
& Control Unit, Ministry of Health, Bandar Seri Begawan, Brunei 
(S Ong FAMS); Institute of Health Science, University of Brunei 
Darussalam, Gadong, Brunei (S Ong FAMS); Graduate School of Public 
Health, San Diego State University, San Diego, CA, USA 
(Prof E Oren PhD); School of Medicine, Autonomous University of 
Madrid, Madrid, Spain (Prof A Ortiz MD); Department of Nephrology 
and Hypertension, The Institute for Health Research Foundation 
Jiménez Díaz University Hospital, Madrid, Spain (Prof A Ortiz MD); 
Department of Global Health Nursing, St Luke’s International 
University, Chuo-ku, Japan (Prof E Ota PhD); The Center for Healthcare 
Quality Assessment and Control, Ministry of Health of the Russian 
Federation, Moscow, Russia (S S Otstavnov PhD); Moscow Institute of 
Physics and Technology, Moscow State University, Dolgoprudny, Russia 
(S S Otstavnov PhD); Institute for Advanced Medical Research and 
Training, University of Ibadan, Ibadan, Nigeria 
(Prof M O Owolabi DrM); Department of TB & Respiratory Medicine, 
Jagadguru Sri Shivarathreeswara University, Mysore, India 
(Prof M P A DNB); University of Chichester, Chichester, UK 
(R Pacella PhD); Health Outcomes, Center for Health Outcomes & 
Evaluation, Bucharest, Romania (A Pana MD); Department of Medical 
Humanities and Social Medicine, Kosin University, Busan, South Korea 
(Prof E Park PhD); Department of Medicine, Maimonides Medical 
Center, Brooklyn, NY, USA (S Patel MD); Krishna Institute of Medical 
Sciences, Deemed University, Karad, India (S T Patil MPH); 
International Institute of Health Management Research, New Delhi, 
India (A Patle MPH); Population Health Group (Prof G C Patton MD), 
Murdoch Children’s Research Institute, Melbourne, VIC, Australia 
(R G Weintraub MB); Clinical Research Department, Diabetes Research 
Society, Hyderabad, India (Prof V R Paturi MD); Clinical Research 
Department, DiabetOmics, Portland, OR, USA (Prof V R Paturi MD); 
Health, Nutrition, and HIV/AIDS Program, Save the Children, 
Kathmandu, Nepal (D Paudel PhD); Center for International Health, 
Ludwig Maximilians University, Munich, Germany (D Paudel PhD); 
Cartagena University, Cartagena, Colombia (Prof D M Pereira PhD); 
Institute of Medicine, University of Gothenburg, Gothenburg, Sweden 
(Prof M Petzold PhD); School of Public Health, University of 
Witwatersrand, Johannesburg, South Africa (Prof M Petzold PhD); 
Shanghai Mental Health Center, Shanghai Jiao Tong University, 
Shanghai, China (Prof M R Phillips MD); Basic Medical Sciences 
Department, Durban University of Technology, Durban, South Africa 
(J D Pillay PhD); Institute for Mental Health Policy Research, Centre for 
Addiction and Mental Health, Toronto, ON, Canada (S Popova PhD); 
Ashok & Rita Patel Institute of Physiotherapy, Charotar University of 
Science and Technology, Anand, India (V Prakash PhD); Independent 
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Consultant, Glenelg, SA, Australia (Prof K Pesudovs PhD); 
Non-communicable Diseases Research Center, Alborz University of 
Medical Sciences, Karaj, Iran (M Qorbani PhD); Department of 
Environmental & Occupational Health, Drexel University, Philadelphia, 
PA, USA (D Quistberg PhD); Medichem, Barcelona, Spain 
(A Radfar MD); Department of Epidemiology & Biostatistics, Contech 
School of Public Health, Lahore, Pakistan (A Rafay MS); Department of 
Clinical Pediatrics, Sweidi Hospital, Riyadh, Saudi Arabia 
(Prof S U Rahman MBBS); Department of Pediatrics 
(Prof S U Rahman), Hypertension in Africa Research Team 
(Prof A E Schutte PhD), North-West University, Peshawar, Pakistan; 
Society for Health and Demographic Surveillance, Suri, India 
(R Rai MPH); Department of Economics, University of Göttingen, 
Göttingen, Germany (R Rai); Gonçalo Moniz Institute, Oswaldo Cruz 
Foundation, Salvador, Brazil (Prof D Rasella PhD); University College 
London Hospitals, London, UK (D L Rawaf MD); Public Health England, 
London, UK (Prof S Rawaf PhD); Brien Holden Vision Institute, Sydney, 
NSW, Australia (Prof S Resnikoff MD); Organization for the Prevention 
of Blindness, Paris, France (Prof S Resnikoff MD); Department of 
Clinical Research, Federal University of Uberlândia, Uberlândia, Brazil 
(L Roever PhD); Golestan Research Center of Gastroenterology and 
Hepatology, Golestan University of Medical Sciences, Gorgan, Iran 
(G Roshandel PhD); Biotechnology, Ikiam Amazon Regional University, 
Ciudad De Tena, Ecuador (E Rubagotti PhD); Department of Ocean 
Science and Engineering, Southern University of Science and 
Technology, Shenzhen, China (E Rubagotti PhD); Neuropsychiatric 
Institute, Prince of Wales Hospital, Randwick, NSW, Australia 
(Prof P S Sachdev MD); Neurogenic Inflammation Research Center 
(A Sahebkar PhD), Biotechnology Research Center (A Sahebkar PhD), 
Mashhad University of Medical Sciences, Mashhad, Iran; College of 
Medicine, Al-Imam Mohammad Ibn Saud Islamic University, Riyadh, 
Saudi Arabia (N Salam PhD); School of Health and Policy Management, 
Faculty of Health, York University, Toronto, ON, Canada 
(Prof P Salamati MD); Punjab University College of Pharmacy, Anarkali, 
Pakistan (Z Saleem PharmD); Center for Health Policy & Center for 
Primary Care and Outcomes Research, Stanford University, Stanford, 
CA, USA (Prof J A Salomon PhD); Clinical Research Division, Chest 
Research Foundation, Pune, India (Prof S S Salvi MD); Health and 
Disability Intelligence Group, Ministry of Health, Wellington, 
New Zealand (I Salz MD); Department of Surgery, Marshall University, 
Huntington, WV, USA (Prof J Sanabria MD); Department of Nutrition 
and Preventive Medicine, Case Western Reserve University, Cleveland, 
OH, USA (Prof J Sanabria MD); Nephrology Group, Jimenez Diaz 
Foundation University Hospital Institute for Health Research, Madrid, 
Spain (M Sanchez-Niño PhD); Department of Public Health, Regional 
Health Administration Do Norte I P, Vila Nova De Gaia, Portugal 
(J V Santos MD); Department of Medicine, University of Massachusetts 
Medical School, Worcester, MA, USA (M Sardana MD); Department of 
Health and Society, Faculty of Medicine, University of Applied and 
Environmental Sciences, Bogotá, Colombia 
(Prof R Sarmiento-Suárez MPH); Department of Public Health 
Medicine, University of Kwazulu-Natal, Durban, South Africa 
(Prof B Sartorius PhD); Surgery Department, Hamad Medical 
Corporation, Doha, Qatar (B Sathian PhD); Faculty of Health & Social 
Sciences, Bournemouth University, Bournemouth, UK (B Sathian PhD); 
UGC Centre of Advanced Study in Psychology, Utkal University, 
Bhubaneswar, India (M Satpathy PhD); Udyam-Global Association for 
Sustainable Development, Bhubaneswar, India (M Satpathy PhD); 
Dr D Y Patil Vidyapeeth, Pune, India (A R Sawant MD); Department of 
Public Health Sciences, University of North Carolina at Charlotte, 
Charlotte, NC, USA (M Sawhney PhD); School of Health Sciences, 
Federal University of Santa Catarina, Ararangua, Brazil 
(Prof I J C Schneider PhD, Prof D A S Silva PhD); Department of 
Medical Statistics, Epidemiology and Medical Informatics, University of 
Zagreb, Zagreb, Croatia (M Sekerija PhD); Division of Epidemiology and 
Prevention of Chronic Noncommunicable Diseases, Croatian Institute of 
Public Health, Zagreb, Croatia (M Sekerija PhD); Langone Medical 
Center, New York University, New York, NY, USA (A Shafieesabet MD); 
Public Health Division, An-Najah National University, Nablus, Palestine 
(A A Shaheen PhD); Independent Consultant, Karachi, Pakistan 
(M A Shaikh MD); Department of Molecular Hepatology, Middle East 
Liver Disease Center, Tehran, Iran (H Sharafi PhD); Department of 
Laboratory Sciences (Prof M Sharif PhD), Department of Basic Sciences 
(Prof M Sharif PhD), Islamic Azad University, Sari, Iran; Policy and 
Planning Division, Ministry of Health, Thimphi, Bhutan 
(J Sharma MPH); University School of Management and 
Entrepreneurship, Delhi Technological University, New Delhi, India 
(R Sharma PhD); Department of Pulmonary Medicine, Fudan 
University, Shanghai, China (J She MD); Usher Institute of Population 
Health Sciences and Informatics, University of Edinburgh, Edinburgh, 
UK (Prof A Sheikh MD, I N Soyiri PhD); Friedman School of Nutrition 
Science and Policy, Tufts University, Boston, MA, USA (P Shi PhD); 
National Institute of Infectious Diseases, Tokyo, Japan 
(M Shigematsu PhD); Institute of Medical Epidemiology, Martin Luther 
University Halle-Wittenberg, Halle, Germany (I Shiue PhD); School of 
Health, University of Technology Sydney, Sydney, NSW, Australia 
(S Siabani PhD); Department of Psychology, Reykjavik University, 
Reykjavik, Iceland (Prof I D Sigfusdottir PhD, R Sigurvinsdottir PhD); 
Brasília University, Brasília, Brazil (Prof D A Silveira MD); Max Hospital, 
Ghaziabad, India (Prof N P Singh MD); Department of Pulmonary 
Medicine, Asthma Bhawan, Jaipur, India (Prof V Singh MD); 
Department of Epidemiology, School of Preventive Oncology, Patna, 
India (D N Sinha PhD); Pediatric Department, King Khalid University 
Hospital, Riyadh, Saudi Arabia (B H Sobaih MD); Division of 
Community Medicine, International Medical University, Kuala Lumpur, 
Malaysia (C T Sreeramareddy MD); Central Research Institute of 
Cytology and Genetics (E Varavikova PhD), Federal Research Institute 
for Health Organization and Informatics of the Ministry of Health 
(FRIHOI), Moscow, Russia (Prof V I Starodubov DSc, 
S K Vladimirov PhD); Department of Neuromedicine and Movement 
Science, Norwegian University of Science and Technology, Trondheim, 
Norway (Prof T J Steiner PhD, Prof L J Stovner PhD); Neuro Centre, St 
Olavs Hospital, Trondheim, Norway (Prof L J Stovner PhD); Department 
of Nursing, Muhammadiyah University of Surakarta, Kartasura, 
Indonesia (A Sudaryanto MPH); Department of Community Health 
(B F Sunguya PhD), Muhimbili University of Health and Allied 
Sciences, Dar Es Salaam, Tanzania (B F Sunguya PhD); School of 
Medicine, University of California Riverside, Riverside, CA, USA 
(P J Sur MPH); Department of Criminology, Law and Society, University 
of California Irvine, Irvine, CA, USA (Prof B L Sykes PhD); Department 
of Medicine (Prof R Tabarés-Seisdedos PhD), Department of Pediatrics, 
Obstetrics and Gynecology (Prof M Tortajada-Girbés PhD), University of 
Valencia, Valencia, Spain; Carlos III Health Institute, Biomedical 
Research Networking Center for Mental Health Network (CIBERSAM), 
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